US20230330127A1 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors - Google Patents

6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors Download PDF

Info

Publication number
US20230330127A1
US20230330127A1 US18/187,463 US202318187463A US2023330127A1 US 20230330127 A1 US20230330127 A1 US 20230330127A1 US 202318187463 A US202318187463 A US 202318187463A US 2023330127 A1 US2023330127 A1 US 2023330127A1
Authority
US
United States
Prior art keywords
alkyl
group
hydrogen
formula
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/187,463
Inventor
Tongfei Wu
Dirk Brehmer
Lijs Beke
An Boeckx
Gaston Stanislas Marcella Diels
Ronaldus Amodus Hendrika Joseph Gilissen
Edward Charles Lawson
Vineet Pande
Marcus Cornelius Bernardus Catharina Paradé
Wim Bert Griet Schepens
Johannes Wilhelmus John F. Thuring
Marcel Viellevoye
Weimei Sun
Lieven Meerpoel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to US18/187,463 priority Critical patent/US20230330127A1/en
Publication of US20230330127A1 publication Critical patent/US20230330127A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the present invention relates to novel 6-6 bicyclic aromatic ring substituted nucleoside analogues useful as PRMT5 inhibitors.
  • the invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
  • PRMT5 also described as Hsl7, Jbp1, Skb1, Capsuleen or Dart5
  • Hsl7, Jbp1, Skb1, Capsuleen or Dart5 is one of the major methyltransferases responsible for mono- and symmetric dimethylation of arginines.
  • Post-translational arginine methylation on histones and non-histone proteins seems to be crucial for a variety of biological processes, like genome organisation, transcription, differentiation, spliceosome function, signal transduction and regulation of cell-cycle progression, stem cells and T-cell fate [Stopa, N. et al., Cell Mol Life Sci, 2015. 72(11): p. 2041-59] [Geoghegan, V. et al., Nat Commun, 2015. 6: p. 6758].
  • Metazoan PRMT5 forms a functional complex with the methylosome protein 50 (MEP50) also named as Wdr77, androgen receptor coactivator p44 and Valois. Both, elevated PRMT5-MEP50 protein level and cytoplasmic accumulation are implicated in cancer tumorigenesis and have recently been correlated with poor clinical outcome [Shilo, K. et al., Diagn Pathol, 2013. 8: p. 201]. Cellular rescue experiments that addressed both the catalytic and scaffold function of the PRMT5-MEP50 complex, beside comprehensive enzymological studies have substantiate the oncogenic link between protein level, localisation and enzymatic function [Gu, Z. et al., Biochem J, 2012. 446(2): p.
  • PRMT5 is a member of the type II PRMT subfamily that utilises S-adenosylmethionine (SAM) to generate symmetric dimethylated arginine on histones and non-histone protein substrates and S-adenosylhomocysteine (SAH).
  • SAM S-adenosylmethionine
  • SAH S-adenosylhomocysteine
  • PRMT5 human hetereo-octameric complex
  • MEP50 histone H4 peptide substrate illustrated the mechanism of methylation and substrate recognition [Antonysamy, S. et al., Proc Natl Acad Sci U S A, 2012. 109(44): p. 17960-5].
  • the regulation of PRMT5 activity occurs through a vast number of different binding partners, post-translational modification cross talk, miRNAs and subcellular localisation.
  • Non-histone methylation can occur either in the cytoplasm or nucleus dependent on the cellular localisation of PRMT5.
  • Further evidence for PRMT5 involved in splicing has been provided by the conditional PRMT5 knockout in mouse neural stem cells. Cells that lack PRMT5 showed a selective retention of introns and skipping of exons with weak 5′ donor sites [Bezzi, M. et al., Genes Dev, 2013. 27(17): p. 1903-16].
  • PRMT5 influences key pathways involved in cell fate and homeostasis by direct methylation of key signalling nodules like p53 [Jansson, M. et al., Nat Cell Biol, 2008. 10(12): p. 1431-9], EGFR [Hsu, J.M. et al., Nat Cell Biol, 2011. 13(2): p. 174-81], CRAF [Andreu-Perez, P. et al., Sci Signal, 2011. 4(190): p. ra58], PI3K/AKT [Wei, T.Y. et al., Cell Signal, 2014. 26(12): p. 2940-50], NF ⁇ B [Wei, H. et al., Proc Natl Acad Sci U S A, 2013. 110(33): p. 13516-21].
  • PRMT5 is one of the major sym-Arg methyltransferases and involved in a multitude of cellular processes, an increased protein expression appears to be an important factor in its tumourigenicity.
  • MCL mantle cell lymphoma
  • miRNAs the translation of PRMT5 in mantle cell lymphoma (MCL) seems to be regulated by miRNAs.
  • MCL cells show less mRNA and a slower transcription rate of PRMT5 than normal B lymphocytes, the PRMT5 level and the methylation of H3R8 and H4R3 are significantly increased [Pal, S. et al., EMBO J, 2007. 26(15): p. 3558-69].
  • PRMT5 is considered as a clinical relevant target, very few selective PRMT5 inhibitors have been published, yet. Very recently, a novel sub-nanomolar potent PRMT5 inhibitor (EPZ015666) with anti-tumour activity in multiple MCL xenograft models has been described to be the first chemical probe suitable for further validation of PRMT5′s biology and role in cancer [Chan-Penebre, E. et al., Nat Chem Biol, 2015. 11(6): p. 432-7].
  • WO2014100695A1 discloses compounds useful for inhibiting PRMT5 activity; Methods of using the compounds for treating PRMT5-mediated disorders are also described.
  • WO2014100730A1 discloses PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof.
  • WO2003070739 discloses partial and full agonists of A1 adenosine receptors, their preparation, and their therapeutic use.
  • WO2012082436 discloses compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity.
  • WO2014100719 discloses PRMT5 inhibitors and uses thereof.
  • WO03074083 discloses combination therapies that selectively kill methylthioadenosine phosphorylase deficient cells. Analogs of MTA are described herein as anti-toxicity agents.
  • WO2012075500 discloses 7-deazapurine modulators of histone methyltransferase.
  • WO2014035140 discloses compounds and compositions for modulating histone methyltransferase activity.
  • WO2015200680 describes PRMT5 inhibitors and uses thereof.
  • the compounds of the present invention are structurally different and may have improved properties such as for example improved potency, or improved pharmacokinetics (PK) and oral bioavailability, compared with compounds disclosed in the prior art.
  • improved potency or improved pharmacokinetics (PK) and oral bioavailability, compared with compounds disclosed in the prior art.
  • PK pharmacokinetics
  • the compounds of the present invention are useful as PRMT5 inhibitors.
  • the compounds according to the invention and compositions thereof may be useful for the treatment or prevention, in particular for the treatment, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.
  • the present invention concerns novel compounds of Formula (I):
  • the present invention also concerns methods for the preparation of compounds of the present invention and pharmaceutical compositions comprising them.
  • the compounds of the present invention were found to inhibit PRMT5 per se or can undergo metabolism to a (more) active form in vivo (prodrugs), and therefore may be useful in the treatment or prevention, in particular in the treatment, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.
  • diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.
  • the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof may be suitable in the treatment or prevention, in particular in the treatment, of any one of the diseases or conditions mentioned hereinbefore or hereinafter, in particular cancer.
  • the present invention also concerns the use of compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the inhibition of PRMT5, for the treatment or prevention of any one of the diseases or conditions mentioned hereinbefore or hereinafter, in particular cancer.
  • substituted is used in the present invention, it is meant, unless otherwise is indicated or is clear from the context, to indicate that one or more hydrogens, in particular from 1 to 3 hydrogens, preferably 1 or 2 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using “substituted” are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
  • substituents When two or more substituents are present on a moiety they may, unless otherwise is indicated or is clear from the context, replace hydrogens on the same atom or they may replace hydrogen atoms on different atoms in the moiety.
  • C x-y refers to the number of carbon atoms in a given group.
  • a C 1-4 alkyl group contains from 1 to 4 carbon atoms
  • a C 1-3 alkyl group contains from 1 to 3 carbon atoms and so on.
  • halo as a group or part of a group is generic for fluoro, chloro, bromo, iodo unless otherwise is indicated or is clear from the context.
  • C 1-4 alkyl refers to a hydrocarbyl radical of Formula C n H 2n+1 wherein n is a number ranging from 1 to 4.
  • C 1-4 alkyl groups comprise from 1 to 4 carbon atoms, preferably from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms.
  • C 1-4 alkyl groups may be linear or branched and may be substituted as indicated herein. When a subscript is used herein following a carbon atom, the subscript refers to the number of carbon atoms that the named group may contain.
  • C 1-4 alkyl includes all linear, or branched alkyl groups with between 1 and 4 carbon atoms, and thus includes methyl, ethyl, n-propyl, i-propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n-butyl, isobutyl and tert-butyl), and the like.
  • C 1-4 alkoxy or ‘C 1-4 alkyloxy’ as a group or part of a group refers to a radical having the Formula -OR c wherein R c is C 1-4 alkyl.
  • suitable C 1-4 alkyloxy include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec-butyloxy and tert-butyloxy.
  • C 2-4 alkenyl as used herein as a group or part of a group represents a straight or branched chain hydrocarbon group containing from 2 to 4 carbon atoms and containing a carbon carbon double bond such as, but not limited to, ethenyl, propenyl, butenyl, 1-propen-2-yl, and the like.
  • C 2-6 alkenyl as used herein as a group or part of a group represents a straight or branched chain hydrocarbon group containing from 2 to 6 carbon atoms and containing a carbon carbon double bond such as, but not limited to, ethenyl, propenyl, butenyl, pentenyl, 1-propen-2-yl, hexenyl and the like.
  • C 3-6 cycloalkyl as used herein as a group or part of a group represents cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • R 12 is a saturated ring.
  • R 12 are 1-piperidinyl, 1-pyrrolidinyl, 1-morpholinyl, 1-azetidinyl, and the like.
  • a substituent on a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms may replace any hydrogen atom on a ring carbon atom or where possible on a ring nitrogen atom (in which case a hydrogen on a nitrogen atom may be replaced by a substituent).
  • a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms may be attached to the remainder of the molecule of Formula (I) through any available ring carbon or nitrogen atom as appropriate, if not otherwise specified. It will be clear for the skilled person that the same is applicable to the 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms (as in the definition of R 13 ).
  • a carbonyl group is present in said bicyclic aromatic ring system as exemplified by the structure shown below:
  • Ar group being a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom, are shown below:
  • the 10 members of the 10-membered Ar group are 10 carbon atoms, 9 carbon atoms and 1 nitrogen atom, or 8 carbon atoms and 2 nitrogen atoms.
  • Ar is optionally substituted according to any of the embodiments.
  • subject refers to an animal, preferably a mammal (e.g. cat, dog, primate or human), more preferably a human, who is or has been the object of treatment, observation or experiment.
  • a mammal e.g. cat, dog, primate or human
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medicinal doctor or other clinician, which includes alleviation or reversal of the symptoms of the disease or disorder being treated.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
  • treatment is intended to refer to all processes wherein there may be a slowing, interrupting, arresting or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.
  • tautomer or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
  • proton tautomers also known as prototropic tautomers
  • Valence tautomers include interconversions by reorganisation of some of the bonding electrons.
  • R, S a particular configuration
  • any particular chiral atom is not specified in the structures shown herein, then all stereoisomers are contemplated and included as the compounds of the invention, either as a pure stereoisomer or as a mixture of two or more stereoisomers.
  • compound of Formula (I) is meant to include the stereoisomers thereof and the tautomeric forms thereof.
  • stereochemistry as mentioned in the previous paragraph, is specified by bonds which are shown as solid wedged or hashed wedged bonds, or are otherwise indicated as having a particular configuration (e.g. R, S), then that stereoisomer is so specified and defined. It will be clear this also applies to subgroups of Formula (I).
  • stereoisomers “stereoisomeric forms” or “stereochemically isomeric forms” hereinbefore or hereinafter are used interchangeably.
  • Enantiomers are stereoisomers that are non-superimposable mirror images of each other.
  • a 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.
  • Atropisomers are stereoisomers which have a particular spatial configuration, resulting from a restricted rotation about a single bond, due to large steric hindrance. All atropisomeric forms of the compounds of Formula (I) are intended to be included within the scope of the present invention.
  • Diastereomers are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration. Substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration; for example if a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration. Therefore, the invention includes enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.
  • the absolute configuration is specified according to the Cahn-Ingold-Prelog system.
  • the configuration at an asymmetric atom is specified by either R or S.
  • Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
  • resolved enantiomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
  • stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers.
  • a compound of Formula (I) is for instance specified as (R)
  • a compound of Formula (I) is for instance specified as E
  • Z Z isomer
  • a compound of Formula (I) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.
  • salts of the compounds of Formula (I) and solvates thereof are those wherein the counterion is pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • salts include acid addition salts and base addition salts.
  • Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration).
  • Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
  • compositions of Formula (I) and solvates thereof are able to form.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e.
  • salt forms can be converted by treatment with an appropriate base into the free base form.
  • the compounds of Formula (I) and solvates thereof containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g.
  • primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • the salt form can be converted by treatment with acid into the free acid form.
  • prodrugs are also included within the scope of the invention.
  • prodrug of a relevant compound of the invention includes any compound that, following oral or parenteral administration, in particular oral administration, is metabolised in vivo to a form that compound in an experimentally-detectable amount, and within a predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily)).
  • parenteral administration includes all forms of administration other than oral administration, in particular intravenous (IV), intramuscular (IM), and subcutaneous (SC) injection.
  • Prodrugs may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is administered to a mammalian subject.
  • prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxyl functional groups, N-acyl derivatives and N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. “Design of Prodrugs” p. 1-92, Elesevier, New York-Oxford (1985).
  • solvate comprises the hydrates and solvent addition forms which the compounds of Formula (I) are able to form, as well as pharmaceutically acceptable addition salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • the compounds of the invention as prepared in the processes described below may be synthesized in the form of mixtures of enantiomers, in particular racemic mixtures of enantiomers, that can be separated from one another following art-known resolution procedures.
  • a manner of separating the enantiomeric forms of the compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof involves liquid chromatography using a chiral stationary phase.
  • Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • the present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature).
  • isotopes and isotopic mixtures of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form.
  • Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 122 I, 123 I, 125 I, 131 I, 75 Br, 76 Br, 77 Br and 82 Br.
  • the radioactive isotope is selected from the group of 2 H, 3 H, 11 C and 18 F. More preferably, the radioactive isotope is 2 H.
  • deuterated compounds are intended to be included within the scope of the present invention.
  • Certain isotopically-labeled compounds of the present invention are useful in compound and for substrate tissue distribution assays.
  • Tritiated ( 3 H) and carbon-14 ( 14 C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Positron emitting isotopes such as 15 O, 13 N, 11 C and 18 F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy.
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (1), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
  • the present invention concerns novel compounds of Formula (I), wherein
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
  • the present invention concerns novel compounds of Formula (I), wherein
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (1), wherein
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • the present invention concerns novel compounds of Formula (I), wherein
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 1 and R 2 represent hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents —O—.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents —CH 2 — or —CF 2 —; in particular wherein Y represents —CH 2 —.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein maximum one of Q 1 and Q 2 represents N.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q 1 represents CR 6a ; and Q 2 represents CR 6b ; in particular wherein Q 1 represents CH; and Q 2 represents CH.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents (a-1); Q 1 represents CR 6a ; and Q 2 represents CR 6b ; in particular wherein Q 1 represents CH; and Q 2 represents CH.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-4).
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 1 and R 2 represent hydrogen; and Y represents —O—.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3).
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2).
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-4).
  • the present invention relates to those compounds of Formula (1) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system of Formula (a-1).
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 1 and R 2 represent hydrogen; Y represents —O—; and Het represents a bicyclic aromatic heterocyclic ring system of Formula (a-1).
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents an optionally substituted 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that the nitrogen atom does not replace one of the two fused carbon atoms.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one or two substituents according to any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one substituent according to any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 3a , R 3c , R 3b represent hydrogen, when R 4a , R 4c , R 4b are different from hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 3a , R 3c , R 3b , R 3d , R 3e represent hydrogen, when R 4a , R 4c , R 4b , R 4d , R 4c , R 4f , R 4g are different from hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4a , R 4c , R 4b represent hydrogen, when R 3a , R 3c , R 3b are different from hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4a , R 4c , R 4b , R 4d , R 4c , R 4f , R 4g represent hydrogen, when R 3a , R 3c , R 3b , R 3d , R 3e are different from hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted according to any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted according to any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted according to any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted according to any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted according to any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is other than
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Ar is substituted with one, two, three or four substituents each independentlyselected from the group consisting of halo, —NH 2 , -NH-C 1-4 alkyl, -N(C 1-4 alkyl) 2 , -NHR 10d , -NR 10c R 10d .
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Ar is substituted in the position indicated by ⁇ with a halo substituent; in particular chloro or bromo; more in particular bromo.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represent (a-1); Q 1 represents CR 6a ; Q 2 represents CR 6b ; and Ar represents
  • Ar is substituted in the position indicated by ⁇ with a halo substituent; in particular chloro or bromo; more in particular bromo.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is substituted with one substituent selected from the group consisting of —NH 2 , -NH-C 1-4 alkyl -N(C 1-4 alkyl) 2 , -NHR 10d , -NR 10c R 10d ; and wherein Ar is optionally substituted with another substituent selected from the list of substituents on Ar in any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 5b , R 5g and R 5h represent hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q 1 represents CR 6a ; and Q 2 represents CR 6b .
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents —O—; Q 1 represents CR 6a ; and Q 2 represents CR 6b .
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents —O—; Q 1 represents CH; and Q 2 represents CR H .
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q 2 represents CR 6b .
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR 5a R 5b -.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents —O—CH 2 —.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR 5a R 5b -; X represents —O—; and R 5a and R 5b represent hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents —O— or -NR 11 -; in particular X represents —O—.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 7a and R 7b represent hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents (a-1); R 3a represents -NR 7a R 7b ; and R 7a and R 7b represent hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 3a , R 3b and R 3c represent other than halo.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 3a , R 3c , R 3b , R 3d and R 3e represent other than halo.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R 3a , R 3b and R 3c represent —NH 2 .
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • each Ar is optionally substituted in position a with a substituent selected from the group consisting of —NH 2 , -NH-C 1-4 alkyl, -N(C 1-4 alkyl) 2 , -NHR 10d , and -NR 10c R 10d ; and wherein Ar is optionally substituted in another position with a halo substituent.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-a1):
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-a1):
  • R 3a represents —NH 2 ; and R 4a represents hydrogen.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-a1):
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-a1):
  • the present invention concerns novel compounds of Formula (I-a1)
  • the present invention concerns novel compounds of Formula (I-a1)
  • the present invention concerns novel compounds of Formula (I-a1)
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR 5a R 5b - or —CH 2 CH 2 —.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR 5a R 5b - or —CH 2 CH 2 —;
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents —O—.
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
  • the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents —CH 2 —; and Z represents —CH 2 CH 2 —.
  • the present invention relates to a subgroup of Formula (I) as defined in the general reaction schemes.
  • the compound of Formula (I) is selected from the group consisting of compounds 2 and 58.
  • the compound of Formula (I) is selected from the group consisting of compounds 2 and 80.
  • the compound of Formula (I) is selected from the group consisting of compounds 74, 75, 76, 77, 78, 79, 80 and 81.
  • the compound of Formula (I) is selected from the group consisting of compounds 2, 58, 74, 75, 76, 77, 78, 79, 80, 81, 154, 159, 235, 240 and 247.
  • the compound of Formula (I) is selected from the group consisting of compounds 2 and 58, and pharmaceutically acceptable addition salts, and solvates thereof.
  • the compound of Formula (I) is selected from the group consisting of compounds 2 and 80, and pharmaceutically acceptable addition salts, and solvates thereof.
  • the compound of Formula (I) is selected from the group consisting of compounds 74, 75, 76, 77, 78, 79, 80 and 81, and pharmaceutically acceptable addition salts, and solvates thereof.
  • the compound of Formula (I) is selected from the group consisting of compounds 2, 58, 74, 75, 76, 77, 78, 79, 80, 81, 154, 159, 235, 240 and 247 and pharmaceutically acceptable addition salts, and solvates thereof.
  • the compound of Formula (I) is selected from the group consisting of any of the exemplified compounds, and the free bases, the pharmaceutically acceptable addition salts, and the solvates thereof.
  • references to Formula (I) also include all other sub-groups and examples thereof as defined herein.
  • compounds of the present invention may also be prepared by analogous reaction protocols as described in the general schemes below, combined with standard synthetic processes commonly used by those skilled in the art of organic chemistry.
  • reaction work-up refers to the series of manipulations required to isolate and purify the product(s) of a chemical reaction such as for example quenching, column chromatography, extraction).
  • microwave heating may be used instead of conventional heating to shorten the overall reaction time.
  • the starting materials is available as a salt form
  • a base such as for example N,N-diisopropylethylamine (DIPEA).
  • DIPEA N,N-diisopropylethylamine
  • LG 1 is defined as a suitable leaving group such as for example halogen
  • LG 2 is defined as a suitable leaving group such as for example halogen or -SCH 3 .
  • LG 3 is defined as a leaving group such as halogen and -SCH 3 . All other variables in Scheme 1 are defined according to the scope of the present invention.
  • step 1 When R 3a , R 3b or R 3c is halogen, step 1 can be skipped.
  • R 3a , R 3b or R 3c is NR 7a R 7b , in the presence of a suitable amine of formula HNR 7a R 7b , with a suitable solvent such as for example, H 2 O, MeOH, or EtOH, at a suitable temperature such as for example between 100-130° C. typicall under microwave conditions or using an autoclave vessel for heating.
  • a suitable solvent such as for example, H 2 O, MeOH, or EtOH
  • R 3a , R 3b or R 3c is -O-C 1-4 alkyl, in the presence of a suitable HO-C 1-4 alkyl, with a suitable base such as for example NaH, potassium tert-butoxide (tBuOK) in a suitable solvent such as for example tetrahydrofuran (THF) at a suitable temperature.
  • a suitable base such as for example NaH, potassium tert-butoxide (tBuOK)
  • THF tetrahydrofuran
  • R 3a , R 3b or R 3c is hydrogen, under hydrogenation conditions: H 2 -gas atmosphere in the presence of a catalyst such as for example Raney Ni, Pd/C (for example 5 wt% or 10 wt%) or Pt/C (for example 5 wt%) in a suitable solvent such as for example methanol (MeOH), ethanol (EtOH) or THF;
  • a catalyst such as for example Raney Ni, Pd/C (for example 5 wt% or 10 wt%) or Pt/C (for example 5 wt%) in a suitable solvent such as for example methanol (MeOH), ethanol (EtOH) or THF;
  • R 3a , R 3b or R 3c is C 1-4 alkyl, in the presence of a suitable boronic acid or ester such as for example methylboronic acid with a suitable catalyst such as for example 1,1′-bis(diphenylphosphino)ferrocene and with with a suitable base such as for example K 3 PO 4 in a in a suitable solvent mixture such as for example dioxane/ H 2 O ratio 5 to 1 at a suitable temperature such as for example 100° C.;
  • a suitable boronic acid or ester such as for example methylboronic acid
  • a suitable catalyst such as for example 1,1′-bis(diphenylphosphino)ferrocene
  • a suitable base such as for example K 3 PO 4
  • a suitable solvent mixture such as for example dioxane/ H 2 O ratio 5 to 1 at a suitable temperature such as for example 100° C.
  • a suitable acid such as for example 4M HCl in dioxane or 4M HCl in MeOH
  • a suitable solvent such as for example MeOH
  • a suitable acid such as for example trifluoroacetic acid (TFA) in dichloromethane (DCM) at a suitable temperature, or acetic acid in THF and water at a suitable temperature such as for example room temperature.
  • THF trifluoroacetic acid
  • a base such as for example K 2 CO 3 , trietylamine (Et 3 N) or DIPEA, in a suitable solvent such as CH 3 CN, DCM or N,N-dimethylacetamide (DMA).
  • a base such as for example K 2 CO 3 , trietylamine (Et 3 N) or DIPEA
  • a suitable solvent such as CH 3 CN, DCM or N,N-dimethylacetamide (DMA).
  • a base such as for example K 2 CO 3 , Et 3 N or DIPEA
  • a suitable solvent such as CH 3 CN, DCM or N,N-dimethylacetamide (DMA).
  • LG 1 is defined as a leaving group such as for example halogen
  • LG 2 is defined as a leaving group such as for example halogen or —SCH 3
  • LG 3 is defined as leaving group such as halogen or —SCH 3 . All other variables in Scheme 5 are defined according to the scope of the present invention.
  • a base such as for example K 2 CO 3 , Et 3 N or DIPEA
  • a suitable solvent such as CH 3 CN, DCM or N,N-dimethylacetamide (DMA).
  • reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, trituration and chromatography.
  • the chirally pure forms of the compounds of Formula (I) form a preferred group of compounds. It is therefore that the chirally pure forms of the intermediates and their salt forms are particularly useful in the preparation of chirally pure compounds of Formula (I). Also enantiomeric mixtures of the intermediates are useful in the preparation of compounds of Formula (I) with the corresponding configuration.
  • compounds of the present invention bind to the PRMT5 enzyme, and competitively with natural substrate SAM (S-adenosyl-L-methionine), to inhibit such enzyme.
  • SAM S-adenosyl-L-methionine
  • the compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries and the like.
  • diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries and the like.
  • the compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as allergy, asthma, hematopoietic cancer, lung cancer, prostate cancer, melanoma, metabolic disorder, diabetes, obesity, blood disorder, sickle cell anemia, and the like.
  • diseases such as allergy, asthma, hematopoietic cancer, lung cancer, prostate cancer, melanoma, metabolic disorder, diabetes, obesity, blood disorder, sickle cell anemia, and the like.
  • the compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a proliferative disorder, such as an autoimmune disease, cancer, a benign neoplasm, or an inflammatory disease.
  • diseases such as a proliferative disorder, such as an autoimmune disease, cancer, a benign neoplasm, or an inflammatory disease.
  • the compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a metabolic disorder comprising diabetes, obesity; a proliferative disorder comprising cancer, hematopoietic cancer, lung cancer, prostate cancer, melanoma, or pancreatic cancer; blood disorder; hemoglobinopathy: sickle cell anemia; ⁇ -thalessemia, an inflammatory disease, and autoimmune disease e.g. rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, diarrhea, gastroesophageal reflux disease, and the like.
  • diseases such as a metabolic disorder comprising diabetes, obesity; a proliferative disorder comprising cancer, hematopoietic cancer, lung cancer, prostate cancer, melanoma, or pancreatic cancer; blood disorder; hemoglobinopathy: sickle cell anemia; ⁇ -thalessemia, an inflammatory disease, and autoimmune disease e.g. rheum
  • the inhibition of PRMT5 by a provided compound may be useful in treating or preventing, in particular treating, the following non-limiting list of cancers: breast cancer, lung cancer, esophageal cancer, bladder cancer, hematopoietic cancer, lymphoma, medulloblastoma, rectum adenocarcinoma, colon adenocarcinoma, gastric cancer, pancreatic cancer, liver cancer, adenoid cystic carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma, brain tumors, hepatocellular carcinoma, renal cell carcinoma, melanoma, oligodendroglioma, ovarian clear cell carcinoma, and ovarian serous cystadenoma.
  • cancers breast cancer, lung cancer, esophageal cancer, bladder cancer, hematopoietic cancer, lymphoma, medulloblastoma, rectum adenocarcinoma, colon adenocarcinoma,
  • metabolic disorders which may be treated or prevented, in particular treated, include, but are not limited to, diabetes or obesity.
  • blood disorders which may be treated or prevented, in particular treated, include, but are not limited to, hemoglobinopathy, such as sickle cell disease or ⁇ -thalassemia.
  • cancers which may be treated or prevented, in particular treated, include, but are not limited to, acoustic neuroma, adenocarcinoma, adrenal gland cancer, anal cancer, angiosarcoma (e.g., lymphangio sarcoma, lymphangioendothelio sarcoma, hemangio sarcoma), appendix cancer, benign monoclonal gammopathy, biliary cancer (e.g., cholangiocarcinoma), bladder cancer, breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast), brain cancer (e.g., meningioma; glioma, e.g., astrocytoma, oligodendroglioma; medulloblastoma), bronchus cancer, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinom
  • Wilms tumor, renal cell carcinoma), liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma), lung cancer (e.g., bronchogenic carcinoma, non-small cell lung cancer (NSCLC), squamous lung cancer (SLC), adenocarcinoma of the lung, Lewis lung carcinoma, lung neuroendocrine tumors: typical carcinoid, atypical carcinoid, small cell lung cancer (SCLC), and large cell neuroendocrine carcinoma), leiomyosarcoma (LMS), mastocytosis (e.g., systemic mastocytosis), myelodysplastic syndromes (MDS), mesothelioma, myeloproliferative disorder (MPD) (e.g., polycythemia Vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a.
  • MMD myeloproliferative disorder
  • MPD
  • myelofibrosis MF
  • chronic idiopathic myelofibrosis chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)
  • neuroblastoma e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis
  • neuroendocrine cancer e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor
  • osteosarcoma ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma, pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors), penile cancer (e.g., Paget’s disease of the pen
  • neurodegenerative diseases which may be treated or prevented, in particular treated, include, but are not limited to, motor neurone disease, progressive supranuclear palsy, corticobasal degeneration, Pick’s disease, Alzheimer’s disease, AIDS-related dementia, Parkinson’s disease, amyotropic lateral sclerosis, retinitis pigmentosa, spinal muscular atropy, and cerebellar degeneration.
  • cardiovascular diseases which may be treated or prevented, in particular treated, include, but are not limited to, cardiac hypertrophy, restenosis, atherosclerosis, and glomerulonephritis.
  • inflammatory diseases which may be treated or prevented, in particular treated, include, but are not limited to, inflammation associated with acne, anemia (e.g., aplastic anemia, haemolytic autoimmune anaemia), rhinitis, asthma, arteritis (e.g., polyarteritis, temporal arteritis, periarteritis nodosa, Takayasu’s arteritis), arthritis (e.g., crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis and Reiter’s arthritis), upper respiratory tract disease, ankylosing spondylitis, amylosis, amyotrophic lateral sclerosis, autoimmune diseases, allergies or allergic reactions, atherosclerosis, bronchitis, bursitis, chronic prostatitis, conjunctivitis, Chagas disease, chronic obstructive pulmonary disease, diverticulitis, cermatomyositis
  • the inflammatory disease is an acute inflammatory disease (e.g., for example, inflammation resulting from infection).
  • the inflammatory disease is a chronic inflammatory disease (e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease).
  • the compounds may also be useful in treating inflammation associated with trauma and non-inflammatory myalgia.
  • the compounds may also be useful in treating inflammation associated with cancer.
  • autoimmune diseases which may be treated or prevented, in particular treated, include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren’s syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet’s disease, haemolytic autoimmune anaemias, amyotrophic lateral sclerosis, amylosis, multiple sclerosis, acute painful shoulder, psoriatic, and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin condition (e.g., psoriasis, eczema, eczema hypersensitivity reactions, bums, dermatitis, pruritus (itch)), enuresis, eosinophilic disease, gastrointestinal disorder
  • a provided compound may be useful in somatic cell reprogramming, such as reprogramming somatic cells into stem cells.
  • a provided compound may be useful in germ cell development, and are thus envisioned useful in the areas of reproductive technology and regenerative medicine.
  • diseases which may be treated or prevented, in particular treated include, but are not limited to, ischemic injury associated myocardial infarctions, immunological diseases, stroke, arrhythmia, toxin-induced or alcohol related liver diseases, aspirin-sensitive rhinosinusitis, cystic fibrosis, cancer pain, and haematological diseases, for example chronic anemia and aplastic anemia.
  • the compounds of the present invention may also have therapeutic applications in sensitising tumour cells for radiotherapy and chemotherapy.
  • the compounds of the present invention may be used as “radiosensitizer” and/or “chemosensitizer” or can be given in combination with another “radiosensitizer” and/or “chemosensitizer”.
  • radiosensitizer is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to ionizing radiation and/or to promote the treatment of diseases which are treatable with ionizing radiation.
  • chemosensitizer is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of cells to chemotherapy and/or promote the treatment of diseases which are treatable with chemotherapeutics.
  • hypoxic cell radiosensitizers e.g., 2- nitroimidazole compounds, and benzotriazine dioxide compounds
  • non-hypoxic cell radiosensitizers e.g., halogenated pyrimidines
  • radiosensitizers include, but are not limited to, the following: metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, E09, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5- iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives of the same.
  • Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent.
  • photodynamic radiosensitizers include the following, but are not limited to: hematoporphyrin derivatives, Photofrin, benzoporphyrin derivatives, tin etioporphyrin, pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.
  • Radiosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of radiosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumour with or without additional radiation; or other therapeutically effective compounds for treating cancer or other diseases.
  • Chemosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of chemosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumour or other therapeutically effective compounds for treating cancer or other disease.
  • Calcium antagonists for example verapamil, are found useful in combination with antineoplastic agents to establish chemosensitivity in tumor cells resistant to accepted chemotherapeutic agents and to potentiate the efficacy of such compounds in drug-sensitive malignancies.
  • the compounds of the present invention might also reduce the risk of cancer recurrence.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for use as a medicament.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for use in the inhibition of PRMT5 activity.
  • the compounds of the present invention can be “anti-cancer agents”, which term also encompasses “anti-tumor cell growth agents” and “anti-neoplastic agents”.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for use in the treatment of diseases mentioned above.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the treatment or prevention, in particular in the treatment, of PRMT5 mediated diseases or conditions.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the inhibition of PRMT5.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the treatment or prevention, in particular for the treatment, of any one of the disease conditions mentioned hereinbefore.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the treatment of any one of the disease conditions mentioned hereinbefore.
  • the invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, can be administered to mammals, preferably humans, for the treatment or prevention of any one of the diseases mentioned hereinbefore.
  • Said methods comprise the administration, i.e. the systemic or topical administration, preferably oral administration, of an effective amount of a compound of Formula (I) or a pharmaceutically acceptable addition salt, or a solvate thereof, to warm-blooded animals, including humans.
  • An effective therapeutic daily amount would be from about 0.005 mg /kg to 50 mg/kg, in particular 0.01 mg/kg to 50 mg/kg body weight, more in particular from 0.01 mg/kg to 25 mg/kg body weight, preferably from about 0.01 mg/kg to about 15 mg/kg, more preferably from about 0.01 mg/kg to about 10 mg/kg, even more preferably from about 0.01 mg/kg to about 1 mg/kg, most preferably from about 0.05 mg/kg to about 1 mg/kg body weight.
  • a particular effective therapeutic daily amount might be from about 0.01 to 1.00 g twice a day (BID), more in particular 0.30 to 0.85 g BID; even more in particular 0.40 g BID.
  • BID twice a day
  • the amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutically effect will of course, vary on case-by-case basis, for example with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated.
  • a method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day.
  • the compounds according to the invention are preferably formulated prior to administration.
  • suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.
  • the compounds of the present invention may be administered alone or in combination with one or more additional therapeutic agents.
  • Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and one or more additional therapeutic agents, as well as administration of the compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and each additional therapeutic agents in its own separate pharmaceutical dosage formulation.
  • a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage formulations.
  • the active ingredient While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition.
  • the present invention further provides a pharmaceutical composition and, as active ingredient, a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof.
  • the present invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof.
  • the carrier or diluent must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • the subject compounds may be formulated into various pharmaceutical forms for administration purposes.
  • the compounds according to the invention in particular the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • Injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • Injectable solutions containing a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, may be formulated in an oil for prolonged action.
  • Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils.
  • Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid or base addition salts of compounds of Formula (I) due to their increased water solubility over the corresponding base or acid form, are more suitable in the preparation of aqueous compositions.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • ⁇ -, ⁇ - or ⁇ -cyclodextrins or their derivatives in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl- ⁇ -cyclodextrin.
  • co-solvents such as alcohols may improve the solubility and/or the stability of the compounds according to the invention in pharmaceutical compositions.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99% by weight, more preferably from 0.1 to 70% by weight, even more preferably from 0.1 to 50% by weight of the compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and from 1 to 99.95% by weight, more preferably from 30 to 99.9% by weight, even more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
  • a combination of a compound of the present invention with another anticancer agent is envisaged, especially for use as a medicine, more specifically for use in the treatment of cancer or related diseases.
  • the compounds of the invention may be advantageously employed in combination with antibody based immune cell redirection, for example T-cell/neutrophil redirection. This can be achieved for example by the use of bispecific monoclonal antibodies or artificial T-cell receptors.
  • the compounds of the invention may be advantageously employed in combination with one or more other medicinal agents, more particularly, with other anti-cancer agents or adjuvants in cancer therapy.
  • anti-cancer agents or adjuvants supporting agents in the therapy
  • the present invention further relates to a product containing as first active ingredient a compound according to the invention and as further active ingredient one or more anticancer agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.
  • the one or more other medicinal agents and the compound according to the present invention may be administered simultaneously (e.g. in separate or unitary compositions) or sequentially in either order. In the latter case, the two or more compounds will be administered within a period and in an amount and manner that is sufficient to ensure that an advantageous or synergistic effect is achieved.
  • the preferred method and order of administration and the respective dosage amounts and regimes for each component of the combination will depend on the particular other medicinal agent and compound of the present invention being administered, their route of administration, the particular tumour being treated and the particular host being treated.
  • the optimum method and order of administration and the dosage amounts and regime can be readily determined by those skilled in the art using conventional methods and in view of the information set out herein.
  • the weight ratio of the compound according to the present invention and the one or more other anticancer agent(s) when given as a combination may be determined by the person skilled in the art. Said ratio and the exact dosage and frequency of administration depends on the particular compound according to the invention and the other anticancer agent(s) used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
  • a particular weight ratio for the present compound of Formula (I) and another anticancer agent may range from 1 ⁇ 10 to 10/1, more in particular from 1 ⁇ 5 to 5/1, even more in particular from 1 ⁇ 3 to 3/1.
  • the platinum coordination compound is advantageously administered in a dosage of 1 to 500 mg per square meter (mg/m 2 ) of body surface area, for example 50 to 400 mg/m 2 , particularly for cisplatin in a dosage of about 75 mg/m 2 and for carboplatin in about 300 mg/m 2 per course of treatment.
  • the taxane compound is advantageously administered in a dosage of 50 to 400 mg per square meter (mg/m 2 ) of body surface area, for example 75 to 250 mg/m 2 , particularly for paclitaxel in a dosage of about 175 to 250 mg/m 2 and for docetaxel in about 75 to 150 mg/m 2 per course of treatment.
  • the camptothecin compound is advantageously administered in a dosage of 0.1 to 400 mg per square meter (mg/m 2 ) of body surface area, for example 1 to 300 mg/m 2 , particularly for irinotecan in a dosage of about 100 to 350 mg/m 2 and for topotecan in about 1 to 2 mg/m 2 per course of treatment.
  • the anti-tumour podophyllotoxin derivative is advantageously administered in a dosage of 30 to 300 mg per square meter (mg/m 2 ) of body surface area, for example 50 to 250 mg/m 2 , particularly for etoposide in a dosage of about 35 to 100 mg/m 2 and for teniposide in about 50 to 250 mg/m 2 per course of treatment.
  • the anti-tumour vinca alkaloid is advantageously administered in a dosage of 2 to 30 mg per square meter (mg/m 2 ) of body surface area, particularly for vinblastine in a dosage of about 3 to 12 mg/m 2 , for vincristine in a dosage of about 1 to 2 mg/m 2 , and for vinorelbine in dosage of about 10 to 30 mg/m 2 per course of treatment.
  • the anti-tumour nucleoside derivative is advantageously administered in a dosage of 200 to 2500 mg per square meter (mg/m 2 ) of body surface area, for example 700 to 1500 mg/m 2 , particularly for 5-FU in a dosage of 200 to 500 mg/m 2 , for gemcitabine in a dosage of about 800 to 1200 mg/m 2 and for capecitabine in about 1000 to 2500 mg/m 2 per course of treatment.
  • the alkylating agents such as nitrogen mustard or nitrosourea is advantageously administered in a dosage of 100 to 500 mg per square meter (mg/m 2 ) of body surface area, for example 120 to 200 mg/m 2 , particularly for cyclophosphamide in a dosage of about 100 to 500 mg/m 2 , for chlorambucil in a dosage of about 0.1 to 0.2 mg/kg, for carmustine in a dosage of about 150 to 200 mg/m 2 , and for lomustine in a dosage of about 100 to 150 mg/m 2 per course of treatment.
  • mg/m 2 body surface area
  • cyclophosphamide in a dosage of about 100 to 500 mg/m 2
  • chlorambucil in a dosage of about 0.1 to 0.2 mg/kg
  • carmustine in a dosage of about 150 to 200 mg/m 2
  • lomustine in a dosage of about 100 to 150 mg/m 2 per course of treatment.
  • the anti-tumour anthracycline derivative is advantageously administered in a dosage of 10 to 75 mg per square meter (mg/m 2 ) of body surface area, for example 15 to 60 mg/m 2 , particularly for doxorubicin in a dosage of about 40 to 75 mg/m 2 , for daunorubicin in a dosage of about 25 to 45 mg/m 2 , and for idarubicin in a dosage of about 10 to 15 mg/m 2 per course of treatment.
  • the antiestrogen agent is advantageously administered in a dosage of about 1 to 100 mg daily depending on the particular agent and the condition being treated.
  • Tamoxifen is advantageously administered orally in a dosage of 5 to 50 mg, preferably 10 to 20 mg twice a day, continuing the therapy for sufficient time to achieve and maintain a therapeutic effect.
  • Toremifene is advantageously administered orally in a dosage of about 60 mg once a day, continuing the therapy for sufficient time to achieve and maintain a therapeutic effect.
  • Anastrozole is advantageously administered orally in a dosage of about 1 mg once a day.
  • Droloxifene is advantageously administered orally in a dosage of about 20-100 mg once a day.
  • Raloxifene is advantageously administered orally in a dosage of about 60 mg once a day.
  • Exemestane is advantageously administered orally in a dosage of about 25 mg once a day.
  • Antibodies are advantageously administered in a dosage of about 1 to 5 mg per square meter (mg/m 2 ) of body surface area, or as known in the art, if different.
  • Trastuzumab is advantageously administered in a dosage of 1 to 5 mg per square meter (mg/m 2 ) of body surface area, particularly 2 to 4 mg/m 2 per course of treatment.
  • These dosages may be administered for example once, twice or more per course of treatment, which may be repeated for example every 7, 14, 21 or 28 days.
  • rt means room temperature
  • Me means methyl
  • MeOH means methanol
  • Et means ethyl
  • EtOH means ethanol
  • NaH means sodium hydride
  • DEAD means diethyl azodicarboxylate
  • HMPT means hexamethylphosphorous triamide
  • Boc 2 O means tert-butoxycarbonyl anhydride
  • Bu t ONO means tert-butyl nitrite
  • TosOH means 4-methylbenzenesulfonic acid
  • TosCl means 4-methylbenzenesulfonyl chloride (also p-toluenesulfonyl chloride)
  • CMBP means cyanomethylenetributylphosphorane
  • DBAD means di-tert-butyl azodicarboxylate
  • LAH means lithium aluminum hydride
  • NaBH means lithium aluminum hydride
  • NaBH means lithium aluminum hydride
  • NaBH means lithium aluminum hydride
  • NaBH means lithium
  • Rh(acac)(eth) 2 means Acetylacetonatobis(ethylene)rhodium(I); “(S)-MonoPhos” means (S)-N,N-dimethyldinaphtho[2,1-D:1′,2′-F][1,3,2]dioxaphosphepin-4-amine; “Tf 2 O” means triflic anhydride; “MeI” means methyliodide; “Me 2 NH” means dimethylamine; “Me 2 NH.HCl” means dimethylamine hydrochloric acid; “Me 4 NCl” means tetramethylammonium chloride; “MeONa” means sodium methoxide; “Ts” means tosyl; “MsCl” means mesylchloride; “DIBAH” means Diisobutylaluminium hydride; “TBDMS” means tertButyl dimethylsilyl; “DIBAH” means Di
  • reaction mixture was quickly washed with ice cold brine (30 mL), dried over anhydrous Na 2 SO 4 and added immediately to a heavily stirred mixture of powdered KOH (6.5 g, 117 mmol), 2,4-dichloro-7h-pyrrolopyrimidine (10.0 g, 53 mmol), tris(3,6-dioxaheptyl)amine (8.27 mL, 26.6 mmol) and toluene (200 ml). The mixture was stirred at room temperature for 48 hours. Then the solvent was concentrated in vacuum.
  • the mixture was concentrated to about 150 mL and solids were precipitated.
  • the slurry was diluted with petroleum ether to about 400 mL and stirred for 16 hours at 20° C.
  • the mixture was filtered and the solid was rinsed with petroleum ether/ethyl acetate (20/1, 100 mL).
  • the solids were collected and dried under high vacuum to afford pure intermediate 14 as white solid (18.6 g, 42% yield for 2 steps).
  • Acetylacetonatobis(ethylene)rhodium(l) (0.837 g, 3.24 mmol) and (R)-N,N-dimethyldinaphtho[2,1-D:1′,2′-F] [1,3,2]dioxaphosphepin-4-amine (2.91 g, 8.11 mmol) were dissolved in EtOH (625 mL) under nitrogen atmosphere. The mixture was stirred at room temperature and flushed through with nitrogen gas for 15 minutes.
  • the crude product was purified by silica gel chromatography (gradient elution: petroleum ether/ethyl acetate from 8/1 to 2/1). The desired fractions were collected and the solvent was evaporated to afford the intermediate 43 as a pale yellow solid (9.5 g, 90% yield).
  • the reaction mixture was stirred for 1 hour at -78° C., then extra 1 M DIBAH in DCM (0.46 mL, 0.46 mmol, 0.1 eq) was added and stirred for another 1.5 hours, then quenched with sodium acetate (4.2 g, 51.2 mmol, 11.1 eq) and acetic acid (4.2 mL, 73.4 mL, 16.0 eq) in a mixture of water/THF (57 mL/12 mL). After the quench, the cooling bath was removed and the mixture was stirred until all ice was melted. The layers were separated and then the aqueous phase was extracted twice with DCM (30 mL).
  • the separated organic layer was combined with the precipitated int. 96 and then dried with MgSO 4 , filtered and the solvents of the filtrate evaporated.
  • the residue was dissolved in ethylacetate and purified over a SiO2 column, type Grace Reveleris SRC, 40 g, Si 40, on a Grace Reveleris X2 purification system using heptanes and ethylacetate as eluens in a gradient starting from 100% heptanes to 100% ethylacetate.
  • the fractions containing product were combined and the solvents were evaporated yielding intermediate 96 (0.51 g, crude). This intermediate was used for next step reaction without further purification.
  • intermediate 72 1.0 g, 1.91 mmol
  • 2 M NaOH 10 mL, 20 mmol
  • the reaction mixture was stirred at 150° C. for 1 hour under microwave condition.
  • the mixture was diluted with water (15 mL), extracted with EtOAc (10 mL ⁇ 3).
  • the organic phase was washed with brine (15 mL), dried over Na 2 SO 4 , filtered and concentrated.
  • the residue was purified by chromatography column (elution: EtOAc/MeOH 85/15). The desired fractions were collected and concentrated to give intermediate 154 (359 mg of a white solid, 41% yield) and intermediate 154a (300 mg, 32% yield).
  • intermediate 166 (340 mg, ⁇ 0.52 mmol) in CF 3 COOH(5 ml) was stirred at 60° C. for 1 h. The mixture was evaporated under vacuo to obtain intermediate 167 as a crude product(300 mg, 85.9% yield).

Abstract

The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (1)wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Description

    FIELD OF THE INVENTION
  • The present invention relates to novel 6-6 bicyclic aromatic ring substituted nucleoside analogues useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    • BACKGROUND OF THE INVENTION
  • PRMT5, also described as Hsl7, Jbp1, Skb1, Capsuleen or Dart5, is one of the major methyltransferases responsible for mono- and symmetric dimethylation of arginines. Post-translational arginine methylation on histones and non-histone proteins seems to be crucial for a variety of biological processes, like genome organisation, transcription, differentiation, spliceosome function, signal transduction and regulation of cell-cycle progression, stem cells and T-cell fate [Stopa, N. et al., Cell Mol Life Sci, 2015. 72(11): p. 2041-59] [Geoghegan, V. et al., Nat Commun, 2015. 6: p. 6758]. Metazoan PRMT5 forms a functional complex with the methylosome protein 50 (MEP50) also named as Wdr77, androgen receptor coactivator p44 and Valois. Both, elevated PRMT5-MEP50 protein level and cytoplasmic accumulation are implicated in cancer tumorigenesis and have recently been correlated with poor clinical outcome [Shilo, K. et al., Diagn Pathol, 2013. 8: p. 201]. Cellular rescue experiments that addressed both the catalytic and scaffold function of the PRMT5-MEP50 complex, beside comprehensive enzymological studies have substantiate the oncogenic link between protein level, localisation and enzymatic function [Gu, Z. et al., Biochem J, 2012. 446(2): p. 235-41] [Di Lorenzo, A. et. al., FEBS Lett, 2011. 585(13): p. 2024-31] [Chan-Penebre, E. et al., Nat Chem Biol, 2015. 11(6): p. 432-7]. This correlation turns PRMT5 into an essential small molecule drug target against cancer and other diseases [Stopa, N. et al., Cell Mol Life Sci, 2015. 72(11): p. 2041-59].
  • PRMT5 is a member of the type II PRMT subfamily that utilises S-adenosylmethionine (SAM) to generate symmetric dimethylated arginine on histones and non-histone protein substrates and S-adenosylhomocysteine (SAH). The crystal structure of the human hetereo-octameric complex (PRMT5)4(MEP50)4 co-crystalised with SAH and a histone H4 peptide substrate illustrated the mechanism of methylation and substrate recognition [Antonysamy, S. et al., Proc Natl Acad Sci U S A, 2012. 109(44): p. 17960-5]. The regulation of PRMT5 activity occurs through a vast number of different binding partners, post-translational modification cross talk, miRNAs and subcellular localisation.
  • Methylation of histones H2A and H4 on Arg3 and histone H3 on Arg8 regulate chromatin organisation for specific repression of gene transcripts that are involved in differentiation, transformation, cell-cycle progression and tumour suppression [Karkhanis, V. et al., Trends Biochem Sci, 2011. 36(12): p. 633-41]. Furthermore, PRMT5-mediated methylation of histone H4 on Arg3 might recruit the DNA-methyltransferase DNMT3A to couple histone and DNA methylation for long-term gene silencing [Zhao, Q. et al., Nat Struct Mol Biol, 2009. 16(3): p. 304-11].
  • Non-histone methylation can occur either in the cytoplasm or nucleus dependent on the cellular localisation of PRMT5. The methylation of the Sm proteins D1 and D3, which are required for the assembly of the nuclear splicesome, takes place in the cytoplasm as part of the PRMT5 containing “methylosome” [Friesen, W.J. et al., Mol Cell Biol, 2001. 21(24): p. 8289-300]. Further evidence for PRMT5 involved in splicing has been provided by the conditional PRMT5 knockout in mouse neural stem cells. Cells that lack PRMT5 showed a selective retention of introns and skipping of exons with weak 5′ donor sites [Bezzi, M. et al., Genes Dev, 2013. 27(17): p. 1903-16].
  • In addition to a role in splicing, PRMT5 influences key pathways involved in cell fate and homeostasis by direct methylation of key signalling nodules like p53 [Jansson, M. et al., Nat Cell Biol, 2008. 10(12): p. 1431-9], EGFR [Hsu, J.M. et al., Nat Cell Biol, 2011. 13(2): p. 174-81], CRAF [Andreu-Perez, P. et al., Sci Signal, 2011. 4(190): p. ra58], PI3K/AKT [Wei, T.Y. et al., Cell Signal, 2014. 26(12): p. 2940-50], NFκB [Wei, H. et al., Proc Natl Acad Sci U S A, 2013. 110(33): p. 13516-21].
  • Since PRMT5 is one of the major sym-Arg methyltransferases and involved in a multitude of cellular processes, an increased protein expression appears to be an important factor in its tumourigenicity. Interestingly, the translation of PRMT5 in mantle cell lymphoma (MCL) seems to be regulated by miRNAs. Although MCL cells show less mRNA and a slower transcription rate of PRMT5 than normal B lymphocytes, the PRMT5 level and the methylation of H3R8 and H4R3 are significantly increased [Pal, S. et al., EMBO J, 2007. 26(15): p. 3558-69]. Re-expression of miRNAs that binds the 3′UTR region of PRMT5 decreases PRMT5 protein level [Wang, L. et al., Mol Cell Biol, 2008. 28(20): p. 6262-77]. Strikingly, a prmt5 antisense RNA has been found within the human prmt5 gene that supports the hypothesis of a specific translational regulation rather than high mRNA expression level [Stopa, N. et al., Cell Mol Life Sci, 2015. 72(11): p. 2041-59].
  • Although PRMT5 is considered as a clinical relevant target, very few selective PRMT5 inhibitors have been published, yet. Very recently, a novel sub-nanomolar potent PRMT5 inhibitor (EPZ015666) with anti-tumour activity in multiple MCL xenograft models has been described to be the first chemical probe suitable for further validation of PRMT5′s biology and role in cancer [Chan-Penebre, E. et al., Nat Chem Biol, 2015. 11(6): p. 432-7].
  • Further development of specific small molecule inhibitors of PRMT5 may lead to novel chemotherapeutic approaches for cancer.
  • WO2014100695A1 discloses compounds useful for inhibiting PRMT5 activity; Methods of using the compounds for treating PRMT5-mediated disorders are also described.
  • WO2014100730A1 discloses PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof.
  • Devkota, K. et al., ACS Med Chem Lett, 2014. 5: p. 293-297, describes the synthesis of a series of analogues of the natural product sinefungin and the ability of these analogues to inhibit EHMTI and EHMT2.
  • WO2003070739 discloses partial and full agonists of A1 adenosine receptors, their preparation, and their therapeutic use.
  • WO2012082436 discloses compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity.
  • WO2014100719 discloses PRMT5 inhibitors and uses thereof.
  • WO03074083 discloses combination therapies that selectively kill methylthioadenosine phosphorylase deficient cells. Analogs of MTA are described herein as anti-toxicity agents.
  • Kung, P.-P. et al., Bioorg Med Chem Lett, 2005. 15: p. 2829-2833, describes the design, synthesis, and biological evaluation of novel human 5′-deoxy-5′-methylthioadenosine phosphorylase (MTAP) substrates.
  • WO2012075500 discloses 7-deazapurine modulators of histone methyltransferase. WO2014035140 discloses compounds and compositions for modulating histone methyltransferase activity.
  • WO2015200680 describes PRMT5 inhibitors and uses thereof.
  • There is thus a strong need for novel PRMT5 inhibitors thereby opening new avenues for the treatment or prevention of cancer, such as e.g. mantle cell lymphoma. It is accordingly an object of the present invention to provide such compounds.
  • The compounds of the present invention are structurally different and may have improved properties such as for example improved potency, or improved pharmacokinetics (PK) and oral bioavailability, compared with compounds disclosed in the prior art.
    • SUMMARY OF THE INVENTION
  • It has been found that the compounds of the present invention are useful as PRMT5 inhibitors. The compounds according to the invention and compositions thereof, may be useful for the treatment or prevention, in particular for the treatment, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.
  • The present invention concerns novel compounds of Formula (I):
  • Figure US20230330127A1-20231019-C00002
  • wherein
    • R1 represents hydrogen or —C(═O)—C 1-4alkyl;
    • R2 represents hydrogen or —C(═O)—C 1-4alkyl;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-;
    • R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen, C1-4alkyl, or C 1-4alkyl substituted with one substituent selected from the group consisting of —OH, —O—C1-4alkyl, R12, —NH2, —NH—C1-4alkyl, and
    • —N(C1-4alkyl)2;
    • R12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, —NH—C1-4alkyl, —N(C1-4alkyl)2, -NHR10d, -NR10cR10d, cyano, —CF3, —C(═O)—NH2, —C(═O)—NH—C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, -C(=O)-O-C1-4alkyl, C3-6cycloalkyl, -O-C3-6cycloalkyl, -NH-C3-6cycloalkyl, -N(C3-6cycloalkyl)2, C2-6alkenyl, C1-4alkyl substituted with one C1- 4alkyloxy, and C1-4alkyloptionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • R10c and R10d each independently represent C3-6cycloalkyl; R13; R14; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R13 and R14;
    • R13 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N;
    • said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C1-4alkyl;
    • p represents 1 or 2;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):
    • Figure US20230330127A1-20231019-C00003
    • Figure US20230330127A1-20231019-C00004
    • Figure US20230330127A1-20231019-C00005
    • Figure US20230330127A1-20231019-C00006
    • Figure US20230330127A1-20231019-C00007
    • R3a, R3b, R3c, R3d and R3e each independently represent hydrogen, halo, -NR7aR7b, C1-4a1kyl, C2-4alkenyl, C3-6cycloalkyl, —OH, or —O—C 1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl;
    • R4a, R4b, R4c, R4d, R4e, R4f and R4g each independently represent hydrogen, halo,
    • -NR8aR8b, or C 1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • Q3 represents N or CR6c;
    • Q4 represents N or CR6d;
    • provided that maximum one of Q3 and Q4 represents N;
    • Q8 represents N or CR6g;
    • Q9 represents N or CR6h;
    • Q10 represents N or CR6i;
    • Q11 represents N or CR6j;
    • Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents CR3d; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents N; and Q7 represents N;
    • R6a, R6b, R6c, R6d, R6c, R6f, R6g, R6h, R6i and R6j each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof;
    • provided that the following compounds, and pharmaceutically acceptable addition salts, and solvates thereof are excluded:
    • Figure US20230330127A1-20231019-C00008
    • Figure US20230330127A1-20231019-C00009
    • Figure US20230330127A1-20231019-C00010
  • The present invention also concerns methods for the preparation of compounds of the present invention and pharmaceutical compositions comprising them.
  • The compounds of the present invention were found to inhibit PRMT5 per se or can undergo metabolism to a (more) active form in vivo (prodrugs), and therefore may be useful in the treatment or prevention, in particular in the treatment, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.
  • In view of the aforementioned pharmacology of the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, it follows that they may be suitable for use as a medicament.
  • In particular the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, may be suitable in the treatment or prevention, in particular in the treatment, of any one of the diseases or conditions mentioned hereinbefore or hereinafter, in particular cancer.
  • The present invention also concerns the use of compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the inhibition of PRMT5, for the treatment or prevention of any one of the diseases or conditions mentioned hereinbefore or hereinafter, in particular cancer.
  • The present invention will now be further described. In the following passages, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
    • DETAILED DESCRIPTION
  • When describing the compounds of the invention, the terms used are to be construed in accordance with the following definitions, unless a context dictates otherwise.
  • When any variable occurs more than one time in any constituent or in any formula (e.g. Formula (I)), its definition in each occurence is independent of its definition at every other occurrence.
  • Whenever the term “substituted” is used in the present invention, it is meant, unless otherwise is indicated or is clear from the context, to indicate that one or more hydrogens, in particular from 1 to 3 hydrogens, preferably 1 or 2 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using “substituted” are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
  • When two or more substituents are present on a moiety they may, unless otherwise is indicated or is clear from the context, replace hydrogens on the same atom or they may replace hydrogen atoms on different atoms in the moiety.
  • The prefix “Cx-y” (where x and y are integers) as used herein refers to the number of carbon atoms in a given group. Thus, a C1-4alkyl group contains from 1 to 4 carbon atoms, a C1-3alkyl group contains from 1 to 3 carbon atoms and so on.
  • The term “halo” as a group or part of a group is generic for fluoro, chloro, bromo, iodo unless otherwise is indicated or is clear from the context.
  • The term “C1-4alkyl” as a group or part of a group refers to a hydrocarbyl radical of Formula CnH2n+1 wherein n is a number ranging from 1 to 4. C1-4alkyl groups comprise from 1 to 4 carbon atoms, preferably from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms. C1-4alkyl groups may be linear or branched and may be substituted as indicated herein. When a subscript is used herein following a carbon atom, the subscript refers to the number of carbon atoms that the named group may contain. C1-4alkyl includes all linear, or branched alkyl groups with between 1 and 4 carbon atoms, and thus includes methyl, ethyl, n-propyl, i-propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n-butyl, isobutyl and tert-butyl), and the like.
  • The skilled person will realize that the term ‘C1-4alkoxy’ or ‘C1-4alkyloxy’ as a group or part of a group refers to a radical having the Formula -ORc wherein Rc is C1-4alkyl. Non-limiting examples of suitable C1-4alkyloxy include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec-butyloxy and tert-butyloxy.
  • The term “C2-4alkenyl” as used herein as a group or part of a group represents a straight or branched chain hydrocarbon group containing from 2 to 4 carbon atoms and containing a carbon carbon double bond such as, but not limited to, ethenyl, propenyl, butenyl, 1-propen-2-yl, and the like.
  • The term “C2-6alkenyl” as used herein as a group or part of a group represents a straight or branched chain hydrocarbon group containing from 2 to 6 carbon atoms and containing a carbon carbon double bond such as, but not limited to, ethenyl, propenyl, butenyl, pentenyl, 1-propen-2-yl, hexenyl and the like.
  • The term ‘C3-6cycloalkyl’ as used herein as a group or part of a group represents cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • In case Z is -X-CR5aR5b-, it is intended that X is attached to Ar.
  • In case Z is -CR5c=CR5d-, it is intended that the C-atom with the R5c substituent is attached to Ar.
  • In case Z is -CR5eR5g-CR5fR5h-, it is intended that the C-atom with the R5e and R5g substituents is attached to Ar.
  • In case Z is -CR5aR5b-X-, it is intended that the C-atom with the R5a and R5b substituents is attached to Ar.
  • The skilled person will realize that the 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom (in the definition of R12) particularly is a saturated ring. Non-limiting examples of R12 are 1-piperidinyl, 1-pyrrolidinyl, 1-morpholinyl, 1-azetidinyl, and the like.
  • It will be clear for the skilled person that, unless otherwise is indicated or is clear from the context, a substituent on a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms (as in the definition of R13) (non-limiting examples are pyrrolyl, pyridinyl, furanyl, and the like), may replace any hydrogen atom on a ring carbon atom or where possible on a ring nitrogen atom (in which case a hydrogen on a nitrogen atom may be replaced by a substituent). It will be clear for the skilled person that the same is applicable to the 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms (as in the definition of R13) (non-limiting examples are indolyl, quinolinyl, and the like).
  • A 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms (as in the definition of R13), may be attached to the remainder of the molecule of Formula (I) through any available ring carbon or nitrogen atom as appropriate, if not otherwise specified. It will be clear for the skilled person that the same is applicable to the 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms (as in the definition of R13).
  • In case a nitrogen atom replaces one of the two fused carbon atoms in the Ar group, a carbonyl group is present in said bicyclic aromatic ring system as exemplified by the structure shown below:
  • Figure US20230330127A1-20231019-C00011
  • which is optionally substituted according to any of the embodiments. It will be clear this example is non-limiting.
  • Other, non-limiting, examples of the Ar group being a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom, are shown below:
  • Figure US20230330127A1-20231019-C00012
  • Figure US20230330127A1-20231019-C00013
  • Figure US20230330127A1-20231019-C00014
  • Figure US20230330127A1-20231019-C00015
  • Figure US20230330127A1-20231019-C00016
  • Figure US20230330127A1-20231019-C00017
  • Figure US20230330127A1-20231019-C00018
  • Figure US20230330127A1-20231019-C00019
  • Figure US20230330127A1-20231019-C00020
  • each of which are optionally substituted according to any of the embodiments.
  • The skilled person will understand that the 10 members of the 10-membered Ar group (the 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom), are 10 carbon atoms, 9 carbon atoms and 1 nitrogen atom, or 8 carbon atoms and 2 nitrogen atoms. Ar is optionally substituted according to any of the embodiments.
  • Whenever substituents are represented by chemical structure, “---” represents the bond of attachment to the remainder of the molecule of Formula (I). Lines drawn from substituents into ring systems indicate that the bond may be attached to any of the suitable ring atoms.
  • For example
  • Figure US20230330127A1-20231019-C00021
  • covers any one of the following ring systems:
  • Figure US20230330127A1-20231019-C00022
  • Figure US20230330127A1-20231019-C00023
  • Figure US20230330127A1-20231019-C00024
  • Figure US20230330127A1-20231019-C00025
  • Figure US20230330127A1-20231019-C00026
  • is an alternative representation for
  • Figure US20230330127A1-20231019-C00027
  • The term “subject” as used herein, refers to an animal, preferably a mammal (e.g. cat, dog, primate or human), more preferably a human, who is or has been the object of treatment, observation or experiment.
  • The term “therapeutically effective amount” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medicinal doctor or other clinician, which includes alleviation or reversal of the symptoms of the disease or disorder being treated.
  • The term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
  • The term “treatment”, as used herein, is intended to refer to all processes wherein there may be a slowing, interrupting, arresting or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.
  • The term “compounds of the (present) invention” as used herein, is meant to include the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof.
  • Some of the compounds of Formula (I) may also exist in their tautomeric form. The term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerisations. Valence tautomers include interconversions by reorganisation of some of the bonding electrons.
  • Such forms in so far as they may exist, although not explicitly indicated in the above Formula (I), are intended to be included within the scope of the present invention.
  • As used herein, any chemical formula with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds, or otherwise indicated as having a particular configuration (e.g. R, S) around one or more atoms, contemplates each possible stereoisomer, or mixture of two or more stereoisomers. Where the stereochemistry of any particular chiral atom is not specified in the structures shown herein, then all stereoisomers are contemplated and included as the compounds of the invention, either as a pure stereoisomer or as a mixture of two or more stereoisomers.
  • Hereinbefore and hereinafter, the term “compound of Formula (I)” is meant to include the stereoisomers thereof and the tautomeric forms thereof. However where stereochemistry, as mentioned in the previous paragraph, is specified by bonds which are shown as solid wedged or hashed wedged bonds, or are otherwise indicated as having a particular configuration (e.g. R, S), then that stereoisomer is so specified and defined. It will be clear this also applies to subgroups of Formula (I).
  • It follows that a single compound may, where possible, exist in both stereoisomeric and tautomeric form.
  • The terms “stereoisomers”, “stereoisomeric forms” or “stereochemically isomeric forms” hereinbefore or hereinafter are used interchangeably.
  • Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.
  • Atropisomers (or atropoisomers) are stereoisomers which have a particular spatial configuration, resulting from a restricted rotation about a single bond, due to large steric hindrance. All atropisomeric forms of the compounds of Formula (I) are intended to be included within the scope of the present invention.
  • Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration. Substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration; for example if a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration. Therefore, the invention includes enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.
  • The meaning of all those terms, i.e. enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof are known to the skilled person.
  • The absolute configuration is specified according to the Cahn-Ingold-Prelog system. The configuration at an asymmetric atom is specified by either R or S. Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. For instance, resolved enantiomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
  • When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers. Thus, when a compound of Formula (I) is for instance specified as (R), this means that the compound is substantially free of the (S) isomer; when a compound of Formula (I) is for instance specified as E, this means that the compound is substantially free of the Z isomer; when a compound of Formula (I) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.
  • For therapeutic use, salts of the compounds of Formula (I) and solvates thereof, are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • Pharmaceutically-acceptable salts include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
  • The pharmaceutically acceptable addition salts as mentioned hereinabove or hereinafter are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of Formula (I) and solvates thereof, are able to form.
  • Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids. Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.
  • The compounds of Formula (I) and solvates thereof containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.
  • For the purposes of this invention prodrugs are also included within the scope of the invention.
  • The term “prodrug” of a relevant compound of the invention includes any compound that, following oral or parenteral administration, in particular oral administration, is metabolised in vivo to a form that compound in an experimentally-detectable amount, and within a predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily)). For the avoidance of doubt, the term “parenteral” administration includes all forms of administration other than oral administration, in particular intravenous (IV), intramuscular (IM), and subcutaneous (SC) injection. Prodrugs may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is administered to a mammalian subject. The modifications typically are achieved by synthesising the parent compound with a prodrug substituent. In general, prodrugs include compounds of the invention wherein a hydroxyl, amino, sulfhydryl, carboxy or carbonyl group in a compound of the invention is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, sulfhydryl, carboxy or carbonyl group, respectively; in particular wherein a hydroxyl group in a compound of the invention is bonded to any group (e.g. -C(=O)-C1-4alkyl) that may be cleaved in vivo to regenerate the free hydroxyl. Within the context of this invention, prodrugs in particular are compounds of Formula (I) or subgroups thereof wherein R1 and/or R2 represent -C(=O)-C1-4alkyl.
  • Examples of prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxyl functional groups, N-acyl derivatives and N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. “Design of Prodrugs” p. 1-92, Elesevier, New York-Oxford (1985).
  • The term solvate comprises the hydrates and solvent addition forms which the compounds of Formula (I) are able to form, as well as pharmaceutically acceptable addition salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • The compounds of the invention as prepared in the processes described below may be synthesized in the form of mixtures of enantiomers, in particular racemic mixtures of enantiomers, that can be separated from one another following art-known resolution procedures. A manner of separating the enantiomeric forms of the compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound would be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • The present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature).
  • All isotopes and isotopic mixtures of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15O, 17O, 18O, 32P, 33P, 35S, 18F, 36Cl, 122I, 123I, 125I, 131I, 75Br, 76Br, 77Br and 82Br. Preferably, the radioactive isotope is selected from the group of 2H, 3H, 11C and 18F. More preferably, the radioactive isotope is 2H. In particular, deuterated compounds are intended to be included within the scope of the present invention.
  • Certain isotopically-labeled compounds of the present invention (e.g., those labeled with 3H and 14C) are useful in compound and for substrate tissue distribution assays. Tritiated (3H) and carbon-14 (14C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Positron emitting isotopes such as 15O, 13N, 11C and 18F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy.
  • In all embodiments below, the following compounds, and pharmaceutically acceptable addition salts, and solvates thereof are excluded:
  • Figure US20230330127A1-20231019-C00028
  • Figure US20230330127A1-20231019-C00029
  • Figure US20230330127A1-20231019-C00030
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen or C1-4alkyl;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2,
    • -NHR10d, -NR10cR10d, cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, -C(=O)-O-C1-4alkyl, C3-6cycloalkyl, -O-C3-6cycloalkyl, -NH-C3-6cycloalkyl, -N(C3-6cycloalkyl)2, C2-6alkenyl, C1-4alkyl substituted with one C1- 4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C 1-4alkyl;
    • R10c and R10d each independently represent C3-6cycloalkyl; R14; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, and R14;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):
    • Figure US20230330127A1-20231019-C00031
    • Figure US20230330127A1-20231019-C00032
    • Figure US20230330127A1-20231019-C00033
    • Figure US20230330127A1-20231019-C00034
    • Figure US20230330127A1-20231019-C00035
    • R3a, R3b, R3c, R3d and R3e each independently represent hydrogen, halo, -NR7aR7b, C1-4alkyl, C2-4alkenyl, C3-6cycloalkyl, —OH, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl;
    • R4a, R4b, R4c, R4d, R4e, R4f and R4g each independently represent hydrogen, halo,
    • -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • Q3 represents N or CR6c;
    • Q4 represents N or CR6d;
    • provided that maximum one of Q3 and Q4 represents N;
    • Q8 represents N or CR6g;
    • Q9 represents N or CR6h;
    • Q10 represents N or CR6i;
    • Q11 represents N or CR6j;
    • Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents CR3d; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents N; and Q7 represents N;
    • R6a, R6b, R6c, R6d, R6c, R6f, R6g, R6h, R6i and R6j each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1-4alkyl;
    • X represents —O—, —S—, or -NR11;
    • R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, -O-C1-4alkyl, R12, —NH2, -NH-C1-4alkyl, and
    • -N(C1-4alkyl)2;
    • R12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d, cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, -C(=O)-O-C1-4alkyl, C3-6cycloalkyl, -O-C3-6cycloalkyl, -NH-C3-6cycloalkyl, -N(C3-6cycloalkyl)2, C2-6alkenyl, C1-4alkyl substituted with one C1- 4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • R10c and R10d each independently represent C3-6cycloalkyl; R13; R14; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R13 and R14;
    • R13 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N;
    • said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C1-4alkyl;
    • p represents 1 or 2;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):
    • Figure US20230330127A1-20231019-C00036
    • Figure US20230330127A1-20231019-C00037
    • Figure US20230330127A1-20231019-C00038
    • Figure US20230330127A1-20231019-C00039
    • Figure US20230330127A1-20231019-C00040
    • R3a, R3b, R3c, R3d and R3e each independently represent hydrogen, halo, -NR7aR7b, C1-4alkyl, C2-4alkenyl, C3-6cycloalkyl, —OH, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl;
    • R4a, R4b, R4c, R4d, R4e, R4f and R4g each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • Q3 represents N or CR6c;
    • Q4 represents N or CR6d;
    • provided that maximum one of Q3 and Q4 represents N;
    • Q8 represents N or CR6g;
    • Q9 represents N or CR6h;
    • Q10 represents N or CR6i;
    • Q11 represents N or CR6j;
    • Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents CR3d; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents N; and Q7 represents N;
    • R6a, R6b, R6c, R6d, R6e, R6f, R6g, R6h, R6i and R6j each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, -O-C1-4alkyl, R12, —NH2, -NH-C1-4alkyl, and -N(C1-4alkyl)2;
    • R12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d, cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, —C(═O)—C1- 4alkyl, C1-4alkyloxy, -C(=O)-O-=C1-4alkyl, C3-6cycloalkyl, C2-6alkenyl, C1-4alkyl substituted with one C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • R10c and R10d each independently represent C3-6cycloalkyl; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R13 and R14;
    • R13 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N;
    • said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C1-4alkyl;
    • p represents 1 or 2;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):
    • Figure US20230330127A1-20231019-C00041
    • Figure US20230330127A1-20231019-C00042
    • Figure US20230330127A1-20231019-C00043
    • R3a, R3b and R3c each independently represent hydrogen, halo, -NR7aR7b, C1-4alkyl, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a, R4b and R4c each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl; R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • Q3 represents N or CR6c;
    • Q4 represents N or CR6d;
    • provided that maximum one of Q3 and Q4 represents N;
    • R6a, R6b, R6c, R6d, R6e and R6f each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, —O—C1-4alkyl, R12, —NH2, —NH—C1-4alkyl, and -N(C1-4alkyl)2;
    • R12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):
    • Figure US20230330127A1-20231019-C00044
    • Figure US20230330127A1-20231019-C00045
    • Figure US20230330127A1-20231019-C00046
    • R3a, R3b and R3c each independently represent hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a, R4b and R4c each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • Q3 represents N or CR6c;
    • Q4 represents N or CR6d;
    • provided that maximum one of Q3 and Q4 represents N;
    • R6a, R6b, R6c, R6d, R6e and R6f each independently represent hydrogen, halogen, C1- 4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, —O—C1-4alkyl, R12, —NH2, -NH-C1-4alkyl, and
    • -N(C1-4alkyl)2;
    • R12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,
    • Figure US20230330127A1-20231019-C00047
      • wherein at least 1 ring carbon atom of ring B is replaced by a nitrogen atom;
      • wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d, cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, -C(=O)-O-C1-4alkyl, C3-6cycloalkyl, -O-C3-6cycloalkyl, -NH-C3-6cycloalkyl, -N(C3-6cycloalkyl)2, C2-6alkenyl, C1-4alkyl substituted with one C1- 4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • R10c and R10d each independently represent C3-6cycloalkyl; R13; R14; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R13 and R14;
    • R13 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N;
    • said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C1-4alkyl;
    • p represents 1 or 2;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):
    • Figure US20230330127A1-20231019-C00048
    • Figure US20230330127A1-20231019-C00049
    • Figure US20230330127A1-20231019-C00050
    • Figure US20230330127A1-20231019-C00051
    • Figure US20230330127A1-20231019-C00052
    • R3a, R3b, R3c, R3d and R3e each independently represent hydrogen, halo, -NR7aR7b, C1-4alkyl, C2-4alkenyl, C3-6cycloalkyl, —OH, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl;
    • R4a, R4b, R4c, R4d, R4e, R4f and R4g each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • Q3 represents N or CR6c;
    • Q4 represents N or CR6d;
    • provided that maximum one of Q3 and Q4 represents N;
    • Q8 represents N or CR6g;
    • Q9 represents N or CR6h;
    • Q10 represents N or CR6i;
    • Q11 represents N or CR6j;
    • Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents CR3d; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents N; and Q7 represents N;
    • R6a, R6b, R6c, R6d, R6e, R6f, R6g, R6h, R6i and R6j each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (1), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR 5e R 5g -CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or-NR11-;
    • R11 represents hydrogen, C i-aalkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, —O—C1-4alkyl, R12, —NH2, —NH—C1-4alkyl, and -N(C1-4alkyl)2;
    • R 12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d, cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, -C(=O)-O-C1-4alkyl, C3-6cycloalkyl, -O-C3-6cycloalkyl, -NH-C3-6cycloalkyl, -N(C3-6cycloalkyl)2, C2-6alkenyl, C1-4alkyl substituted with one C1- 4alkyloxy, and C1-4alkyl optionally substituted with one -NRl0aRl0b;
    • R10a and R10b each independently represent hydrogen or C 1-4a1kyl;
    • R10c and R10d each independently represent C3-6cycloalkyl; R13; R14; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R13 and R14;
    • R13 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N;
    • said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C1-4alkyl;
    • p represents 1 or 2;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):
    • Figure US20230330127A1-20231019-C00053
    • Figure US20230330127A1-20231019-C00054
    • Figure US20230330127A1-20231019-C00055
    • Figure US20230330127A1-20231019-C00056
    • Figure US20230330127A1-20231019-C00057
    • R3a, R3b, R3c, R3d and R3e each independently represent hydrogen, halo, -NR7aR7b, C1-4alkyl, C2-4alkenyl, C3-6cycloalkyl, —OH, or -O-C 1-4a1kyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl;
    • R4a, R4b, R4c, R4d, R4e, R4f and R4g each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • Q3 represents N or CR6c;
    • Q4 represents N or CR6d;
    • provided that maximum one of Q3 and Q4 represents N;
    • Q8 represents N or CR6g;
    • Q9 represents N or CR6h;
    • Q10 represents N or CR6i;
    • Q11represents N or CR6j;
    • Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents CR3d; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents N; and Q7 represents N;
    • R6a, R6b, R6c, R6d, R6e, R6f, R6g, R 6h, R 6i and R6j each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen orC1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5gCR5fR5h-, or —C≡C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, —O—C1-4alkyl, R12, —NH2, -NH-C1-4alkyl, and -N(C1-4alkyl)2;
    • R 12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C 1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
    • R3a, R3b and R3c each independently represent hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a, R4b and R4c each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • Q3 represents N or CR6c;
    • Q4 represents N or CRd;
    • provided that maximum one of Q3 and Q4 represents N;
    • R6a, R6b, R6c, R6d, R6e and R6f each independently represent hydrogen, halogen, C1- 4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or-NR11-;
    • R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, -O-C1-4alkyl, R12, —NH2, -NH-C1-4alkyl, and -N(C1-4alkyl)2;
    • R 12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, —NH—C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, -C(=O)-O-C1-4alkyl, C3-6cycloalkyl, -O-C3-6cycloalkyl, -NH-C3-6cycloalkyl, -N(C3-6cycloalkyl)2, C2-6alkenyl, C1-4alkyl substituted with one C1- 4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C 1-4a1kyl;
    • R10cand R10deach independently represent C3-6cycloalkyl; R13; R14; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R13 and R14;
    • R13 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N;
    • said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C1-4alkyl;
    • p represents 1 or 2;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, C1-4alkyl, C2-4alkenyl, C3-6cycloalkyl, —OH, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl;
    • R4a represents hydrogen, halo, -NR8aR8b, or C 1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • in particular Q1 and Q2 represent CH;
    • R6a and R6b, each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O—, —CH2— or —CF2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2— or —CF2—, then Z can also represent —O— or -CR5aR5b-X-; R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, -O-C1-4alkyl, R12, —NH2, -NH-C1-4alkyl, and -N(C1-4alkyl)2;
    • R 12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NRl0aRl0b;
    • R10a and R10b each independently represent hydrogen or C 1-4a1kyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents N or CR6a;
    • Q2 represents N or CR6b;
    • in particular Q1 and Q2 represent CH;
    • R6a and R6b each independently represent hydrogen, halogen, C1-4alkyl,-NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O— or —CH2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g -CR5fR5h-, or —C═C—;
    • and when Y represents —CH2—═, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1- 4alkyl;
    • X represents —O—, —S—, or-NR11-;
    • R11 represents hydrogen or C1-4alkyl;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, C1-4alkyloxy, -C(=O)-O-C1- 4alkyl, C3-6cycloalkyl, C2-6alkenyl, C1-4alkyl substituted with one C1-4alkyloxy, and C1- 4alkyl optionally substituted with one -NRl0aRl0b;
    • R10aand R10b represent C1-4alkyl;
    • R10d represents C3-6cycloalkyl; R14; C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, and R14;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-4);
    • R3a, R3b, R3c and R3d each independently represent hydrogen, halo, -NR7aR7b, C2-4alkenyl, C3-6cycloalkyl, —OH, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl;
    • R4a, R4b, R4c, R4d, R4e and R4f each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • Q8 represents CR6g;
    • Q9 represents CR6h;
    • Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents CR3d; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents N;
    • R6a, R6b, R6c, R6d, R6c, R6f, R6g and R6h each independently represent hydrogen, halogen, or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • Y represents —O—, or —CH2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR 5e R 5g-CR 5fR5h– or —C═C—;
    • and when Y represents —CH2—, then Z can also represent —O— or -CR5aR5b-X-;
    • R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1-4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen or C1-4alkyl;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4a1kyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
    • R3a, R3b and R3c each independently represent hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a, R4b and R4c each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • Q3 represents CR6c;
    • Q 4 represents CR6d;
    • R6a, R6b, R6c, R6d, R6e and R6f each independently represent hydrogen, halogen, C1- 4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C 1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C 1-4alkyl;
    • Y represents —O—, or —CH2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2—, then Z can also represent —O— or -CR5aR5b-X-;
    • R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1-4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen or C1-4alkyl;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alk-yl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);
    • R3a, R3b and R3c represent -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a, R4b and R4c each independently represent hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • Q3 represents CR6c;
    • Q4 represents CR6d;
    • R6a, R6b, R6c, R6d, R6e and R6f each independently represent hydrogen, halogen,
    • C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C 1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl; in particular R1 and R2 represent hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C 1-4alkyl;
    • X represents —O—, —S—, or -NR 11-;
    • R11 represents hydrogen or C1-4alkyl;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2);
    • R3a and R3c each independently represent halo, -NR7aR7b, or -O-C 1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a, and R4c each independently represent hydrogen, halo, or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a, R6b, R6e and R6f each independently represent hydrogen, halogen, or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl; in particular R1 and R2 represent hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—;
    • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C 1-4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen or C1-4alkyl;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, cyano, —CF3, -C(=O)-NH-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl;
    • R10d represents C1-4alkyl substituted with one, two or three halo substituents; or
    • C1-4alkyl substituted with one C3-6cycloalkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2);
    • R3a and R3c each independently represent hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a, and R4c each independently represent hydrogen, halo, or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a, R6b, R6e and R6f each independently represent hydrogen, halogen, or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
    • (i) R1 and R2 represent hydrogen;
    • (ii) Y represents —O— or —CH2—; in particular Y represents —O—;
    • (iii) Z represents —CH2—, -X-CR5aR5b-, -CR5c=CR5d-, -CR5eR5g-CR5fR5h-, or —C═C—; and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • (iv) R5a, R5b, R5c, R5d, R5c, R5f, R5g, and R5h represent hydrogen;
    • (v) X represents —O—;
    • (vi) R11 represents hydrogen or C1-4alkyl;
    • (vii) Ar is optionally substituted with one, two or three substituents, in particular one substituent, each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, C1-4alkyloxy, and C1- 4alkyl;
    • (viii) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2);
    • (ix) R3a and R3c each independently represent halo, -NR7aR7b, or -O-C1-4alkyl;
    • (x) R7a and R7b represent hydrogen;
    • (xi) R4a, and R4c each independently represent hydrogen, halo, or C1-4alkyl;
    • (xii) Q1 represents CR6a;
    • (xiii) Q2 represents CR6b;
    • (xiv) R6a, R6b, R6e and R6f each independently represent hydrogen, halogen, or C1-4alkyl.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents -X-CR5aR5b- or -CR5eR5g-CR5fR5h-;
    • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5c, R5f, R5g, and R5h represent hydrogen;
    • X represents —O—;
    • Ar represents
    • Figure US20230330127A1-20231019-C00058
    • wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, and -NHR10d; and wherein Ar is optionally substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF3;
    • provided however that Ar is substituted in at least one of the positions indicated by a or β;
    • R10d represents C3-6cycloalkyl; C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-4);
    • R3a and R3d each independently represent hydrogen, halo, -NR7aR7b, C1-4alkyl, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a, R4d and R4f each independently represent hydrogen or halo;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • Q8 represents CR6g;
    • Q9 represents CR6h;
    • Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f;
    • R6a, R6b, R6g, and R6h represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
    • (i) R1 and R2 represent hydrogen;
    • (ii) Y represents —O— or —CH2—;
    • (iii) Z represents -X-CR5aR5b- or -CR5eR5g-CR5fR5h-;
      • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • (iv) R 5a, R 5b, R5e, R5f, R5g, and R5h represent hydrogen;
    • (v) X represents —O—;
    • (vi) Ar represents
    • Figure US20230330127A1-20231019-C00059
      • wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, and -NHR10d; and
      • wherein Ar is optionally substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF3;
      • provided however that Ar is substituted in at least one of the positions indicated by a or β;
    • (vii) R10d represents C3-6cycloalkyl; C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • (viii) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-4);
    • (ix) R3a and R3d each independently represent hydrogen, halo, -NR7aR7b, C1-4alkyl, or -O-C1-4alkyl;
    • (x) R7a represents hydrogen;
    • (xi) R7b represents hydrogen or C1-4alkyl;
    • (xii) R4a, R4d and R4f each independently represent hydrogen or halo;
    • (xiii) Q1 represents CR6a;
    • (xiv) Q2 represents CR6b;
    • (xv) Q8 represents CR6g;
    • (xvi) Q9 represents CR 6h;
    • (xvii) Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f;
    • (xviii) R6a, R6b, R6g, and R6h represent hydrogen.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents -X-CR5aR5b- or -CR5eR5g-CR5fR5h-;
    • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5c, R5f, R5g, and R5h represent hydrogen;
    • X represents —O—;
    • Ar represents
    • Figure US20230330127A1-20231019-C00060
      • wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, and -NHR10d; and
      • wherein Ar is optionally substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF3;
      • provided however that Ar is substituted in at least one of the positions indicated by a or β;
    • R10d represents C3-6cycloalkyl; C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, C1-4alkyl, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen or halo;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents -X-CR5aR5b- or -CR5eR5g-CR5fR5h-;
    • R5a, R5b, R5e, R5f, R5g, and R5h represent hydrogen;
    • X represents —O—;
    • Ar represents
    • Figure US20230330127A1-20231019-C00061
      • wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, and -NHR10d; and
      • wherein Ar is optionally substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF3;
      • provided however that Ar is substituted in at least one of the positions indicated by a or β;
    • R10d represents C3-6cycloalkyl; C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, C1-4alkyl, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen or halo;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents -X-CR5aR5b- or -CR5eR5g-CR5fR5h-;
    • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5e, R5f, R5g, and R5h represent hydrogen;
    • X represents —O—;
    • Ar represents
    • Figure US20230330127A1-20231019-C00062
      • wherein Ar is substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, and -NHR10d;
    • R10d represents C3-6cycloalkyl; or C 1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, and R14;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
    • Het represents the bicyclic aromatic heterocyclic ring system (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents -X-CR5aR5b- or -CR5eR5g-CR5fR5h-;
    • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5e, R5f, R5g, and R5h represent hydrogen;
    • X represents —O—;
    • Ar represents
    • Figure US20230330127A1-20231019-C00063
      • wherein Ar is optionally substituted in the position indicated by a with —NH2; and
      • wherein Ar is substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF3;
    • Het represents the bicyclic aromatic heterocyclic ring system (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents -X-CR5aR5b- or -CR5eR5g-CR5fR5h-;
    • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5e, R5f, R5g, and R5h represent hydrogen;
    • X represents —O—;
    • Ar represents
    • Figure US20230330127A1-20231019-C00064
      • wherein Ar is substituted in the position indicated by a with —NH2; and
      • wherein Ar is substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF3;
    • Het represents the bicyclic aromatic heterocyclic ring system (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —O— or —CH2—;
    • Z represents -X-CR5aR5b- or -CR5eR5g-CR5fR5h-;
    • and when Y represents —CH2—, then Z can also represent -CR5aR5b-X-;
    • R5a, R5b, R5e, R5f, R5g, and R5h represent hydrogen;
    • X represents —O—;
    • Ar represents
    • Figure US20230330127A1-20231019-C00065
    • Het represents the bicyclic aromatic heterocyclic ring system (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C 1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C 1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —CH2— or —O—;
    • Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b each independently represent hydrogen or C1-4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, —NH—C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a represents hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —CH2—;
    • Z represents -CR5eR5g-CR5fR5h-;
    • R5e, R5f, R5g, and R5h represent hydrogen;
    • Ar represents any one of the following 10-membered bicyclic aromatic ring systems:
    • Figure US20230330127A1-20231019-C00066
    • Figure US20230330127A1-20231019-C00067
    • Figure US20230330127A1-20231019-C00068
    • Figure US20230330127A1-20231019-C00069
    • Figure US20230330127A1-20231019-C00070
    • Figure US20230330127A1-20231019-C00071
    • Figure US20230330127A1-20231019-C00072
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d;
    • R10c and R10d each independently represent C3-6cycloalkyl; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C 1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, -NR7aR7b, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen;
    • R2 represents hydrogen;
    • Y represents —CH2—;
    • Z represents -CR5eR5g-CR5fR5h-;
    • R5e, R5f, R5g, and R5h represent hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00073
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d;
    • R10d represents C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, -NR7aR7b, or -O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • R4a represents hydrogen;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
    • (i) R1 represents hydrogen;
      • R2 represents hydrogen;
    • (ii) Y represents —CH2—;
    • (iii) Z represents -CR5eR5g-CR5fR5h-;
    • (iv) R5e, R5f, R5g, and R5h represent hydrogen;
    • (v) Ar represents
  • Figure US20230330127A1-20231019-C00074
      • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d;
    • (vi) R10d represents C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • (vii) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • (viii) R3a represents hydrogen, -NR7aR7b, or -O-C1-4alkyl;
    • (ix) R7a represents hydrogen;
      • R7b represents hydrogen or C1-4alkyl;
    • (x) R4a represents hydrogen;
    • (xi) Q1 represents CR6a;
      • Q2 represents CR6b;
    • (xii) R6a and R6b represent hydrogen.
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
    • (i) R1 represents hydrogen or-C(=O)-C1-4alkyl;
      • R2 represents hydrogen or -C(=O)-C 1-4alkyl;
      • in particular R1 and R2 represent hydrogen;
    • (ii) Y represents —CH2— or —O—;
    • (iii) Z represents -X-CR5aR5b- or —CH2CH2—;
    • (iv) R5a and R5b each independently represent hydrogen or C1-4alkyl;
    • (v) X represents —O—, —S—, or -NR11-;
    • (vi) R11 represents hydrogen;
    • (vii) Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • (viii) R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • (ix) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • (x) R3a represents hydrogen, halo, -NR7aR7b, or —O—C1-4alkyl;
    • (xi) R7a represents hydrogen;
      • R7b represents hydrogen;
    • (xii) R4a represents hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • (xiii) R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • (xiv) Q1 represents CR6a;
    • (xv) Q2 represents CR6b;
    • (xvi) R6a and R6b each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • (xvii) R9a and R9b each independently represent hydrogen or C1-4alkyl.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C 1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C 1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —O—;
    • Z represents -X-CR5aR5b-;
    • R5a and R5b each independently represent hydrogen or C1-4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen;
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or-O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a represents hydrogen, halo, -NR8aR8b, or C 1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
    • (i) R1 represents hydrogen or -C(=O)-C1-4alkyl;
      • R2 represents hydrogen or -C(=O)-C 1-4alkyl;
      • in particular R1 and R2 represent hydrogen;
    • (ii) Y represents —O—;
    • (iii) Z represents -X-CR5aR5b-;
    • (iv) R5a and R5b each independently represent hydrogen or C1-4alkyl;
    • (v) X represents —O—, —S—, or -NR11-;
    • (vi) R11 represents hydrogen;
    • (vii) Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • (viii) R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • (ix) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • (x) R3a represents hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl;
    • (xi) R7a represents hydrogen;
      • R7b represents hydrogen;
    • (xii) R4a represents hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • (xiii) R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • (xiv) Q1 represents CR6a;
    • (xv) Q2 represents CR6b;
    • (xvi) R6a and R6b each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • (xvii) R9a and R9b each independently represent hydrogen or C1-4alkyl.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C 1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —CH2— or —O—;
    • Z represents -X-CR5aR5b- or —CH2CH2—
    • R5a and R5b each independently represent hydrogen or C1-4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00075
    • in particular Ar represents
    • Figure US20230330127A1-20231019-C00076
    • Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C 1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or-O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a represents hydrogen, halo, -NR8aR8b, or C 1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (1), wherein
    • R1 represents hydrogen or -C(=O)-C 1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C 1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —O—;
    • Z represents -X-CR5aR5b-;
    • R5a and R5b each independently represent hydrogen or C1-4alkyl;
    • X represents —O—, —S—, or -NR11-;
    • R11 represents hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00077
    • in particular Ar represents
    • Figure US20230330127A1-20231019-C00078
    • Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R10a and R10b each independently represent hydrogen or C 1-4alkyl;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents hydrogen, halo, -NR7aR7b, or-O-C1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a represents hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • Q1 represents CR6a;
    • Q2 represents CR6b;
    • R6a and R6b each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • R9a and R9b each independently represent hydrogen or C1-4alkyl;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
    • (i) R1 represents hydrogen or-C(=O)-C1-4alkyl;
      • R2 represents hydrogen or -C(=O)-C1-4alkyl;
      • in particular R1 and R2 represent hydrogen;
    • (ii) Y represents —O—;
    • (iii) Z represents -X-CR5aR5b-;
    • (iv) R5a and R5b each independently represent hydrogen or C1-4alkyl;
    • (v) X represents —O—, —S—, or-NR11-;
    • (vi) R11 represents hydrogen;
    • (vii) Ar represents
    • Figure US20230330127A1-20231019-C00079
    • in particular Ar represents
    • Figure US20230330127A1-20231019-C00080
    • (viii) Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • (ix) R10a and R10b each independently represent hydrogen or C1-4alkyl;
    • (x) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • (xi) R3a represents hydrogen, halo, -NR7aR7b, or-O-C1-4alkyl;
    • (xii) R7a represents hydrogen;
      • R7b represents hydrogen;
    • (xiii) R4a represents hydrogen, halo, -NR8aR8b, or C1-4alkyl;
    • (xiv) R8a and R8b each independently represent hydrogen or C1-4alkyl;
    • (xv) Q1 represents CR6a;
    • (xvi) Q2 represents CR6b;
    • (xvii) R6a and R6b each independently represent hydrogen, halogen, C1-4alkyl, -NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
    • (xviii) R9a and R9b each independently represent hydrogen or Ci-4alkyl.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —O— or —CH2—; Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b represent hydrogen; X represents —O—;
    • R11 represents hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00081
    • Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, and —CF3;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a represents hydrogen;
    • Q1 represents CR6a; Q2 represents CR6b; R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —O— or —CH2—; Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b represent hydrogen; X represents —O—;
    • R11 represents hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00082
    • Ar is optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, and —CF3;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a represents hydrogen;
    • Q1 represents CR6a; Q2 represents CR6b; R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —O—; Z represents -X-CR5aR5b-;
    • R5a and R5b represent hydrogen; X represents —O—;
    • R11 represents hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00083
    • Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, and —CF3;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a represents hydrogen;
    • Q1 represents CR6a; Q2 represents CR6b; R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —O—; Z represents -X-CR5aR5b-;
    • R5a and R5b represent hydrogen; X represents —O—;
    • R11 represents hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00084
    • Ar is optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, and —CF3;
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents -NR7aR7b;
    • R7a represents hydrogen;
    • R 7b represents hydrogen;
    • R4a represents hydrogen;
    • Q1 represents CR6a; Q2 represents CR6b; R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —O— or —CH2—; Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b represent hydrogen; X represents —O—;
    • R11 represents hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00085
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • R4a represents hydrogen;
    • Q1 represents CR6a; Q2 represents CR6b; R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
    • R1 represents hydrogen or -C(=O)-C1-4alkyl;
    • R2 represents hydrogen or -C(=O)-C1-4alkyl;
    • in particular R1 and R2 represent hydrogen;
    • Y represents —O—; Z represents -X-CR5aR5b-;
    • R5a and R5b represent hydrogen; X represents —O—;
    • R11 represents hydrogen;
    • Ar represents
    • Figure US20230330127A1-20231019-C00086
    • Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • R3a represents -NR7aR7b;
    • R7a represents hydrogen;
    • R 7b represents hydrogen;
    • R4a represents hydrogen;
    • Q1 represents CR6a; Q2 represents CR6b; R6a and R6b represent hydrogen;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
    • (i) R1 represents hydrogen or-C(=O)-C1-4alkyl;
      • R2 represents hydrogen or -C(=O)-C1-4alkyl;
      • in particular R1 and R2 represent hydrogen;
    • (ii) Y represents —O—;
    • (iii) Z represents -X-CR5aR5b-;
    • (iv) R5a and R5b represent hydrogen;
    • (v) X represents —O—;
    • (vi) R11 represents hydrogen;
    • (vii) Ar represents
    • Figure US20230330127A1-20231019-C00087
      • Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, and —CF3; in particular Ar is optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, and —CF3;
      • more in particular Ar represents
      • Figure US20230330127A1-20231019-C00088
      • even more in particular Ar represents
      • Figure US20230330127A1-20231019-C00089
    • (ix) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
    • (x) R3a represents -NR7aR7b;
    • (xi) R7a represents hydrogen;
      • R7b represents hydrogen;
    • (xii) R4a represents hydrogen;
    • (xiii) Q1 represents CR6a;
    • (xiv) Q2 represents CR6b;
    • (xv) R6a and R6b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R1 and R2 represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R1 represents-C(=O)-C1-4alkyl; R2 represents-C(=O)-C1-4alkyl.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R1 and R2 represent hydrogen;
    • Het represents (a-1);
    • Q1 represents CH; Q2 represents CH; and
    • Ar represents
    • Figure US20230330127A1-20231019-C00090
    • optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R1 and R2 represent hydrogen;
    • Het represents (a-1);
    • Q1 represents CH; Q2 represents CH; and
    • Ar represents
    • Figure US20230330127A1-20231019-C00091
      • wherein Ar is substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d;
    • R10c and R10d each independently represent C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents —O—.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents —CH2— or —CF2—; in particular wherein Y represents —CH2—.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein maximum one of Q1 and Q2 represents N.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q1 represents CR6a; and Q2 represents CR6b; in particular wherein Q1 represents CH; and Q2 represents CH.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents (a-1); Q1 represents CR6a; and Q2 represents CR6b; in particular wherein Q1 represents CH; and Q2 represents CH.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f; or
    • Q5 represents CR3d; Q6 represents CR4e; and Q7 represents N; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents CR4f; or
    • Q5 represents N; Q6 represents CR4e; and Q7 represents N.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-4).
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R1 and R2 represent hydrogen; and Y represents —O—.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3).
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2).
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-4).
  • In an embodiment, the present invention relates to those compounds of Formula (1) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system of Formula (a-1).
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R1 and R2 represent hydrogen; Y represents —O—; and Het represents a bicyclic aromatic heterocyclic ring system of Formula (a-1).
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents an optionally substituted 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that the nitrogen atom does not replace one of the two fused carbon atoms.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one or two substituents according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one substituent according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R3a, R3c, R3b represent hydrogen; and
    • R4a, R4c, R4b represent hydrogen, halo, or C1-4alkyl; in particular R4a, R4c, R4b represent halo, or C1-4alkyl.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R3a, R3c, R3b, R3d and R3e represent hydrogen; and
    • R4a, R4c, R4b, R4d, R4c, R4f and R4g represent hydrogen, halo, or C1-4alkyl; in particular R4a, R4c, R4b, R4d, R4c, R4f and R4g represent halo, or C1-4alkyl.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R3a, R3c, R3b represent hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl; in particular R3a, R3c, R3b represent halo, -NR7aR7b, or-O-C1-4alkyl;
    • R4a, R4c, R4b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R3a, R3c, R3b, R3d and R3e represent hydrogen, halo, -NR7aR7b, or -O-C1-4alkyl; in particular R3a, R3c, R3b, R3d and R3e represent halo, -NR7aR7b, or -O-C1-4alkyl;
    • R4a, R4c, R 4b, R4d, R4c, R4f and R4g represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R3a, R3c, R3b represent hydrogen, when R4a, R4c, R4b are different from hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R3a, R3c, R3b, R3d, R3e represent hydrogen, when R4a, R4c, R4b, R4d, R4c, R4f, R4g are different from hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R4a, R4c, R4b represent hydrogen, when R3a, R3c, R3b are different from hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R4a, R4c, R4b, R4d, R4c, R4f, R4g represent hydrogen, when R3a, R3c, R3b, R3d, R3e are different from hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,
    • Figure US20230330127A1-20231019-C00092
      • wherein at least1 ring carbon atom of ring B is replaced by a nitrogen atom;
      • wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,
    • Figure US20230330127A1-20231019-C00093
      • wherein at least1 ring carbon atom of ring B is replaced by a nitrogen atom;
      • wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d, cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, —C(═O)—C1- 4alkyl, C1-4alkyloxy, -C(=O)-O-C1-4alkyl, C3-6cycloalkyl, C2-6alkenyl, C1-4alkyl substituted with one C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • in particular Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings with the following structure,
    • Figure US20230330127A1-20231019-C00094
      • wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted according to any of the other embodiments.
  • It will be clear that
  • Figure US20230330127A1-20231019-C00095
  • covers any one of the following ring systems:
  • Figure US20230330127A1-20231019-C00096
  • Figure US20230330127A1-20231019-C00097
  • Figure US20230330127A1-20231019-C00098
  • Figure US20230330127A1-20231019-C00099
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00100
  • Figure US20230330127A1-20231019-C00101
  • Figure US20230330127A1-20231019-C00102
  • Figure US20230330127A1-20231019-C00103
  • Figure US20230330127A1-20231019-C00104
  • Figure US20230330127A1-20231019-C00105
  • Figure US20230330127A1-20231019-C00106
  • Figure US20230330127A1-20231019-C00107
  • Figure US20230330127A1-20231019-C00108
  • Figure US20230330127A1-20231019-C00109
  • Figure US20230330127A1-20231019-C00110
  • Figure US20230330127A1-20231019-C00111
  • Figure US20230330127A1-20231019-C00112
  • wherein each Ar is optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00113
  • Figure US20230330127A1-20231019-C00114
  • Figure US20230330127A1-20231019-C00115
  • Figure US20230330127A1-20231019-C00116
  • Figure US20230330127A1-20231019-C00117
  • Figure US20230330127A1-20231019-C00118
  • Figure US20230330127A1-20231019-C00119
  • wherein each Ar is optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00120
  • Figure US20230330127A1-20231019-C00121
  • Figure US20230330127A1-20231019-C00122
  • Figure US20230330127A1-20231019-C00123
  • Figure US20230330127A1-20231019-C00124
  • Figure US20230330127A1-20231019-C00125
  • Figure US20230330127A1-20231019-C00126
  • Figure US20230330127A1-20231019-C00127
  • Figure US20230330127A1-20231019-C00128
  • Figure US20230330127A1-20231019-C00129
  • Figure US20230330127A1-20231019-C00130
  • Figure US20230330127A1-20231019-C00131
  • Figure US20230330127A1-20231019-C00132
  • Figure US20230330127A1-20231019-C00133
  • wherein each Ar is optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00134
  • Figure US20230330127A1-20231019-C00135
  • Figure US20230330127A1-20231019-C00136
  • Figure US20230330127A1-20231019-C00137
  • Figure US20230330127A1-20231019-C00138
  • Figure US20230330127A1-20231019-C00139
  • Figure US20230330127A1-20231019-C00140
  • Figure US20230330127A1-20231019-C00141
  • Figure US20230330127A1-20231019-C00142
  • Figure US20230330127A1-20231019-C00143
  • Figure US20230330127A1-20231019-C00144
  • Figure US20230330127A1-20231019-C00145
  • Figure US20230330127A1-20231019-C00146
  • Figure US20230330127A1-20231019-C00147
  • Figure US20230330127A1-20231019-C00148
  • wherein each Ar is optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00149
  • Figure US20230330127A1-20231019-C00150
  • Figure US20230330127A1-20231019-C00151
  • Figure US20230330127A1-20231019-C00152
  • Figure US20230330127A1-20231019-C00153
  • Figure US20230330127A1-20231019-C00154
  • Figure US20230330127A1-20231019-C00155
  • Figure US20230330127A1-20231019-C00156
  • Figure US20230330127A1-20231019-C00157
  • Figure US20230330127A1-20231019-C00158
  • Figure US20230330127A1-20231019-C00159
  • Figure US20230330127A1-20231019-C00160
  • wherein each Ar is optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is
  • Figure US20230330127A1-20231019-C00161
  • wherein Ar is optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is other than
  • Figure US20230330127A1-20231019-C00162
  • wherein Ar is optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00163
  • wherein Ar is substituted with one, two, three or four substituents each independentlyselected from the group consisting of halo, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00164
    • wherein Ar is substituted with one substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d; and optionally substituted with a halo substituent;
    • R10c and R10d each independently represent C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00165
    • wherein Ar is substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d; and
    • wherein Ar is optionally substituted in the position indicated by β with a halo substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00166
    • wherein Ar is substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d; and
    • wherein Ar is optionally substituted in the position indicated by β with a halo substituent;
    • R10c and R10d each independently represent C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00167
  • wherein Ar is substituted in the position indicated by β with a halo substituent; in particular chloro or bromo; more in particular bromo.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represent (a-1); Q1 represents CR6a; Q2 represents CR6b; and Ar represents
  • Figure US20230330127A1-20231019-C00168
  • wherein Ar is substituted in the position indicated by β with a halo substituent; in particular chloro or bromo; more in particular bromo.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is substituted with one substituent selected from the group consisting of —NH2, -NH-C1-4alkyl -N(C1-4alkyl)2, -NHR10d, -NR10cR10d; and wherein Ar is optionally substituted with another substituent selected from the list of substituents on Ar in any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00169
  • optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00170
    • optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl;
    • in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —NH2, -NH-C1-4alkyl, cyano, —CF3, C1-4alkyloxy, and C1-4alkyl;
      • more in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, or —CF3;
      • more in particular optionally substituted with one or two halo substituents;
      • more in particular substituted with one or two halo substituents;
      • even more in particular substituted with one halo substituent;
      • most in particular substituted with one chloro substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00171
  • optionally substituted according to any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00172
    • optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl;
    • in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —NH2, -NH-C1-4alkyl, cyano, —CF3, C1-4alkyloxy, and C1-4alkyl;
    • more in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, or —CF3;
    • more in particular optionally substituted with one or two halo substituents;
    • more in particular substituted with one or two halo substituents;
    • even more in particular substituted with one halo substituent;
    • most in particular substituted with one chloro substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Het represents (a-1); and
    • Ar represents
    • Figure US20230330127A1-20231019-C00173
      • optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl;
      • in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —NH2, -NH-C1-4alkyl, cyano, —CF3, C1-4alkyloxy, and C1-4alkyl;
      • more in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, or —CF3;
      • more in particular optionally substituted with one or two halo substituents;
      • more in particular substituted with one or two halo substituents;
      • even more in particular substituted with one halo substituent;
      • most in particular substituted with one chloro substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Het represents (a-1); and
    • Ar represents
    • Figure US20230330127A1-20231019-C00174
      • in particular Ar represents
      • Figure US20230330127A1-20231019-C00175
      • Figure US20230330127A1-20231019-C00176
      • more in particular Ar represents
      • Figure US20230330127A1-20231019-C00177
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00178
    • in particular Ar represents
    • Figure US20230330127A1-20231019-C00179
    • Figure US20230330127A1-20231019-C00180
    • more in particular Ar represents
    • Figure US20230330127A1-20231019-C00181
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R5b, R5g and R5h represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q1 represents CR6a; and Q2 represents CR6b.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents —O—; Q1 represents CR6a; and Q2 represents CR6b.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents —O—; Q1 represents CH; and Q2 represents CRH.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R5b, R5g and R5h represent hydrogen;
    • Y represents —CH2— or —CF2—; in particular Y represents —CH2—; and
    • Het represents (a-1);
    • Q1 represents CR6a; and Q2 represents CR6b; in particular wherein Q1 represents CH;
    • and Q2 represents CH.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R5b, R5g and R5h represent hydrogen; Y represents —O—; and
    • Het represents (a-1);
    • Q1 represents CR6a; and Q2 represents CR6b; in particular wherein Q1 represents CH; and Q2 represents CH.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q2 represents CR6b.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR5aR5b-.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents —O—CH2—.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR5aR5b-; X represents —O—; and R5a and R5b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents —O— or -NR11-; in particular X represents —O—.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R7a and R7b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents (a-1); R3a represents -NR7aR7b; and R7a and R7b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R3a, R3b and R3c represent -NR7aR7b; and R7a and R7b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • R3a, R3c, R3b, R3d and R3e represent -NR7aR7b; and R7a and R7b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R3a, R3b and R3c represent other than halo.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R3a, R3c, R3b, R3d and R3e represent other than halo.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R3a, R3b and R3c represent -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R3a, R3b and R3c represent —NH2.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • Het represents (a-1); R3a represents -NR7aR7b; and R7a and R7b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • Ar is substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, —C(═O)—C1- 4alkyl, C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b;
    • Het represents (a-1); R3a represents -NR7aR7b; and R7a and R7b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
  • Figure US20230330127A1-20231019-C00182
    • optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, —CF3, -C(=O)-NH-C1-4alkyl, C1- 4alkyloxy, and C1-4alkyl;
    • in particular optionally substituted with one substituent selected from the group consisting of halo, —NH2, -NH-C1-4alkyl, cyano, —CF3, C1-4alkyloxy, and C1-4alkyl;
    • more in particular optionally substituted with one substituent selected from the group consisting of halo, and —CF3;
    • more in particular optionally substituted with one halo substituent;
    • more in particular substituted with one halo substituent;
    • even more in particular substituted with one chloro substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00183
  • Figure US20230330127A1-20231019-C00184
  • Figure US20230330127A1-20231019-C00185
  • Figure US20230330127A1-20231019-C00186
  • Figure US20230330127A1-20231019-C00187
  • wherein each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00188
  • Figure US20230330127A1-20231019-C00189
  • Figure US20230330127A1-20231019-C00190
  • Figure US20230330127A1-20231019-C00191
  • Figure US20230330127A1-20231019-C00192
  • Figure US20230330127A1-20231019-C00193
  • Figure US20230330127A1-20231019-C00194
  • wherein each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00195
  • Figure US20230330127A1-20231019-C00196
  • Figure US20230330127A1-20231019-C00197
  • wherein each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00198
  • Figure US20230330127A1-20231019-C00199
  • Figure US20230330127A1-20231019-C00200
    • wherein each Ar is optionally substituted in position a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, and -NR10cR10d;
    • R10c and R10d each independently represent C3-6cycloalkyl; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R13 and R14;
    • R13 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(═O)p and N;
    • said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C1-4alkyl;
    • p represents 1 or 2;
    • R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00201
  • Figure US20230330127A1-20231019-C00202
  • Figure US20230330127A1-20231019-C00203
  • wherein each Ar is optionally substituted in position a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, and -NR10cR10d; and wherein Ar is optionally substituted in another position with a halo substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:
  • Figure US20230330127A1-20231019-C00204
  • Figure US20230330127A1-20231019-C00205
  • Figure US20230330127A1-20231019-C00206
    • wherein each Ar is substituted in position a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, and -NR10cR10d;
    • and wherein Ar is optionally substituted in another position with a halo substituent.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,
    • wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
    • wherein each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d, cyano, —CF3, —C(═O)—NH2, -C(=O)-NH-C1-4alkyl, -C(=O)-C1-4alkyl, C1-4alkyloxy, -C(=O)-O-C1-4alkyl, C2-6alkenyl, C1-4alkyl substituted with one C1-4alkyloxy, and C1-4alkyl optionally substituted with one -NR10aR10b.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents
    • Figure US20230330127A1-20231019-C00207
    • Ar is optionally substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, and —CF3;
    • more in particular Ar represents
    • Figure US20230330127A1-20231019-C00208
    • even more in particular Ar represents
    • Figure US20230330127A1-20231019-C00209
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Ar represents
    • Figure US20230330127A1-20231019-C00210
    • Ar is substituted with one substituent selected from the group consisting of halo, —OH, —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, cyano, and —CF3;
    • more in particular Ar represents
    • Figure US20230330127A1-20231019-C00211
    • even more in particular Ar represents
    • Figure US20230330127A1-20231019-C00212
    • Het represents (a-1); R3a represents -NR7aR7b; and R7a and R7b represent hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-a1):
  • Figure US20230330127A1-20231019-C00213
  • It will be clear that all variables in the structure of Formula (I-a1), may be defined as defined for the compounds of Formula (I) or any subgroup thereof as mentioned in any of the other embodiments.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-a1):
  • Figure US20230330127A1-20231019-C00214
  • wherein R3a represents —NH2; and R4a represents hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-a1):
  • Figure US20230330127A1-20231019-C00215
    • wherein R3a represents —NH2; R4a represents hydrogen; and
    • Ar represents
    • Figure US20230330127A1-20231019-C00216
    • more in particular Ar represents
    • Figure US20230330127A1-20231019-C00217
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-a1):
  • Figure US20230330127A1-20231019-C00218
  • wherein
    • R1 and R2 represent hydrogen;
    • R3a represents hydrogen, -NR7aR7b, or —OC1-4alkyl;
    • R4a represents hydrogen; and
    • Ar represents
    • Figure US20230330127A1-20231019-C00219
      • wherein Ar is substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d; and
      • wherein Ar is optionally substituted in the position indicated by β with a halo substituent;
    • R10c and R10d each independently represent C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent.
  • In an embodiment, the present invention concerns novel compounds of Formula (I-a1)
  • Figure US20230330127A1-20231019-C00220
  • wherein
    • R1 and R2 represent hydrogen;
    • R3a represents hydrogen, -NR7aR7b, or -OC1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • Z represents —CH2CH2—;
    • Y represents —O—, —CH2— or —CF2—; in particular —CH2—;
    • R4a represents hydrogen; and
    • Ar represents
    • Figure US20230330127A1-20231019-C00221
      • wherein Ar is substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d; and
      • wherein Ar is optionally substituted in the position indicated by β with a halo substituent;
    • R10c and R10d each independently represent C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I-a1)
  • Figure US20230330127A1-20231019-C00222
  • wherein
    • R1 and R2 represent hydrogen;
    • R3a represents hydrogen, -NR7aR7b, or -OC1-4alkyl;
    • R7a represents hydrogen;
    • R7b represents hydrogen or C1-4alkyl;
    • Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b represent hydrogen; X represents —O—;
    • Y represents —O—, —CH2— or —CF2—; in particular —CH2—;
    • R4a represents hydrogen; and
    • Ar represents
    • Figure US20230330127A1-20231019-C00223
      • wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, -N(C1-4alkyl)2, -NHR10d, -NR10cR10d; and
      • wherein Ar is optionally substituted in the position indicated by β with a halo substituent;
    • R10c and R10d each independently represent C1-4alkyl substituted with one, two or three halo substituents; or C1-4alkyl substituted with one C3-6cycloalkyl substituent;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention concerns novel compounds of Formula (I-a1)
  • Figure US20230330127A1-20231019-C00224
  • wherein
    • R1 and R2 represent hydrogen;
    • R3a represents -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen;
    • Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b represent hydrogen; X represents —O—;
    • Y represents —O— or —CH2—;
    • R4a represents hydrogen; and
    • Ar represents
    • Figure US20230330127A1-20231019-C00225
      • wherein Ar is optionally substituted in the position indicated by a with —NH2; and
      • wherein Ar is substituted in the position indicated by β with a halo substituent, in particular Br;
    • and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR5aR5b- or —CH2CH2—.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b represent hydrogen;
    • X represents —O—.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b represent hydrogen;
    • X represents —O—;
    • Het represents (a-l).
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Z represents -X-CR5aR5b- or —CH2CH2—\;
    • R5a and R5b represent hydrogen;
    • X represents —O—;
    • Het represents (a-1);
    • R3a represents-NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents —O—.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Z represents -X-CR5aR5b- or —CH2CH2—;
    • R5a and R5b represent hydrogen;
    • X represents —O—;
    • Ar represents
    • Figure US20230330127A1-20231019-C00226
      • wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of —NH2, -NH-C1-4alkyl, and -NHR10d; and
      • wherein Ar is optionally substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF3;
      • provided however that Ar is substituted in at least one of the positions indicated by a or β;
    • Het represents (a-1);
    • R3a represents-NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • Het represents (a-1);
    • R3a represents-NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R3a, R3b, R3c, R3d and R3e represent -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R3a, R3b, R3c, R3d and R3e represent -NR7aR7b;
    • R7a represents hydrogen;
    • R7b represents hydrogen.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
    • R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, —O—C1-4alkyl, —NH2, -NH-C1-4alkyl, and -N(C1-4alkyl)2; and
    • R10c and R10d each independently represent C3-6cycloalkyl; R14; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and -O-C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -O-C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, and R14.
  • In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents —CH2—; and Z represents —CH2CH2—.
  • In an embodiment, the present invention relates to a subgroup of Formula (I) as defined in the general reaction schemes.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2 and 58.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2 and 80.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 74, 75, 76, 77, 78, 79, 80 and 81.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2, 58, 74, 75, 76, 77, 78, 79, 80, 81, 154, 159, 235, 240 and 247.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2 and 58, and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2 and 80, and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 74, 75, 76, 77, 78, 79, 80 and 81, and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2, 58, 74, 75, 76, 77, 78, 79, 80, 81, 154, 159, 235, 240 and 247 and pharmaceutically acceptable addition salts, and solvates thereof.
  • In an embodiment the compound of Formula (I) is selected from the group consisting of any of the exemplified compounds, and the free bases, the pharmaceutically acceptable addition salts, and the solvates thereof.
  • All possible combinations of the above-indicated embodiments are considered to be embraced within the scope of this invention.
    • Methods for the Preparation
  • In this section, as in all other sections unless the context indicates otherwise, references to Formula (I) also include all other sub-groups and examples thereof as defined herein.
  • The general preparation of some typical examples of the compounds of Formula (I) is described hereunder and in the specific examples, and are generally prepared from starting materials which are either commercially available or prepared by standard synthetic processes commonly used by those skilled in the art. The following schemes are only meant to represent examples of the invention and are in no way meant to be a limit of the invention.
  • Alternatively, compounds of the present invention may also be prepared by analogous reaction protocols as described in the general schemes below, combined with standard synthetic processes commonly used by those skilled in the art of organic chemistry.
  • The skilled person will realize that in the reactions described in the Schemes, it may be necessary to protect reactive functional groups, for example hydroxy, amino, or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used in accordance with standard practice. This is illustrated in the specific examples.
  • The skilled person will realize that in the reactions described in the Schemes, it may be advisable or necessary to perform the reaction under an inert atmosphere, such as for example under N2-gas atmosphere, for example when NaH is used in the reaction.
  • It will be apparent for the skilled person that it may be necessary to cool the reaction mixture before reaction work-up (refers to the series of manipulations required to isolate and purify the product(s) of a chemical reaction such as for example quenching, column chromatography, extraction).
  • The skilled person will realize that heating the reaction mixture under stirring may enhance the reaction outcome. In some reactions microwave heating may be used instead of conventional heating to shorten the overall reaction time.
  • The skilled person will realize that another sequence of the chemical reactions shown in the Schemes below, may also result in the desired compound of Formula (I).
  • The skilled person will realize that intermediates and compounds shown in the schemes below may be further functionalized according to methods well-known by the person skilled in the art.
  • The skilled person will realize that more Compounds of Formula (I) can be prepared by using similar synthetic protocols as described in the Schemes below.
  • In case one of the starting materials is available as a salt form, the skilled person will realize that it may be necessary to first treat the salt with a base, such as for example N,N-diisopropylethylamine (DIPEA).
  • All variables are defined as mentioned hereabove unless otherwise is indicated or is clear from the context.
  • The skilled person will understand that analogous chemistry as described in Schemes 1 to 9, may also be applied to make compounds of Formula (I) wherein Het represents a bicyclic aromatic heterocyclic rings system (a-4) or (a-5). Some typical examples are illustrated in the specific examples. In addition, this information may be combined with standard synthetic processes commonly used by those skilled in the art of organic chemistry to obtain more compounds of Formula (I) wherein Het represents (a-4) or (a-5).
  • In general, compounds of Formula (I) can be prepared according to Scheme 1:
    • General Scheme 1
  • Figure US20230330127A1-20231019-C00227
    Figure US20230330127A1-20231019-C00228
    Figure US20230330127A1-20231019-C00229
  • In scheme 1, ‘LG1’ is defined as a suitable leaving group such as for example halogen; ‘LG2’ is defined as a suitable leaving group such as for example halogen or -SCH3.
  • ‘LG3’ is defined as a leaving group such as halogen and -SCH3. All other variables in Scheme 1 are defined according to the scope of the present invention.
  • In scheme 1, the following reaction conditions typically apply:
  • 1: Different sets of reaction conditions dependent on the definition of R3a, R3b or R3c:
  • 1a: When R3a, R3b or R3c is halogen, step 1 can be skipped.
  • 1b: When R3a, R3b or R3c is NR7aR7b, in the presence of a suitable amine of formula HNR7aR7b, with a suitable solvent such as for example, H2O, MeOH, or EtOH, at a suitable temperature such as for example between 100-130° C. typicall under microwave conditions or using an autoclave vessel for heating.
  • 1c: When R3a, R3b or R3c is -O-C1-4alkyl, in the presence of a suitable HO-C1-4alkyl, with a suitable base such as for example NaH, potassium tert-butoxide (tBuOK) in a suitable solvent such as for example tetrahydrofuran (THF) at a suitable temperature. Alternatively in the presence of the suitable HO-C1-4alkyl as solvent with a suitable acid such as for example HCl.
  • 1d: When R3a, R3b or R3c is hydrogen, under hydrogenation conditions: H2-gas atmosphere in the presence of a catalyst such as for example Raney Ni, Pd/C (for example 5 wt% or 10 wt%) or Pt/C (for example 5 wt%) in a suitable solvent such as for example methanol (MeOH), ethanol (EtOH) or THF;
  • 1e: When R3a, R3b or R3c is C1-4alkyl, in the presence of a suitable boronic acid or ester such as for example methylboronic acid with a suitable catalyst such as for example 1,1′-bis(diphenylphosphino)ferrocene and with with a suitable base such as for example K3PO4 in a in a suitable solvent mixture such as for example dioxane/ H2O ratio 5 to 1 at a suitable temperature such as for example 100° C.;
  • 2: in the presence of a suitable acid, such as for example 4M HCl in dioxane or 4M HCl in MeOH, with a suitable solvent such as for example MeOH at a suitable temperature such as for example room temperature; or alternatively in the presence of a suitable acid such as for example trifluoroacetic acid (TFA) in dichloromethane (DCM) at a suitable temperature, or acetic acid in THF and water at a suitable temperature such as for example room temperature.
  • 3: in the presence of suitable acid anhydride of formula (C1-4alkylC=O)2O with a suitable solvent such as pyridine at a suitable temperature. When R3a, R3bor R3c is NH2, (C1-4alkylC=O)2O can react with the NH2 to obtain the N(C1-4alkylC=O)2 intermediate. Such an intermediate can be converted to the targeted product in a suitable solvent such as for example MeOH at a suitable temperature such as for example 100-130° C. under microwave conditions or using an autoclave vessel for heating. The reaction may benefit from the presence of an acid, such as HCl or C1-4 alkylCO2H.
  • The starting materials in scheme 1 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in following general schemes.
    • General Scheme 2a
  • In general, intermediates of Formula III, V and VII wherein Z represents -O-CHR5a- can be prepared according to Scheme 2a. All other variables in Scheme 2a are defined according to the scope of the present invention. The skilled person will realize a suitable protection group is needed when R3a, R3b or R3c is —NH2 or -NHR7b;
  • Figure US20230330127A1-20231019-C00230
  • Figure US20230330127A1-20231019-C00231
  • Figure US20230330127A1-20231019-C00232
  • In scheme 2a, the following reaction conditions apply:
    • 1: The Mitsunobu reaction:
      • 1a: In the presence of PPh3-Polymer supported, diisopropyl azodicarboxylate (DIAD) or diethyl azodicarboxylate (DEAD) or Bis(1,1-dimethytethyl)-azodicarboxylate (DBAD) in a suitable solvent such as for example anhydrous THF at a suitable temperature such as for example room temperature.
      • 1b: In the presence of triphenylphosphine (PPh3), DIAD or DEAD in a suitable solvent such as for example anhydrous THF at a suitable temperature such as for example room temperature.
      • 1c: In the presence of cyanomethylenetributylphosphorane (CMBP) or cyanomethylenetrimethylphosphorane (CMMP), in a suitable solvent such as for example anhydrous toluene at a suitable temperature such as for example 80° C.
  • The starting materials in scheme 2a are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in following general schemes. The skilled person will realize that when R5a is C1-4alkyl, the different isomers can be separated from each other by using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) or Supercritical Fluid Chromatography (SFC).
    • General Scheme 2b
  • Intermediates of Formula II, IV and VI wherein Z represents -Xa-CHR5a- can be prepared according to Scheme 2b. In scheme 2b, ‘Xa’ is defined as O or S; ‘LG’ is defined as a leaving group such as for example halogen, mesylate (MsO) and tosylate (TosO), preferably TosO. ‘LG1’ is defined as leaving group such as for example halogen; ‘LG2’ is defined as a leaving group such as for example halogen or —SCH3. ‘LG3’ is defined as a leaving group such as for example halogen or —SCH3. All other variables in Scheme 2b are defined according to the scope of the present invention.
  • Figure US20230330127A1-20231019-C00233
  • Figure US20230330127A1-20231019-C00234
  • Figure US20230330127A1-20231019-C00235
  • In scheme 2b, the following reaction conditions apply:
  • 1: in the presence of a base such as for example K2CO3, trietylamine (Et3N) or DIPEA, in a suitable solvent such as CH3CN, DCM or N,N-dimethylacetamide (DMA).
  • The starting materials in scheme 2b are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in following general schemes. The skilled person will realize that when R5a is C1-4alkyl, the different isomers can be separated from each other by using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) or Supercritical Fluid Chromatography (SFC).
    • General Scheme 2c
  • Intermediates III, V and VII wherein Z represents -Xa-CHR5a- can be prepared according to Scheme 2c. In scheme 2c, ‘Xa’ is defined as O or S. ‘LG’ is defined as a leaving group such as for example halogen, MsO or TosO, preferably TosO. All other variables in Scheme 2c are defined according to the scope of the present invention. The skilled person will realize that a suitable protection group is needed when R3a, R3b or R3c is —NH2 or -NHR7b.
  • Figure US20230330127A1-20231019-C00236
  • Figure US20230330127A1-20231019-C00237
  • Figure US20230330127A1-20231019-C00238
  • In scheme 2c, the following reaction conditions apply:
  • 1: in the presence of a base such as for example K2CO3, Et3N or DIPEA, in a suitable solvent such as CH3CN, DCM or N,N-dimethylacetamide (DMA).
  • The starting materials in scheme 2c are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in following general schemes. The skilled person will realize that when R5a is C1-4alkyl, the different isomers can be separated from each other by using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) or Supercritical Fluid Chromatography (SFC).
    • General Scheme 3
  • In general, intermediates wherein Z represents -X-CHR5a- ; and wherein X represents -NH- or -NR11- can be prepared according to Scheme 3. In scheme 3, ‘LG1’ is defined as a leaving group such as for example halogen; ‘LG2’ is defined as a leaving group such as for example halogen or —SCH3. ‘LG3’ is defined as a leaving group such as for example halogen or —SCH3. All other variables in Scheme 3 are defined according to the scope of the present invention.
    Figure US20230330127A1-20231019-C00239
    Figure US20230330127A1-20231019-C00240
    Figure US20230330127A1-20231019-C00241
  • In scheme 3, the following reaction conditions apply:
    • 1: in the presence of a suitable reduction reagent such as for example sodium triacetoxyborohydride (NaBH(AcO)3) together with a suitable solvent such as for example DCM at a suitable temperature such as for example room temperature; or alternatively NaBH3CN together with a suitable solvent such as for example MeOH at a suitable temperature such as for example between room temperature and 50° C.
    • 2: in the presence of a suitable base such as for example NaH together with a suitable solvent such as for example anhydrous THF, N,N-dimethylformamide (DMF), DMA at a suitable temperature such as for example between room temperature and 50° C.
  • The starting materials in scheme 3 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part. The skilled person will realize that when R5a is C1-4alkyl, the different isomers can be separated from each other by using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) or Supercritical Fluid Chromatography (SFC).
    • General Scheme 4
  • In general, intermediates wherein Z represents — C═C—, —CH═CH—, or —CH2—CH2— can be prepared according to Scheme 4. In scheme 4, ‘LG1’ is defined as a leaving group such as for example halogen; ‘LG2’ is defined as a leaving group such as for example halogen or —SCH3. ‘LG3’ is defined as leaving group such as for example halogen or —SCH3. All other variables in Scheme 4 are defined according to the scope of the present invention.
    Figure US20230330127A1-20231019-C00242
  • Figure US20230330127A1-20231019-C00243
  • Figure US20230330127A1-20231019-C00244
  • In scheme 4, the following reaction conditions apply:
    • 1: In the presence of suitable amine, such as HNR′R″ or NaOR′, with a suitable solvent such as for example H2O, MeOH, or EtOH at a suitable temperature such as for example between 100-130° C. under microwave condition or using an autoclave vessel for heating.
    • 2: In the presence of suitable catalyst, such as bis(triphenylphosphine)palladium(II) dichloride and copper(I) iodide in a suitable solvent, such as 2-methyltetrahydrofuran with a suitable base, such as for example triethylamine at a suitable temperature, such as for example 80° C.
    • 3: in the presence of a suitable salt, such as for example tetraethylammonium chloride (Et4NCl), in a suitable solvent, such as for example DMF, with a suitable base such as for example DIPEA and a palladium catalyst, such as for example Pd(OAc)2 (palladium(II) acetate) at suitable temperature such as for example 100° C.
    • 4: in the presence of a H2-gas atmosphere and a catalyst such as for example Pd/C (for example 5 wt% or 10 wt%) in a suitable solvent such as for example MeOH.
  • The starting materials in scheme 4 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.
    • General Scheme 5
  • In general, intermediates wherein Y represents CH2 or CF2, hereby named Ya, and wherein Z represents —CH2O— can be prepared according to Scheme 5.
  • In scheme 5, ‘LG1’ is defined as a leaving group such as for example halogen; ‘LG2’ is defined as a leaving group such as for example halogen or —SCH3. ‘LG3’ is defined as leaving group such as halogen or —SCH3. All other variables in Scheme 5 are defined according to the scope of the present invention.
  • Figure US20230330127A1-20231019-C00245
  • Figure US20230330127A1-20231019-C00246
  • Figure US20230330127A1-20231019-C00247
  • In scheme 5, the following reaction conditions apply:
  • 1: in the presence of a base such as for example K2CO3, Et3N or DIPEA, in a suitable solvent such as CH3CN, DCM or N,N-dimethylacetamide (DMA).
    • General Scheme 6
  • In general, intermediates wherein Z represents —CH2— can be prepared according to Scheme 6. In scheme 6, ‘LG1’ is defined as a leaving group such as for example halogen; ‘LG2’ is defined as a leaving group such for example halogen or —SCH3. ‘LG3’ is defined as a leaving group such as for example halogen or —SCH3. All other variables in Scheme 6 are defined according to the scope of the present invention.
  • Figure US20230330127A1-20231019-C00248
  • Figure US20230330127A1-20231019-C00249
  • Figure US20230330127A1-20231019-C00250
  • In scheme 6, the following reaction conditions apply:
    • 1: In the presence of tosylhydrazide, with a suitable solvent such as for example, MeOH, EtOH, or DCM at a suitable temperature such as room temperature.
    • 2: In the presence of Boronic acids, with suitable base such as K2CO3, Na2CO3, CS2CO3, with a suitable solvent such as for example, 1,4-dioxane at a suitable temperature such 90° C.
  • The starting materials in scheme 6 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.
    • General Scheme 7
  • In general, intermediates wherein Z represents —CH2—CH2— can be prepared according to Scheme 7. In scheme 7, ‘LG1’ is defined as a leaving group such as for example halogen; ‘LG2’ is defined as a leaving group such as for example halogen or —SCH3. ‘LG3’ is defined as leaving group such as for example halogen or —SCH3. All other variables in Scheme 7 are defined according to the scope of the present invention.
  • Figure US20230330127A1-20231019-C00251
  • Figure US20230330127A1-20231019-C00252
  • Figure US20230330127A1-20231019-C00253
  • In scheme 7, the following reaction conditions typically apply:
    • 1: In a first step in the presence of an alkene precursor and a 9-Borabicyclo(3.3.1)nonane (9-BBN) solution 0.5 M in THF under nitrogen atmosphere at a temperature between room temperature and reflux and a reaction time between 1 to 3 hours. In a second step in the presence of, for example, a suitable Ar-bromide or Ar-iodide and a suitable catalyst as for example 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and in the presence of a suitable base as for example potassium phosphate tribasic in a suitable solvent mixture as for example THF and water at a suitable temperature between 50° C. and reflux and a suitable reaction time between 1 and 3 hours.
    • 2: Different sets of reaction conditions dependent on the definition of R3a, R36 or R3c:
      • 2a: When R3a, R3bor R3c is halogen, step 1 can be skipped.
      • 2b: When R3a, R3bor R3c is NR7aR7b, in the presence of a suitable amine of formula HNR7aR7b, with a suitable solvent such as for example, H2O, MeOH, or EtOH, at a suitable temperature such as for example between 100-130° C. typicall under microwave conditions or using an autoclave vessel for heating.
      • 2c: When R3a, R3b or R3c is -O-C1-4alkyl, in the presence of a suitable HO-C1-4alkyl, with a suitable base such as for example NaH, potassium tert-butoxide (tBuOK) in a suitable solvent such as for example tetrahydrofuran (THF) at a suitable temperature. Alternatively in the presence of the suitable HO-C1-4alkyl as solvent with a suitable acid such as for example HCl.
      • 2d: When R3a, R3b or R3c is hydrogen, under hydrogenation conditions: H2-gas atmosphere in the presence of a catalyst such as for example Raney Ni, Pd/C (for example 5 wt% or 10 wt%) or Pt/C (for example 5 wt%) in a suitable solvent such as for example methanol (MeOH), ethanol (EtOH) or THF;
      • 2e: When R3a, R3b or R3c is C1-4alkyl, in the presence of a suitable boronic acid or ester such as for example methylboronic acid with a suitable catalyst such as for example 1,1′-bis(diphenylphosphino)ferrocene and with with a suitable base such as for example K3PO4 in a in a suitable solvent mixture such as for example dioxane/ H2O ratio 5 to 1 at a suitable temperature such as for example 100° C.
  • The starting materials in scheme 7 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.
    • General Scheme 8
  • In general, intermediates wherein Z represents —CH2—CH2— can be prepared according to Scheme 8. In scheme 8, ‘LG1’ is defined as a leaving group such as for example halogen; ‘LG2’ is defined as a leaving group such as for example halogen or —SCH3. ‘LG3’ is defined as leaving group such as for example halogen or —SCH3. All other variables in Scheme 8 are defined according to the scope of the present invention.
  • Figure US20230330127A1-20231019-C00254
  • Figure US20230330127A1-20231019-C00255
  • Figure US20230330127A1-20231019-C00256
  • In scheme 8, the following reaction conditions typically apply:
    • 1: Different sets of reaction conditions dependent on the definition of R3a, R3bor R3c:
      • 1a: When R3a, R3bor R3c is halogen, step 1 can be skipped.
      • 1b: When R3a, R3bor R3c is NR7aR7b, in the presence of a suitable amine of formula HNR7aR7b, with a suitable solvent such as for example, H2O, MeOH, or EtOH, at a suitable temperature such as for example between 100-130° C. typicall under microwave conditions or using an autoclave vessel for heating.
      • 1c: When R3a, R3b or R3c is -O-C1-4alkyl, in the presence of a suitable HO-C1-4alkyl, with a suitable base such as for example NaH, potassium tert-butoxide (tBuOK) in a suitable solvent such as for example tetrahydrofuran (THF) at a suitable temperature. Alternatively in the presence of the suitable HO-C1-4alkyl as solvent with a suitable acid such as for example HCl.
      • 1d: When R3a, R3bor R3c is hydrogen, under hydrogenation conditions: H2-gas atmosphere in the presence of a catalyst such as for example Raney Ni, Pd/C (for example 5 wt% or 10 wt%) or Pt/C (for example 5 wt%) in a suitable solvent such as for example methanol (MeOH), ethanol (EtOH) or THF;
      • 1e: When R3a, R3b or R3c is C1-4alkyl, in the presence of a suitable boronic acid or ester such as for example methylboronic acid with a suitable catalyst such as for example 1,1′-bis(diphenylphosphino)ferrocene and with with a suitable base such as for example K3PO4 in a in a suitable solvent mixture such as for example dioxane/ H2O ratio 5 to 1 at a suitable temperature such as for example 100° C.;
    • 2: In a first step in the presence of an alkene precursor and a 9-BBN solution 0.5 M in THF under nitrogen atmosphere at a temperature between room temperature and reflux and a reaction time between 1 to 3 hours. In a second step in the presence of suitable (het)arylbromide or (het)aryliodide and a suitable catalyst as for example 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and in the presence of a suitable base as for example potassium phosphate tribasic in a suitable solvent mixture as for example THF and water at a suitable temperature between 50° C. and reflux and a suitable reaction time between 1 and 3 hours.
  • The starting materials in scheme 8 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.
    • General Scheme 9
  • In general, intermediates as shown in Scheme 9 wherein Z represents —CH2—CH2— can be prepared according to Scheme 9. In scheme 9, ‘LG1’ is defined as a leaving group such as for example halogen. All other variables in Scheme 9 are defined according to the scope of the present invention
  • Figure US20230330127A1-20231019-C00257
  • 1: In a first step in the presence of an alkene precursor and a 9-BBN solution 0.5 M in THF under nitrogen atmosphere at a temperature between room temperature and reflux and a reaction time between 1 to 3 hours. In a second step in the presence of, for example, a suitable Ar-bromide or Ar-iodide (X being Br or I respectively) and a suitable catalyst as for example 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and in the presence of a suitable base as for example potassium phosphate tribasic in a suitable solvent mixture as for example THF and water at a suitable temperature between 50° C. and reflux and a suitable reaction time between 1 and 3 hours.
  • 2: In the presence of triflic anhydride and a suitable base as for example pyridine in a suitable solvent as for example DCM at a suitable temperature as for example 0° C. under an inert atmosphere of N2 gas.
  • 3: In the presence of a suitable base as for example CS2CO3 in a suitable solvent as for example DMF at a suitable temperature as for example room temperature under an inert atmosphere of N2 gas.
  • The starting materials in scheme 9 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.
  • In all these preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, trituration and chromatography.
  • The chirally pure forms of the compounds of Formula (I) form a preferred group of compounds. It is therefore that the chirally pure forms of the intermediates and their salt forms are particularly useful in the preparation of chirally pure compounds of Formula (I). Also enantiomeric mixtures of the intermediates are useful in the preparation of compounds of Formula (I) with the corresponding configuration.
    • Pharmacology
  • It has been found that the compounds of the present invention inhibit PRMT5 activity.
  • In particular compounds of the present invention bind to the PRMT5 enzyme, and competitively with natural substrate SAM (S-adenosyl-L-methionine), to inhibit such enzyme.
  • It is therefore anticipated that the compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries and the like.
  • In particular the compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as allergy, asthma, hematopoietic cancer, lung cancer, prostate cancer, melanoma, metabolic disorder, diabetes, obesity, blood disorder, sickle cell anemia, and the like.
  • The compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a proliferative disorder, such as an autoimmune disease, cancer, a benign neoplasm, or an inflammatory disease.
  • The compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a metabolic disorder comprising diabetes, obesity; a proliferative disorder comprising cancer, hematopoietic cancer, lung cancer, prostate cancer, melanoma, or pancreatic cancer; blood disorder; hemoglobinopathy: sickle cell anemia; β -thalessemia, an inflammatory disease, and autoimmune disease e.g. rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, diarrhea, gastroesophageal reflux disease, and the like.
  • In some embodiments, the inhibition of PRMT5 by a provided compound may be useful in treating or preventing, in particular treating, the following non-limiting list of cancers: breast cancer, lung cancer, esophageal cancer, bladder cancer, hematopoietic cancer, lymphoma, medulloblastoma, rectum adenocarcinoma, colon adenocarcinoma, gastric cancer, pancreatic cancer, liver cancer, adenoid cystic carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma, brain tumors, hepatocellular carcinoma, renal cell carcinoma, melanoma, oligodendroglioma, ovarian clear cell carcinoma, and ovarian serous cystadenoma.
  • Examples of metabolic disorders which may be treated or prevented, in particular treated, include, but are not limited to, diabetes or obesity.
  • Examples of blood disorders which may be treated or prevented, in particular treated, include, but are not limited to, hemoglobinopathy, such as sickle cell disease or β-thalassemia.
  • Examples of cancers which may be treated or prevented, in particular treated, include, but are not limited to, acoustic neuroma, adenocarcinoma, adrenal gland cancer, anal cancer, angiosarcoma (e.g., lymphangio sarcoma, lymphangioendothelio sarcoma, hemangio sarcoma), appendix cancer, benign monoclonal gammopathy, biliary cancer (e.g., cholangiocarcinoma), bladder cancer, breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast), brain cancer (e.g., meningioma; glioma, e.g., astrocytoma, oligodendroglioma; medulloblastoma), bronchus cancer, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinoma), chordoma, choriocarcinoma, craniopharyngioma, colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), epithelial carcinoma, ependymoma, endothelio sarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial cancer (e.g., uterine cancer, uterine sarcoma), esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett′ s adenocarinoma), Ewing sarcoma, eye cancer (e.g., intraocular melanoma, retinoblastoma), familiar hypereosinophilia, gall bladder cancer, gastric cancer (e.g., stomach adenocarcinoma), gastrointestinal stromal tumor (GIST), head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma (OSCC), throat cancer (e.g., pharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)), hematopoietic cancers (e.g., leukemia such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T- cell CLL); lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma (DLBCL)), follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., “Waldenstrom’s macro globulinemia”), immunoblastic large cell lymphoma, hairy cell leukemia (HCL), precursor B -lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T-lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungiodes, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma); a mixture of one or more leukemia/lymphoma as described above; and multiple myeloma (MM)), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease), hemangioblastoma, inflammatory myofibroblastic tumors, immunocytic amyloidosis, kidney cancer (e.g., nephroblastoma a.k.a. Wilms’ tumor, renal cell carcinoma), liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma), lung cancer (e.g., bronchogenic carcinoma, non-small cell lung cancer (NSCLC), squamous lung cancer (SLC), adenocarcinoma of the lung, Lewis lung carcinoma, lung neuroendocrine tumors: typical carcinoid, atypical carcinoid, small cell lung cancer (SCLC), and large cell neuroendocrine carcinoma), leiomyosarcoma (LMS), mastocytosis (e.g., systemic mastocytosis), myelodysplastic syndromes (MDS), mesothelioma, myeloproliferative disorder (MPD) (e.g., polycythemia Vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)), neuroblastoma, neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis), neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor), osteosarcoma, ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma, pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors), penile cancer (e.g., Paget’s disease of the penis and scrotum), pinealoma, primitive neuroectodermal tumor (PNT), prostate cancer (e.g., prostate adenocarcinoma), rectal cancer, rhabdomyosarcoma, salivary gland cancer, skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)), small bowel cancer (e.g., appendix cancer), soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sebaceous gland carcinoma, sweat gland carcinoma, synovioma, testicular cancer (e.g., seminoma, testicular embryonal carcinoma), thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer), urethral cancer, vaginal cancer, and vulvar cancer (e.g., Paget’s disease of the vulva).
  • Examples of neurodegenerative diseases which may be treated or prevented, in particular treated, include, but are not limited to, motor neurone disease, progressive supranuclear palsy, corticobasal degeneration, Pick’s disease, Alzheimer’s disease, AIDS-related dementia, Parkinson’s disease, amyotropic lateral sclerosis, retinitis pigmentosa, spinal muscular atropy, and cerebellar degeneration.
  • Examples of cardiovascular diseases which may be treated or prevented, in particular treated, include, but are not limited to, cardiac hypertrophy, restenosis, atherosclerosis, and glomerulonephritis.
  • Examples of inflammatory diseases which may be treated or prevented, in particular treated, include, but are not limited to, inflammation associated with acne, anemia (e.g., aplastic anemia, haemolytic autoimmune anaemia), rhinitis, asthma, arteritis (e.g., polyarteritis, temporal arteritis, periarteritis nodosa, Takayasu’s arteritis), arthritis (e.g., crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis and Reiter’s arthritis), upper respiratory tract disease, ankylosing spondylitis, amylosis, amyotrophic lateral sclerosis, autoimmune diseases, allergies or allergic reactions, atherosclerosis, bronchitis, bursitis, chronic prostatitis, conjunctivitis, Chagas disease, chronic obstructive pulmonary disease, diverticulitis, cermatomyositis, diabetes (e.g., type I diabetes mellitus, type 2 diabetes mellitus), a skin condition (e.g., psoriasis, eczema, eczema hypersensitivity reactions, bums, dermatitis, pruritus (itch)), endometriosis, Guillain-Barre syndrome, infection, ischaemic heart disease, Kawasaki disease, glomerulonephritis, gingivitis, hypersensitivity, headaches (e.g., migraine headaches, tension headaches), ileus (e.g., postoperative ileus and ileus during sepsis), idiopathic thrombocytopenic purpura, interstitial cystitis (painful bladder syndrome), gastrointestinal disorder (e.g., selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet’s syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS)), lupus, morphea, myeasthenia gravis, myocardial ischemia, multiple sclerosis, nephrotic syndrome, pemphigus vulgaris, pernicious aneaemia, peptic ulcers, polymyositis, primary biliary cirrhosis, neuroinflammation associated with brain disorders (e.g., Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease), prostatitis, chronic inflammation associated with cranial radiation injury, pelvic inflammatory disease, reperfusion injury, regional enteritis, rheumatic fever, systemic lupus erythematosus, schleroderma, scierodoma, sarcoidosis, spondyloarthopathies, Sjogren’s syndrome, thyroiditis, transplantation rejection, tendonitis, trauma or injury (e.g., frostbite, chemical irritants, toxins, scarring, bums, physical injury), vasculitis, vitiligo and Wegener’s granulomatosis.
  • In particular the inflammatory disease is an acute inflammatory disease (e.g., for example, inflammation resulting from infection). In particular the inflammatory disease is a chronic inflammatory disease (e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease). The compounds may also be useful in treating inflammation associated with trauma and non-inflammatory myalgia. The compounds may also be useful in treating inflammation associated with cancer.
  • Examples of autoimmune diseases which may be treated or prevented, in particular treated, include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren’s syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet’s disease, haemolytic autoimmune anaemias, amyotrophic lateral sclerosis, amylosis, multiple sclerosis, acute painful shoulder, psoriatic, and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin condition (e.g., psoriasis, eczema, eczema hypersensitivity reactions, bums, dermatitis, pruritus (itch)), enuresis, eosinophilic disease, gastrointestinal disorder (e.g., selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet’s syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS)), and disorders ameliorated by a gastroprokinetic agent (e.g., ileus, postoperative ileus and ileus during sepsis; gastroesophageal reflux disease (GORD, or its synonym GERD); eosinophilic esophagitis, gastroparesis such as diabetic gastroparesis: food intolerances and food allergies and other functional bowel disorders, such as non-ulcerative dyspepsia (NUD) and non-cardiac chest pain (NCCP, including costo-chondritis)).
  • In a particular embodiment, a provided compound may be useful in somatic cell reprogramming, such as reprogramming somatic cells into stem cells. In a particular embodiment, a provided compound may be useful in germ cell development, and are thus envisioned useful in the areas of reproductive technology and regenerative medicine.
  • Other diseases which may be treated or prevented, in particular treated, include, but are not limited to, ischemic injury associated myocardial infarctions, immunological diseases, stroke, arrhythmia, toxin-induced or alcohol related liver diseases, aspirin-sensitive rhinosinusitis, cystic fibrosis, cancer pain, and haematological diseases, for example chronic anemia and aplastic anemia.
  • The compounds of the present invention may also have therapeutic applications in sensitising tumour cells for radiotherapy and chemotherapy.
  • Hence the compounds of the present invention may be used as “radiosensitizer” and/or “chemosensitizer” or can be given in combination with another “radiosensitizer” and/or “chemosensitizer”.
  • The term “radiosensitizer”, as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to ionizing radiation and/or to promote the treatment of diseases which are treatable with ionizing radiation.
  • The term “chemosensitizer”, as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of cells to chemotherapy and/or promote the treatment of diseases which are treatable with chemotherapeutics.
  • Several mechanisms for the mode of action of radiosensitizers have been suggested in the literature including: hypoxic cell radiosensitizers (e.g., 2- nitroimidazole compounds, and benzotriazine dioxide compounds) mimicking oxygen or alternatively behave like bioreductive agents under hypoxia; non-hypoxic cell radiosensitizers (e.g., halogenated pyrimidines) can be analogoues of DNA bases and preferentially incorporate into the DNA of cancer cells and thereby promote the radiation-induced breaking of DNA molecules and/or prevent the normal DNA repair mechanisms: and various other potential mechanisms of action have been hypothesized for radiosensitizers in the treatment of disease.
  • Many cancer treatment protocols currently employ radiosensitizers in conjunction with radiation of x-rays. Examples of x-ray activated radiosensitizers include, but are not limited to, the following: metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, E09, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5- iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives of the same.
  • Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent. Examples of photodynamic radiosensitizers include the following, but are not limited to: hematoporphyrin derivatives, Photofrin, benzoporphyrin derivatives, tin etioporphyrin, pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.
  • Radiosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of radiosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumour with or without additional radiation; or other therapeutically effective compounds for treating cancer or other diseases.
  • Chemosensitizers may be administered in conjunction with a therapeutically effective amount of one or more other compounds, including but not limited to: compounds which promote the incorporation of chemosensitizers to the target cells; compounds which control the flow of therapeutics, nutrients, and/or oxygen to the target cells; chemotherapeutic agents which act on the tumour or other therapeutically effective compounds for treating cancer or other disease. Calcium antagonists, for example verapamil, are found useful in combination with antineoplastic agents to establish chemosensitivity in tumor cells resistant to accepted chemotherapeutic agents and to potentiate the efficacy of such compounds in drug-sensitive malignancies.
  • The compounds of the present invention might also reduce the risk of cancer recurrence.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for use as a medicament.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for use in the inhibition of PRMT5 activity.
  • The compounds of the present invention can be “anti-cancer agents”, which term also encompasses “anti-tumor cell growth agents” and “anti-neoplastic agents”.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for use in the treatment of diseases mentioned above.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the treatment or prevention, in particular for the treatment, of said diseases.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the treatment or prevention, in particular in the treatment, of PRMT5 mediated diseases or conditions.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the inhibition of PRMT5.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the treatment or prevention, in particular for the treatment, of any one of the disease conditions mentioned hereinbefore.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the treatment of any one of the disease conditions mentioned hereinbefore.
  • The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, can be administered to mammals, preferably humans, for the treatment or prevention of any one of the diseases mentioned hereinbefore.
  • In view of the utility of the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, there is provided a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded animals, including humans, to suffer from any one of the diseases mentioned hereinbefore.
  • Said methods comprise the administration, i.e. the systemic or topical administration, preferably oral administration, of an effective amount of a compound of Formula (I) or a pharmaceutically acceptable addition salt, or a solvate thereof, to warm-blooded animals, including humans.
  • Those of skill in the treatment of such diseases could determine the effective therapeutic daily amount from the test results presented hereinafter. An effective therapeutic daily amount would be from about 0.005 mg /kg to 50 mg/kg, in particular 0.01 mg/kg to 50 mg/kg body weight, more in particular from 0.01 mg/kg to 25 mg/kg body weight, preferably from about 0.01 mg/kg to about 15 mg/kg, more preferably from about 0.01 mg/kg to about 10 mg/kg, even more preferably from about 0.01 mg/kg to about 1 mg/kg, most preferably from about 0.05 mg/kg to about 1 mg/kg body weight. A particular effective therapeutic daily amount might be from about 0.01 to 1.00 g twice a day (BID), more in particular 0.30 to 0.85 g BID; even more in particular 0.40 g BID. The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutically effect will of course, vary on case-by-case basis, for example with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated.
  • A method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day. In these methods of treatment the compounds according to the invention are preferably formulated prior to administration. As described herein below, suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.
  • The compounds of the present invention, that can be suitable to treat or prevent cancer or cancer-related conditions, may be administered alone or in combination with one or more additional therapeutic agents. Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and one or more additional therapeutic agents, as well as administration of the compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and each additional therapeutic agents in its own separate pharmaceutical dosage formulation. For example, a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage formulations.
  • While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition.
  • Accordingly, the present invention further provides a pharmaceutical composition and, as active ingredient, a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof.
  • Accordingly, the present invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof.
  • The carrier or diluent must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • For ease of administration, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. The compounds according to the invention, in particular the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs.
  • To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally, rectally, percutaneously, by parenteral injection or by inhalation. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, may be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid or base addition salts of compounds of Formula (I) due to their increased water solubility over the corresponding base or acid form, are more suitable in the preparation of aqueous compositions.
  • It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • In order to enhance the solubility and/or the stability of the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, in pharmaceutical compositions, it can be advantageous to employ α-, β- or γ-cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds according to the invention in pharmaceutical compositions.
  • Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99% by weight, more preferably from 0.1 to 70% by weight, even more preferably from 0.1 to 50% by weight of the compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and from 1 to 99.95% by weight, more preferably from 30 to 99.9% by weight, even more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
  • As another aspect of the present invention, a combination of a compound of the present invention with another anticancer agent is envisaged, especially for use as a medicine, more specifically for use in the treatment of cancer or related diseases.
  • For the treatment of the above conditions, the compounds of the invention may be advantageously employed in combination with antibody based immune cell redirection, for example T-cell/neutrophil redirection. This can be achieved for example by the use of bispecific monoclonal antibodies or artificial T-cell receptors.
  • For the treatment of the above conditions, the compounds of the invention may be advantageously employed in combination with one or more other medicinal agents, more particularly, with other anti-cancer agents or adjuvants in cancer therapy. Examples of anti-cancer agents or adjuvants (supporting agents in the therapy) include but are not limited to:
    • platinum coordination compounds for example cisplatin optionally combined with amifostine, carboplatin or oxaliplatin;
    • taxane compounds for example paclitaxel, paclitaxel protein bound particles (Abraxane™) or docetaxel;
    • topoisomerase I inhibitors such as camptothecin compounds for example irinotecan, SN-38, topotecan, topotecan hcl;
    • topoisomerase II inhibitors such as anti-tumour epipodophyllotoxins or podophyllotoxin derivatives for example etoposide, etoposide phosphate or teniposide;
    • anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine;
    • anti-tumour nucleoside derivatives for example 5-fluorouracil, leucovorin, gemcitabine, gemcitabine hcl, capecitabine, cladribine, fludarabine, nelarabine;
    • alkylating agents such as nitrogen mustard or nitrosourea for example cyclophosphamide, chlorambucil, carmustine, thiotepa, mephalan (melphalan), lomustine, altretamine, busulfan, dacarbazine, estramustine, ifosfamide optionally in combination with mesna, pipobroman, procarbazine, streptozocin, temozolomide, uracil;
    • anti-tumour anthracycline derivatives for example daunorubicin, doxorubicin optionally in combination with dexrazoxane, doxil, idarubicin, mitoxantrone, epirubicin, epirubicin hcl, valrubicin;
    • molecules that target the IGF-1 receptor for example picropodophilin;
    • tetracarcin derivatives for example tetrocarcin A;
    • glucocorticoïds for example prednisone;
    • antibodies for example trastuzumab (HER2 antibody), rituximab (CD20 antibody), gemtuzumab, gemtuzumab ozogamicin, cetuximab, pertuzumab, bevacizumab, alemtuzumab, eculizumab, ibritumomab tiuxetan, nofetumomab, panitumumab, tositumomab, CNTO 328;
    • estrogen receptor antagonists or selective estrogen receptor modulators or inhibitors of estrogen synthesis for example tamoxifen, fulvestrant, toremifene, droloxifene, faslodex, raloxifene or letrozole;
    • aromatase inhibitors such as exemestane, anastrozole, letrazole, testolactone and vorozole;
    • differentiating agents such as retinoids, vitamin D or retinoic acid and retinoic acid metabolism blocking agents (RAMBA) for example accutane;
    • DNA methyl transferase inhibitors for example azacytidine or decitabine;
    • antifolates for example premetrexed disodium;
    • antibiotics for example antinomycin D, bleomycin, mitomycin C, dactinomycin, carminomycin, daunomycin, levamisole, plicamycin, mithramycin;
    • antimetabolites for example clofarabine, aminopterin, cytosine arabinoside or methotrexate, azacitidine, cytarabine, floxuridine, pentostatin, thioguanine;
    • apoptosis inducing agents and antiangiogenic agents such as Bcl-2 inhibitors for example YC 137, BH 312, ABT 737, gossypol, HA 14-1, TW 37 or decanoic acid;
    • tubuline-binding agents for example combrestatin, colchicines or nocodazole;
    • kinase inhibitors (e.g. EGFR (epithelial growth factor receptor) inhibitors, MTKI (multi target kinase inhibitors), mTOR inhibitors) for example flavoperidol, imatinib mesylate, erlotinib, gefitinib, dasatinib, lapatinib, lapatinib ditosylate, sorafenib, sunitinib, sunitinib maleate, temsirolimus;
    • farnesyltransferase inhibitors for example tipifamib;
    • histone deacetylase (HDAC) inhibitors for example sodium butyrate, suberoylanilide hydroxamic acid (SAHA), depsipeptide (FR 901228), NVP-LAQ824, R306465, JNJ-26481585, trichostatin A, vorinostat;
    • Inhibitors of the ubiquitin-proteasome pathway for example PS-341, MLN .41 or bortezomib:
    • Yondelis;
    • Telomerase inhibitors for example telomestatin;
    • Matrix metalloproteinase inhibitors for example batimastat, marimastat, prinostat or metastat.
    • Recombinant interleukins for example aldesleukin, denileukin diftitox, interferon alfa 2a, interferon alfa 2b, peginterferon alfa 2b
    • MAPK inhibitors
    • Retinoids for example alitretinoin, bexarotene, tretinoin
    • Arsenic trioxide
    • Asparaginase
    • Steroids for example dromostanolone propionate, megestrol acetate, nandrolone (decanoate, phenpropionate), dexamethasone
    • Gonadotropin releasing hormone agonists or antagonists for example abarelix, goserelin acetate, histrelin acetate, leuprolide acetate
    • Thalidomide, lenalidomide
    • Mercaptopurine, mitotane, pamidronate, pegademase, pegaspargase, rasburicase
    • BH3 mimetics for example ABT-737
    • MEK inhibitors for example PD98059, AZD6244, CI-1040
    • colony-stimulating factor analogs for example filgrastim, pegfilgrastim, sargramostim; erythropoietin or analogues thereof (e.g. darbepoetin alfa); interleukin 11; oprelvekin; zoledronate, zoledronic acid; fentanyl; bisphosphonate; palifermin
    • a steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitor (CYP17), e.g. abiraterone, abiraterone acetate
    • Glycolysis inhibitors, such as 2-deoxyglucose
    • mTOR inhibitors such as rapamycins and rapalogs, and mTOR kinase inhibitors
    • PI3K inhibitors and dual mTOR/PI3K inhibitors
    • autophagy inhibitors, such as chloroquine and hydroxy-chloroquine
    • antibodies that re-activate the immune response to tumors, for example nivolumab (anti-PD-1), lambrolizumab (anti-PD-1), ipilimumab (anti-CTLA4), and MPDL3280A (anti-PD-L1).
  • The present invention further relates to a product containing as first active ingredient a compound according to the invention and as further active ingredient one or more anticancer agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.
  • The one or more other medicinal agents and the compound according to the present invention may be administered simultaneously (e.g. in separate or unitary compositions) or sequentially in either order. In the latter case, the two or more compounds will be administered within a period and in an amount and manner that is sufficient to ensure that an advantageous or synergistic effect is achieved. It will be appreciated that the preferred method and order of administration and the respective dosage amounts and regimes for each component of the combination will depend on the particular other medicinal agent and compound of the present invention being administered, their route of administration, the particular tumour being treated and the particular host being treated. The optimum method and order of administration and the dosage amounts and regime can be readily determined by those skilled in the art using conventional methods and in view of the information set out herein.
  • The weight ratio of the compound according to the present invention and the one or more other anticancer agent(s) when given as a combination may be determined by the person skilled in the art. Said ratio and the exact dosage and frequency of administration depends on the particular compound according to the invention and the other anticancer agent(s) used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. A particular weight ratio for the present compound of Formula (I) and another anticancer agent may range from ⅒ to 10/1, more in particular from ⅕ to 5/1, even more in particular from ⅓ to 3/1.
  • The platinum coordination compound is advantageously administered in a dosage of 1 to 500 mg per square meter (mg/m2) of body surface area, for example 50 to 400 mg/m2, particularly for cisplatin in a dosage of about 75 mg/m2 and for carboplatin in about 300 mg/m2 per course of treatment.
  • The taxane compound is advantageously administered in a dosage of 50 to 400 mg per square meter (mg/m2) of body surface area, for example 75 to 250 mg/m2, particularly for paclitaxel in a dosage of about 175 to 250 mg/m2 and for docetaxel in about 75 to 150 mg/m2 per course of treatment.
  • The camptothecin compound is advantageously administered in a dosage of 0.1 to 400 mg per square meter (mg/m2) of body surface area, for example 1 to 300 mg/m2, particularly for irinotecan in a dosage of about 100 to 350 mg/m2 and for topotecan in about 1 to 2 mg/m2 per course of treatment.
  • The anti-tumour podophyllotoxin derivative is advantageously administered in a dosage of 30 to 300 mg per square meter (mg/m2) of body surface area, for example 50 to 250 mg/m2, particularly for etoposide in a dosage of about 35 to 100 mg/m2 and for teniposide in about 50 to 250 mg/m2 per course of treatment.
  • The anti-tumour vinca alkaloid is advantageously administered in a dosage of 2 to 30 mg per square meter (mg/m2) of body surface area, particularly for vinblastine in a dosage of about 3 to 12 mg/m2, for vincristine in a dosage of about 1 to 2 mg/m2, and for vinorelbine in dosage of about 10 to 30 mg/m2 per course of treatment.
  • The anti-tumour nucleoside derivative is advantageously administered in a dosage of 200 to 2500 mg per square meter (mg/m2) of body surface area, for example 700 to 1500 mg/m2, particularly for 5-FU in a dosage of 200 to 500 mg/m2, for gemcitabine in a dosage of about 800 to 1200 mg/m2 and for capecitabine in about 1000 to 2500 mg/m2 per course of treatment.
  • The alkylating agents such as nitrogen mustard or nitrosourea is advantageously administered in a dosage of 100 to 500 mg per square meter (mg/m2) of body surface area, for example 120 to 200 mg/m2, particularly for cyclophosphamide in a dosage of about 100 to 500 mg/m2, for chlorambucil in a dosage of about 0.1 to 0.2 mg/kg, for carmustine in a dosage of about 150 to 200 mg/m2, and for lomustine in a dosage of about 100 to 150 mg/m2 per course of treatment.
  • The anti-tumour anthracycline derivative is advantageously administered in a dosage of 10 to 75 mg per square meter (mg/m2) of body surface area, for example 15 to 60 mg/m2, particularly for doxorubicin in a dosage of about 40 to 75 mg/m2, for daunorubicin in a dosage of about 25 to 45 mg/m2, and for idarubicin in a dosage of about 10 to 15 mg/m2 per course of treatment.
  • The antiestrogen agent is advantageously administered in a dosage of about 1 to 100 mg daily depending on the particular agent and the condition being treated. Tamoxifen is advantageously administered orally in a dosage of 5 to 50 mg, preferably 10 to 20 mg twice a day, continuing the therapy for sufficient time to achieve and maintain a therapeutic effect. Toremifene is advantageously administered orally in a dosage of about 60 mg once a day, continuing the therapy for sufficient time to achieve and maintain a therapeutic effect. Anastrozole is advantageously administered orally in a dosage of about 1 mg once a day. Droloxifene is advantageously administered orally in a dosage of about 20-100 mg once a day. Raloxifene is advantageously administered orally in a dosage of about 60 mg once a day. Exemestane is advantageously administered orally in a dosage of about 25 mg once a day.
  • Antibodies are advantageously administered in a dosage of about 1 to 5 mg per square meter (mg/m2) of body surface area, or as known in the art, if different. Trastuzumab is advantageously administered in a dosage of 1 to 5 mg per square meter (mg/m2) of body surface area, particularly 2 to 4 mg/m2 per course of treatment.
  • These dosages may be administered for example once, twice or more per course of treatment, which may be repeated for example every 7, 14, 21 or 28 days.
  • The following examples illustrate the present invention. In case no specific stereochemistry is indicated for a stereocenter of a compound, this means that a mixture of the R and the S enantiomers was obtained. In case more than 1 stereocenter is present in a structure, each stereocenter for which no specific stereochemistry is indicated was obtained as a mixture of R and S.
  • The skilled person will realize that typically after a column purification, the desired fractions were collected and the solvent was evaporated to obtain the desired compound or intermediate.
    • EXAMPLES
  • Hereinafter, the term “rt”, “r.t.” or “RT” means room temperature; “Me” means methyl; “MeOH” means methanol; “Et” means ethyl; “EtOH” means ethanol; “NaH” means sodium hydride; “DEAD” means diethyl azodicarboxylate; “HMPT” means hexamethylphosphorous triamide; “Boc2O” means tert-butoxycarbonyl anhydride; “ButONO” means tert-butyl nitrite; “TosOH” means 4-methylbenzenesulfonic acid; “TosCl” means 4-methylbenzenesulfonyl chloride (also p-toluenesulfonyl chloride); “CMBP” means cyanomethylenetributylphosphorane; “DBAD” means di-tert-butyl azodicarboxylate; “LAH” means lithium aluminum hydride; “NaBH(AcO)3” or “NaBH(OAc)3” means sodium triacetoxyborohydride; “EtOAc” means ethyl acetate; “TEA” or “Et3N” means triethylamine; “DCM” means dichloromethane; “q.s.” means quantum sufficit; “Int.” Means intermediate; “MeCN” or “ACN” means acetonitrile; “DMF” means N,N-dimethyl formamide; “DMA” means N,N-dimethylacetamide; “DMF-DMA” means N,N-Dimethylformamide dimethyl acetal; “Pd(dppf)Cl2” means [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II); “THF” means tetrahydrofuran; “C34H28FeP2.Cl2Pd” means [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium(ii); “i-PrOH” or “iPrOH” means 2-propanol; “LC” means liquid chromatography; “LCMS” means Liquid Chromatography/Mass spectrometry; “HPLC” means high-performance liquid chromatography; “int.” means intermediate; “prep-HPLC” means preparative high-performance liquid chromatography; “m-CPBA” means meta-Chloroperoxybenzoic acid; “TFA” means trifluoroacetic acid; “m.p.” means melting point; “RP” means reversed phase; “min” means minute(s); “h” means hour(s); “PE” means petroleum ether; “v/v” means volume per volume; “Celite®” means diatomaceous earth; “DMSO” means dimethyl sulfoxide; “SFC” means Supercritical Fluid Chromatography; “DIPE” means diisopropyl ether; “dppf” or “DPPF” means 1,1′-Bis(diphenylphosphino)ferrocene; “DIPEA” or “DIEA” means N,N-diisopropylethylamine; “PPh3” means triphenylphosphine; “Et2O” means diethyl ether; “Pd/C” means palladium on carbon; “Pt/C” means platina on carbon; “Pd(OH)2/C” means palladium hydroxide on carbon; “CPME” means cyclopentyl methyl ether; “Pd2(dba)3 means Tris(dibenzylideneacetone)dipalladium; “DIAD” means diisopropyl azodicarboxylate; “TMSCF3” means trimethyl(trifluoromethyl)silane; “TBAF” means tetrabutylammonium fluoride; “psi” means pound-force per square inch; “Et4NCl” means tetraethylammonium chloride; “eq.” means equivalent(s); “Pd(OAc)2” means palladium(II) acetate; “AcOH” means acetic acid; “DMAP” means 4-(dimethylamino)pyridine; “t-BuOK”, “tBuOK” or “KOtBu″means potassium tert-butoxide; “Dess-Martin periodinane” means 1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one; “TBDMSCl” means tert-Butyldimethylsilyl chloride; “PPh3-polymer” or “PPh3-pol” means triphenylphosphine polymer bound; “Ph3PCH3Br” means methyltriphenylphosphonium bromide; “Bn” means benzyl; “Bz” means benzoyl; “p-TSA” means 4-methylbenzenesulfonic acid; “BF3.Et2O” means Boron Trifluoride-Ethyl Ether Complex; “9-BBN” means 9-Borabicyclo[3.3.1 ]nonane; “Pd-118” means Dichloro[1,1′-bis(di-tert-butylphosphino)ferrocene]palladium(II); and “TLC” means thin layer chromatography; “prep-TLC” means preparative TLC; “p-MeC6H4SO3H.H2O” means para toluenesulfonic acid hydrate; “PMB” means para methoxybenzyl; “KOAc” means potassium acetate; “PTSA” para toluenesulfonic acid; “MTBE” means methyl tert. butyl ether; Rh(acac)(eth)2” means Acetylacetonatobis(ethylene)rhodium(I); “(S)-MonoPhos” means (S)-N,N-dimethyldinaphtho[2,1-D:1′,2′-F][1,3,2]dioxaphosphepin-4-amine; “Tf2O” means triflic anhydride; “MeI” means methyliodide; “Me2NH” means dimethylamine; “Me2NH.HCl” means dimethylamine hydrochloric acid; “Me4NCl” means tetramethylammonium chloride; “MeONa” means sodium methoxide; “Ts” means tosyl; “MsCl” means mesylchloride; “DIBAH” means Diisobutylaluminium hydride; “TBDMS” means tertButyl dimethylsilyl; “Pd(dppf)Cl2.CH2Cl2” means [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane,: “PPA” means polyphosphoric acid;“NH2Bn” means benzylamine; “Pd(PPh3)2Cl2” means Dichlorobis(triphenylphosphine)palladium(II).
  • Intermediates containing a double bond with substituents which may be in the E or the Z configuration are show in one particular configuration in the experimental part below. However, unless explicitly indicated by (E) or (Z), it is unkown if these intermediates were obtained in the E or Z configuration or as a mixture of both configurations. For example intermediates 24-26, 29-31, 72-76, and intermediates 79-88 might be in the E or Z configuration or might be mixtures thereof.
  • For example Intermediates 44, 97-100, 136-138, 150 and compounds 55, 57, 57a and 61 were obtained in the E configuration and are explicitly indicated as such (E) in the experimental part below.
  • For intermediates that were used in a next reaction step as a crude or as a partially purified intermediate, estimated mol amounts (in some cases indicated by ≈) are indicated in the reaction protocols described below, or alternatively theoretical mol amounts are indicated.
    • A. Preparation of Intermediates Example A1 Preparation of Intermediate 1
  • Figure US20230330127A1-20231019-C00258
  • To a mixture of 6-chloro-7-deazapurinebeta-d-riboside (25.0 g, 87.5 mmol) in acetone (330 mL) was added 2,2-dimethoxypropane (18.2 g, 175 mmol) and 4-methylbenzenesulfonic acid (TosOH) (1.51 g, 8.75 mmol) in one portion at 25° C. under N2.The mixture was stirred at 60° C. for 2 hours. The mixture was cooled to 25° C. The reaction was quenched by adding saturated NaHCO3 (100 mL) slowly and then extracted with ethyl acetate (125 mL × 5).The combined organic phase was washed with saturated brine (120 mL), dried with anhydrous MgSO4, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (gradient elution: DCM/Ethyl acetate from 1:0 to 2:1) to afford crude intermediate 1 (38.0 g) as light yellow gum.
    • Example A2 Preparation of Intermediate 3
  • Figure US20230330127A1-20231019-C00259
  • To a solution of 5-O-tert-Butyldimethylsilyl-2,3-o-isopropylidene-D-ribofuranose (intermediate 2) ( 24.3 g, 79.8 mmol) in CCl4 (12.8 mL, 133 mmol) and toluene (200 ml) was added dropwise HMPT at -50° C. over 30 minutes. After the mixture was stirred at -50° C. for 2 hours, the reaction mixture was quickly washed with ice cold brine (30 mL), dried over anhydrous Na2SO4 and added immediately to a heavily stirred mixture of powdered KOH (6.5 g, 117 mmol), 2,4-dichloro-7h-pyrrolopyrimidine (10.0 g, 53 mmol), tris(3,6-dioxaheptyl)amine (8.27 mL, 26.6 mmol) and toluene (200 ml). The mixture was stirred at room temperature for 48 hours. Then the solvent was concentrated in vacuum. The residue was treated with 250 ml NH4Cl solution and extracted with ethyl acetate (300 ml × 2).The organic layers were combined and dried with Na2SO4, filtered and the filtrate was concentrated in vacuum. The residue was purified by column chromatography over silica gel (gradient elution: petroleum ether/ethyl acetate from 25:1 to 15:1). The product fractions were collected and the solvent was evaporated to give the desired intermediate 3 (6.50 g, crude)
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 3 using the appropriate starting materials (Table 1).
  • TABLE 1
    Int. Structure Starting materials
    4
    Figure US20230330127A1-20231019-C00260
         		Intermediate 2 and 4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine
    5
    Figure US20230330127A1-20231019-C00261
         		Intermediate 2 and 4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine
    185
    Figure US20230330127A1-20231019-C00262
         		Intermediate 2 and 4-Chloro-5-methyl-7H-pyrrolo[2,3-d]-pyrimidine
    189
    Figure US20230330127A1-20231019-C00263
         		Intermediate 2 and 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]-pyrimidine
    282
    Figure US20230330127A1-20231019-C00264
         		Intermediate 2 and 4-Chloro-6-Iodo-7H-pyrrolo[2,3-d]-pyrimidine
    • Example A3 Preparation of Intermediate 6
  • Figure US20230330127A1-20231019-C00265
  • Intermediate 3 (7.00 g, 14.8 mmol) was dissolved into the solvent mixture of acetic acid, water and THF with ratio as 13:7:3 (100 mL). The reaction mixture was stirred at room temperature for 12 hours. The solvent was removed under reduced pressure at 60° C., afforded 6.8 g of crude intermediate 6 together with by-product. To the solution of the above crude product in acetone (50 mL) was added 2,2-dimethoxypropane (5 mL, 42 mmol) and 4-methylbenzenesulfonic acid mono hydrate (13 mg, 0.07 mmol) at room temperature under N2. The mixture was stirred at 60° C. for 2 hours. The solvent was removed under reduced pressure below 30° C. The residue was purified by column chromatography (gradient elution: EtOAc/ petroleum ether from ⅒ to ⅓) on silica gel to afford the desired intermediate 6 (3.02 g, 34% yield).
    • Example A4 Preparation of Intermediate 7
  • Figure US20230330127A1-20231019-C00266
  • To a solution of intermediate 4 (9.50 g, 20.9 mmol) in THF (82 mL) was added 1 M TBAF solution in THF (41.8 mL, 41.8 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. The mixture was evaporated to dryness. The residue was taken up into water and extracted with DCM (150 ml × 2). The organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in vacuum. The residue was purified by column chromatography over silica gel (gradient elution: petroleum ether/ethyl acetate from 10/1 to 4/1) to give the desired intermediate 7 (3.68 g, 88% yield)
  • Below intermediate was prepared by an analogous reaction protocol as was used for the preparation of intermediate 7 using the appropriate starting materials (Table 2).
  • TABLE 2
    Int. Structure Starting material
    8
    Figure US20230330127A1-20231019-C00267
         		Intermediate 5
    186
    Figure US20230330127A1-20231019-C00268
         		Intermediate 185
    190
    Figure US20230330127A1-20231019-C00269
         		Intermediate 189
    • Example A5 Preparation of Intermediate 10
  • Figure US20230330127A1-20231019-C00270
    • Step A)
  • Figure US20230330127A1-20231019-C00271
  • To a mixture of 4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine (14.0 g, 52.8 mmol) and (1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol hydrochloride (10.7 g, 58.1 mmol) in propan-2-ol/H2O (208 mL, 7:1), was added Et3N (13.4 g, 132 mmol) in one portion at 25° C. under N2. The mixture was stirred at 90° C. for 23 hours. The mixture was cooled to 50° C. and 4M HCl (24 mL, 106 mmol) was added slowly. The residue was then stirred at 50° C. for 2 hours. The reaction mixture was cooled to 25° C. and NaHCO3 (14 g, 100 mmol) was added slowly. Ethyl acetate (230 mL) was added, followed by the addition of a half-saturated NaHCO3 solution (q.s.). The organic phase was isolated and the aqueous phase was extracted with ethyl acetate (230 mL × 2).The combined organic phase was dried with anhydrous MgSO4, filtered and concentrated in vacuum to afford intermediate 9 as yellow solid (17.4 g, quantitative yield in 2 steps). The crude product was directly used as such in the next reaction step without further purification.
    • Step B)
  • Figure US20230330127A1-20231019-C00272
  • To a mixture of intermediate 9 (17.4 g, ≈52.7 mmol) in acetone (250 mL) was added 2,2-dimethoxypropane (11.0 g, 105 mmol) and TsOH.H2O (908 mg, 5.27 mmol) in one portion at 25° C. under N2.The mixture was stirred at 60° C. for 2 hours. The mixture was cooled to 25° C. and the solution was concentrated in vacuum, quenched by saturated NaHCO3 (100 mL) slowly and then extracted with ethyl acetate (100 mL × 3).The combined organic phase was washed with saturated brine (100 mL), dried with anhydrous MgSO4, filtered and concentrated in vacuum. The residue was purified by flash chromatography on silica gel (gradient elution: DCM/Ethyl acetate from 1/0 to 2/1) to afford intermediate 10 as light yellow gum (15.5 g, 89% yield).
    • Example A6 Preparation of Intermediate 14
  • Figure US20230330127A1-20231019-C00273
    • Step A)
  • Figure US20230330127A1-20231019-C00274
  • An oven-dried flask was charged with 7-bromo-4-(methylthio)pyrrolo[2,1-f][ 1,2,4]triazine (45.0 g, 184 mmol) and dry THF (1.20 L) under N2. The yellow solution was cooled to -78° C., and a yellow suspension was formed. n-BuLi (2.5 M, 79.6 mL) was added dropwise to the reaction mixture over period of 25 minutes at -78° C. The reaction mixture was stirred at -78° C. for 1 hour and a yellow-brown solution formed. A pre-cooled solution of intermediate 10 (84.0 g, 201 mmol) in dry THF (800 mL) in another flask (-78° C.) was added to the solution under N2. The resulting red-brown solution was stirred at -78° C. for 1.5 h. 2 batches were carried out in parallel. The reaction was quenched by addition of a saturated NH4Cl aqueous solution (300 mL) at -78° C., and subsequently the mixture was warmed to 10° C. The mixture was extracted with ethyl acetate (500 mL × 3). The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was load on silica gel then purified by column chromatography (SiO2, gradient elution: Petroleum ether/Ethyl acetate from 10/1 to 3:1) to afford intermediate 11 (149 g, 56% yield) as an orange gum.
    • Step B)
  • Figure US20230330127A1-20231019-C00275
  • To a stirred solution of intermediate 11 (74.0 g, 127 mmol) and triethylsilane (59.9 g, 515 mmol) in DCM (1.80 L) was added BF3.Et2O (90.9 g, 640 mmol) dropwise at30~-20° C. 2 batches were carried out in parallel. The resulting orange solution was stirred between -30 and -20° C. for 4.5 hours. The reaction mixture was carefully poured into a saturated NaHCO3 aqueous solution (2.5 L) with vigorous stirring (gas evolution). The mixture was stirred for 2 hours. The organic layer was separated and the aqueous phase was extracted with DCM (200 mL × 3). The combined organic layers were washed with brine (500 mL × 2), dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, gradient elution: petroleum ether:ethyl acetate: from 12:1 to 8:1), affording intermediate 12 as a light yellow gum (125.7 g, 83% yield,)
    • Step C)
  • Figure US20230330127A1-20231019-C00276
  • 1 M BCl3 in CH2Cl2 (860 mL, 860 mmol) was added dropwise at -78° C. to a stirred solution of intermediate 12 (75.0 g, 132 mmol) in DCM (1.20 L) dropwise over period of 2.5 hour under N2. The mixture was stirred at -78° C. for 1 hour. The reaction mixture was slowly warmed to -40° C. The reaction mixture was poured into MeOH (2.5 L, 20° C.) with stirring. The resulting red solution was stirred for 3 hours. Water (250 mL) was added into the mixture and left at 20° C. for 16 h. The solution was portion wise poured onto solid NaHCO3 (500 g) carefully with vigorous stirring (gas evolution, the color of mixture was turned from orange-red to yellow). The resulting suspension was filtered and the filtrate was concentrated under reduced pressure. The residue was dispensed in iPrOH/CH2Cl2 (1:3, 1 L) then filtered (to remove some inorganic salt) and the filtrate was concentrated under reduced pressure. The residue was triturated with petroleum ether (500 mL × 3) to afford crude intermediate 13 (40.2 g, crude) as an orange solid, which used in the next reaction step without further purification.
    • Step D)
  • Figure US20230330127A1-20231019-C00277
  • To a suspension of intermediate 13 (40.2 g, crude) and 2,2-dimethoxypropane (34 mL, 277 mmol) in acetone (600 mL) was added TsOH.H2O (5.92 g, 31.10 mmol, 0.23 eq) at 25° C. (pH = 2). The resulting mixture was heated at 60° C. for 2 hours. After being cooled to 25° C., the reaction mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (500 mL) and saturated aqueous NaHCO3 solution (500 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, gradient elution: CH2Cl2/Ethyl acetate from 10/1 to 6/1). The fractions containing desired intermediate 14 were combined and concentrated under reduced pressure. The residue (28 g, about 80% purity) was purified again by column chromatography (silica gel, gradient elution: Petroleum ether/Ethyl acetate: from 20/1 to 4/1). The desired fractions were combined and concentrated under reduced pressure. The residue was diluted with CH2Cl2 (15 mL) then petroleum ether/ethyl acetate (4:1, 200 mL) was added. The mixture was concentrated to about 150 mL and solids were precipitated. The slurry was diluted with petroleum ether to about 400 mL and stirred for 16 hours at 20° C. The mixture was filtered and the solid was rinsed with petroleum ether/ethyl acetate (20/1, 100 mL). The solids were collected and dried under high vacuum to afford pure intermediate 14 as white solid (18.6 g, 42% yield for 2 steps).
    • Example A7 Preparation of Intermediate 15
  • Figure US20230330127A1-20231019-C00278
  • The intermediate 1 (10.0 g, ≈28.6 mmol), TEA (12 mL, 85.7 mmol) and DMAP (0.70 g, 5.71 mmol) were dissolved in CH2Cl2 (100 mL). p-toluenesulfonyl chloride (10.9 g, 57.1 mmol) was added at 0° C. The mixture was stirred at room temperature overnight. Water (100 mL) was added to the above solution. The aqueous layer was extracted with DCM (100 mL × 3). The combined organic layer was dried over Na2SO4 and concentrated to dryness. The residue was purified by flash column (gradient elution: petroleum ether/EtOAc from 1/0 to 3/1). The product fractions were collected and the solvent was evaporated to give intermediate 15 as yellow oil (14.5 g, 97% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 15 using the appropriate starting materials (Table 3).
  • TABLE 3
    Int. structure Starting material
    16
    Figure US20230330127A1-20231019-C00279
         		Intermediate 8
    17
    Figure US20230330127A1-20231019-C00280
         		Intermediate 10
    • Example A8 Preparation of Intermediate 18
  • Figure US20230330127A1-20231019-C00281
  • Intermediate 1 (100.0 g, theoretically 307 mmol) was dissolved in 400 mL of 1, 4-dioxane. Then 400 mL of Ammonia water (28-30% NH3 basis) was added. The mixture was stirred in a sealed tube at 100° C. for 20 hours. The mixture was cooled to room temperature. The reaction mixture was evaporated in vacuum to remove half of the solvent. Water (200 mL) was added and extracted with EtOAc (500 mL × 3). The combined organic layers were washed with brine (200 ml × 2), dried and concentrated to give Intermediate 18 as white solid (93 g, 93% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 18 using the appropriate starting materials (Table 4).
  • TABLE 4
    Intermediates structure Starting material
    19
    Figure US20230330127A1-20231019-C00282
         		Intermediate 6
    20
    Figure US20230330127A1-20231019-C00283
         		Intermediate 7
    283
    Figure US20230330127A1-20231019-C00284
         		Intermediate 282
    502
    Figure US20230330127A1-20231019-C00285
         		Intermediate 10
    • Example A9 Preparation of Intermediate 23
  • Figure US20230330127A1-20231019-C00286
    • Step A:
  • Figure US20230330127A1-20231019-C00287
  • To a solution of intermediate 21 (6.6 g, 9.75 mmol) in THF (130 mL) was added ammonia (28% in H2O, 65 mL) at room temperature. The reaction mixture was stirred at 100° C. (using an autoclave) for 16 hours. The reaction mixture cooled to room temperature and evaporated to dryness under reduced pressure. The residue was taken up into water (100 mL) and DCM (100 mL) and stirred for 1 hour. The layers were separated and the water layer was washed again with DCM (100 mL) to remove impurities. The water layer was filtered and the filtrate was evaporated to dryness. The residue was purified on flash chromatgraphy on silica (gradient eluention: DCM/MeOH from 95:5 to 90:10). The desired fractions were collected and the solvent was evaporated, yielding intermediate 22 (3.4 g, crude). The crude product was directly used for the next reaction step without further purification.
    • Step B:
  • Figure US20230330127A1-20231019-C00288
  • To a mixture of intermediate 22 (1.0 g, crude) in acetone (32 mL) was added 2,2-dimethoxypropane (1.78 mL g, 14.5 mmol) and 4-methylbenzenesulfonic acid (0.61 g, 3.19 mmol) in one portion at room temperature. The mixture was stirred at 60° C. for 3 hours. The mixture was cooled to room temperature and quenched by adding saturated NaHCO3 (10 mL) slowly and then extracted with ethyl acetate (50 mL × 5). The combined organic phase was washed with saturated brine (120 mL), dried with MgSO4, filtered and concentrated in vacuum, offered intermediate 23 (0.80 g, crude). The crude product was directly used for the next reaction step without further purification.
    • Example A10 Preparation of Intermediate 24
  • Figure US20230330127A1-20231019-C00289
  • Intermediate 18 (10.0 g, 32.6 mmol) was dissolved in THF (200 ml). Then Dimethylformamide Dimethylacetal (DMF-DMA) (5.84 g, 49.0 mmol) was added. The mixture was stirred at 60° C. for 24 hours. The mixture was cooled to room temperature and the solvent was concentrated in vacuum. The residue was triturated with EtOAc (200 mL) and water (100 mL). The organic layer was separated, the aqueous was extracted with EtOAc (200 mL × 1), the combined organic layer was washed by brine (50 mL), dried over anhydrous Na2SO4, filtration and concentration to afford the desired intermediate 24 as a yellow solid (10.5 g, 85% yield)
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 24 using the appropriate starting materials (Table 5).
  • TABLE 5
    Intermediates structure Starting material
    25
    Figure US20230330127A1-20231019-C00290
         		Intermediate 19
    26
    Figure US20230330127A1-20231019-C00291
         		Intermediate 20
    503
    Figure US20230330127A1-20231019-C00292
         		Intermediate 502
    • Example A 11
  • Figure US20230330127A1-20231019-C00293
    • Step A:
  • Figure US20230330127A1-20231019-C00294
  • To the mixture of intermediate 18 (88.0 g, 287 mmol) and imidazole (39.1 g, 575 mmol) in DMF (300.0 mL) was added TBDMSCl (52.0 g, 345 mmol) in one portion at 0° C. under N2. The reaction mixture was stirred overnight at room temperature. Subsequently, water (500 ml) was added and the mixture was extracted with EtOAc (800 mL × 3). The organic layer was washed with brine (500 mL). Then the organic phase was dried with anhydrous Na2SO4, filtered, and the organic phase was concentrated under vacuum to give the crude product. The crude product was purified by column chromatography over silica gel (gradiente elution: petroleum ether/ ethyl acetate 1:1). The desired fraction was concentrated to give the intermediate 27 as oil (120 g, 96% yield).
    • Step B:
  • Figure US20230330127A1-20231019-C00295
  • To the solution of intermediate 27(12.4 g, ≈24.4 mmol) and DMAP (0.30 g, 2.44 mmol) in THF (50 mL) was added (Boc)2O (13.3 g, 61.0 mmol) dropwise at room temperature. The reaction mixture was stirred at room temperature for 3 hours. Then 1 M TBAF solution in THF (24.4 mL, 24.4 mL) was added dropwise. The reaction mixture was stirred at rt for 18 hours. The reaction mixture was poured into 250 ml of water and extracted with ethylacetate (250 mL × 2). The organice layer was washed (water) and brine, dried with Na2SO4, and concentrated to be dry. The residue was purified by flash chromatography (elution: ethylacetate / heptane = 50/50). The desired fraction was collected and the residue was stirred in heptane. The solid product is filtered off and dried at rt under reduced pressure, yielding intermediate 28 (10.2 g, 83% yield) as solid product.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 28 using the appropriate starting materials (Table 23).
  • TABLE 23
    Intermediates structure Starting material
    284
    Figure US20230330127A1-20231019-C00296
         		Intermediate 283
    • Example A12 Preparation of Intermediate 29
  • Figure US20230330127A1-20231019-C00297
  • To a reaction mixture of intermediate 24 (15.0 g, 41.7 mmol), Et3N (11.6 mL, 83.3 mmol) and DMAP (509 mg, 4.17 mmol) in DCM ( 200 mL) was added p-Toluenesulfonyl chloride ( 8.74 g, 45.9 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. Water (100 mL) was added into the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with EtOAc (100 mL × 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated to yield the crude intermediate 29 as a brown solid, which was used in the next reaction step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 29 using the appropriate starting materials (Table 6)
  • TABLE 6
    Int. structure Starting material
    30
    Figure US20230330127A1-20231019-C00298
         		Intermediate 25
    31
    Figure US20230330127A1-20231019-C00299
         		Intermediate 26
    32
    Figure US20230330127A1-20231019-C00300
         		Intermediate 28
    285
    Figure US20230330127A1-20231019-C00301
         		Intermediate 284
    • Example A12b Preparation of Intermediate 32
  • Figure US20230330127A1-20231019-C00302
  • Intermediate 28 (4.5 g, 8.89 mmol), TEA (2.70 g, 26.6 mmol), DMAP (0.54 g, 4.4 mmol) and DCM (40 ml) were stirred on an ice bath. p-Toluenesulfonyl chloride (3.39 g, 17.8 mmol) was added dropwise. The mixture was stirred at room temperature for 5 hours. The reaction mixture was poured into water and was extracted with DCM. The organic layer was evaporated and purified with flash chromatography on silica (eluent: DCM 98% MeOH 2%) to give intermediate 32 (5.6 g, 95% yield).
    • Example A13 Preparation of Intermediate 33
  • Figure US20230330127A1-20231019-C00303
  • To a mixture of intermediate 1 (2.00 g, theoretically 6.18 mmol) in DCM (40 mL) was added Dess-Martin periodinane (5.24 g, 12.36 mmol) in one portion at 0° C. under N2.The mixture was stirred at 0° C. for 3 hours. To the mixture was added Na2S2O3 (4 g) in saturated NaHCO3 (20 mL) and stirred for 10 min. The aqueous phase was extracted with DCM (20 mL × 3).The combined organic phase was washed with saturated brine (20 mL × 2), dried with anhydrous MgSO4, filtered and concentrated in vacuum to afford intermediate 33 (1.80 g, crude) as light yellow gum. The crude product was directly used for the next reaction step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 33 using the appropriate starting materials (Table 7).
  • TABLE 7
    Int. structure Starting material
    34
    Figure US20230330127A1-20231019-C00304
         		intermediate 7
    35
    Figure US20230330127A1-20231019-C00305
         		intermediate 10
    36
    Figure US20230330127A1-20231019-C00306
         		intermediate 14
    512
    Figure US20230330127A1-20231019-C00307
         		intermediate 28
    • Example A14 Preparation of Intermediate 37
  • Figure US20230330127A1-20231019-C00308
  • To a solution of intermediate 33 (6.5 g, crude, ≈15.46 mmol) in THF (200 mL) was added dropwise MeMgBr (1 M, 18.55 ml, 18.55 mmol) at -78° C. under N2. The mixture was stirred overnight at room temperature under N2. The reaction mixture was concentrated under vacuum to give crude product as a yellow solid. The crude product was purified by column chromatography (gradient elution: petroleum ether/EtOAc from 40:1 to 10:1). The desired fractions were collected and the solvent was evaporated to give Intermediate 37 as light yellow oil (700 mg crude; and 3 g crude with more impurities).
    • Example A15 Preparation of Intermediate 38 Method 1
  • Figure US20230330127A1-20231019-C00309
  • To a mixture of methyltriphenylphosphonium bromide (4.87 g, 13.62 mmol) in THF (500 mL) was added t-BuOK (11.4 mL, 1 M in THF, 1.27 g, 11.35 mmol,) dropwise at 0° C. under N2. The suspension was turned to bright yellow and stirred at 0° C. for 0.5 h and then warmed to 25° C. for 0.5 h. The mixture was cooled to -40° C. The solution of Intermediate 35 (1.46 g, theoretically 4.54 mmol) in THF (130.0 mL) was added drop-wise and then stirred at -20° C. for 1 h, after this, the mixture was warmed to 25° C. for 2 h. To the mixture was added saturated NH4Cl (300 ml) and stirred for 10 min. Layers were separated and the aqueous phase was extracted with DCM (300 mL × 2).The combined organic phase was washed with saturated brine (500 mL), dried with anhydrous MgSO4, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Gradient eluention: From 0 to 15% of Ethyl acetate / Petroleum ether). The desired fractions were collected and the solvent was evaporated. Intermediate 38 was obtained as off-white solid (530 mg, 36% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 38 (Method 1) using the appropriate starting materials (Table 8).
  • TABLE 8
    Int. structure Starting material
    39
    Figure US20230330127A1-20231019-C00310
         		Intermediate 33
    40
    Figure US20230330127A1-20231019-C00311
         		Intermediate 36
    513
    Figure US20230330127A1-20231019-C00312
         		Intermediate 512
    • Method 2
  • Figure US20230330127A1-20231019-C00313
  • A solution of Intermediate 35 (10.0 g, theoretically 31.1 mmol) in THF (100 mL) was added drop-wise under N2 over a period of 30 minutes to a bis(iodozincio)methane solution in THF (180 mL, 0.31 M, 55.9 mmol, prepared according to the procedure described in Tetrahedron 2002. 58, 8255-8262), stirring was continued until complete conversion (approximately 2 hours). The reaction mixture was quenched by the slow addition of a saturated aqueous NH4Cl solution, during which salt formation was observed. Prior to extraction (EtOAc, 2 × 200 mL), the salts were dissolved again by the addition of an aqueous ammonia solution (25%). The combined organic phases were washed with an aqueous sodium bisulfite solution and brine, dried with anhydrous MgSO4, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (eluent: dichloromethane/EtOAc 95/5) to provide Intermediate 38 as an off-white solid (6.9 g, 66%).
    • Method 3 Step 1 Preparation of Intermediate 408
  • Figure US20230330127A1-20231019-C00314
  • Acetylacetonatobis(ethylene)rhodium(l) (0.837 g, 3.24 mmol) and (R)-N,N-dimethyldinaphtho[2,1-D:1′,2′-F] [1,3,2]dioxaphosphepin-4-amine (2.91 g, 8.11 mmol) were dissolved in EtOH (625 mL) under nitrogen atmosphere. The mixture was stirred at room temperature and flushed through with nitrogen gas for 15 minutes. Then (-)-(3AR,6AR)-3A,6A-dihydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-one (25 g, 162.16 mmol) and potassium vinyltrifluoroborate (45.73 g, 324.33 mmol) were added and then the reaction mixture was stirred and refluxed for 4 hours. The reaction mixture (suspension) was cooled down to room temperature. The precipitate was filtered off over a pad of Celite and washed with ethanol. The solvents of the filtrate were evaporated. 1 L heptane was added to the residue. The resulting suspension was filtered off over a pad of Celite and washed with heptanes resulting in a dark brown solid residue. The filtrate was washed three times with 300 mL NH4OH, washed with brine, dried with MgSO4, filtered and the solvents of the filtrate evaporated yielding intermediate 408 (16.18 g, 51% yield).
    • Step 2 Preparation of Intermediate 409
  • Figure US20230330127A1-20231019-C00315
  • A solution of intermediate 408 (16.18 g, 82.58 mmol) in THF (200 mL) was added dropwise to a stirred solution of lithium aluminum hydride 1 M in THF (24.78 mL, 1 M, 24.78 mmol) in THF (400 mL) at -78° C. under nitrogen atmosphere. The reaction mixture was stirred at -78° C. under nitrogen atmosphere for 30 minutes. The reaction was quenched by the dropwise addition of acetone (6.1 mL) followed by 50 mL water at -78° C. After addition the reaction mixture was allowed to warm up to room temperature and then 400 mL EtOAc was added. The mixture was shaken vigorously. The organic layer was seprated, washed three times with water, washed with brine, dried with MgSO4, filtered and the solvents of the filtrate evaporated. The residue was dissolved in ethylacetate and purified over a SiO2 column, type Grace Reveleris SRC, 80 g, Si 40, on an Armen Spot II Ultimate purification system using ethyl acetate and heptane as eluent in a gradient starting from 100% heptanes and ending with 50% heptane and 50% ethyl acetate. The fractions containing product were combined and the solvents were evaporated yielding intermediate 409 (10.77 g, 71% yield).
    • Step 3 Preparation of Intermediate 410
  • Figure US20230330127A1-20231019-C00316
  • A solution of Tf2O (13.31 mL, 1.71 g/mL, 80.93 mmol) in DCM, anhydrous (60 ml) was added dropwise to a mixture of intermediate 409 (9.94 g, 53.95 mmol) and pyridine, anhydrous (85 mL) in DCM, anhydrous (140 mL) at 0° C. The reaction mixture was stirred for 30 minutes and then 75 mL cold water was added. The layers were separated and the organic layer was washed three times with 75 mL water, dried with MgSO4. filtered and the solvents evaporated and co-evaporated with 200 mL toluene. The residue was dissolved in heptane and ethyl acetate and purified over a SiO2 column, type Grace Reveleris SRC, 40 g, Si 40, on an Armen Spot II Ultimate purification system using ethyl acetate and heptane as eluent in a gradient starting from 100% heptane and ending with 50% heptane and 50% ethyl acetate. The fractions containing product were combined and the solvents were evaporated yielding intermediate 410 (13.0 g, 67% yield).
    • Step 4 Preparation of Intermediate 411
  • Figure US20230330127A1-20231019-C00317
  • A mixture of 4-chloro-7H-pyrrolo[2,3-D]pyrimidine (100 g, 651 mmol) and KOtBu (73.07 g, 651 mmol) in THF (1 L) was stirred at room temperature for 45 minutes until a clear solution was obtained. The solvents were evaporated. The residue was triturated in DIPE. The white solids were filtered off and dried in vacuo at 30° C. yielding intermediate 411 (112.6 g, 90% yield).
    • Step 5 Preparation of Intermediate 38
  • Figure US20230330127A1-20231019-C00318
  • A solution of intermediate 410 (13 g, 41.1 mmol) in DMF (50 mL) was added dropwise to a stirred solution of intermediate 411 (7.88 g, 41.1 mmol) in DMF (150 mL) at 0° C. After addition the reaction mixture was allowed to warm up to room temperature and was then stirred for 18 hours. Another amount of intermediate 411 (1.57 g, 8.22 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was poured out into a beaker with ice and water (-0.5 L). The resulting suspension was stirred for 2 hours and then filtered off. The residue was washed three times with water and then dried in vacuo at 50° C. yielding intermediate 38 as a white solid (8.75 g, 65% yield).
    • Example A 54 Preparation of Intermediate 433
  • Figure US20230330127A1-20231019-C00319
  • A solution of intermediate 38 (18.3 g, 57.22 mmol) in a mixture of aqueous ammonia (25%, 100 ml) and THF (100 ml) was heated in a sealed metal pressure vessel at 110° C. until complete conversion (~16 h).The reaction mixture was allowed to cool to room temperature, after which ethyl acetate and brine were added. Both layers were separated, the water layer was extracted once with ethyl acetate. The combined organic phases were washed with brine, dried with anhydrous MgSO4, filtered and concentrated in vacuum to give Intermediate 433 as a light yellow solid (17.2 g, 100%), which was used in the next reaction step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 433 using the appropriate starting materials (Table 24
  • TABLE 24
    Int. structure Starting materials
    487
    Figure US20230330127A1-20231019-C00320
         		Intermediate 38 methylamine
    490
    Figure US20230330127A1-20231019-C00321
         		Intermediate 39 methylamine
    • Example A1 6 Preparation of Intermediate 41
  • Figure US20230330127A1-20231019-C00322
  • To a solution of potassium tert-butoxide (1.28 g; 11.4 mmol) in THF (30 mL) at -78° C. was added a solution of dimethyl (1-diazo-2-oxopropyl)phosphonate (1.72 g; 11.4 mmol) in THF (5 mL). The solution was stirred for 5 min and then the solution of intermediate 33 (1.90 g; theoretically 5.87 mmol) in THF (20 mL) was added. The solution was allowed to warm to room temperature and stirred at room temperature for 15 minutes. Water and EtOAc were added, the organic layer was separated, dried over MgSO4, filtered and evaporated in vacuo. The residues were purified by preparative LC (Irregular SiOH 15-40 µm, 80 g Grace, DCM loading, mobile phase gradient elution: heptane : 10% MeOH in EtOAc from 90:10, to 70:30). The desired fractions were collected and the solvent was evaporated to yield intermediate 41 as a colorless oil (1.08 g, 58% yield).
    • Example A17 Preparation of Intermediate 43
  • Figure US20230330127A1-20231019-C00323
  • To a solution of intermediate 42 (9.2 g, 34.114 mmol) in acetone (100 mL) was added 2,2-dimethoxypropane (7.1 g, 68.118 mmol) and p-TSA (1.8 g, 10.184 mmol). The reaction mixture was stirred overnight at room temperature.The reaction mixture was treated with aqueous NaHCO3 (PH to 7-8), then concentrated under reduced pressure. The resulting residue was diluted with water (100 mL) and extracted with ethyl acetate (100 mL × 3). The organic layer was dried and concentrated under reduced pressure.
  • The crude product was purified by silica gel chromatography (gradient elution: petroleum ether/ethyl acetate from 8/1 to 2/1). The desired fractions were collected and the solvent was evaporated to afford the intermediate 43 as a pale yellow solid (9.5 g, 90% yield).
    • Example A18 Preparation of Intermediate 44
  • Figure US20230330127A1-20231019-C00324
  • A solution of intermediate 1 (2.00 g, theoretically 6.18 mmol) in DCM (30.00 mL) was added dropwise to a suspension of Dess-Martin periodinane (3.14 g, 7.41 mmol) in DCM (30.00 mL) at 0° C. under N2. The reaction mixture was allowed to warm to room temperature and stirred until oxidation was finished (2 hours). Subsequently, MeOH (60 mL) and tosylhydrazide (1.50 g, 8.03 mmol) were added and stirring was continued for 3 hours. Water and ethyl acetate were added to the reaction mixture, the organic phase was separated and washed with saturated Na2CO3, dried with anhydrous MgSO4, filtered and concentrated in vacuum. The crude product was purified by silica gel column chromatography (gradient elution: dichloromethane / methanol from 100:0 to 98.5:1.5). The desired fractions were collected and the solvent was evaporated to yield intermediate 44 as a white powder (2.60 g, 70% yield; (E)).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 44 using the appropriate starting materials (Table 25
  • TABLE 25
    Int. Structure Starting materials
    207
    Figure US20230330127A1-20231019-C00325
         		Intermediate 10
    • Example A 55 Preparation of Intermediate 224
  • Figure US20230330127A1-20231019-C00326
    • Step 1 Preparation of Intermediate 222
  • DIAD (7.6 mL, 38.4 mmol, 2.5 eq) was added to a solution of intermediate 2 (5.0 g, 15.3 mmol, 1.0 eq), triphenylphosphine (10.0 g, 38.4 mmol, 2.5 eq) and acetone cyanohydrin (5.6 mL, 61.4 mmol, 4.0 eq) in anhydrous THF (75 mL) at r.t.. The reaction mixture was stirred for 1 hour and then concentrated in vacuo. The crude product was purified by normal phase flash chromatography using heptane and DCM as eluent (SiO2 column, gradient: 50% to 100% DCM, isocratic 100% DCM ) and then followed by a preparative reversed phase flash chromatography using acetonitrile and water with 0.2% NH4HCO3 as eluent to afford intermediate 222 as white solid product (2.8 g, 8.5 mmol, yield 55%)
    • Step 2 Preparation of Intermediate 223 and Intermediate 224
  • A solution of intermediate 222 (1.54 g, 4.6 mmol, 1 eq) in anhydrous DCM was dried overnight over molecular sieves and filtered. The filtrate was cooled to -78° C. and then 1 M DIBAH in DCM (4.6 mL, 4.6 mmol, 1 eq) was added dropwise. The reaction mixture was stirred for 1 hour at -78° C., then extra 1 M DIBAH in DCM (0.46 mL, 0.46 mmol, 0.1 eq) was added and stirred for another 1.5 hours, then quenched with sodium acetate (4.2 g, 51.2 mmol, 11.1 eq) and acetic acid (4.2 mL, 73.4 mL, 16.0 eq) in a mixture of water/THF (57 mL/12 mL). After the quench, the cooling bath was removed and the mixture was stirred until all ice was melted. The layers were separated and then the aqueous phase was extracted twice with DCM (30 mL). The organic phases were combined, washed twice with brine, dried over MgSO4 and filtered. To the obtained filtrate containing intermediate 223 was added MeOH (50 mL), p-toluenesulfonyl hydrazide (1.1 g, 6.0 mmol, 3 eq) and then stirred at r.t. for 40 minutes The reaction mixture was washed three times with sat. NaHCO3, twice with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by normal phase flash chromatography using heptane and EtOAc as eluent (gradient: 40% to 60% EtOAc to afford the crude product. The mixture was further purified by normal phase flash chromatography using EtOAc and heptane as eluent (SiO2 column, gradient: 40% to 60% EtOAc ) to afford intermediate 224 (0.5 g, 0.6 mmol, yield: 14%).
    • Example A19 Preparation of Intermediate 45
  • Figure US20230330127A1-20231019-C00327
  • Intermediate 1 (300 mg, theoretically 0.921 mmol), 7-Quinolinol (160 mg, 1.11 mmol) and polymer-bounded Triphenylphosphine (~3 mmol/g triphenylphosphine loading, 0.8 g, 2.4 mmol) were stirred in anhydrous THF (12 mL) under N2. Subsequently, DIAD (0.465 g, 2.30 mmol) was added dropwise at 0° C. The mixture was stirred at room temperature for 12 hours under N2. The reaction mixture was filtered over a pad of diatomaceous earth. The residue was washed with MeOH. The filtrate was concentrated in vacuum. The residue was purified by column chromatography over silica gel (eluent: petroleum ether/ethyl acetate from 10/1 to 3/1). The desired fractions were collected and the solvent was evaporated to give the crude intermediate 45 as oil (342 mg).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 45 using the appropriate starting materials (Table 9).
  • TABLE 9
    Int. Structure Starting materials
    46
    Figure US20230330127A1-20231019-C00328
    J    		 a) Intermediate 1 b) 7-isoquinolinol
    47
    Figure US20230330127A1-20231019-C00329
         		a) Intermediate 1 b) 6-hydroxyquinoline
    48
    Figure US20230330127A1-20231019-C00330
         		a) Intermediate 1 b) 3-hydroxyquinoline
    49
    Figure US20230330127A1-20231019-C00331
         		a) Intermediate 1 b) 8-hydroxyisoquinoline
    50
    Figure US20230330127A1-20231019-C00332
         		a) Intermediate 1 b) 1,5-naphthyridin-3-ol
    51
    Figure US20230330127A1-20231019-C00333
         		a) Intermediate 1 b) 6-quinoxalinol
    52
    Figure US20230330127A1-20231019-C00334
         		a) Intermediate 1 b) Quinazolin-7-ol
    53
    Figure US20230330127A1-20231019-C00335
         		a) Intermediate 1 b) 2-(trifluoromethyl)-quinolin-7-ol
    54
    Figure US20230330127A1-20231019-C00336
         		a) Intermediate 1 b) 4-chloro-7-hydroxyquinoline
    55
    Figure US20230330127A1-20231019-C00337
         		a) Intermediate 1 b) 3-chloroquinolin-7-ol
    56
    Figure US20230330127A1-20231019-C00338
         		a) Intermediate 1 b) 4-chloro-7-hydroxy-quinoline-3-carbonitrile
    57
    Figure US20230330127A1-20231019-C00339
    J    		 a) Intermediate 1 b) 4-chloro-7-hydroxy-6-methoxyquinoline-3-carbonitrile
    58
    Figure US20230330127A1-20231019-C00340
         		a) Intermediate 1 b) 4-chloro-6-methoxyquinolin-7-ol
    59
    Figure US20230330127A1-20231019-C00341
         		a) Intermediate 1 b) 3-bromoquinolin-7-ol
    60
    Figure US20230330127A1-20231019-C00342
    J    		 a) Intermediate 34 b) 7-quinolinol
    187
    Figure US20230330127A1-20231019-C00343
         		a) Intermediate 186 b) 7-quinolinol
    191
    Figure US20230330127A1-20231019-C00344
         		a) Intermediate 190 b) 7-quinolinol
    233
    Figure US20230330127A1-20231019-C00345
         		a) Intermediate 190 b) 3-bromoquinolin-7-ol
    • Example A19b Preparation of Intermediate 59
  • Figure US20230330127A1-20231019-C00346
  • Diisopropyl azodicarboxylate (0.221 mL, 1.125 mmol) was added dropwise to a stirred suspension of intermediate 1 (0.27 g, 0.80 mmol), 3-bromoquinolin-7-ol (0.18 g, 0.80 mmol) and triphenylphosphine resin (0.375 g, 3 mmol/g, 1.125 mmol) in THF (8 ml ) at room temperature. After addition the reaction mixture was stirred for 18 hours. The reaction mixture was filtered over a pad of DicaliteⓇ. The residue was washed with methanol. The solvents of the filtrate were evaporated. The residue was used as such in the next step.
    • Example A20 Preparation of Intermediate 61
  • Figure US20230330127A1-20231019-C00347
  • The mixture of intermediate 1 (2.46 g, theoretically 7.54 mmol), 2-methylquinolin-7-ol (1.2 g, 7.54 mmol) and PPh3 (5.93 g, 22.6 mmol) in dry THF (40 ml) was stirred at room temperature under N2. DIAD (4.57 g, 22.6 mmol) was added dropwise. The reaction mixture was stirred overnight at room temperature. Water (80 mL) was added to the mixture, extracted with EtOAc (100 mL × 3). The combined organic layers were washed by brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by column chromatography (gradient elution: EtOAc/Petroleum ether from 1:20 to 1:1). The desired fractions were collected and the solvent was evaporated to yield intermediate 61 (3.0 g, crude). The crude intermediate 61 was used for the next reaction step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 61 using the appropriate starting materials (Table 10).
  • TABLE 10
    Int. Structure Starting materials
    62
    Figure US20230330127A1-20231019-C00348
         		a) Intermediate 1 b) 5-Quinolinol
    63
    Figure US20230330127A1-20231019-C00349
         		a) Intermediate 1 b) 5-Isoquinolinol
    64
    Figure US20230330127A1-20231019-C00350
         		a) Intermediate 1 b) 8-Quinolinol
    65
    Figure US20230330127A1-20231019-C00351
         		a) Intermediate 1 b) 6-Isoquinolinol
    66
    Figure US20230330127A1-20231019-C00352
         		a) Intermediate 1 b) 1,8-naphthyridin-2-ol
    67
    Figure US20230330127A1-20231019-C00353
         		a) Intermediate 1 b) 2-chloroquinolin-7-ol
    68
    Figure US20230330127A1-20231019-C00354
         		a) Intermediate 1 b) 3-(trifluoromethyl)quinolin-7-ol
    69
    Figure US20230330127A1-20231019-C00355
         		a) Intermediate 10 b) 7-Quinolinol
    70
    Figure US20230330127A1-20231019-C00356
         		a) Intermediate 14 b) 7-Quinolinol
    515
    Figure US20230330127A1-20231019-C00357
         		a) Intermediate 1 b) 2-Quinolinecarboxylic acid, 7-hydroxy-, methyl ester
    • Example A21 Preparation of Intermediate 71
  • Figure US20230330127A1-20231019-C00358
  • To a solution of intermediate 1 (1.00 g, ≈2.92 mmol) and 2-naphthol (463 mg, 3.21 mmol) in toluene (30 mL) was added CMBP (1.15 mL, 4.38 mmol). The solution was heated at 80° C. for 18 hours and was then cooled down to room temepature. The reaction mixture was evaporated in vacuo. The residues were purified by preparative LC (Irregular SiOH 15-40 µm, 120 g Grace, DCM deposit, mobile phase gradient: heptane /EtOAc from 80/20 to 70/30) to give intermediate 71 as a colourless gum (1.00 g, 76% yield).
    • Example A22 Preparation of Intermediate 72
  • Figure US20230330127A1-20231019-C00359
  • A mixture of PPh3 (9.07 g, 34.6 mmol) and DEAD (4.82 g, 27.7 mmol) in THF (100 mL) was stirred at room temperature for 10 min. Then Intermediate 24 (5.0 g, theoretically 13.8 mmol) was added, followed by 2-chloroquinolin-7-ol (2.98 g, 16.6 mmol). The resulting mixture was stirred at room temperature overnight. Subsequently, the mixture was diluted with EtOAc (100 mL), washed with water and brine. The organic phase was dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography (elution: Petroleum ether/EtOAc = 5/95). The desired fractions were collected and concentrated to give Intermediate 72 as solid (6.0 g, 83% yield).
    • Example A23 Preparation of Intermediate 73
  • Figure US20230330127A1-20231019-C00360
  • To a solution of intermediate 24 (700 mg, theoretically 1.94 mmol) and 4-methylquinolin-7-ol (370 mg, 2.32 mmol) in THF (20 mL) were added triphenylphosine (624 mg, 2.71 mmol) and DBAD (711 mg, 2.71 mmol). The mixture was stirred overnight at room temperature and was then evaporated in vacuo. The crude was purified by preparative LC (irregular SiOH, 15-40 µm, 50 g, Merck, dry loading (Celite®) mobile phase gradient: from Heptane 80%, EtOAc 18%, MeOH 2% to Heptane 10%, EtOAc 81%, MeOH 9%) to give intermediate 73 as an off-white foam (697 mg, 67% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 73 using the appropriate starting materials (Table 12).
  • TABLE 12
    Int. Structure Starting materials
    74
    Figure US20230330127A1-20231019-C00361
         		a) Intermediate 24 b) 6-iodoquinolin-7-ol
    75
    Figure US20230330127A1-20231019-C00362
         		a) Intermediate 24 b) 8-methylQuinolin-7-ol
    76
    Figure US20230330127A1-20231019-C00363
         		a) Intermediate 24 b) 8-iodoquinolin-7-ol
    504
    Figure US20230330127A1-20231019-C00364
         		a) Intermediate 503 b) 3-chloroquinolin-7-ol
    517
    Figure US20230330127A1-20231019-C00365
         		a) Intermediate 24 b) 2-Quinolinecarboxylic acid, 7-hydroxy-, methyl ester
    • Example A24 Preparation of Intermediate 77
  • Figure US20230330127A1-20231019-C00366
  • Cesium Carbonate (2.18 g, 6.70 mmol) was added to a solution of intermediate 17 (1.15 g, ≈2.23 mmol) and 3-bromoquinolin-7-ol (0.5 g, 2.23 mmol) in DMF ( 25 mL). The mixture was stirred overnight at room temperature. The reaction mixture was treated with H2O (100 ml) and filtrated. The resulting residue was washed with H2O (30 mL) and dried under reduced pressure to obtain desired crude intermediate 77 as a pale yellow solid (1.1 g).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 77 using the appropriate starting materials (Table 13).
  • TABLE 13
    Int. Structure Starting materials
    78
    Figure US20230330127A1-20231019-C00367
         		a) Intermediate 16 b) 7-Quinolinol
    262
    Figure US20230330127A1-20231019-C00368
         		a) Intermediate 15 b) 2-amino-7-hydroxy quinoline
    264
    Figure US20230330127A1-20231019-C00369
         		a) Intermediate 15 b) Intermediate 263
    270
    Figure US20230330127A1-20231019-C00370
         		a) Intermediate 15 b) 2-Quinolinamine, 7-hydroxy-N-methyl-
    275
    Figure US20230330127A1-20231019-C00371
         		a) Intermediate 15 b) Intermediate 274
    461
    Figure US20230330127A1-20231019-C00372
         		a) Intermediate 17 b) 7-Quinolinol, 2,3-dichloro-
    463
    Figure US20230330127A1-20231019-C00373
         		a) Intermediate 17 b) Intermediate 274
    466
    Figure US20230330127A1-20231019-C00374
         		a) Intermediate 17 b) 2-Quinolinamine, 7-hydroxy-N-methyl-
    469
    Figure US20230330127A1-20231019-C00375
         		a) Intermediate 17 b) Intermediate 468
    478
    Figure US20230330127A1-20231019-C00376
         		a) Intermediate 15 b) Intermediate 477
    484
    Figure US20230330127A1-20231019-C00377
         		a) Intermediate 17 b) Intermediate
    • Example A25 Preparation of Intermediate 79
  • Figure US20230330127A1-20231019-C00378
  • To a solution of intermediate 29 (500 mg, crude, ≈0.67 mmol) in DMF (20 mL) were added 3-methoxyquinolin-7-ol (187 mg, 0.80 mmol) and Cs2O3 (652 mg, 2.0 mmol). The reaction mixture was stirred at room temperature for 12 hours. The mixture was quenched with water (80 ml) and extracted with DCM (50 ml × 3). The organic layers were dried (Na2SO4), filtered and the solvent was concentrated in vacuum to give the crude intermediate 79 as a yellow oil ( 650 mg).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 79 using the appropriate starting materials (Table 14).
  • TABLE 14
    Int. structure Starting materials
    80
    Figure US20230330127A1-20231019-C00379
         		a) Intermediate 29 b) 3-fluoroquinolin-7-ol
    81
    Figure US20230330127A1-20231019-C00380
         		a) Intermediate 29 b) 5-(trifluoromethyl)quinolin-7-ol
    82
    Figure US20230330127A1-20231019-C00381
         		a) Intermediate 29 b) 6-(trifluoromethyl)quinolin-7-ol
    83
    Figure US20230330127A1-20231019-C00382
         		a) Intermediate 29 b) 8-chloroquinolin-7-ol
    84
    Figure US20230330127A1-20231019-C00383
         		a) Intermediate 29 b) 3,4-dichloroquinolin-7-ol (which was Prepared from 3,4-dichloro-7-methoxyquinoline)
    85
    Figure US20230330127A1-20231019-C00384
         		a) Intermediate 29 b) 7-cinnolinol
    86
    Figure US20230330127A1-20231019-C00385
         		a) Intermediate 30 b) 3-chloroquinolin-7-ol
    87
    Figure US20230330127A1-20231019-C00386
         		a) Intermediate 30 b) 3-bromoquinolin-7-ol
    88
    Figure US20230330127A1-20231019-C00387
         		a) Intermediate 31 b) 3-bromoquinolin-7-ol
    199
    Figure US20230330127A1-20231019-C00388
         		a) Intermediate 29 b) 7-Quinolinol, 6-chloro
    • Example A26 Preparation of Intermediate 89
  • Figure US20230330127A1-20231019-C00389
  • Intermediate 32 (48.3 g, ≈67.99 mmol) was dissolved in 400 ml of DMF. 7-Br-quinolin-7-ol (16.03 g, ≈67.98 mmol) and CS2CO3 (44.33 g, 135.97 mmol) were added into the reaction mixture and the mixture was stirred at room temperature 16 hours. The reaction mixture was poured into 1000 ml of cold water and extracted by EtOAc (2× 600 mL). The organic layer was washed with water (300 mL × 2), dried with anhydrous Na2SO4, filtered and the solvent was concentrated in vacuum to give the crude intermediate 89 (52 g) as an oil which was used in the next step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 89 using the appropriate starting materials (Table 26
  • TABLE 26
    Int. structure Starting materials
    201
    Figure US20230330127A1-20231019-C00390
         		a) Intermediate 32 b) Intermediate 200
    206
    Figure US20230330127A1-20231019-C00391
         		a) Intermediate 32 b)Intermediate 205
    211
    Figure US20230330127A1-20231019-C00392
         		a) Intermediate 32 b)Intermediate 210
    213
    Figure US20230330127A1-20231019-C00393
         		a) Intermediate 32 b)Intermediate 212
    215
    Figure US20230330127A1-20231019-C00394
         		a) Intermediate 32 b) 7-Quinolinol. 4-(trifluoromethyl)-
    217
    Figure US20230330127A1-20231019-C00395
         		a) Intermediate 32 b)Intermediate 216
    219
    Figure US20230330127A1-20231019-C00396
         		a) Intermediate 32 b) Intermediate 218
    221
    Figure US20230330127A1-20231019-C00397
         		a) Intermediate 32 b) Intermediate 220a
    227
    Figure US20230330127A1-20231019-C00398
         		a) Intermediate 32 b) 7-Quinolinol, 4-methoxy-
    228
    Figure US20230330127A1-20231019-C00399
         		a) Intermediate 32 b) 3-Quinolinecarboxylic acid, 7-hydroxy-, methyl ester
    230
    Figure US20230330127A1-20231019-C00400
         		a) Intermediate 32 b) Intermediate 229
    232
    Figure US20230330127A1-20231019-C00401
         		a) Intermediate 32 b) Intermediate 231
    236
    Figure US20230330127A1-20231019-C00402
         		a) Intermediate 32 b) Intermediate 235
    241
    Figure US20230330127A1-20231019-C00403
         		a) Intermediate 32 b) Intermediate 240
    247
    Figure US20230330127A1-20231019-C00404
         		a) Intermediate 32 b) Intermediate 246
    279
    Figure US20230330127A1-20231019-C00405
         		a) Intermediate 32 b) Intermediate 274
    286
    Figure US20230330127A1-20231019-C00406
         		a) Intermediate285 b) 7- hydroxy quinoline
    • Example A27 Preparation of Intermediate 90
  • Figure US20230330127A1-20231019-C00407
  • A mixture of intermediate 15 (893 mg, ≈1.68 mmol), 7-quinolinethiol (1.6 g, 3.374 mmol, crude) and Cs2CO3 (1.21 g, 3.72 mmol) in DMF (20 mL) was stirred overnight at room temperature. The reaction was quenched with water (100 mL). The aqueous phase was extracted with ethyl acetate (200 mL × 2). The combined organic layer was washed with brine (100 ml), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column (gradient elution: Petroleum ether/ethyl acetate from 100/0 to 1/1) to give desired compound intermediate 90 (170 mg, 20% yield) as off-white solid.
    • Example A28 Preparation of Intermediate 91
  • Figure US20230330127A1-20231019-C00408
  • 7-aminoquinoline (Ar-NH2 in scheme above) (700 mg, 4.85 mmol) was added to a solution of intermediate 33 (2.20 g, theoretically 6.80 mmol) in DCM (45 mL) and acetic acid (278 µL, 4.85 mmol). The solution was stirred for 10 min then sodium triacetoxyborohydride (2.98 g; 14.1 mmol) was added and the mixture was stirred at room temperature for 18 hours. A saturated aqueous solution of NaHCO3 was added and the mixture was stirred for 30 minutes. The layers were separated and the aqueous layer was extracted with DCM. The combined organic layers were dried over MgSO4, filtered off and evaporated in vacuo. The residues were purified by preparative LC (Irregular SiOH 15-40 µm, 80 g Grace, mobile phase gradient: from DCM 100% to DCM 95%, MeOH 5%) to give intermediate 91 as a yellow oil which crystallized on standing (1.22 g, 56% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 91 using the appropriate starting materials (Table 15).
  • TABLE 15
    Int. structure Starting materials
    92
    Figure US20230330127A1-20231019-C00409
         		a) Intermediate 33 b) 3-chloroquinlin-7-amine
    93
    Figure US20230330127A1-20231019-C00410
         		a) Intermediate 33 b) 3-bromoquinolin-7-amine
    94
    Figure US20230330127A1-20231019-C00411
         		a) Intermediate 34 b) 3-bromoquinolin-7-amine
    95
    Figure US20230330127A1-20231019-C00412
         		a) Intermediate 35 b) 3-bromoquinolin-7-amine
    • Example A29 Preparation of Intermediate 96
  • Figure US20230330127A1-20231019-C00413
  • To a stirred solution of intermediate 93 (1.0 g, 1.88 mmol) in DMF (20 mL) was added NaH (60% dispersion in mineral oil) (0.151 g, 3.77 mmol) at 0° C. under nitrogen atmosphere. Subsequently, the reaction mixture was stirred at room temperature for 30 minutes. Then CH3I (0.141 mL, 2.261 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was quenched by pouring it out into a beaker with ice and water under nitrogen atmosphere. The precipitate was filtered off yielding the precipitated int. 96. The remaining product was extracted from the water layer with ethylacetate. The separated organic layer was combined with the precipitated int. 96 and then dried with MgSO4, filtered and the solvents of the filtrate evaporated. The residue was dissolved in ethylacetate and purified over a SiO2 column, type Grace Reveleris SRC, 40 g, Si 40, on a Grace Reveleris X2 purification system using heptanes and ethylacetate as eluens in a gradient starting from 100% heptanes to 100% ethylacetate. The fractions containing product were combined and the solvents were evaporated yielding intermediate 96 (0.51 g, crude). This intermediate was used for next step reaction without further purification.
  • Below intermediates were also formed with the same reaction protocol as was used for the preparation of intermediate 96 (Table 27).
  • TABLE 27
    Int. structure Starting materials
    195
    Figure US20230330127A1-20231019-C00414
         		intermediate 93
    196
    Figure US20230330127A1-20231019-C00415
         		intermediate 93
    • Example A30 Preparation of Intermediate 97
  • Figure US20230330127A1-20231019-C00416
  • A mixture of intermediate 38 (520 mg, 1.60 mmol), 7-bromoquinoline (390 mg, 1.87 mmol) and Et4NCl (261 mg, 1.79 mmol,) in DMF (15.00 mL) was degassed under vacuum and purged with N2 for three times. DIEA (1.05 g, 8.15 mmol) and Pd(OAc)2 (54.9 mg, 244 µmol,) were added to the reaction mixture. The mixture was stirred at 100° C. for 16 hours. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phase was dried with anhydrous MgSO4, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, gradient elutionL from 100% of DCM to 25% Ethyl acetate in DCM), yielded Intermediate 97 as off-white solid. (670 mg, 91% yield; (E)).
  • The intermediates in Table 16 (all in the E configuration) were prepared by an analogous reaction protocol as was used for the preparation of intermediate 97 using the appropriate starting materials (Table 16).
  • TABLE 16
    Int. Structure Starting materials
    98
    Figure US20230330127A1-20231019-C00417
         		a) Intermediate 38 b) 7-bromo-3-chloroquinoline
    99
    Figure US20230330127A1-20231019-C00418
         		a) Intermediate 39 b) 7-bromo-3-chloroquinoline
    100
    Figure US20230330127A1-20231019-C00419
         		a) Intermediate 40 b) 7-bromoquinoline
    • Example A31 Preparation of Intermediate 101
  • Figure US20230330127A1-20231019-C00420
  • In a sealed tube, bis(triphenylphosphine)palladium(II) dichloride (79.0 mg; 113 µmol) and copper(I) iodide (21.4 mg; 113 µmol) were added to a solution of 7-bromoquninoline (468 mg; 2.25 mmol) in 2-methyltetrahydrofuran (8 mL) previously degassed with N2. The reaction mixture was degassed with N2 and Et3N (1.25 mL; 9.01 mmol) was added, followed by adding intermediate 41 (1.08 g; 3.38 mmol) in (4 mL). The reaction mixture was degassed with N2 then refluxed (80° C.) for 18 h. After cooling down to room temperature, the crude was partitioned between EtOAc and H2O. The aqueous layer was separated and extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered off and evaporated in vacuo. The residues were purified by preparative LC (Irregular SiOH 15-40 µm, 50 g Merck, DCM loading, mobile phase gradient: from heptane 80%, EtOAc 20% to heptane 50%, EtOAc 50%) to give intermediate 101 as a pale yellow oil (304 mg, yield: 27%).
    • Example A32 Preparation of Intermediate 102
  • Figure US20230330127A1-20231019-C00421
  • To a solution of intermediate 43 (100 mg, 0.323 mmol) and 7-(bromomethyl)quinoline ( 117 mg, 0.387 mmol) in DMF ( 3 mL) was added NaH (117 mg, 80% purity in mineral oil, 1.615 mmol). The mixture was stirred at room temperature for 5 h. The reaction mixture was quenched with saturated aqueous NH4Cl (10 mL) and extracted with ethyl acetate (50 mL × 3). The organic phase was washed with H2O (25 mL × 3), dried with anhydrous Na2SO4 and concentrated under reduced pressure to give the crude product. The crude product was purified with Preparative-TLC (petroleum ether/ethyl acetate = 3/2) to give intermediate 102 as a colourless oil (50 mg, 91% purity, 35% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 102 using the appropriate starting materials (Table 17).
  • TABLE 17
    Int. Structure Starting materials
    102a
    Figure US20230330127A1-20231019-C00422
         		a) Intermediate 43 b) 6-(Bromomethyl)quinoline
    102b
    Figure US20230330127A1-20231019-C00423
         		a) Intermediate 43 b)6-(Bromomethyl)isoquinoline
    333
    Figure US20230330127A1-20231019-C00424
         		a) Intermediate 43 b) intermediate 332
    • Example A33 Preparation of Intermediate 103
  • Figure US20230330127A1-20231019-C00425
  • Potassium carbonate (507 mg, 3.67 mmol) was added in one portion to a solution of intermediate 44 (600 mg, 1.23 mmol) and quinolin-7-ylboronic acid (254 mg, 1.47 mmol) in dioxane (15 mL). The reaction mixture was stirred at 90° C. under N2 for 2 hours, after which the mixture was allowed to cool to room temperature. Subsequently, ethyl acetate was added, the organic phase was washed with saturated Na2CO3 and brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (gradient eluention: heptane/ethyl acetate from 100/0 to 40/60) to give intermediate 103 (100 mg, 19% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 103 using the appropriate starting materials (Table 28).
  • TABLE 28
    Int. structure Starting material
    197
    Figure US20230330127A1-20231019-C00426
         		Intermediate 207 and 2-naphthaleneboronic acid
    208
    Figure US20230330127A1-20231019-C00427
         		Intermediate 207 and isoquinoline-7-boronic acid
    225
    Figure US20230330127A1-20231019-C00428
         		Intermediate 224 and isoquinoline-7-boronic acid
    • Example A34 Preparation of Intermediate 104
  • Figure US20230330127A1-20231019-C00429
  • Intermediate 45 (350 mg, crude, ≈0.626 mmol) was dissolved in 5 mL of dioxane. Then 5 mL of NH3.H2O was added. The mixture was heated in a sealed tube (autoclave) at 90° C. for 12 hours. The mixture was cooled to room temperature. The solvent was concentrated in vacuum to give the crude intermediate 104 (300 mg,) as a yellow oil.
    • Example A35 Preparation of Intermediate 105
  • Figure US20230330127A1-20231019-C00430
  • The crude Intermediate 59 (q.s., theoretically 0.83 mmol) was dissolved in 7 M NH3 in MeOH (20 mL, 7 M, 140 mmol). The resulting solution was stirred and heated at 130° C. using microwave irradiation for 2 hour. The solvents were evaporated. The residue was dissolved in dichloromethane and purified over a SiO2 column, type Grace Reveleris SRC, 12 g, Si 40, on a Grace Reveleris X2 purification system using dichloromethane and methanol as eluens in a gradient starting from 100% DCM for 20 column volumes to 20% MeOH and 80% DCM over 20 column volumes. The fractions containing the product were combined and the solvents were evaporated yielding crude Intermediate 105 (175 mg) used as such in the next reaction step.
  • The intermediates in Table 18 were prepared by an analogous reaction protocol as described in A34 or A35 using the appropriate starting materials (Table 18). Intermediates 136, 137 and 138 were obtained in the E-configuration.
  • TABLE 18
    Int. structure Ref Starting material
    106
    Figure US20230330127A1-20231019-C00431
         		A34 Intermediate 62
    107
    Figure US20230330127A1-20231019-C00432
         		A34 Intermediate 63
    108
    Figure US20230330127A1-20231019-C00433
         		A34 Intermediate 49
    109
    Figure US20230330127A1-20231019-C00434
         		A34 Intermediate 64
    110
    Figure US20230330127A1-20231019-C00435
         		A34 Intermediate 71
    111
    Figure US20230330127A1-20231019-C00436
         		A34 Intermediate 48
    112
    Figure US20230330127A1-20231019-C00437
         		A34 Intermediate 47
    113
    Figure US20230330127A1-20231019-C00438
         		A34 Intermediate 65
    114
    Figure US20230330127A1-20231019-C00439
         		A34 Intermediate 46
    115
    Figure US20230330127A1-20231019-C00440
         		A34 Intermediate 50
    116
    Figure US20230330127A1-20231019-C00441
         		A34 Intermediate 51
    117
    Figure US20230330127A1-20231019-C00442
         		A35 Intermediate 52
    118
    Figure US20230330127A1-20231019-C00443
         		A34 Intermediate 66
    119
    Figure US20230330127A1-20231019-C00444
         		A34 Intermediate 67
    120
    Figure US20230330127A1-20231019-C00445
         		A34 Intermediate 61
    121
    Figure US20230330127A1-20231019-C00446
         		A35 Intermediate 53
    122
    Figure US20230330127A1-20231019-C00447
         		A35 Intermediate 55
    123
    Figure US20230330127A1-20231019-C00448
         		A34 Intermediate 68
    124
    Figure US20230330127A1-20231019-C00449
         		A35 Intermediate 54
    125
    Figure US20230330127A1-20231019-C00450
         		A35 Intermediate 58
    126
    Figure US20230330127A1-20231019-C00451
         		A34 Intermediate 78
    127
    Figure US20230330127A1-20231019-C00452
         		A34 Intermediate 69
    128
    Figure US20230330127A1-20231019-C00453
         		A34 intermediate 77
    129
    Figure US20230330127A1-20231019-C00454
         		A34 intermediate 90
    130
    Figure US20230330127A1-20231019-C00455
         		A34 intermediate 91
    131
    Figure US20230330127A1-20231019-C00456
         		A34 Intermediate 92
    132
    Figure US20230330127A1-20231019-C00457
         		A34 Intermediate 93
    133
    Figure US20230330127A1-20231019-C00458
         		A35 Intermediate 96
    134
    Figure US20230330127A1-20231019-C00459
         		A34 Intermediate 94
    135
    Figure US20230330127A1-20231019-C00460
         		A34 Intermediate 95
    136
    Figure US20230330127A1-20231019-C00461
         		A34 Intermediate 99
    137
    Figure US20230330127A1-20231019-C00462
         		A34 intermediate 97
    138
    Figure US20230330127A1-20231019-C00463
         		A34 Intermediate 98
    139
    Figure US20230330127A1-20231019-C00464
         		A35 Intermediate 101
    140
    Figure US20230330127A1-20231019-C00465
         		A34 Intermediate 60
    141
    Figure US20230330127A1-20231019-C00466
         		A34 Intermediate 102
    142
    Figure US20230330127A1-20231019-C00467
         		A34 Intermediate 102a
    143
    Figure US20230330127A1-20231019-C00468
         		A35 Intermediate 103
    188
    Figure US20230330127A1-20231019-C00469
         		A34 Intermediate 187
    192
    Figure US20230330127A1-20231019-C00470
         		A34 Intermediate 191
    194
    Figure US20230330127A1-20231019-C00471
         		A34 Intermediate 102b
    198
    Figure US20230330127A1-20231019-C00472
         		A35 Intermediate 197
    209
    Figure US20230330127A1-20231019-C00473
         		A34 Intermediate 208
    226
    Figure US20230330127A1-20231019-C00474
         		A34 Intermediate 225
    234
    Figure US20230330127A1-20231019-C00475
         		A35 Intermediate 233
    265
    Figure US20230330127A1-20231019-C00476
         		A34 Intermediate 264
    334
    Figure US20230330127A1-20231019-C00477
         		A34 Intermediate 333
    462
    Figure US20230330127A1-20231019-C00478
         		A34 Intermediate 461
    464
    Figure US20230330127A1-20231019-C00479
         		A34 Intermediate 463
    485
    Figure US20230330127A1-20231019-C00480
         		A34 Intermediate 484
    496
    Figure US20230330127A1-20231019-C00481
         		A34 Intermediate 495
    498
    Figure US20230330127A1-20231019-C00482
         		A34 Intermediate 497
    500
    Figure US20230330127A1-20231019-C00483
         		A34 Intermediate 499
    501
    Figure US20230330127A1-20231019-C00484
         		A34 Intermediate 497
    516
    Figure US20230330127A1-20231019-C00485
         		A34 Intermediate 515
    518
    Figure US20230330127A1-20231019-C00486
         		A34 Intermediate 517
    520
    Figure US20230330127A1-20231019-C00487
         		A34 Intermediate 519
    522
    Figure US20230330127A1-20231019-C00488
         		A34 Intermediate 521
    524
    Figure US20230330127A1-20231019-C00489
         		A34 Intermediate 523
    • Example A36 Preparation of Intermediate 144 and 144a
  • Figure US20230330127A1-20231019-C00490
  • A solution of Intermediate 56 (35.7 mg, ≈0.0662 mmol) in 7 M NH3 in MeOH ( 1 mL, 7 mmol) was stirred and heated at 130° C. using microwave irradiation for 1 hour. The solvents were evaporated. The residues were purified with Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-10 µm, 30 × 150 mm, Mobile phase: 0.25% NH4HCO3 solution in water, CH3CN). The solvents of the purified fractions were evaporated and co-evaporated with MeOH yielding Intermediate 144 (12.9 mg, 37% yield) and Intermediate 144a (26.5 mg, 73%).
    • Example A37 Preparation of Intermediate 145 and 145a
  • Figure US20230330127A1-20231019-C00491
  • A solution of crude Intermediate 57 (theoretically 2.36 mmol) in 7 M NH3 in MeOH (20 mL, 7 mmol) was stirred and heated at 130° C. using microwave irradiation for 2 hours. The solvents were evaporated. The residue was dissolved in DCM with MeOH and purified over a SiO2 column, type Grace Reveleris SRC, 40 g, Si 40, on a Armen Spot II Ultimate purification system (gradient elution: DCM:MeOH from 100:0 to 20:80). The fractions containing product were combined and the solvents were removed, yielding crude Intermediate 145 (0.64 g) and crude Intermediate 145a (0.13 g). Both crude intermediates were used for the next reaction step reaction without further purification.
    • Example A38 Preparation of Intermediate 146
  • Figure US20230330127A1-20231019-C00492
  • To a mixture of Intermediate 137 (340 mg, theoretically 795 µmol) in MeOH (10.0 mL) was added Pd/C (100 mg, 10%) at 25° C. The suspension was degassed under vacuum and purged with H2 (several times). The mixture was stirred under H2 (15 psi) at 25° C. for 5 hours. The mixture was filtered and the filtrate was concentrated. The residue was purified by preperative-HPLC (Column: Diamonsil 150*20 mm,5 µm, Mobile phase: from 15% MeCN in water (0.225% formic acid) to 45% MeCN in water (0.225% formic acid)
  • Flow Rate (ml/min): 25 ml/min), The fractions containing the desired product were combined and lyophilized. The residues were further purified by Chiral SFC (Column: OD (250 mm*30 mm,10 µm), Mobile phase: Supercritical CO2 / EtOH + NH3.H2O (0.1%) = 50/50 Flow rate: 80 ml/min). Intermediate 146 (130 mg, 38% yield) was obtained as a white solid.
  • Below intermediates were prepared by an analogous reaction protocol as described for preparing intermediate 146 using the appropriate starting materials (Table 19).
  • TABLE 19
    Int. structure Starting material
    147
    Figure US20230330127A1-20231019-C00493
         		Intermediate 138
    148
    Figure US20230330127A1-20231019-C00494
         		Intermediate 136
    • Example A39 Preparation of Intermediate 149
  • Figure US20230330127A1-20231019-C00495
  • To a solution of Intermediate 70 (360 mg, ≈542 µmol) in THF (3.00 mL) was added iPrOH (3.00 mL) and ammonia (28% in water, 6.00 mL). The mixture was stirred at 85° C. for 72 hours in an autoclave. The solvent was removed and the residue was purified by flash column on silica gel (gradient elution: MeOH/DCM from 0/100 to 4/96), yielded Intermediate 149 as a white solid. (230 mg, 65% yield).
  • The intermediate in Table 20 was prepared by an analogous reaction protocol as was used for the preparation of intermediate 149 using the appropriate starting materials (Table 20). Intermediate 150 was obtained in the E-configuration.
  • TABLE 20
    Int. structure Starting material
    150
    Figure US20230330127A1-20231019-C00496
         		Intermediate 100
    • Example A40 Preparation of Intermediate 151
  • Figure US20230330127A1-20231019-C00497
  • A suspension of intermediate 150 (150 mg, 349 µmol) and Pd/C (80 mg, 10%) was stirred under an atmosphere of H2 (15 Psi) for 7 hours at 15° C. The reaction mixture was filtered through Celite. The filtrate was concentrated under reduced pressure to afford intermediate 151 as a yellow solid (135 mg, 90% yield).
    • Example A41 Preparation of Intermediate 152
  • Figure US20230330127A1-20231019-C00498
  • To the solution of Intermediate 119 (550 mg, theoretically 1.18 mmol) in DMA ( 20 mL) were added Zinc cyanide (410 mg, 3.49 mmol), Zinc (55 mg,0.86 mmol), Tris(dibenzylideneacetone)dipalladium (46 mg, 0.051 mmol), 1,1′-Bis(diphenylphosphino)ferrocene (92 mg, 0.17 mmol). The mixture was stirred at 100° C. for 12 hours under N2. The catalyst was filtered and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (gradient eluent: EtOAc/Petroleum ether from 1/20 to 1/0). The solvent was evaporated to give the intermediate 152 as oil (450 mg, 70% yield).
    • Example A56 Preparation of Intermediate 214
  • Figure US20230330127A1-20231019-C00499
  • A mixture of intermediate 105 (512. mg, 1 mmol), CuCN ( 358.2 mg, 4 mmol), Pd2dba3(92 mg, 0.1 mmol) and DPPF ( 221.7 mg, 0.4 mmol) in dioxane(6 ml) were stirred at 100° C. for 16 h. The reaction mixture was cooled, poured into water and extracted three times with ethylacetate. The organic layer was washed two times with water. The organic layer was dried and evaporated to dryness. The residue was purified by Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-10 µm, 50×150 mm, Mobile phase: 0.25% NH4HCO3 solution in water, CH3CN) yielding intermediate 214 (363 mg, 79% yield).
    • Example A42 Preparation of Intermediate 153
  • Figure US20230330127A1-20231019-C00500
  • The mixture of intermediate 23 (50 mg, theoretically 0.13 mmol), 7-hydroxyquinoline (22 mg, 0.156 mmol) and PPh3 (53 mg, 0.26 mmol) in dry THF (20 ml) was stirred at room temperature under N2. DIAD (6.47 g, 32.037 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrate to dryness, yielding crude intermediate 153.
    • Example A43 Preparation of Intermediate 154 and Intermediate 154a
  • Figure US20230330127A1-20231019-C00501
  • To a solution of intermediate 72 (1.0 g, 1.91 mmol) in 1,4-dioxane (10 mL) was added 2 M NaOH (10 mL, 20 mmol). The reaction mixture was stirred at 150° C. for 1 hour under microwave condition. The mixture was diluted with water (15 mL), extracted with EtOAc (10 mL × 3). The organic phase was washed with brine (15 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography column (elution: EtOAc/MeOH 85/15). The desired fractions were collected and concentrated to give intermediate 154 (359 mg of a white solid, 41% yield) and intermediate 154a (300 mg, 32% yield).
    • Example A44 Preparation of Intermediate 155
  • Figure US20230330127A1-20231019-C00502
  • Sodium (440 mg, 19.1 mmol) was stirred in MeOH (25 mL) at room temperature until sodium was dissolved compeletly. Then intermediate 72 (1.0 g, 1.91 mmol) was added into the reaction mixture and the reaction mixture was refluxed for 72 hours. The mixture was diluted with DCM (100 mL), washed with water (10 mL), brine (10 mL).The organic phase was dried over Na2SO4, filtered and concentrated to give crude intermediate 155 which was used as such for the next reation step without further purification.
    • Example A45 Preparation of Intermediate 157
  • Figure US20230330127A1-20231019-C00503
  • 7- bromo-2-chloro-quinoline (10.0 g, 41.2 mmol) and cyclopropylmethylamine (18 mL) in EtOH (80 mL) was stirred in a sealed tube at 120° C. overnight. The mixture was evaporated under vacuo to give intermediate 157 (15 g; crude) as a brown solid which used as such in the next reaction step without further purification.
    • Preparation of Intermediate 159
  • Figure US20230330127A1-20231019-C00504
  • Intermediate 38 (3.8 g, 11.9 mmol) in 9-BBN (0.5 M in THF, 95.1 mL, 47.5 mmol) was refluxed for 1h under N2. The mixture was cooled to room temperature, then K3PO4 (7.56 g, 35.6 mmol) in H2O (20 mL) was added, followed by THF (150 mL), intermediate 157 (4.4 g, ≈13 mmol) and Pd-118 (155 mg, 0.24 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H2O (100 mL), extracted with ethyl acetate (150 mL), the organic phase was dried by Na2SO4, then filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to ⅓) to give intermediate 159 (3.1 g, yield: 42.8%) as a yellow oil.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 159 using the appropriate starting materials (Table 29).
  • TABLE 29
    Int. Structure Starting materials
    242
    Figure US20230330127A1-20231019-C00505
         		a) Intermediate 38 b) 3-methyl-7-bromoquinoline
    245
    Figure US20230330127A1-20231019-C00506
         		a) Intermediate 38 b) Intermediate 244
    248
    Figure US20230330127A1-20231019-C00507
         		a) Intermediate 38 b) 7-bromo-N-methyl-2-quinolinamine
    249
    Figure US20230330127A1-20231019-C00508
         		a) Intermediate 39 b) 7-bromo-3-ethyl-quinoline
    251
    Figure US20230330127A1-20231019-C00509
         		a) Intermediate 39 b) 7-bromo-3-methyl-quinoline
    254
    Figure US20230330127A1-20231019-C00510
         		a) Intermediate 38 b) Intermediate 253
    256
    Figure US20230330127A1-20231019-C00511
         		a) Intermediate 38 b) 7-bromo-3-ethyl-quinoline
    259
    Figure US20230330127A1-20231019-C00512
         		a) Intermediate 39 b) 7-bromo-N-methyl-2-quinolinamine
    266
    Figure US20230330127A1-20231019-C00513
         		a) Intermediate 39 b) 7-bromo-2-Quinolinamine
    268
    Figure US20230330127A1-20231019-C00514
         		a) Intermediate 39 b) Intermediate 253
    272
    Figure US20230330127A1-20231019-C00515
         		a) Intermediate 39 b) Intermediate 157
    277
    Figure US20230330127A1-20231019-C00516
         		a) Intermediate 38 b) Intermediate 276
    281
    Figure US20230330127A1-20231019-C00517
         		a) Intermediate 38 b) Intermediate 280
    288
    Figure US20230330127A1-20231019-C00518
         		a) Intermediate 38 b) Intermediate 287
    291
    Figure US20230330127A1-20231019-C00519
         		a) Intermediate 38 b) Intermediate 290
    294
    Figure US20230330127A1-20231019-C00520
         		a) Intermediate 38 b) Intermediate 293
    297
    Figure US20230330127A1-20231019-C00521
         		a) Intermediate 38 b) Intermediate 296
    300
    Figure US20230330127A1-20231019-C00522
         		a) Intermediate 38 b) Intermediate 299
    303
    Figure US20230330127A1-20231019-C00523
         		a) Intermediate 38 b) Intermediate 302
    306
    Figure US20230330127A1-20231019-C00524
         		a) Intermediate 38 b) Intermediate 305
    309
    Figure US20230330127A1-20231019-C00525
         		a) Intermediate 38 b) Intermediate 308
    312
    Figure US20230330127A1-20231019-C00526
         		a) Intermediate 38 b) Intermediate 311
    315
    Figure US20230330127A1-20231019-C00527
         		a) Intermediate 38 b) Intermediate 314
    318
    Figure US20230330127A1-20231019-C00528
         		a) Intermediate 38 b) Intermediate 317
    321
    Figure US20230330127A1-20231019-C00529
         		a) Intermediate 38 b) Intermediate 320
    324
    Figure US20230330127A1-20231019-C00530
         		a) Intermediate 38 b) Intermediate 323
    327
    Figure US20230330127A1-20231019-C00531
         		a) Intermediate 39 b) Intermediate 326
    330
    Figure US20230330127A1-20231019-C00532
         		a) Intermediate 38 b) Intermediate 329
    336
    Figure US20230330127A1-20231019-C00533
         		a) Intermediate 38 b) Intermediate 335
    473
    Figure US20230330127A1-20231019-C00534
         		a) Intermediate 39 b) Intermediate 329
    • Preparation of Intermediate 160
  • Figure US20230330127A1-20231019-C00535
  • Reaction performed in a sealed tube. Intermediate 159 (3.1 g, ≈5.1 mmol) was added to NH3.H2O (30 mL) and dioxane (30 mL) and was stirred at 120° C. overnight. The mixture was concentrated in vacuo to give crude intermediate 160. This residue was purified by silica gel chromatography (ethylacetate 100% to ethyl acetate/MeOH 90/10) to give intermediate 160 (3.95 g, yield: 77%).
    • Example A46 Preparation of Intermediate 161
  • Figure US20230330127A1-20231019-C00536
  • 7- Bromo-2- chloro-quinoline (1.5 g, 6.18 mmol) and 2,2-difluoroethylamine (0.552 g, 6.804 mmol) in EtOH (30 mL) were heated in a sealed tube at 120° C. overnight. The mixture was evaporated under vacuo to give intermediate 161 (1.8 g, yield: 88.1%) as a brown solid which used for next step without further purification.
    • Preparation of Intermediate 162
  • Figure US20230330127A1-20231019-C00537
  • Intermediate 38 (500 mg, 1.56 mmol) in 9-BBN (0.5 M in THF, 15.6 mL, 7.8 mmol) was refluxed for 1h under N2. The mixture was cooled to room temperature, then K3PO4 (995.6 mg, 4.7 mmol) in H2O (2 mL) was added, followed by THF (20 mL), intermediate 161 (538.7 mg, ≈1.88 mmol) and Pd-118 (20.4 mg, 0.031 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H2O (60 mL), extracted with ethyl acetate (100 mL × 2), the combined organic phases were dried by Na2SO4, then filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate: petroleum ether ratio 1:10 to 1:5) to give intermediate 162 (650 mg, yield: 68.1%) as yellow oil.
    • Preparation of Intermediate 163
  • Figure US20230330127A1-20231019-C00538
  • Reaction performed in a sealed tube. Intermediate 162 (650 mg, ≈1.06 mmol) was added to NH3.H2O (15 mL) and dioxane (10 mL) and was stirred at 120° C. overnight. The mixture was concentrated in vacuo to give intermediate 163 (680 mg, yield: 97.9%).
    • Example A47 Preparation of Intermediate 164
  • Figure US20230330127A1-20231019-C00539
  • A mixture of 7- bromo-2-chloroquinoline (10 g, 41.24 mmol) and 4-methoxybenzylamine (11.3 g, 82.5 mmol) in ethanol (40 ml) was heated in a sealed tube at 120° C. for 72 h. The mixture was evaporated under reduced pressure and purified by chromatography column (gradient eluent: CH2Cl2/petroleum ether from ⅒ to 1/0) to afford the desired product intermediate 164 (13 g, 82% yield) as a white solid.
    • Preparation of Intermediate 165
  • Figure US20230330127A1-20231019-C00540
  • A mixture of intermediate 38 (2 g, 5.0 mmol ) in 9-BBN (50.0 ml, 25.0 mmol, 0.5 M in THF) was refluxed for 1 h under N2. The mixture was cooled to room temperature, then K3PO4(3.18 mg, 15.0 mmol ) in H2O (10 mL) was added, followed by THF (20 ml), intermediate 164 (2.58 mg, ≈7.50 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)(163.0 mg, 0.25 mmol).The resulting mixture was refluxed for 3 h. The mixture was concentrated. The residue was dissolved in ethyl acetate (40 ml), washed with water(6 ml), brine(6 ml).The organic phase was dried over Na2SO4, filtered and concentrated to obtain the crude product. This was purified by chromatography column (gradient eluent: ethyl acetate/petroleum ether from ⅒ to 1/1). The desired fractions were collected and concentrated to give product intermediate 165 as a solid (2 g, 52.4% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 165 using the appropriate starting materials (Table 30).
  • TABLE 30
    Int. Structure Starting materials
    237
    Figure US20230330127A1-20231019-C00541
         		a) Intermediate 38 b) 2-amino-7-bromoquinoline
    238
    Figure US20230330127A1-20231019-C00542
         		a) Intermediate 39 b) 3-bromo-7-iodoquinoline
    260
    Figure US20230330127A1-20231019-C00543
         		a) Intermediate 38 b) 3-bromo-7-iodoquinoline
    482
    Figure US20230330127A1-20231019-C00544
         		a) Intermediate 39 b)intermediate 175
    488
    Figure US20230330127A1-20231019-C00545
         		a) Intermediate 487 b)intermediate 175
    491
    Figure US20230330127A1-20231019-C00546
         		a) Intermediate 490 b) intermediate 175
    514
    Figure US20230330127A1-20231019-C00547
         		a) Intermediate 513 b) intermediate 314
    • Preparation of Intermediate 166
  • Figure US20230330127A1-20231019-C00548
  • A mixture of intermediate 165 (500 mg, ≈0.655 mmol) and NH3.H2O(10 ml) in dioxane(10 ml) was heated in a sealed tube at 120° C. for 14 h. This reaction was evaporated under vacuo to obtain intermediate 166 (400 mg, 93.5% yield) as an oil.
    • Preparation of Intermediate 167
  • Figure US20230330127A1-20231019-C00549
  • The mixture of intermediate 166 (340 mg, ≈0.52 mmol) in CF3COOH(5 ml) was stirred at 60° C. for 1 h. The mixture was evaporated under vacuo to obtain intermediate 167 as a crude product(300 mg, 85.9% yield).
    • Example A48 Preparation of Intermediate 168
  • Figure US20230330127A1-20231019-C00550
  • Intermediate 165 (300 mg, ≈0.39 mmol)was dissolved in EtOH(20 ml) and ethyl acetate (4 ml) and hydrogenated under 1 atm of H2 over Pd(OH)2/C (30 mg) for 7 hours. The mixture was filtered and evaporated under vacuo to obtain intermediate 168 as a crude product(200 mg, 70.6% yield).
    • Preparation of Intermediate 169
  • Figure US20230330127A1-20231019-C00551
  • The mixture of intermediate 168 (200 mg, ≈0.278 mmol) in CF3COOH (5 ml) was stirred at 60° C. for 1 h. The mixture was evaporated under vacuo to obtain intermediate 169 as a crude product(120 mg, 89.0%yield).
    • Example A49 Preparation of Intermediate 170
  • Figure US20230330127A1-20231019-C00552
  • A mixture of intermediate 165 (310 mg, ≈0.406 mmol) and CH3NH2/H2O (5 ml) in dioxane (5 ml) was stirred in a sealed tube at 120° C. for 14 h. This mixture was evaporated under vacuo to obtain intermediate 170 (200 mg, 80.1% yield) as a crude product.
    • Preparation of Intermediate 171
  • Figure US20230330127A1-20231019-C00553
  • The mixture of intermediate 170 (200 mg, ≈0.325 mmol) in CF3COOH (5 ml) was stirred at 50° C. for 1 h. The mixture was evaporated under vacuo to obtain intermediate 171(160 mg, 84.0% yield) as a crude product.
    • Example A50 Preparation of Intermediate 172
  • Figure US20230330127A1-20231019-C00554
  • A mixture of intermediate 165 (300 mg, 0.393 mmol) and sodium methoxide (63.7 mg, 1.18 mmol) in methanol (10 ml) was refluxed at 60° C. for 12 h. The mixture was evaporated under vacuo to give a crude product. Water (10 ml) was added, the mixture was extracted with ethyl acetate(10 ml × 2), the organic layers were combined and evaporated under vacuo to obtain intermediate 172 (200 mg, 71.8% yield) as a crude product.
    • Preparation of Intermediate 173
  • Figure US20230330127A1-20231019-C00555
  • The mixture of intermediate 172 (200 mg, ≈0.282 mmol) in TFA (5 ml) was stirred at 60° C. for 1 h.. The mixture was evaporated under vacuo to obtain intermediate 173 (250 mg, 85.3% yield,) as the crude product.
    • Example A51 Preparation of Intermediate 174
  • Figure US20230330127A1-20231019-C00556
  • 3-Bromoiodo-quinoline (5.99 g, 17.7 mmol) was dissolved in dichloromethane (60 mL), then m-CPBA (4.57 g, 26.5 mmol) was added in portions. The mixture was stirred at room temperature for 4 days. The mixture was quenched by a saturated Na2S2O3 aqueous solution (40 mL) and a saturated NaHCO3 aqueous solution (PH to 6-7), then extracted by dichloromethane (50 mL × 3). The organic phase was washed with H2O (50 mL), dried with anhydrous Na2SO4 and evaporated under reduced pressure. The residue was purified by silica gel column (eluent: petroleum ether/ethyl acetate = 10/1 to 1/1) to afford the desired product intermediate 174 (1.9 g, 14.1% yield) as a yellow solid.
    • Preparation of Intermediate 175
  • Figure US20230330127A1-20231019-C00557
  • To a solution of intermediate 174 (2.9 g, 8.29 mmol) in chloroform (60 mL) was added phosphoryl trichloride (8.3 g, 54.1 mmol). The mixture was stirred at 80° C. for 12 h. The mixture was evaporated under reduced pressure to obtain crude product. The crude product was purified by chromatography column (eluent: petroleum ether/ethyl acetate = 10/1 to 1/1). The desired fractions were collected and concentrated to give product intermediate 175 (1.3 g, 41.5% yield) as a white solid.
    • Preparation of Intermediate 176
  • Figure US20230330127A1-20231019-C00558
  • 4-methoxybenzylamine(1.34 g, 9.78 mmol) was added into the mixture of intermediate 175 (0.8 g, ≈1.95 mmol) in ethanol (10 ml). The mixture was heated in a sealed tube at 100° C. for 12 h. The mixture was evaporated under vacuo to obtain the crude product. This was purified by chromatography column (gradient eluent: ethyl acetate/petroleum ether from 0/1 to ⅒). The desired fractions were collected and concentrated to give product intermediate 176 (600 mg, 51.6% yield) as an oil.
    • Preparation of Intermediate 177
  • Figure US20230330127A1-20231019-C00559
  • A mixture of intermediate 38 (44 mg, 0.138 mmol) in 9-BBN (1.3 ml, 0.69 mmol, 0.5 M in THF) was refluxed for 1h under N2. The mixture was cooled to room temperature, then K3PO4(87 mg, 0.413 mmol) in H2O (1 mL) was added, followed by THF (5 ml), intermediate 176 (122.727 mg, ≈0.206 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (4.48 mg, 0.007 mmol). The reaction mixture was refluxed for 3 hours. The mixture was concentrated. The residue was dissolved in ethyl acetate (40 ml), washed with water (6 ml), brine (6 ml).The organic phase was dried over Na2SO4, filtered and concentrated to give crude intermediate 177 fraction 1 (120 mg, 71.5% yield).
  • A mixture of intermediate 38 (233.7 mg, 0.73 mmol) in 9-BBN (7.31 ml, 3.65 mmol, 0.5 M in THF) was refluxed for 1 h under N2. The mixture was cooled to room temperature, then K3PO4 (87 mg, 0.413 mmol) in H2O(1 mL) was added, followed by THF (5 ml), intermediate 176 (478 mg, ≈0.80 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)( 23.8 mg, 0.037 mmol). The reaction mixture was refluxed for 3 hours. The mixture was concentrated. The residue was dissolved in ethyl acetate (40 ml), washed with water (6 ml), brine (6 ml). The organic phase was dried over Na2SO4, filtered and concentrated to with crude intermediate 177 fraction 2 (600 mg, 63.1% yield).
  • The two fractions were combined and purified by chromatography column (gradient eluent: ethyl acetate/petroleum ether from ⅒ to 1/1). The desired fractions were collected and concentrated to give intermediate 177 (300 mg, 61.0% yield) as a solid.
    • Preparation of Intermediate 178
  • Figure US20230330127A1-20231019-C00560
  • A mixture of intermediate 177 (300 mg, ≈0.446 mmol) and NH3.H2O (10 ml) in dioxane (10 ml) was stirred in a sealed tube at 120° C. for 14 h. This reaction was evaporated under vacuo to obtain intermediate 178 (250 mg, 87.1% yield) as an oil.
    • Preparation of Intermediate 179
  • Figure US20230330127A1-20231019-C00561
  • The mixture of intermediate 178 (250 mg, ≈0.388 mmol ) in TFA (5 ml) was stirred at 50° C. for 1 h. The mixture was evaporated under vacuo to obtain intermediate 179 (350 mg, 63.4% yield) as an oil.
    • Example A52 Preparation of Intermediate 180
  • Figure US20230330127A1-20231019-C00562
  • 3-Chloro-7-bromo-quinoline (10 g, 41.2 mmol) was dissolved in dichloromethane (150 mL). Then m-CPBA (7.83 g, 45.3 mmol) was added in portions. The mixture was stirred at 35° C. for 16 hours. The mixture was poured into a saturated Na2SO3 aqueous solution. The mixture was extracted by CH2Cl2. Then the mixture was washed by a saturated Na2SO3 aqueous solution (50 mL × 2) and a saturated NaHCO3 aqueous solution (50 mL × 2). The organic was dried over anhydrous Na2SO4 and concentrated. The white solid was precipitated and filtered to give intermediate 180 (10 g, 78.8% yield) as a yellow solid.
    • Preparation of Intermediate 181
  • Figure US20230330127A1-20231019-C00563
  • To a solution of intermediate 180 (6 g, 23.2 mmol) in chloroform (30 mL) was added phosphoryl trichloride (18.8 g, 122.5 mmol). The mixture was stirred at 80° C. for 1 h. The mixture was poured into water slowly. Then a saturated NaHCO3 aqueous solution was added into the mixture to change the PH to approximately 7.
  • The mixture was extracted by CH2Cl2 (50 mL × 2) and dried over anhydrous Na2SO4. The organic phase was concentrated. The crude product was purified by chromatography column (eluent: petroleum ether/ethyl acetate = 1/0 to 4/1). The desired fractions were collected and concentrated to give intermediate 181 (5 g, 72.3% yield).
    • Preparation of Intermediate 182
  • Figure US20230330127A1-20231019-C00564
  • To NH3 in H2O (10 ml) and dioxane (15 ml) was added intermediate 181 (1 g, 3.6 mmol). The mixture was heated in a sealed tube at 120° C. for 16 h. The mixture was extracted by EtOAc. The organic layer was dried by anhydrous Na2SO4 and concentrated. The residue was purified by chromatography column (gradient eluent: ethyl acetate/petrol ether from 0/1 to ⅓). The desired fractions were collected and concentrated to give product intermediate 182 (650 mg, 69.2% yield) as a pink solid.
    • Preparation of Intermediate 183
  • Figure US20230330127A1-20231019-C00565
  • A mixture of intermediate 38 (100 mg, 0.313 mmol ) in 9-BBN (2.19 ml, 1.09 mmol, 0.5 M in THF) was refluxed for 1.5 h under N2. The mixture was cooled to room temperature, then K3PO4 (199 mg, 0.938 mmol) in H2O (2 mL) was added, followed by THF( 8 ml), intermediate 182 (88.6 mg, 0.344 mmol) and Pd-118 (26.48 mg, 0.407 mmol).The mixture was refluxed for 3 hours. The mixture was concentrated. The residue was dissolved in water, extracted with in ethyl acetate (20 × 2 ml) and washed with brine (10 ×2 ml).The organic phase was dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography column (gradient eluent: ethyl acetate/petroleum ether from 0/1 to ⅓). The desired fractions were collected and concentrated to give intermediate 183 (100 mg, 55.4% yield).
    • Preparation of Intermediate 184
  • Figure US20230330127A1-20231019-C00566
  • A mixture of intermediate 183 (800 mg, ≈1.605 mmol ) and NH3.H2O (10 ml) in dioxane (10 ml) was heated in a sealed tube at 120° C. for 48 h. The mixture was extracted by EtOAc (30 mL × 3). The organic phase was concentrated to obtain intermediate 184 (800 mg, 90% yield).
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 184 using the appropriate starting materials (Table 31).
  • TABLE 31
    Int. Structure Starting materials
    239
    Figure US20230330127A1-20231019-C00567
         		Intermediate 238
    243
    Figure US20230330127A1-20231019-C00568
         		Intermediate 242
    250
    Figure US20230330127A1-20231019-C00569
         		Intermediate 249
    252
    Figure US20230330127A1-20231019-C00570
         		Intermediate 251
    255
    Figure US20230330127A1-20231019-C00571
         		Intermediate 254
    257
    Figure US20230330127A1-20231019-C00572
         		Intermediate 256
    258
    Figure US20230330127A1-20231019-C00573
         		Intermediate 248
    261
    Figure US20230330127A1-20231019-C00574
         		Intermediate 260
    267
    Figure US20230330127A1-20231019-C00575
         		Intermediate 266
    269
    Figure US20230330127A1-20231019-C00576
         		Intermediate 268
    271
    Figure US20230330127A1-20231019-C00577
         		Intermediate 259
    273
    Figure US20230330127A1-20231019-C00578
         		Intermediate 272
    278
    Figure US20230330127A1-20231019-C00579
         		Intermediate 277
    289
    Figure US20230330127A1-20231019-C00580
         		Intermediate 288
    292
    Figure US20230330127A1-20231019-C00581
         		Intermediate 291
    295
    Figure US20230330127A1-20231019-C00582
         		Intermediate 294
    298
    Figure US20230330127A1-20231019-C00583
         		Intermediate 297
    301
    Figure US20230330127A1-20231019-C00584
         		Intermediate 300
    304
    Figure US20230330127A1-20231019-C00585
         		Intermediate 303
    307
    Figure US20230330127A1-20231019-C00586
         		Intermediate 306
    310
    Figure US20230330127A1-20231019-C00587
         		Intermediate 309
    313
    Figure US20230330127A1-20231019-C00588
         		Intermediate 312
    316
    Figure US20230330127A1-20231019-C00589
         		Intermediate 315
    319
    Figure US20230330127A1-20231019-C00590
         		Intermediate 318
    322
    Figure US20230330127A1-20231019-C00591
         		Intermediate 321
    325
    Figure US20230330127A1-20231019-C00592
         		Intermediate 324
    328
    Figure US20230330127A1-20231019-C00593
         		Intermediate 327
    331
    Figure US20230330127A1-20231019-C00594
         		Intermediate 330
    337
    Figure US20230330127A1-20231019-C00595
         		Intermediate 336
    483
    Figure US20230330127A1-20231019-C00596
         		Intermediate 482
    • Example A57 Preparation of Intermediate 316
  • Figure US20230330127A1-20231019-C00597
  • Intermediate 433 (10.8 g, 35.96 mmol) was dissolved in 60 mL of THF and 9- BBN 0.5 M in THF (226.5 ml, 113.2 mmol)) was added and the reaction mixture was stirred for 2 hours. K3PO4 (38.1 g, 179.78 mmol) in 65 ml of water was added and the reaction mixture was vigoursly stirred for 30 min. Intermediate 314 (10.46 g, 35.96 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(ii) were added, and the reaction mixture was degassed. The resulting mixture was stirred for 2 hours at 60° C. and allowed to cool to room temperature overnight. EtOAc was added to the reaction mixture, the organic layer was washed with water and brine, dried on MgSO4 and concentrated under reduced pressure to give crude product. The residue was purified by normal phase HPLC (Stationary phase: silicagel type: 60A 25_40 µm (Merck), Mobile phase: Gradient from 95% Dichloromethane, 5% methanol to 90% Dichloromethane, 10% methanol).The desired fractions were collected and evaporated. The residue was re-purified by normal phase HPLC (Stationary phase: silicagel type 60A 25_40 um (Merck), Mobile phase: isocratic 95% Ethyl acetate and 5% ethanol yielding intermediate 316 (7.9 g, 43% yield).
    • Example A 99 Preparation of Intermediate 528
  • Figure US20230330127A1-20231019-C00598
  • Intermediate 175 (630 mg, 1.71 mmol) was dissolved in dioxane (10 ml). Then NH3.H2O (10 ml) was added. The reaction mixture was stirred at 120° C. for 24 hours in a sealed tube. The reaction mixture was extracted with EtOAc (50 ml × 3). The organic layers were combined, dried with Na2SO4, and the solvent was evaporated to give intermediate 528 (380 mg, 62% yield) as a solid.
    • Preparation of Intermediate 529
  • Figure US20230330127A1-20231019-C00599
  • A mixture of intermediate 433 (22 g, 72.7 mmol) in 9-BBN/THF (0.5 M THF solution, 585 mL, 292.3 mmol) was stirred at 50° C. for 1 hour under N2. The mixture was cooled to room temperature, and K3PO4 (77.6 g, 365.6 mmol) and H2O (80 mL) were added.
  • The mixture stirred at room temperature for 0.5 hour, then THF (95 mL), intermediate 528 (22.9 g, 65.8 mmol) and Pd(dppf)Cl2 (4.77 g, 7.30 mmol) were added under N2. The resulting mixture was stirred at 50° C. for 3 hours. The mixture was concentrated. The residue was dissolved in ethyl acetate (120 ml). The organic layer was washed with water (10 mL) and brine (10 mL). The organic phase was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate ratio 1/1 to petroleum ether/ ethyl acetate ratio 0/1). The pure fractions were collected and the solvent was evaporated under vacuum to give 23.5 g of intermediate 529.
    • Example A53 Preparation of Intermediate 193
  • Figure US20230330127A1-20231019-C00600
  • To a solution of intermediate 105 (256 mg, 0.5 mmol) and cyclopropylboronic acid (107.5 mg, 1.25 mmol) in dioxane (3 ml) at r.t. was added Pd(dppf)Cl2.CH2Cl2 (41 mg, 0.05 mmol). Nitrogen was purged through reaction mixture for one minute followed by addition of K2CO3 (174 mg, 1.25 mmol) and water (0.2 ml) and again nitrogen was purged through reaction mixture for one minute. The reaction mixture was heated in a closed vessel up to 100° C. for 16 h. The reaction mixture was filtered over decalite and evaporated to dryness. The residue was purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-10 µm, 50 ×150 mm, Mobile phase: 0.25% NH4HCO3 solution in water, CH3CN yielding intermediate 193 ( 110 mg, 46.5%)
    • Example A58 Step 1 Preparation of Intermediate 434
  • Figure US20230330127A1-20231019-C00601
  • 2-bromomalonaldehyde (2.1 g, 13.96 mmol) was added in portions to a solution of 4-chloro-3-methoxyaniline (2.0 g, 12.69 mmol) in EtOH (100 mL) at 0° C. under N2 atmosphere. After stirring at room temperature for 2 h, the mixture was concentrated to give intermediate 434 (4.0 g, 69.5% yield) which used in the next step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 434 using the appropriate starting materials (Table 32).
  • TABLE 32
    Intermediates Structure Starting materials
    435
    Figure US20230330127A1-20231019-C00602
         		a) 2-chloro-3-methoxyaniline b) 2-bromomalonaldehyde
    436
    Figure US20230330127A1-20231019-C00603
         		a) 4-fluoro-3-methoxyaniline b) 2-bromomalonaldehyde
    • Step 2 Preparation of Intermediate 437
  • Figure US20230330127A1-20231019-C00604
  • The reaction was executed twice.
  • A mixture of intermediate 434 (1.0 g, 3.44 mmol) and PPA (1.0 g) in EtOH (20 mL) was heated at 95° C. in a Microwave Tube for 1 h. The two reaction mixtures were combined and concentrated. The residue was diluted with water and extracted with CH2Cl2 (50 mL × 5). The organic phase was washed with aq.NaHCO3, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography column (eluens: Petroleum ether/EtOAc 85/15). The desired fractions were collected and concentrated to give intermediate 437 (0.77 g, 41% yield) as a yellow solid.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 437 using the appropriate starting materials (Table 33).
  • TABLE 33
    Int. Structure Starting materials
    438
    Figure US20230330127A1-20231019-C00605
         		intermediate 435
    439
    Figure US20230330127A1-20231019-C00606
         		intermediate 436
    • Step 3 Preparation of Intermediate 200
  • Figure US20230330127A1-20231019-C00607
  • BBr3 (1.6 mL, 16.60 mmol) was added to a solution of intermediate 437 (1.28 g, 4.70 mmol) in CHCl3 (25 mL) at 0° C. The reaction mixture was refluxed for 48 hours. The reaction mixture was adjusted to pH 7 with a sat. sodium hydrogen carbonate solution. The mixture was concentrated until CHCl3 was removed. The resulting mixture was filtered to give intermediate 200 (1.1 g, 91% yield) as a solid.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 200 using the appropriate starting materials (Table 34).
  • TABLE 34
    Int. Structure Starting materials
    205
    Figure US20230330127A1-20231019-C00608
         		intermediate 438
    229
    Figure US20230330127A1-20231019-C00609
         		intermediate 439
    • Example A59 Step 1 Preparation of Intermediate 440
  • Figure US20230330127A1-20231019-C00610
  • A mixture of intermediate 437 (720 mg, 2.64 mmol), Tetramethylammonium Chloride (2.90 g, 26.42 mmol), Copper(I) Oxide (378.0 mg, 2.64 mmol) and L-Proline (608.3 mg, 5.28 mmol) in EtOH (15 mL) was stirred at 110° C. in a microwave tube for 60 min. The mixture was filtered, and the filtrate was concentrated. The residue was purified by chromatography (eluens: Petroleum ether/EtOAc 3/1). The desired fractions were collected and concentrated to give intermediate 440 (290 mg, 48-% yield) as solid.
    • Step 2 Preparation of Intermediate 216
  • Figure US20230330127A1-20231019-C00611
  • BBr3 (2.34 mL, 24.5 mmol) was added to a solution of intermediate 440 (280 mg, 1.23 mmol) in ClCH2CH2Cl (15 mL) at 0° C. The reaction mixture was refluxed overnight. The reaction mixture was adjusted to pH 7 with a sat. sodium hydrogen carbonate solution. The mixture was concentrated until ClCH2CH2Cl was removed. The resulting solid was filtered to give intermediate 216 (250 mg, 87.5% yield).
    • Example A60 Step1 Preparation of Intermediate 441
  • Figure US20230330127A1-20231019-C00612
  • The quinoline-2,7-diol (20 g, 124.1 mmol, 1.0 eq) was taken up into DMF (40 mL), POCl3 (107.7 g, 702.5 mmol, 5.7 eq) was added at room temperature. The reaction mixture was stirred at 70° C. for 1 h. The solvent was removed under reduced pressure, the residue was poured slowly into water (300 mL) at 0° C. To the solution was added a saturation Na2CO3 aq. until pH = 8. The mixture was extracted with ethyl acetate 1000 mL × 2. The organic layer was washed with brine 1000 mL and concentrated under vacuum to afford the product intermediate 441 (20 g, 88% yield) as a solid.
    • Step 2 Preparation of Intermediate 442
  • Figure US20230330127A1-20231019-C00613
  • Intermediate 441 (2.5 g, 13.9 mmol, 1.0 eq) was dissolved in DMF (25 mL), K2CO3 (5.76 g, 41.76 mmol, 3 eq) and CH3I (5.2 g, 36.6 mmol, 2.63 eq) were added. The reaction mixture was stirred at 25° C. for 12 hr.. The reaction mixture was poured into water (100 mL) and was extracted with EtOAc (150 mL). The organic layer was washed by water (80 mL × 2), brine (800 mL) and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give intermediate 442 (2.6 g, 96% yield) as a white solid.
    • Step 3 Preparation of Intermediate 443
  • Figure US20230330127A1-20231019-C00614
  • To a solution of intermediate 442 (900 mg, 4.5 mmol, 1.0 eq.), NH2Bn (0.578 g, 5.4 mmol, 1.2 eq) and Cs2CO3 (2.93 g, 9 mmol, 2.0 eq) in DMF (5 mL) were added Pd2(dba)3 (412 mg, 0.45 mmol, 0.1 eq) and BINAP (280 mg, 0.45 mmol, 0.1 eq). The resulted mixture was stirred at 100° C. under N2 for 12 hr. The solvent was removed under reduced pressure, the residue was triturated with EtOAc (100 mL) and water (100 mL). The aqueous layer was extractedwith EtOAc (100 mL). The combined organic layers were washed with brine (60 mL) and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure, the residue was purified by column chromatography (eluent: EtOAc/ petroleum ether ratio 0/1 to ⅕) to afford intermediate 443 (450 mg, 37% yield) as a yellow solid.
    • Step 4 Preparation of Intermediate 231
  • Figure US20230330127A1-20231019-C00615
  • Intermediate 443 (500 mg, 1.78 mmol, 1.0 eq.) and pyridine hydrochloride (3.2 g, 28 mmol, 16 eq) were placed in a tube. The reaction mixture was stirred at 180° C. for 2 hr. The reaction mixture was cooled to room temperature. The reaction mixture was dissolved in 25 ml of DCM and 25 ml of H2O, and the pH was adjusted to around 8-9 by progressively adding solid K2CO3, and the layers were separated. The aqueous layer was extracted with DCM (20 mL × 3). The combined organic layers were dried (Na2SO4), filtered and the solvent was concentrated in vacuum to give intermediate 231 (440 mg, 96% yield) as an oil which was used in the next step without further purification.
    • Example A61 Step 1 Preparation of Intermediate 444
  • Figure US20230330127A1-20231019-C00616
  • A mixture of CuI (6.80 g, 35.84 mmol), CsF (14.15 g, 93.18 mmol) 1-iodo-2-methoxy-4-nitrobenzene (10 g, 35.84 mmol) and sulfolane (20 ml), was stirred rapidly at 45° C. To this mixture was added trimethyl(trifluoromethyl)silane (13.25 g, 93.18 mmol) dropwise over 4 hours using a syringe pump, and the resulting mixture was stirred at 45° C. for 18 hours. The mixture was diluted with ethyl acetate (500 mL) and stirred with Celite for 5 min. The reaction mixture was filtered through a pad of Celite, diluted with ethyl acetate (500 mL). The organic layer was washed with 10% NH4OH, 1.0 N HCl, brine, dried over Na2SO4, filtered, and concentrated to give the crude product.The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to ¼) to give intermediate 444 (8 g, 91% yield) as a white solid.
    • Step 2 Preparation of Intermediate 445
  • Figure US20230330127A1-20231019-C00617
  • Intermediate 444 (7.1 g, 28.9 mmol) was taken up into methanol (100 mL and then 5% Pd/C (0.7 g,) was added. The mixture was hydrogenated at room temperature for 48 hours under H2 (50 Psi) atmosphere. The mixture was filtered and the filtrate was evaporated under vacuum to obtain intermediate 445 (7 g) as a white solid.
    • Step 3 Preparation of Intermediate 446
  • Figure US20230330127A1-20231019-C00618
  • A mixture of intermediate 445 (6.2 g, 32.4 mmol), 2-bromomalonaldehyde (5.38 g, 35.7 mmol) and i-PrOH (120 mL) was stirred at room temperature for 5 min. The mixture was filtered and the filtered cake was washed with i-prOH (10 mL).The filtered cake was dried under vacuum to obtain intermediate 446 (6 g, 51% yield) as a yellow solid.
    • Step 4 Preparation of Intermediate 447
  • Figure US20230330127A1-20231019-C00619
  • A mixture of intermediate 446 (6 g, 18.5 mmol) and PPA (10 mL) in ethanol (150 mL) was stirred at 80° C. overnight. The mixture was evaporated under vacuum. Water (100 mL) was added to the mixture and the mixture was extracted with ethyl acetate (100 mL × 3). The organic layers were combined and evaporated under vacuum to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to ⅒) to give intermediate 447 (3.3 g, 54% yield) as a white solid.
    • Step 5 Preparation of Intermediate 210
  • Figure US20230330127A1-20231019-C00620
  • A mixture of intermediate 447 (1 g, 3.27 mmol) and pyridine hydrochloride (6 g, 51.9 mmol) was stirred at 210° C. for 2 hours. The reaction mixture was cooled to room temperature. Water (20 mL) was added into the mixture. The mixture was extracted with ethyl acetate (20 mL × 3). The organic layers were combined and evaporated under vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to ⅒) to obtain intermediate 210 (500 mg, 49% yield) as a white solid.
    • Example A62 Step 1 Preparation of Intermediate 448
  • Figure US20230330127A1-20231019-C00621
  • 3- bromo-7-hydroxyquinoline (5 g, 22.3 mmol) was dissolved in a mixture of DMF (50 mL) and CH3OH (50 mL). [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium(ii) (0.816 g, 1.12 mmol) and N(C2H5)3 (6.76 g, 66.9 mmol) were added. The mixture was stirred at 140° C. overnight under a CO atmosphere (3 MPa). The mixture was evaporated under vacuum. Then residue was purified by column chromatography (eluent: petroleum ether/ethyl acetate: ratio 10/1 to 0/1). The product fractions were collected and the solvent was evaporated to afford intermediate 448 (2.5 g, yield: 45.1%) as a yellow solid.
    • Step 2 Preparation of Intermediate 449
  • Figure US20230330127A1-20231019-C00622
  • Cs2CO3 (15.76 g, 48.37 mmol) was added to the mixture of intermediate 448 (4 g, 16.1 mmol) and benzyl bromide (2.76 g, 16.1 mmol) in DMF (50 mL) under ice cooling. The mixture was stirred at room temperature for 12 h. The reaction mixture was filtered. The filtrate was concentrated under vacuo to give the crude product as brown solid. The crude product was purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate: ratio 20/1 to 5/1) to give intermediate 449 (4.2 g, yield: 82%) as a yellow solid.
    • Step 3 Preparation of Intermediate 450
  • Figure US20230330127A1-20231019-C00623
  • LiAlH4 (1.1 g, 28.3 mmol) was added to the mixture of intermediate 449 (3 g, 9.45 mmol) in THF (60 mL) under N2 with ice cooling. The mixture was stirred at room temperature for 2 h. H2O (0.3 mL) and aq.NaOH (10%, 0.3 mL) were added to the mixture. The mixture was filtered. The filtrate was treated with H2O (20 mL) and extracted with EtOAc (40 mL × 2). The organic layer was concentrated under vacuo to give crude product as solid. The product was purified by chromatography column (eluent: petroleum ether/EtOAc ½) to give the intermediate 450 (822 mg, yield: 32%) as a solid.
    • Step 4 Preparation of Intermediate 451
  • Figure US20230330127A1-20231019-C00624
  • NaH 60% (178 mg, 4.46 mmol,) was added to the mixture of intermediate 450 (600 mg, 2.23 mmol) in THF (30 mL) under N2 with ice cooling. CH3I (316 mg, 2.23 mmol) was added and the reaction was stirred at room temperature overnight. EtOAc (40 mL) and water (20 mL) were added to the mixture. The organic phase was separated and dried over Na2SO4, filtered and concentrated to give crude product as a yellow oil. The crude product was purified by chromatography column (eluent: Petroleum ether/EtOAc ½) to give intermediate 451 (620 mg, yield: 98%) as an oil.
    • Step 5 Preparation of Intermediate 246
  • Figure US20230330127A1-20231019-C00625
  • BBr3 (1 g, 4.29 mmol) was added to solution of intermediate 451 (600 mg, 2.15 mmol) in CH2Cl2 (60 mL) at -70° C. and the reaction was stirred for 30 min. MeOH (40 mL) was added to the reaction mixture at -70° C. The reaction mixture was stirred for 10 min. The mixture was concentrated under vacuum to give intermediate 246 (400 mg, yield: 95%) as yellow oil.
    • Example A63 Preparation of Intermediate 263
  • Figure US20230330127A1-20231019-C00626
  • Intermediate 441 (1.2 g, 6.68 mmol), 4-chlorobenzylamine (2.84 g, 20.0 mmol) and DIEA (1.73 g, 13.36 mmol) were dissolved in CH3CN (25 mL). The mixture was heated at 120° C. for 1.5 hours by microwave. The mixture was concentrated under reduced pressure to give the crude product as a brown oil. The crude product was purified by chromatography on silica gel (petroleum ether/ethyl acetate: ratio from 20/1 to 3/1) to give intermediate 263 (1.2 g, 35% yield) as a yellow solid.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 263 using the appropriate starting materials (Table 35).
  • TABLE 35
    Int. Structure Starting materials
    274
    Figure US20230330127A1-20231019-C00627
         		a) Intermediate 441 b) cyclopropylmethanamine
    • Example A66 Step 1 Preparation of Intermediate 452
  • Figure US20230330127A1-20231019-C00628
  • To the solution of intermediate 441 (5 g, 27.84 mmol) and imidazole (2.27 g, 33.5 mmol) in CH2Cl2 (100 mL) was added TBDMSCI (5.04 g, 33.4 mmol) at 0° C. The reaction was stirred at room temperature for 4 hours. Water (100 ml) was added and the mixture was extracted with CH2Cl2 (80 mL × 3). The organic phase was washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated to give the crude product. The crude product was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate: ratio10/1). The desired fractions were concentrated to give intermediate 452 (8.0 g, 98% yield) as an oil.
    • Step 2 Preparation of Intermediate 453
  • Figure US20230330127A1-20231019-C00629
  • A solution of intermediate 452 (5 g, 17.0 mmol), Pd(PPh3)2Cl2 (1.19 g, 1.70 mmol) and Et3N (3.44 g, 34.0 mmol) in DMF (10 mL) and MeOH (60 mL) was stirred in an autoclave at room temperature under CO (50 psi) atmosphere. The solution was heated to 80° C. overnight. The reaction mixture was then filtered. The filtrate was concentrated to give the crude product. The crude product was purified by column chromatography on silica gel (petroleum ether/ ethyl acetate, from 20/1 to 1/1) to afford intermediate 453 (3.4 g, 98% yield) as a light yellow solid.
    • Step 3 Preparation of Intermediate 454
  • Figure US20230330127A1-20231019-C00630
  • To the solution of intermediate 453 (1.5 g, 7.38 mmol) and imidazole (0.60 g, 8.86 mmol) in CH2Cl2 (80 mL) was added TBDMSCl (1.34 g, 8.86 mmol) at 0° C.
  • The reaction was stirred at room temperature for 2 hours. The reaction was poured into water and extracted with ethyl acetate (150 mL × 3) and the organic phase was washed with brine (80 mL). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated to give the crude product. The crude product was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate: ratio 5:1). The desired fractions were concentrated to give intermediate 454 (2.4 g, 97.5% yield) as a white oil.
    • Step 4 Preparation of Intermediate 455
  • Figure US20230330127A1-20231019-C00631
  • To a solution of NaBH4 (2.264 g, 59.85 mmol) in EtOH (20 mL) cooled to 0° C. was added dropwise a solution of intermediate 454 (1.9 g, 5.98 mmol) in THF (20 mL) over 5 min under N2. The solution was allowed to warm to room temperature and was stirred for 2 hours. A saturated aqueous NaHCO3 solution (20 mL) and water (50 mL) were added to the reaction. The mixture was extracted with EtOAc (80 ml × 3). The combined organic layers were washed with brine (50 ml), dried with Na2SO4, filtered and concentrated to give the crude product intermediate 455 (1.2 g, 66.5% yield).
    • Step 5 Preparation of Intermediate 456
  • Figure US20230330127A1-20231019-C00632
  • To a solution of intermediate 455 (1.2 g, 4.15 mmol) and Et3N (1.26 g, 12.44 mmol) cooled in THF (20 mL) was added MsCl (569.9 mg, 4.98 mmol) dropwise under N2. The reaction mixture was stirred at 0° C. under N2 for 30 minutes. Dimethylamine hydrochloride (1.69 g, 20.73 mmol, 5 eq) and Et3N (4.195 g, 10 eq) were added. The reaction mixture was stirred at room temperature for 2 days. Water (40 ml) was added and the mixture was extracted with ethyl acetate (50 ml × 3). The organic layers were combined, dried over Na2SO4, filtered and concentrated to give the crude product as an oil. The crude product was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate: ratio 1/1). The desired fractions were concentrated to give intermediate 456 (550 mg ) as an oil.
    • Step 6 Preparation of Intermediate 212
  • Figure US20230330127A1-20231019-C00633
  • To a solution of intermediate 456 (500 mg, 1.58 mmol) in THF (20 mL) was added TBAF (1 M solution in THF, 1.58 mL, 1.58 mmol) dropwise at room temperature under N2. The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water (40 ml) and was extracted with EtOAc (50 ml × 3). The organic layers were combined, dried over Na2SO4, filtered and evaporated to give the crude product. The crude product was purified by TLC (CH2Cl2/MeOH: ratio 5/1) to give intermediate 212 (80 mg, 22.5% yield) as a light yellow oil.
    • Example A67 Step 1 Preparation of Intermediate 457 and Intermediate 458
  • Figure US20230330127A1-20231019-C00634
  • 3-chloro-5-bromoaniline (1 g, 4.84 mmol) was dissolved in 75% H2SO4 (10 mL). Then glycerol (1.11 g, 12.1 mmol) and nitrobenzene (0.59 g, 4.84 mmol) were added. The reaction mixture was stirred at 150° C. for 3 hours under N2. EtOAc (50 ml) was added and the mixture was adjusted to pH to 6-7 with a 30% solution of NaOH in water. The solid was filtered off over celite and the organic layer was separated and evaporated. The residue was purified by flash column chromatograph over silica gel (gradient eluent: petroleum ether/EtOAc from 20/1 to 5/1). The desired fractions were collected and the solvent was evaporated to give a mixture of intermediate 457 and intermediate 458 (750 mg) as a white solid.
    • Step 2 Preparation of Intermediate 459 and Intermediate 460
  • Figure US20230330127A1-20231019-C00635
  • A mixture of intermediate 457 and intermediate 458 (750 mg), bis(pinacolato)diboron (942.5 mg, 3.7 mmol), Pd(dppf)Cl2 (113.1 mg, 0.155 mmol) and KOAc (910.6 mg, 9.28 mmol) in THF (20 mL) was stirred at 60° C. for 2 hours under N2. Water (30 ml) was added and extracted with EtOAc (30 mL × 3). The organic layers were combined, dried over Na2SO4, filtered and concentrated to give a mixture of intermediate 459 and intermediate 460 (1.0 g) as a yellow oil.
    • Step 3 Preparation of Intermediate 220a and Intermediate 220b
  • Figure US20230330127A1-20231019-C00636
  • To a mixture of intermediate 459 and intermediate 460 (1 g) in acetone (10 mL) was added a solution of oxone (1.25 g 2.03 mmol) in H2O (10 mL) dropwise under N2 at 0° C. The reaction mixture was stirred at 0° C. for 1 hour. Water (20 ml) was added and the mixture was extracted with EtOAc (3 × 30 ml). The organic layer was combined, dried over Na2SO4, filtered and concentrated. The residue was triturated under EtOAc/ petroleum ether (⅒). The precipitate was filtered off and dried give a mixture of intermediate 220a and intermediate 220b (150 mg) as a yellow solid.
    • Example A68 Preparation of Intermediate 218
  • Figure US20230330127A1-20231019-C00637
  • A mixture of intermediate 205 (400 mg, 1.55 mmol), Me4NCl (1.36 g, 12.4 mmol), Cu2O (88.5 mg, 0.62 mmol) and L-Proline (142.5 mg, 1.24 mmol) in EtOH (10 mL) was stirred at 110° C. for 120 min using a single mode microwave. The reaction mixture was concentrated and purified by column chromatography (eluent: petroleum ether/ethyl acetate: ratio1/0 to 1/1). The product fractions were collected and the solvent was evaporated to afford intermediate 218 (350 mg, 97%) as a yellow solid.
    • Example A69 Preparation of Intermediate 235
  • Figure US20230330127A1-20231019-C00638
  • The reaction was performed twice.
  • To a solution of 3 bromo-7- hydroxyquinoline (500 mg, 2.23 mmol) in THF (10 mL) was added cyclopentylzinc(II) bromide (0.5 M solution, 7.14 mL, 3.57 mmol), bis(tri-tert-butylphosphine)palladium(O) (114.0 mg, 0.223 mmol) and t-BuOK (250.4 mg, 2.23 mmol) under a N2 atmosphere. The reaction mixture was heated to 100° C. for 45 min in a microwave. The reaction mixture was cooled to room temperature, filtrered and concentrated under reduced pressure to give the crude product as a yellow oil. The two crude products were combined and purified on silica gel column (petroleum ether/ethyl acetate ratio: 5/1 to 1/1) to obtain intermediate 235 (300 mg) as a yellow solid.
    • Preparation of Intermediate 240
  • Figure US20230330127A1-20231019-C00639
  • The reaction was performed twice.
  • To a solution of 3 bromo-7- hydroxyquinoline (700 mg 3.12 mmol) in THF (10 mL) was added isobutylzinc(II) bromide (0.5 M solution, 9.37 mL, 4.69 mmol), bis(tri-tert-butylphosphine)palladium(0) (319.3 mg 0.625 mmol) and t-BuOK (350.58 mg 3.12 mmol) under a N2 atmosphere. The reaction mixture was heated at 100° C. for 45 min in a microwave. The reaction mixture was cooled to room temperature, filtrered and concentrated under reduced pressure to give the crude product. The two crude products were combined and purified on silica gel column (petroleum ether/ethyl acetate: ratio 3/1 to 1/1) to obtain intermediate 240 (410 mg) as a yellow solid.
    • Example A98 Step 1 Preparation of Intermediate 505
  • Figure US20230330127A1-20231019-C00640
  • 3- bromo 7- methoxyquinoline ( 5 g, 21 mmol) was dissolved in dichloromethane (50 mL). Then 3-chloroperoxybenzoic acid (5.116 g, 25.2 mmol) was added into the mixture in fractions at 0° C. The resulting mixture was stirred at room temperature overnight. The mixture was poured into a sat. Na2SO3 aqueous solution (30 ml). The mixture was extracted by dichloromethane (50 mL × 2). Then the organic phase was washed with a sat.NaHCO3 aqueous solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4. A white solid precipitated which was filtered to obtain intermediate 505 (6.4 g, 87% yield).
    • Step 2 Preparation of Intermediate 506
  • Figure US20230330127A1-20231019-C00641
  • Intermediate 505 (6.4 g, 18.25 mmol) was dissolved in chloroform (100 mL). Then phosphorus oxychloride (20 ml) was added and the reaction mixture was refluxed at 80° C. for 3 hours. The solvent was removed under reduced pressure to obtain intermediate 506 (5.8 g, 97% yield) as a white solid, which was used in the next step without further purification.
    • Step 3 Preparation of Intermediate 507
  • Figure US20230330127A1-20231019-C00642
  • A mixture of intermediate 506 (3 g, 11 mmol ) and NH3.H2O (20 ml) in dioxane ( 20 ml) was heated in a sealed tube at 120° C. for 72 h. The mixture was extracted with CH2Cl2 (50 mL × 3). The organic phase was concentrated under vacuum to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/20 to 1/20) to obtain intermediate 507 (0.9 g, 32% yield) as a white solid.
    • Step 4 Preparation of Intermediate 477
  • Figure US20230330127A1-20231019-C00643
  • Intermediate 507 (1.2 g, 4.74 mmol) was dissolved in CH2Cl2 (12 ml). Then the yellow clear reaction was cooled to 0° C. and BBr3 (23.75 g,94.82 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with MeOH slowly at 0° C. and stirred at 15° C. for 15 min. The red suspension was concentrated. The residue was adjusted to pH 8 with aqueous NaHCO3. The precipitate was filtered and washed with H2O (10 mL). The filter cake was dried in vacuum to obtain intermediate 477 (1.1 g, 97% yield) as off-white solid.
    • Example A99 Step 1 Preparation of Intermediate 508
  • Figure US20230330127A1-20231019-C00644
  • A mixture of 3- bromo 7- methoxyquinoline (10 g, 42 mmol), CuCl (20 g, 204 mmol), NaCl (20 g, 345 mmol) and N-methylpyrrolidin-2-one (200 ml) was heated at 120° C. for 2 hours. Then the reaction mixture was stirred at 170° C. for 2 hours. The reaction was diluted with a saturated aqueous ammonium chloride solution, ethyl acetate was added and the mixture was stirred to dissolve the product. The mixture was filtered to remove the insoluble material and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (200 mL × 3) and the insoluble material was washed with warm ethyl acetate (200 mL × 3). The ethyl acetate fractions were combined, washed with water, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by flash chromatography (gradient eluent: EtOAc/petrol ether from 1/20 to ⅕) to obtain intermediate 508 (2 g, 22% yield) as white solid.
    • Step 2 Preparation of Intermediate 509
  • Figure US20230330127A1-20231019-C00645
  • Intermediate 508 (2 g, 10.3 mmol) was dissolved in dichloromethane (40 mL). Then 3-chloroperoxybenzoic acid (3.565 g, 20.65 mmol) was added into the mixture in fractions at 0° C. The resulting mixture was stirred at room temperature overnight. The mixture was poured into a sat. Na2SO3 aqueous solution (30 ml). The mixture was extracted by dichloromethane (50 mL × 2). Then the organic phase was washed with a sat. NaHCO3 aqueous solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na2SO4. A white solid precipitated and was filtered to obtain intermediate 509 (2 g, 83% yield).
    • Step 3 Preparation of Intermediate 510
  • Figure US20230330127A1-20231019-C00646
  • Intermediate 509 (2.4 g, 18.25 mmol) was dissolved in chloroform (50 mL). Then phosphorus oxychloride (10.5 g, 68.69 mmol) was added and the reaction mixture was refluxed at 80° C. for 2 hours. The reaction mixture was slowly poured into water. Then a sat. NaHCO3 aqueous solution was added into the mixture to change the pH to ~7. The reaction mixture was extracted with dichloromethane (200 mL × 2 ) and the organic layer was dried over anhydrous Na2SO4. The organic phase was concentrated to obtain intermediate 510 (2.5 g, 93% yield) as a white solid.
    • Step 4 Preparation of Intermediate 511
  • Figure US20230330127A1-20231019-C00647
  • A mixture of intermediate 510 (2.2 g, 9.64 mmol), benzophenone imine (1.78 g, 9.83 mmol), Pd(OAc)2 (0.21 g,0.96 mmol), BINAP (0.6 g, 0.96 mmol) Cs2CO3 (6.28 g, 19.29 mmol) and toluene (50 mL) was heated at 110° C. for 48 hours under N2. The catalyst was filtered and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (gradient eluent: EtOAc/petrol ether from 1/15 to 1/1). The product fractions were collected and the solvent was evaporated to obtain intermediate 511 (2 g, 54% yield) as an oil.
    • Step 5 Preparation of Intermediate 468
  • Figure US20230330127A1-20231019-C00648
  • Intermediate 511 (2 g, 5.2 mmol) was dissolved in CH2Cl2 (100 ml). Then the yellow clear reaction was cooled to 0° C. and BBr3 (20 g, 79.84 mmol) was added. The reaction mixture was stirred at room temperature for 14 hours. The reaction mixture was adjusted to pH 7 with sat. sodium hydrogen carbonate solution and extracted with EtOAc (3 × 300 mL).The combined organic layers were separated, dried with Na2SO4, and the solvent was evaporated to obtain intermediate 468 (2 g, 69.5% yield) as white solid.
    • Example A70 Preparation of Intermediate 305
  • Figure US20230330127A1-20231019-C00649
  • A mixture of 7-Bromo-2-Chloroquinoline (2.45 g, 10.1 mmol) and 2,2,2-Trifluoroethylamine ( 5.0 g, 50.5 mol) in EtOH (60 mL) was stirred in a sealed tube at 120° C. overnight. The reaction mixture was treated with aq. NaCl (80 mL) and extracted with EtOAc (80 mL × 2). The organic layers were combined and concentrated under vacuo to give crude product. The crude product was purified by silica gel chromatography (ethyl acetate/petroleum ether 0/1 to 3/7) to give intermediate 305 (2.5 g, 62.5% yield) as white solid.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 305 using the appropriate starting materials (Table 36).
  • TABLE 36
    Int. Structure Starting materials
    244
    Figure US20230330127A1-20231019-C00650
         		7-bromo-2-chloroquinoline (4-chlorophenyl)methanamine
    263
    Figure US20230330127A1-20231019-C00651
         		2-chloro-7-hydroxyquinoline (4-chlorophenyl)methanamine
    274
    Figure US20230330127A1-20231019-C00652
         		2-chloro-7-hydroxyquinoline cyclopropylmethylamine
    299
    Figure US20230330127A1-20231019-C00653
         		propan-2-amine 7-bromo-2-chloroquinoline
    308
    Figure US20230330127A1-20231019-C00654
         		7-bromo-2-chloroquinoline Cyclopropylamine
    320
    Figure US20230330127A1-20231019-C00655
         		7-bromo-2-chloroquinoline Cyclobutylamine
    302
    Figure US20230330127A1-20231019-C00656
         		7-bromo-2-chloroquinoline Tert.-butylamine
    290
    Figure US20230330127A1-20231019-C00657
         		7-bromo-2-chloroquinoline Cyclopentylamine
    293
    Figure US20230330127A1-20231019-C00658
         		intermediate 181 cyclopropylmethylamine
    296
    Figure US20230330127A1-20231019-C00659
         		intermediate 175 cyclopropylmethylamine
    311
    Figure US20230330127A1-20231019-C00660
         		intermediate 175 cyclopropylamine
    317
    Figure US20230330127A1-20231019-C00661
         		Intermediate 400 cyclopropylmethylamine
    • Example A71 Preparation of Intermediate 338
  • Figure US20230330127A1-20231019-C00662
  • A mixture of intermediate 306 (520 mg, 0.95 mmol) and CH3NH2/EtOH (15 mL) in EtOH (15 mL) was stirred at 120° C. overnight in a sealed tube. The reaction was concentrated to give intermediate 338 (590 mg) which was used for next step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 338 using the appropriate starting materials (Table 37).
  • TABLE 37
    Int. Structure Starting materials
    339
    Figure US20230330127A1-20231019-C00663
         		Intermediate 248 methylamine
    340
    Figure US20230330127A1-20231019-C00664
         		Intermediate 309 methylamine
    341
    Figure US20230330127A1-20231019-C00665
         		Intermediate 321 methylamine
    342
    Figure US20230330127A1-20231019-C00666
         		Intermediate 162 methylamine
    343
    Figure US20230330127A1-20231019-C00667
         		Intermediate 262 methylamine
    344
    Figure US20230330127A1-20231019-C00668
         		Intermediate 183 methylamine
    345
    Figure US20230330127A1-20231019-C00669
         		Intermediate 183 isopropylamine
    346
    Figure US20230330127A1-20231019-C00670
         		Intermediate 183 cyclopropylamine
    347
    Figure US20230330127A1-20231019-C00671
         		Intermediate 327 methylamine
    348
    Figure US20230330127A1-20231019-C00672
         		Intermediate 315 methylamine
    349
    Figure US20230330127A1-20231019-C00673
         		Intermediate 330 methylamine
    350
    Figure US20230330127A1-20231019-C00674
         		Intermediate 324 methylamine
    351
    Figure US20230330127A1-20231019-C00675
         		Intermediate 300 methylamine
    352
    Figure US20230330127A1-20231019-C00676
         		Intermediate 262 dimethylamine
    405
    Figure US20230330127A1-20231019-C00677
         		Intermediate 159 methylamine
    465
    Figure US20230330127A1-20231019-C00678
         		Intermediate 463 methylamine
    467
    Figure US20230330127A1-20231019-C00679
         		Intermediate 466 methylamine
    470
    Figure US20230330127A1-20231019-C00680
         		Intermediate 469 methylamine
    474
    Figure US20230330127A1-20231019-C00681
         		Intermediate 473 methylamine
    476
    Figure US20230330127A1-20231019-C00682
         		Intermediate 473 NH4OH
    479
    Figure US20230330127A1-20231019-C00683
         		Intermediate 478 methylamine
    480
    Figure US20230330127A1-20231019-C00684
         		Intermediate 478 NH4OH
    481
    Figure US20230330127A1-20231019-C00685
         		Intermediate 478 NH4OH
    486
    Figure US20230330127A1-20231019-C00686
         		Intermediate 484 methylamine
    489
    Figure US20230330127A1-20231019-C00687
         		Intermediate 488 NH4OH
    492
    Figure US20230330127A1-20231019-C00688
         		Intermediate 491 methylamine
    • Example A72 Preparation of Intermediate 353
  • Figure US20230330127A1-20231019-C00689
  • A mixture of intermediate 262 (310 mg, 0.61 mmol) in MeOH (5 mL) was hydrogenated at room temperature (H2, atmospheric pressure) with Pd(OH)2 (20 mg) as catalyst over weekend. After uptake of H2 (1 equiv), the mixture was filtered and the filtrate was evaporated to give intermediate 353 (260 mg, 81.3% yield) which was used in the next step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 353 using the appropriate starting materials (Table 38).
  • TABLE 38
    Int. Structure Starting materials
    354
    Figure US20230330127A1-20231019-C00690
         		Intermediate 248
    355
    Figure US20230330127A1-20231019-C00691
         		Intermediate 268
    356
    Figure US20230330127A1-20231019-C00692
         		Intermediate 159
    357
    Figure US20230330127A1-20231019-C00693
         		Intermediate 266
    358
    Figure US20230330127A1-20231019-C00694
         		Intermediate 272
    359
    Figure US20230330127A1-20231019-C00695
         		Intermediate 259
    360
    Figure US20230330127A1-20231019-C00696
         		Intermediate 275
    361
    Figure US20230330127A1-20231019-C00697
         		Intermediate 254
    362
    Figure US20230330127A1-20231019-C00698
         		Intermediate 254
    401
    Figure US20230330127A1-20231019-C00699
         		Intermediate 264
    402
    Figure US20230330127A1-20231019-C00700
         		Intermediate 270
    • Example A73 Preparation of Intermediate 403
  • Figure US20230330127A1-20231019-C00701
  • A mixture of intermediate 119 (600 mg, 0.82 mmol) and CH3NH2/EtOH (25 mL) in EtOH (25 mL) were stirred at 120° C. overnight in a sealed tube. The reaction mixture was concentrated to give intermediate 403 (600 mg) which used in the next step without further purification.
    • Example A74 Preparation of Intermediate 404
  • Figure US20230330127A1-20231019-C00702
  • Intermediate 228 (350 mg, 0.5 mmol) and methylamine (15 ml, 2 M) in EtOH were stirred at 120° C. for 1.5 hours in a microwave. The mixture was concentrated in vacuo to give intermediate 404 as yellow solid. The crude product was used in the next step directly without purification.
    • Example A75 Step1 Preparation of Intermediate 363
  • Figure US20230330127A1-20231019-C00703
  • A mixture of intermediate 1 (250 mg, 0.77 mmol) and MeONa (331.5 mg, 6.14 mmol) in MeOH was stirred at room temperature for 1h. The mixture was diluted with water (20 mL), and was extracted with CH2Cl2 (50 mL × 3). The organic phase was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated to give intermediate 363 (250 mg, 96% yield) which was used for the next reaction step without further purification.
    • Step 2 Preparation of Intermediate 364
  • Figure US20230330127A1-20231019-C00704
  • TosCl (0.415 g, 2.18 mmol) was added dropwise into the mixture of intermediate 363 (0.35 g, 1.1 mmol), triethylamine (0.455 mL, 3.27 mmol) and 4-dimethylaminopyridine (67 mg, 0.545 mmol) in dichloromethane (5 mL) under ice cooling. The mixture was stirred at room temperature for 3 h. The mixture was quenched with water (10 mL) and extracted with CH2Cl2 (30 mL × 3). The organic phase was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated. Then residue was purified by column chromatography (eluent: Petroleum ether/ethyl acetate ratio 1/0 to 3/1). The product fractions were collected and the solvent was evaporated to afford intermediate 364 (446 mg, 86% yield) as an oil.
    • Step 3 Preparation of Intermediate 365
  • Figure US20230330127A1-20231019-C00705
  • A mixture of intermediate 364 (446 mg, 0.94 mmol), 2-amino-7-hydroxyquinoline (167 mg, 1.04 mmol) and Cs2CO3 (1.02 g, 3.13 mmol) in DMF (5 mL) was stirred at room temperature overnight. The mixture was filtered, and the solvent was evaporated. The residue was purified by column chromatography (eluent: ethyl acetate). The product fractions were collected and the solvent was evaporated to afford intermediate 365 (257.3 mg, 53.3% yield) as solid.
    • Example A76 Preparation of Intermediate 366
  • Figure US20230330127A1-20231019-C00706
  • A mixture of intermediate 306 (400 mg, 0.73 mmol) and MeONa (158.2 mg, 2.93 mmol) in MeOH (10 mL) was stirred at 60° C. for 10 h. The mixture was diluted with water (20 mL), extracted with CH2Cl2 (50 mL × 3). The organic phase was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated to give intermediate 366 which used in the next step without further purification.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 366 using the appropriate starting materials (Table 39).
  • TABLE 39
    Int. Structure Starting materials
    367
    Figure US20230330127A1-20231019-C00707
         		Intermediate 248
    368
    Figure US20230330127A1-20231019-C00708
         		Intermediate 309
    369
    Figure US20230330127A1-20231019-C00709
         		Intermediate 162
    366
    Figure US20230330127A1-20231019-C00710
         		Intermediate 306
    371
    Figure US20230330127A1-20231019-C00711
         		Intermediate 183
    372
    Figure US20230330127A1-20231019-C00712
         		Intermediate 327
    373
    Figure US20230330127A1-20231019-C00713
         		Intermediate 315
    374
    Figure US20230330127A1-20231019-C00714
         		Intermediate 330
    375
    Figure US20230330127A1-20231019-C00715
         		Intermediate 159
    471
    Figure US20230330127A1-20231019-C00716
         		Intermediate 469
    475
    Figure US20230330127A1-20231019-C00717
         		Intermediate 473
    • Example A76 Preparation of Intermediate 472
  • Figure US20230330127A1-20231019-C00718
  • Intermediate 471 (900 mg, 1.36 mmol) was dissolved in TFA (3 ml). The reaction mixture was stirred at 50° C. for 7 hours.
  • The solvent was evaporated to give desired intermediate 472 as an oil.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 472 using the appropriate starting materials (Table49).
  • TABLE 49
    Int. Structure Starting materials
    527
    Figure US20230330127A1-20231019-C00719
         		Intermediate 526
    535
    Figure US20230330127A1-20231019-C00720
         		Intermediate 534
    • Example A77 Preparation of Intermediate 376
  • Figure US20230330127A1-20231019-C00721
  • To intermediate 264 (330 mg, 0.44 mmol) and C3H9B3O3 (164 mg, 1.3 mmol) in dioxane/H2O ( 6 ml, dioxane/H2O ratio 5/1,) was added K3PO4 (277 mg, 1.3 mmol) and 1,1′-bis (di-tert-butylphosphino) ferrocene palladiumdichloride (28.3 mg, 0.04 mmol). The mixture was stirred at 80° C. overnight. The mixture was treated with water (30 mL) and extracted with ethyl acetate (40 mL × 3), dried (Na2SO4), filtered and concentrated by vacuum to give the crude product as a brown oil. The crude product was purified by flash column chromatography (gradient eluent: petroleum ether: ethyl acetate from 20/ 1 to 3/ 1) to give intermediate 376 (170 mg, 69% yield) as a yellow oil.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 376 using the appropriate starting materials (Table 40).
  • TABLE 40
    Int. Structure Starting materials
    377
    Figure US20230330127A1-20231019-C00722
         		Intermediate 248
    378
    Figure US20230330127A1-20231019-C00723
         		Intermediate 268
    379
    Figure US20230330127A1-20231019-C00724
         		Intermediate 159
    380
    Figure US20230330127A1-20231019-C00725
         		Intermediate 266
    381
    Figure US20230330127A1-20231019-C00726
         		Intermediate 245
    • Example A78 Step1 Preparation of Intermediate 382
  • Figure US20230330127A1-20231019-C00727
  • To a solution of intermediate 159 (0.85 g, 1.28 mmol) in dioxane (20 ml) and H2O (5 ml) was added potassium vinyltrifluoroborate (223 mg, 1.67 mmol) and potassium phosphate tribasic (544 mg, 2.57 mmol) at room temperature. 1,1′-bis(di-tert-butylphosphino)ferrocene palladium dichloride (42 mg, 0.064 mmol) was added to the above solution under nitrogen atmosphere. The reaction mixture was stirred at 80° C. under nitrogen atmosphere overnight. The mixture was extracted with ethyl acetate (20 ml × 2), the organic layers were combined and concentrated under vacuo. The residue was purified by chromatography column (gradient eluent: ethyl acetate/petrol ether from ⅒ to 1/1). The desired fractions were collected and concentrated to give product intermediate 382 (400 mg, yield: 60%) as an oil.
    • Step2 Preparation of Intermediate 383
  • Figure US20230330127A1-20231019-C00728
  • Trifluroacetic acid (0.5 ml) was added to a solution of intermediate 382 (400 mg, 0.78 mmol) in CH2Cl2 (10 ml). The mixture was stirred at room temperature for 3 h. The mixture was evaporated under vacuo to give intermediate 383 (300 mg, yield: 48%).
    • Example A79 Preparation of Intermediates 384 and 385
  • Figure US20230330127A1-20231019-C00729
  • Me2NH (20 mL) was added into the mixture of intermediate 262 (200 mg, 0.43 mmol) in dioxane (20 mL) and stirred in sealed tube at 110° C. overnight. The reaction mixture was concentrated to give a mixture of intermediate 384 and intermediate 385 (210 mg) as solid.
    • Example A80 Step1 Preparation of Intermediate 412
  • Figure US20230330127A1-20231019-C00730
  • A mixture of 2-amino-4-bromo-benzaldehyde (13 g, 65 mmol) and urea (54.6 g, 910 mmol) was heated to 180° C. in an oil bath for 2 hours. Then the reaction was cooled to room temperature and H2O (500 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. The solid was collected by filtration to obtain intermediate 412 (16 g, 93% yield) as white solid.
    • Step 2 Preparation of Intermediate 413
  • Figure US20230330127A1-20231019-C00731
  • A mixture of intermediate 412 (16 g, 71 mmol) and POCl3 (280 g, 1.84 mol) was heated to 110° C. in an oil bath under N2 for 3 hours. Then the reaction was cooled to room temperature and poured into ice/water (4000 g). The reaction mixture was stirred at room temperature for 1 hour and was extracted with ethyl acetate (2000 mL × 2). The organic layer washed with brine and dried over anhydrous Na2SO4. The solvent was evaporated under vacuum to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to ⅕) to obtain intermediate 413 (10 g, 53% yield) as white solid.
    • Step 3 Preparation of Intermediate 386
  • Figure US20230330127A1-20231019-C00732
  • A mixture of intermediate 413 (4 g, 16.5 mmol), 4-methoxybenzylamine (3.4 g, 24.6 mmol) and cesium carbonate (15 g, 49.3 mmol) in THF(100 mL) was stirred at room temperature for 12 hours. The reaction mixture was filtered and the filtrate was evaporated under vacuum to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to ⅒) to obtain intermediate 386 (2.3 g, 29%) yield) as oil.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 386 using the appropriate starting materials (Table 42).
  • TABLE 42
    intermediates Structure Starting materials
    276
    Figure US20230330127A1-20231019-C00733
         		intermediate 413
    cyclopropylmethylamine
    287
    Figure US20230330127A1-20231019-C00734
         		intermediate 413
    cyclopropylamine
    • Step 4 Preparation of Intermediate 387
  • Figure US20230330127A1-20231019-C00735
  • Intermediate 38 (1.5 g, 4.69 mmol) in 9-BBN (0.5 M in THF, 56.3 mL, 28.1 mmol) was refluxed for 1h under N2. The mixture was cooled to room temperature, then K3PO4 (2.98 g, 14.1 mmol) in H2O (5 mL) was added, followed by THF (40 mL), intermediate 386 (2.1 g, 6.1 mmol) and Pd-118 (61.1 mg, 0.094 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H2O (50 mL), extracted with ethyl acetate (150 mL), the organic phase was dried by Na2SO4, then filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to ⅒) to give intermediate 387 (1.3 g, yield: 47%) as an oil.
    • Step 5 Preparation of Intermediate 388
  • Figure US20230330127A1-20231019-C00736
  • Intermediate 387 (500 mg, 0.85 mmol) was dissolved in TFA (10 mL) and stirred at 60° C. for 1 hour. The mixture was concentrated to obtain crude intermediate 388 (1 g as a solid.
    • Example A81 Step1 Preparation of Intermediate 389
  • Figure US20230330127A1-20231019-C00737
  • A mixture of intermediate 387 (450 mg, 0.77 mmol) and NH3.H2O (10 mL) in dioxane (10 mL) was heated to 80° C. for 24 hours in a sealed tube. The reaction mixture was extracted with ethyl acetate (50 ml × 3).The organic layers were separated, dried with Na2SO4, and the solvent was evaporated to obtain intermediate 389 (290 mg, 66.6% yield) as oil.
    • Step2 Preparation of Intermediate 390
  • Figure US20230330127A1-20231019-C00738
  • Intermediate 389 (290 mg, 0.51 mmol) was dissolved in TFA (10 mL) and stirred at 60° C. for 1 hour. The mixture was concentrated to obtain crude intermediate 390 (300 mg) as an oil.
    • Example A82 Preparation of Intermediate 347
  • Figure US20230330127A1-20231019-C00739
  • A mixture of intermediate 327 (1100 mg, 2.20 mmol ) in methylamine/ethanol (30 ml, 40%) was heated in a sealed tube at 80° C. for 24 h. The organic phase was concentrated to obtain intermediate 347 (1.2 g, 99% yield)
    • Example A83 Preparation of Intermediate 372
  • Figure US20230330127A1-20231019-C00740
  • A mixture of intermediate 327 (550 mg, 1.1 mmol), sodium methoxide (356.3 mg, 6.60 mmol) in methanol (10 ml) was refluxed at 60° C. for 12 h. The reaction mixture was evaporated under vacuum. Water (10 ml) was added and the mixture was extracted with ethyl acetate (10 mL × 2), the organic layers were combined and evaporated under vacuum to obtain intermediate 372 (510 mg,75% yield) as an oil.
    • Example A84 Step 1 Preparation of Intermediate 393
  • Figure US20230330127A1-20231019-C00741
  • 7-bromo(trifluoromethyl)quinoline) (1.0 g, 3.62 mmol) was dissolved in DCM (30 mL), m-CPBA (1.25 g, 7.25 mmol) was added into the mixture in portions. The resulting mixture was stirred at room temperature overnight. The reaction mixture was poured into a mixture of saturated Na2S2O3 (50.0 mL) and 1N NaOH (50 mL) aqueous solution. The mixture was then extracted with DCM (200 mL × 2), and the combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated to afford the product intermediate 393 (1.0 g, 80% yield) as a brown solid, which was used in the next step without further purification.
    • Step 2 Preparation of Intermediate 394
  • Figure US20230330127A1-20231019-C00742
  • Intermediate 393 (200 mg, 0.685 mmol) was taken up into CHCl3 (10 mL). POCl3 (1.0 mL) was added at room temperature. The reaction mixture was stirred at 80° C. for 12 hours. The solvent was removed under reduced pressure, the residue was triturated with ethyl acetate (50 mL) and sat. Na2CO3 (50 mL), the organic layer was separated, the organic layer was washed with brine (50 mL) and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give intermediate 394 (200 mg, 83%) as a brown oil.
    • Step 3 Preparation of Intermediate 314
  • Figure US20230330127A1-20231019-C00743
  • Intermediate 394 (2.2 g, 5.43 mmol) was dissolved in dioxane (30 mL) and NH3H2O (30 mL) was added. The reaction mixture was stirred at 120° C. in an autoclave overnight. The solvent was removed under reduced pressure, the residue was purified by column chromatography (EtOAc / petroleum ether ratio: 0/10 to ⅒) to afford intermediate 314 (1.4 g, 88.6% yield) as a white solid.
    • Example A85 Preparation of Intermediate 348
  • Figure US20230330127A1-20231019-C00744
  • Intermediate 315 (420 mg, 0.79 mmol) was dissolved in an ethanol solution of MeNH2 (30%, 30 mL) and EtOH (30 mL). The reaction mixture was stirred at 100° C. in an autoclave for 12 hours. The solvent was removed under reduced pressure to afford intermediate 348 (450 mg, crude) as a brown solid, which was used in the next step without further purification.
    • Example A86 Step 1 Preparation of Intermediate 3 73
  • Figure US20230330127A1-20231019-C00745
  • Intermediate 315 (300 mg, 0.56 mmol) was dissolved in MeOH (20 ml), MeONa (483 mg, 4.46 mmol) was added. The reaction mixture was stirred at 70° C. for 12 hours. The solvent was removed under reduced pressure to afford intermediate 373 (340 mg, crude) as a brown solid, which was used in the next step without further purification.
    • Example A87 Step 1 Preparation of Intermediate 395
  • Figure US20230330127A1-20231019-C00746
  • 1H-Isoindole-1,3(2H)-dione, potassium salt (1:1) (50 g, 221.9 mmol) and 2-bromo-1,1-diethoxy-ethane (54.7 g, 277.4 mmol) in DMF were stirred at 150° C. for 4 hours. The DMF was removed under reduced pressure. The residue was purified by column chromatography (elution: petroleum ether/ ethyl acetate ratio 5/1) to afford intermediate 395 (40 g, yield: 64%) as a white solid.
    • Step 2 Preparation of Intermediate 396
  • Figure US20230330127A1-20231019-C00747
  • A mixture of intermediate 395 (22.1 g, 84.0 mmol), 4-bromo-2-amino-benzaldehyde (14 g, 70.0 mmol) and p-MeC6H4SO3H.H2O (13.3 g, 70.0 mmol) in PhMe (200 mL) was refluxed for 4 hours. The mixture was cooled and filtered. The solid was washed with toluene to give the crude PTSA-salt of the product as a brown solid. The solid was stirred in saturated aq. sodium bicarbonate and extracted with dichloromethane The solvent was evaporated and the residual solid was slurried in ethanol and collected to obtain intermediate 396 (14.2 g, 56% yield).
    • Step 3 Preparation of Intermediate 397
  • Figure US20230330127A1-20231019-C00748
  • A suspension of intermediate 396 (14 g, 38.5 mmol) in ethanol (150 mL) was treated with NH2NH2.H2O (4.5 g, 76.9 mmol ) and was refluxed for 1 hour. The mixture was allowed to cool and filtered. The filtrate was collected and evaporated to obtain intermediate 397 (8.6 g, 94% yield).
    • Step 4 Preparation of Intermediate 398
  • Figure US20230330127A1-20231019-C00749
  • Intermediate 397 (8 g, 35.86 mmol) was dissolved in PhCl (80 mL). Boron trifluoride diethyl etherate (4.45 mL) was added drop-wise over 10 mins. The mixture was heated to 60° C. Tert-butyl nitrite (6.1 mL) was added drop-wise over 20 mins at this temperature. The reaction solution was heated to 100° C. and stirred for 1 hour. The mixture was cooled and poured into an ice/aqueous sodium bicarbonate solution. The mixture was extracted with CH2Cl2 (500 mL × 2).The combined organic layers were washed with brine, dried (Na2SO4) and concentrated by vacuum to give the crude product. The crude product was purified by column chromatography (gradient eluent: petroleum ether/ ethyl acetate from 1/0 to 20/1) to obtain intermediate 398 (1.57 g, 19% yield).
    • Step 5 Preparation of Intermediate 399
  • Figure US20230330127A1-20231019-C00750
  • A mixture of intermediate 398 (1.57 g, 6.95 mmol) and m-CPBA (2.1 g, 10.4 mmol) in CHCl3 (30 mL) was stirred at 50° C. overnight. The reaction solution was quenched with a solution of Na2SO3 (50 mL) and basified with a solution of NaHCO3 (50 mL). The mixture was extracted with CH2Cl2 (300 mL × 3). The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated by vacuum to obtain intermediate 399 (2 g, 97.2% yield) as a brown solid.
    • Step 6 Preparation of Intermediate 400
  • Figure US20230330127A1-20231019-C00751
  • The mixture of intermediate 399 (2 g, 6.75 mmol) and POCl3 (10.6 g, 69 mmol) in CHCl3 (40 mL) was refluxed for 3 hours. The reaction solution was poured into water (100 mL), basified with a solution of NaHCO3 (80 mL) to pH > 7 and stirred for 5 mins. The mixture was extracted with DCM (500 mL × 3). The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated in vacuum to give the crude product as yellow solid. The crude product was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate: ratio 1/0 to petroleum ether/ ethyl acetate 10/1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 400 (1.4 g, 78% yield) as a white solid.
    • Step 7 Preparation of Intermediate 329
  • Figure US20230330127A1-20231019-C00752
  • A mixture of intermediate 400 (600 mg, 2.3 mmol) and NH3·H2O (15 mL) in CH3CH2OH (15 mL) was heated in a sealed tube at 120° C. overnight. The mixture was concentrated in vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate from 20/1 to petroleum ether/ ethyl acetate 1/-1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 329 (390 mg, 67% yield) as white solid.
    • Example A88 Step1 Preparation of Intermediate 330
  • Figure US20230330127A1-20231019-C00753
  • Intermediate 38 (470 mg, 1.47 mmol) in 9-BBN (0.5 M in THF, 11.8 mL, 5.9 mmol) was refluxed for 1 h under N2. The mixture was cooled to room temperature, then K3PO4 (936.6 mg, 4.41 mmol) in H2O (2 mL) was added, followed by THF (20 mL), intermediate 329 (390 mg, 1.62 mmol) and Pd-118 (19.2 mg, 0.029 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H2O (80 mL) and extracted with ethyl acetate (150 mL). The organic phase was dried by Na2SO4, then filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate/ petroleum ether from 0/ 1 to 1/3) to give intermediate 330 (460 mg, 55% yield) as a yellow oil.
    • Step 2 Preparation of Intermediate 374
  • Figure US20230330127A1-20231019-C00754
  • A mixture of intermediate 330 (400 mg, 0.70 mmol) and CH3ONa (380.17 mg, 7.04 mmol) in CH3OH (15 mL) was refluxed overnight. The mixture was concentrated by vaccum. The residue was treated with water (60 mL) and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give Intermediate 374 (350 mg, 87% yield) as a brown oil.
    • Example A89 Step 1 Preparation of Intermediate 323
  • Figure US20230330127A1-20231019-C00755
  • A solution of intermediate 400 (400 mg, 1.54 mmol) in CH3NH2 (40% solution in 20 ml CH3CH2OH ) was heated in sealed tube at 120° C. overnight. The mixture was concentrated in vacuum. The crude product was purified by column chromatography (gradient eluent: petroleum ether/ ethylacetate from 20/1 to 5/1) to give intermediate 323 (350 mg, 89% yield) as yellow solid.
    • Step 2 Preparation of Intermediate 324
  • Figure US20230330127A1-20231019-C00756
  • Intermediate 38 (365 mg. 1.14 mmol) in 9-BBN (0.5 mol/L in THF, 11.4 mL, 5.72 mmol) was refluxed for 1h under N2. The mixture was cooled to room temperature, then K3PO4 (728 mg, 3.43 mmol) in H2O (2 mL) was added, followed by THF (20 mL), intermediate 323 (350 mg, 1.37 mmol) and Pd-118 (14.90 mg, 0.023 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H2O (80 mL) and extracted with ethyl acetate (100 mL). The organic phase was dried with Na2SO4, filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate / petroleum ether from 1/10 to ⅕) to give intermediate 324 (350 mg, 61% yield) as a yellow oil.
    • Step 3 Preparation of Intermediate 350
  • Figure US20230330127A1-20231019-C00757
  • A solution of intermediate 324 (350 mg, 0.71 mmol) in CH3NH2 (40% solution in 10 ml EtOH) was heated in sealed tube at 120° C. overnight. The mixture was concentrated by vacuum to give the intermediate 350 (350 mg, 97% yield).
    • Example A90 Preparation of Intermediate 349
  • Figure US20230330127A1-20231019-C00758
  • A solution of intermediate 330 (350 mg, 0.726 mmol) in CH3NH2 (40% solution in 15 ml CH3CH2OH) was heated in sealed tube at 120° C. for overnight. The mixture was concentrated by vacuum to give the intermediate 349 (350 mg, 99.9% yield).
    • Example A91 Step 1 Preparation of Intermediate 414
  • Figure US20230330127A1-20231019-C00759
  • To the solution of intermediate 1 (1.0 g, 4.9 mmol), 7-hydroxyquinoline-2-methylcarboxylate (1.36 g, 4.18 mmol) and PPh3 (2.58 g, 9.84 mmol) in THF (10 mL) was added DIAD (1.99 g, 9.84 mmol) at 0° C. The mixture was stirred at room temperature overnight under N2. Water (25 mL) was added and the mixture was extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (1000 mL). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated to give the crude product as an oil. The crude product was purified by column chromatography over silica gel (elution: petroleum ether/ethyl acetate ratio 1/1). The desired fractions were collected and concentrated to give the product intermediate 414 (1.2 g, 31% yield) as a solid.
    • Step 2 Preparation of Intermediate 415
  • Figure US20230330127A1-20231019-C00760
  • To a solution of intermediate 414 (600 mg, 1.18 mmol) in EtOH (5 mL) was added NaBH4 (0.132 g, 3.53 mmol) at room temperature under N2. The reaction mixture was stirred at room temperature for 3 hours. Water (20 ml) was added and the mixture was extracted with CH2Cl2 (50 ml × 3). The organic layers were combined, dried (Na2SO4), filtered and concentrated to give the desired product as an oil. The crude product was purified by column chromatography over silica gel (eluens: ethyl acetate). The desired fractions were concentrated to give the intermediate 415 (0.27 g, 54.3% yield) as a solid.
    • Step 3 Preparation of Intermediate 416
  • Figure US20230330127A1-20231019-C00761
  • To a solution of intermediate 415 (0.27 g, 0.56 mmol) in anhydrous DMF (5 mL) was added NaH60% (33.5 mg, 0.83 mmol). The reaction mixture was stirred at room temperature for 20 min under argon. Then Mel (158 mg, 1.12 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 1 h. The mixture was poured into ice-water (10 mL) and extracted with CH2Cl2 (40 mL × 3). The combined extracts were washed with brine, dried over Na2SO4, filtered and evaporated to give the product as an oil. The crude product was purified by column (eluens: petroleum ether/ethyl acetate 20/1 to 1/1) to give the intermediate 416 (120 mg, 43% yield) as a solid.
    • Step 4 Preparation of Intermediate 417
  • Figure US20230330127A1-20231019-C00762
  • A solution of intermediate 416 (120 mg, 0.24 mmol) in NH3.H2O (5 mL) and dioxane (5 mL) was stirred in a sealed tube. The mixture was stirred at 90° C. overnight. The reaction was concentrated to give a crude product as an oil. The crude product was purified by prep-TLC (DCM/MeOH: ratio10/1) to give intermediate 417 (70 mg, 44% yield) as a solid.
    • Example A92 Step 1 Preparation of Intermediate 418
  • Figure US20230330127A1-20231019-C00763
  • To a solution of Adenosine (75 g, 281 mmol) in acetone (1200 mL) and DMF (400 mL) was added 2,2-dimethoxypropane (35.1 g, 336.8 mmol) and methanesulfonic acid (40.5 g, 421 mmol) under N2. The reaction mixture was stirred at 60° C. for 6 h. The reaction mixture was treated with aqueous NaHCO3 (PH to 7-8) and then concentrated under reduced pressure. The residue was diluted with H2O (1200 mL) and extracted with ethyl acetate (1500 ml × 3). The organic layers were combined, washed with brine (500 mL), dried and concentrated under reduced pressure to give intermediate 418 (85 g, 96.3% yield) as a white solid.
    • Step 2 Preparation of Intermediate 419
  • Figure US20230330127A1-20231019-C00764
  • To a solution of intermediate 418 (87.8 g, 286 mmol) and imidazole (38.9 g, 571.4 mmol) in DMF (800 mL) was added TBDMSCl (51.67 g, 342.8 mmol) at room temperature under N2. The reaction was stirred at room temperature for overnight. Water (1000 ml) was added at room temperature, then a white solid was formed and filtered off. The solid was collected and dissolved in ethyl acetate (1500 ml) and washed with brine (500 ml). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated to give intermediate 419 (120 g, 99% yield) as a white solid.
    • Step 3 Preparation of Intermediate 420
  • Figure US20230330127A1-20231019-C00765
  • A mixture of intermediate 419 (116.3 g, 275.9 mmol), DMAP (3.37 g, 27.6 mmol) and THF (1500 mL) was stirred at room temperature. Boc2O (150.5 g, 689.7 mmol) was added dropwise. The mixture was stirred at room temperature for 2 hours. The mixture was evaporated under vacuum. The residue was dissolved in ethyl acetate (1500 ml) and washed with brine (1000 ml). The organic phases were combined, dried over anhydrous Na2SO4, filtered and concentrated to give intermediate 420 (170 g, 83% yield) as a white solid.
    • Step 4 Preparation of Intermediate 421
  • Figure US20230330127A1-20231019-C00766
  • To a solution of intermediate 420 (176 g, 238.8 mmol) in THF (2000 mL) was added TBAF (1 M in THF, 238.8 mL, 238.8 mmol) dropwise at room temperature under N2. The reaction mixture was stirred at room temperature for 1 hour. The mixture was poured into water (2000 ml) and extracted with ethyl acetate (2000 ml × 3). The combined organic layers were dried over Na2SO4, filtered and evaporated to give the crude product. This residue was purified by flash column chromatograph over silica gel (eluens: petroleum ether/ethyl acetate 10/1 to 1/1). The desired fractions were collected and the solvent was evaporated to give intermediate 421 (85 g, 72.5%) as a yellow oil.
    • Step 5 Preparation of Intermediate 422
  • Figure US20230330127A1-20231019-C00767
  • To a solution of intermediate 421 (1 g, 1.97 mmol), intermediate 200 (509 mg, 1.97 mmol) and DIAD (1.19 g, 5.91 mmol) in THF (20 mL) was added PPh3(1.55 g, 5.91 mmol) at room temperature under N2. The mixture was stirred at room temperature for 4 hours. Water (40 mL) was added and the mixture was extracted with ethyl acetate (3 × 50 mL). The organic layers were combined, dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product. This residue was purified by flash column chromatograph over silica gel (eluent: petroleum/ethyl acetate from 10/1 to 2/1). The desired fractions were collected and the solvent was evaporated to give the product as a yellow oil. The oil was purified by HPLC column: Phenomenex Gemini C18 250 × 50 mm ×10 µm; Conditions: A: water (0.05% ammonia hydroxide v/v), B: MeCN; at the beginning: A (48%) and B (52%), at the end: A (18%) and B (82%); Gradient Time (min) 30; 100% B Hold Time(min) 5; Flow Rate(ml/min) 90) to give intermediate 422 (650 mg, 41% yield) as a white solid.
    • Example A93 Preparation of Intermediate 423 Step 1
  • Figure US20230330127A1-20231019-C00768
  • A mixture of intermediate 421(2 g, 3.94 mmol), Et3N( 0.797 g, 7.88 mmol) and DMAP( 0.096 g, 0.788 mmol) was stirred in DCM ( 40 ml) at room temperature TosCl ( 1.127 g, 5.91 mmol) was added. The reaction mixture was stirred overnight. Then 50 ml of saturated NaHCO3 was added into the mixture and the layers were separated. The aqueous layer was extracted with DCM (50 mL × 2). The combined organic layers were dried with Na2SO4, filtered and concentrated under vacuum to give crude product as an oil. The crude product was purified by column (eluent: petroleum ether/EtOAc ratio 10 /1 to 3/1) to give intermediate 423 ( 1.25 g, yield 45%)as a white solid.
    • Step 2 Preparation of Intermediate 424
  • Figure US20230330127A1-20231019-C00769
  • To a solution of intermediate 423 (1.1 g, 1.66 mmol), 3- bromo -7- hydroxy quinoline (0.372 g, 1.66 mmol) and DMF (40 mL) was add Cs2CO3 (1.63 g, 4.98 mmol) at room temperature under N2. The mixture was stirred at 40° C. for 6 hours. The reaction mixture was filtered and the filtrate was evaporated. The residue was purified by column over silica gel (eluens: petroleum ether/ethyl acetate: ratio 20/1 to 0/1) to give intermediate 424 (1.1 g, 87% yield) as a yellow oil.
    • Example A94 Step 1 Preparation of Intermediate 425
  • Figure US20230330127A1-20231019-C00770
  • A mixture of intermediate 165 (300 mg, 0.393 mmol,) and NaOH solution (19.2 ml, 38.5 mmol, 2 M) in dioxane (5 ml) was refluxed at 60° C. for 48 h. The mixture was extracted with ethyl acetate (10 ml × 3), the organic layers were combined and evaporated under vacuo to obtain intermediate 425 (300 mg, 42% yield) as a crude product.
    • Step 2 Preparation of Intermediate 426
  • Figure US20230330127A1-20231019-C00771
  • The solution of intermediate 425 (300 mg, 0.164 mmol) in trifluroacetic acid (5 ml) was stirred at 50° C. for 1 h. The mixture was evaporated under vacuo to obtain intermediate 426 (150 mg, 75% yield) as a crude product.
    • Example A95 Step 1 Preparation of Intermediate 427
  • Figure US20230330127A1-20231019-C00772
  • To a solution of intermediate 157 (4 g, 14.4 mmol) in THF (100 mL) was added LiHMDS (28.8 mL, 1 M). The reaction mixture was stirred at 0° C. for 15 min, then Boc2O (6.3 g, 28.8 mmol) was added. The reaction mixture was stirred at room temperature for another 30 min. The reaction mixture was quenched with saturated aq. NH4Cl (50 ml) and extracted with ethyl acetate (50 ml × 2). The organic layers were combined and evaporated under vacuum to obtain intermediate 427 (5 g ) as a crude product.
    • Step 2 Preparation of Intermediate 428
  • Figure US20230330127A1-20231019-C00773
  • To a solution of intermediate 427 (5.0 g, 13.25 mmol) in MeOH (25 mL) and DMF (25 mL) was added Pd(dppf)Cl2 (0.970 g, 1.32 mmol) and Et3N (4.02 g, 39.76 mmol). The reaction mixture was degassed under vacuum and purged with CO— gas three times. The reaction was stirred overnight under CO atmosphere at 120° C. The reaction mixture was diluted with H2O (100 mL) and was then extracted with ethyl acetate (100 mL × 3). The organic layer was washed with H2O (100 mL) and dried with anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate: ratio 5/1 to petroleum ether/ethyl acetate 2/1). The pure fractions were collected and the solvent was evaporated under vacuum to obtain intermediate 428 (4.0 g, 85% yield).
    • Step 3 Preparation of Intermediate 429
  • Figure US20230330127A1-20231019-C00774
  • To a solution of intermediate 428 (4.0 g, 11.2 mmol) in THF (20 mL) was added LiAlH4 (0.426 mg, 11.2 mmol). The reaction mixture was stirred at room temperature for 3 hrs. The mixture was quenched with aq. 10% KOH (0.5 mL), filtered and the filtrate was concentrated under reduced pressure to give intermediate 429 (3.4 g, 90% yield) as an oil.
    • Step 4 Preparation of Intermediate 332
  • Figure US20230330127A1-20231019-C00775
  • To a solution of intermediate 429 (1.3 g, 3.96 mmol) in DCM (20 ml) was added mesyl chloride ( 0.907 g, 7.92 mmol), DMAP ( 96.7 mg, 0.792 mmol) and Et3N ( 1.2 g, 11.88 mmol). The reaction mixture was stirred overnight at room temperature.
  • The reaction mixture was diluted with DCM (100 mL) and the organic phase was then washed with aq. K2CO3 (50 mL × 3). The organic phase was dried with Na2SC4 and was then concentrated under reduced pressure to give intermediate 332 as a yellow oil which was used in the next step reaction without further purification.
    • Example A96 Step 1 Preparation of Intermediate 430
  • Figure US20230330127A1-20231019-C00776
  • Br2 (0.89 mL) was added to the solution of 2-Hydroxyquinoxaline (1.5 g, 10.2 mmol) in HOAc (15 mL) and the reaction was stirred at room temperature for 6 hours. The solid was filtered and washed with ethyl acetate to give intermediate 430 (2.2 g, yield: 95%) as a white solid.
    • Step 2 Preparation of Intermediate 431
  • Figure US20230330127A1-20231019-C00777
  • POCl3 (48.5 g, 316 mmol) was added to intermediate 430 (2.2 g, 9.7 mmol). The mixture was stirred at 70° C. for 2 hours. The mixture was poured slowly into water. aq. NaHCO3 was added into the mixture until no more gas evolution occurred. The mixture was extracted with EtOAc. The organic phase was filtered and washed with brine. The organic phase was dried over Na2SO4 and concentrated to give intermediate 431 (2 g, yield: 81%)
    • Step 3 Preparation of Intermediate 432
  • Figure US20230330127A1-20231019-C00778
  • A solution of intermediate 431 (100 mg, 0.41 mmol) in dioxane (4 mL) and NH3.H2O(10 mL, 25%) was stirred in a sealed tube at 110° C. overnight. The mixture was concentrated to give the crude intermediate 432 (108 mg) as a yellow solid.
    • ExampleA97 Step 1 Preparation of Intermediate 493
  • Figure US20230330127A1-20231019-C00779
  • A mixture of intermediate 408 (10 g, 54.88 mmol) in a 9- BBN 0.5 M solution in THF( 439 ml, 219.5 mmol) was stirred at 50° C. for 1 h under N2. The mixture was cooled to room temperature, then K3PO4 (34.9 g, 164.6 mmol) in H2O (20 mL) were added, followed by THF (110 ml), intermediate 181 (15.19 g, 54. 88 mmol) and Pd-118(1788 mg, 2.74 mmol). The resulting mixture was stirred at 50° C. for 0.5 h.
  • The mixture was concentrated. The residue was dissolved in ethyl acetate (400 ml), washed with water (400 ml) and brine (400 ml). The organic phase was dried over Na2SO4, filtered and concentrated. The crude product was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate 10/1 to petroleum ether/-ethyl acetate 1/1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 393 (19 g, 82% yield) as a solid.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 393 using the appropriate starting materials (Table 50).
  • TABLE 50
    intermediates Structure Starting materials
    530
    Figure US20230330127A1-20231019-C00780
         		intermediate 408
    intermediate 175
    • Step 2 Preparation of Intermediate 494
  • Figure US20230330127A1-20231019-C00781
  • Intermediate 493 (4 g, 10.46 mmol) and pyridine (2.48 g, 31.39 mmol) were dissolved in DCM ( 50 ml) under N2. Triflic anhydride (5.9 g, 20.93 mmol) was added at 0° C. and the reaction mixture was stirred for 0.5 hour. Then the reaction mixture was stirred at 25° C. for 1 hour. The solvent was removed in vacuo. The residue was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate ratio 10/0 to petroleum ether/ ethyl acetate ratio 4/1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 494 (3.5 g, 65% yield) as a white solid.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 394 using the appropriate starting materials (Table 51).
  • TABLE 51
    intermediates Structure Starting materials
    531
    Figure US20230330127A1-20231019-C00782
         		intermediate 530
    • Step 3 Preparation of Intermediate 495
  • Figure US20230330127A1-20231019-C00783
  • 7H-Pyrrolo[2,3-d]pyrimidine, 2,4-dichloro-( 1.24 g, 6.61 mmol) and Cs2CO3( 3.23 g, 9.91 mmol) were dissolved in DMF (20 ml) under N2. Then intermediate 494 was added. The reaction mixture was stirred at 25° C. for 12 hours. To the mixture was added ethyl acetate (50 mL) and water (50 mL). The organic layer was separated, washed with H2O, and dried (Na2SO4). The solvent was removed under reduced pressure. The crude product was purified by column chromatography over silica gel (petroleum ether/-ethyl acetate ratio10/1 to petroleum ether/ ethyl acetate ratio 4/1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 495 ( 900 mg, 37% yield) as a yellow solid.
  • Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 495 using the appropriate starting materials (Table 43).
  • TABLE 43
    intermediates Structure Starting materials
    497
    Figure US20230330127A1-20231019-C00784
         		intermediate 494
    7H-Pyrrolo[2,3-d]pyrimidine. 2-chloro
    499
    Figure US20230330127A1-20231019-C00785
         		intermediate 494
    7H-Pyrrolo[2,3-d]pyrimidine
    519
    Figure US20230330127A1-20231019-C00786
         		intermediate 494
    1H-Pyrrolo[3,2-c]pyridine
    521
    Figure US20230330127A1-20231019-C00787
         		intermediate 494
    1H-Pyrrolo[3,2-d]pyridine
    523
    Figure US20230330127A1-20231019-C00788
         		intermediate 494
    1H-Pyrrolo[2,3-b]pyridine
    525
    Figure US20230330127A1-20231019-C00789
         		intermediate 494
    5H-Pyrrolo[2,3-b]pyrazine
    532
    Figure US20230330127A1-20231019-C00790
         		Intermediate 531
    2H-Pyrrolo[3,2-c]pyridine
    533
    Figure US20230330127A1-20231019-C00791
         		Intermediate 531
    1H-Pyrrolo[3,2-c]pyridine, 4-chloro-
    • Example A100
  • Figure US20230330127A1-20231019-C00792
  • A solution of intermediate 533 (1.75 g, 3.1 mmol), 2,4-dimethoxybenzylamine hydrochloride (2.6 g, 15.6 mmol) and DIPEA(1.2 g, 9.3 mmol) in n-BuOH(5 mL) was stirred at 140° C. for 3 days. The reaction mixture was diluted with CH2Cl2(30 mL) and washed with H2O (20 mL × 2). The organic phase was separated and dried with Na2SO4 and the solvent was removed under vacuo. The crude product was purified by column chromatography over silica gel (petroleum ether/ ethyl acetate ratio 10/1 to petroleum ether/ ethyl acetate ratio ½) to give intermediate 534 (1.1 g, yield 81%) as a yellow solid.
    • Example A98 Preparation of Intermediate 526
  • Figure US20230330127A1-20231019-C00793
  • Intermediate 323 (900 mg, 1.862 mmol), benzophenone imine (354.3 mg, 1.95 mmol) Pd(OAc)2(41.8 mg, 0.186 mmol), BINAP (115.9 mg, 0.186 mmol) and Cs2CO3(1213 mg, 3.72 mmol) were dissolved in toluene ( 20 ml). The mixture was stirred at 110° C. for 14 hours under N2. The catalyst was filtered and the solvent was evaporated.
  • The residue was purified by flash column chromatography over silica gel (gradient eluent: EtOAc/petrol ether from 1/15 to 1/1) The product fractions were collected and the solvent was evaporated to give intermediate 526 (660 mg, 51% yield) as a yellow solid.
    • B. Preparation of the Compounds Example B1 Preparation of Compound 1
  • Figure US20230330127A1-20231019-C00794
  • Intermediate 104 (300 mg, crude, ≈ 0.568 mmol) was dissolved in 5 ml of 4 M HCl/MeOH. The mixture was stirred at room temperature for 3 hours. The solvent was concentrated in vacuum. The residue was dissolved in 4 ml of MeOH and the pH was adjusted to around pH = 9 with a saturated Na2CO3 solution. The solvent was purified by preparative-HPLC (HPLC condition: Column: Gemini 150*25 mm*5 µm; gradient elution: 0.05% ammonia/CH3CN, from 81/19 to 71/29) to give compound 1 (70 mg, 30% yield) as a white solid.
    • Example B2 Preparation of Compound 2
  • Figure US20230330127A1-20231019-C00795
  • 4 M HCl in dioxane (0.7 mL, 2.9 mmol) was added to a stirred solution of intermediate 105 (175.1 mg, crude, ≈ 0.29 mmol) in MeOH (10 mL) at room temperature. The reaction mixture was stirred at room temperature for 18 hours. The reaction was quenched by the addition of 1.5 mL of a 7 N solution of NH3 in MeOH. The solvents were evaporated. The residue was dissolved in DCM. The precipitate was filtered off. The filtrate was purified over a SiO2 column, type Grace Reveleris SRC, 12 g, Si 40, on an Armen Spot II Ultimate purification system using DCM and MeOH as eluens in a gradient starting from 100% DCM and ending with 40% MeOH and 60% DCM. The fractions containing the product were combined and the solvents were evaporated yielding 24.5 mg of compound 2.
    • Example B3 Preparation of Compound 2
  • Figure US20230330127A1-20231019-C00796
  • Intermediate 89 (12.2 g, ≈15.751 mmol) was dissolved in HCl/MeOH (220 ml,4 M). The mixture was stirred at room temperature for 3 days. The solid was precipitate out after 18 hours reaction. The reaction mixture was combined with another batch of reaction mixture (1 g of intermediate 89). The resulting solid was filtered through a funnel collected. The residue was triturated with water, and the pH was adjusted to around 8 by progressively adding solid K2CO3. The resulting solid was filtered through a buchner funnel rinsed with water (100 mL*5) and collected, which was lyophilized to give the compound 2 (5.95 g, 73% yield) as a white solid.
    • Example B4 Preparation of Compound3
  • Figure US20230330127A1-20231019-C00797
  • To a solution of intermediate 74 (249 mg, 0.405 mmol) in DCM (3.5 mL) was added TFA (0.8 mL, 10.5 mmol) and the mixture was stirred at rt for 5 days. The mixture was evaporated in vacuo. The residue was solubilized in MeOH (6 mL) and HCl (3 M in CPME) (1.5 mL, 4.5 mmol) was added and the mixture was stirred overnight at room temperature. The mixture was quenched with NH3 in MeOH (7N) and evaporated in vacuo. The residue was taken-up in DCM/MeOH (1/1), filtered off and the filtrate was evaporated in vacuo. The residues were purified by preparative LC (irregular SiOH, 15-40 µm, 10 g, Merck, dry loading (Celite®), mobile phase gradient elution: from DCM:MeOH/aq. NH3 (9:1) from 97.5:2.5 to 87.5: 12.5) to give compound 3 as a white solid (156 mg, 73% yield).
    • Example B5 Preparation of Compound 4
  • Figure US20230330127A1-20231019-C00798
  • To a solution of intermediate 86 (750 mg, ≈0.71 mmol) in MeOH (40 mL) was added 4 M HCl in MeOH (20 mL) at rt. Subsequently the mixture was stirred at 50° C. for 12 hours. The solvent was concentrated in vacuo. The residues were dissolved in 10 ml MeOH and the pH was adjusted to around 8 with NaHCO3, The mixture was filtered and the solvent was purified by preparative-HPLC (gradient elution: 0.05% NH3.H2O in MeOH / 0.05% NH3.H2O in H2O). The desired fractions were combined and the solvent was evaporated to give compound 4 as a white solid (207 mg, 61%).
  • Below compounds were prepared by an analogous reaction protocol as example B1, B2, B3, B4, B5 or B20 (further in experimental part) using the appropriate starting materials (Table 21). Compounds 55, 57, 57a and 61 were obtained in the E-configuration.
  • TABLE 21
    Compound Structure Reaction protocol Starting material
    5
    Figure US20230330127A1-20231019-C00799
         		B1 Intermediate 106
    6
    Figure US20230330127A1-20231019-C00800
         		B1 Intermediate 107
    7
    Figure US20230330127A1-20231019-C00801
         		B1 Intermediate 108
    8
    Figure US20230330127A1-20231019-C00802
         		B1 Intermediate 109
    9
    Figure US20230330127A1-20231019-C00803
         		B4 Intermediate 110
    10
    Figure US20230330127A1-20231019-C00804
         		B1 Intermediate 111
    11
    Figure US20230330127A1-20231019-C00805
         		B1 Intermediate 112
    12
    Figure US20230330127A1-20231019-C00806
         		B1 Intermediate 113
    13
    Figure US20230330127A1-20231019-C00807
         		B1 Intermediate 114
    14
    Figure US20230330127A1-20231019-C00808
         		B1 Intermediate 115
    15
    Figure US20230330127A1-20231019-C00809
         		B1 Intermediate 116
    16
    Figure US20230330127A1-20231019-C00810
         		B2 Intermediate 117
    17
    Figure US20230330127A1-20231019-C00811
         		B1 Intermediate 118
    18
    Figure US20230330127A1-20231019-C00812
         		B1 Intermediate 154
    19
    Figure US20230330127A1-20231019-C00813
         		B1 Intermediate 155
    20
    Figure US20230330127A1-20231019-C00814
         		B1 Intermediate 119
    21
    Figure US20230330127A1-20231019-C00815
         		B1 Intermediate 120
    22
    Figure US20230330127A1-20231019-C00816
         		B2 Intermediate 121
    23
    Figure US20230330127A1-20231019-C00817
         		B2 Intermediate 154a
    24
    Figure US20230330127A1-20231019-C00818
         		B2 Intermediate 80
    25
    Figure US20230330127A1-20231019-C00819
         		B2 Intermediate 122
    26
    Figure US20230330127A1-20231019-C00820
         		B1 Intermediate 79
    27
    Figure US20230330127A1-20231019-C00821
         		B1 Intermediate 123
    28
    Figure US20230330127A1-20231019-C00822
         		B2 Intermediate 144
    29
    Figure US20230330127A1-20231019-C00823
         		B2 Intermediate 144a
    30
    Figure US20230330127A1-20231019-C00824
         		B2 Intermediate 145
    31
    Figure US20230330127A1-20231019-C00825
         		B2 Intermediate 145a
    32
    Figure US20230330127A1-20231019-C00826
         		B4 Intermediate 73
    33
    Figure US20230330127A1-20231019-C00827
         		B2 Intermediate 124
    34
    Figure US20230330127A1-20231019-C00828
         		B2 Intermediate 54
    35
    Figure US20230330127A1-20231019-C00829
         		B1 Intermediate 84
    36
    Figure US20230330127A1-20231019-C00830
         		B2 Intermediate 125
    37
    Figure US20230330127A1-20231019-C00831
         		B5 Intermediate 81
    38
    Figure US20230330127A1-20231019-C00832
         		B5 Intermediate 82
    39
    Figure US20230330127A1-20231019-C00833
         		B4 Intermediate 75
    40
    Figure US20230330127A1-20231019-C00834
         		B4 Intermediate 76
    41
    Figure US20230330127A1-20231019-C00835
         		B5 Intermediate 83
    42
    Figure US20230330127A1-20231019-C00836
         		B5 Intermediate 87
    43
    Figure US20230330127A1-20231019-C00837
         		B5 Intermediate 88
    44
    Figure US20230330127A1-20231019-C00838
         		B3 Intermediate 126
    45
    Figure US20230330127A1-20231019-C00839
         		B2 Intermediate 153
    46
    Figure US20230330127A1-20231019-C00840
         		B1 Intermediate 127
    47
    Figure US20230330127A1-20231019-C00841
         		B1 Intermediate 128
    48
    Figure US20230330127A1-20231019-C00842
         		B1 Intermediate 129
    49
    Figure US20230330127A1-20231019-C00843
         		B1 Intermediate 130
    50
    Figure US20230330127A1-20231019-C00844
         		B1 Intermediate 131
    51
    Figure US20230330127A1-20231019-C00845
         		B1 Intermediate 132
    52
    Figure US20230330127A1-20231019-C00846
         		B1 Intermediate 133
    53
    Figure US20230330127A1-20231019-C00847
         		B1 Intermediate 134
    54
    Figure US20230330127A1-20231019-C00848
         		B1 Intermediate 135
    54a
    Figure US20230330127A1-20231019-C00849
         		B1 Intermediate 135
    55
    Figure US20230330127A1-20231019-C00850
         		B1 Intermediate 137
    56
    Figure US20230330127A1-20231019-C00851
         		B1 Intermediate 146
    57
    Figure US20230330127A1-20231019-C00852
         		B1 Intermediate 138
    57a
    Figure US20230330127A1-20231019-C00853
         		B1 Intermediate 136
    58
    Figure US20230330127A1-20231019-C00854
         		B1 Intermediate 147
    59
    Figure US20230330127A1-20231019-C00855
         		B1 Intermediate 148
    60
    Figure US20230330127A1-20231019-C00856
         		B1 Intermediate 149
    61
    Figure US20230330127A1-20231019-C00857
         		B1 Intermediate 150
    62
    Figure US20230330127A1-20231019-C00858
         		B1 Intermediate 150
    63
    Figure US20230330127A1-20231019-C00859
         		B2 Intermediate 139
    64
    Figure US20230330127A1-20231019-C00860
         		B1 Intermediate 141
    65
    Figure US20230330127A1-20231019-C00861
         		B1 Intermediate 142
    66
    Figure US20230330127A1-20231019-C00862
         		B1 Intermediate 143
    82
    Figure US20230330127A1-20231019-C00863
         		B1 Intermediate 188
    83
    Figure US20230330127A1-20231019-C00864
         		B1 Intermediate 192
    84
    Figure US20230330127A1-20231019-C00865
         		B20 Intermediate 193
    85
    Figure US20230330127A1-20231019-C00866
         		B1 Intermediate 194
    86
    Figure US20230330127A1-20231019-C00867
         		B2 Intermediate 96
    87
    Figure US20230330127A1-20231019-C00868
         		B2 Intermediate 195
    88
    Figure US20230330127A1-20231019-C00869
         		B2 Intermediate 196
    90
    Figure US20230330127A1-20231019-C00870
         		B1 Intermediate 198
    91
    Figure US20230330127A1-20231019-C00871
         		B5 Intermediate 199
    92
    Figure US20230330127A1-20231019-C00872
         		B3 Intermediate 201
    94
    Figure US20230330127A1-20231019-C00873
         		B3 Intermediate 206
    95
    Figure US20230330127A1-20231019-C00874
         		B1 Intermediate 209
    96
    Figure US20230330127A1-20231019-C00875
         		B3 Intermediate 211
    97
    Figure US20230330127A1-20231019-C00876
         		B3 Intermediate 213
    98
    Figure US20230330127A1-20231019-C00877
         		B2 Intermediate 214
    99
    Figure US20230330127A1-20231019-C00878
         		B3 Intermediate 215
    100
    Figure US20230330127A1-20231019-C00879
         		B3 Intermediate 217
    101
    Figure US20230330127A1-20231019-C00880
         		B3 Intermediate 219
    102
    Figure US20230330127A1-20231019-C00881
         		B3 Intermediate 221
    103
    Figure US20230330127A1-20231019-C00882
         		B1 Intermediate 226
    104
    Figure US20230330127A1-20231019-C00883
         		B3 Intermediate 227
    105
    Figure US20230330127A1-20231019-C00884
         		B3 Intermediate 228
    106
    Figure US20230330127A1-20231019-C00885
         		B3 Intermediate 230
    107
    Figure US20230330127A1-20231019-C00886
         		B3 Intermediate 232
    108
    Figure US20230330127A1-20231019-C00887
         		B20 Intermediate 234
    109
    Figure US20230330127A1-20231019-C00888
         		B3 Intermediate 236
    110
    Figure US20230330127A1-20231019-C00889
         		B1 Intermediate 237
    111
    Figure US20230330127A1-20231019-C00890
         		B20 Intermediate 239
    112
    Figure US20230330127A1-20231019-C00891
         		B3 Intermediate 241
    113
    Figure US20230330127A1-20231019-C00892
         		B1 Intermediate 243
    114
    Figure US20230330127A1-20231019-C00893
         		B1 Intermediate 245
    115
    Figure US20230330127A1-20231019-C00894
         		B1 Intermediate 159
    120
    Figure US20230330127A1-20231019-C00895
         		B3 Intermediate 247
    121
    Figure US20230330127A1-20231019-C00896
         		B1 Intermediate 248
    122
    Figure US20230330127A1-20231019-C00897
         		B1 Intermediate 250
    123
    Figure US20230330127A1-20231019-C00898
         		B1 Intermediate 252
    124
    Figure US20230330127A1-20231019-C00899
         		B1 Intermediate 233
    125
    Figure US20230330127A1-20231019-C00900
         		B1 Intermediate 257
    126
    Figure US20230330127A1-20231019-C00901
         		B1 Intermediate 258
    127
    Figure US20230330127A1-20231019-C00902
         		B1 Intermediate 254
    128
    Figure US20230330127A1-20231019-C00903
         		B1 Intermediate 259
    129
    Figure US20230330127A1-20231019-C00904
         		B20 Intermediate 261
    130
    Figure US20230330127A1-20231019-C00905
         		B2 Intermediate 262
    131
    Figure US20230330127A1-20231019-C00906
         		B2 Intermediate 264
    132
    Figure US20230330127A1-20231019-C00907
         		B2 Intermediate 265
    133
    Figure US20230330127A1-20231019-C00908
         		B1 Intermediate 266
    134
    Figure US20230330127A1-20231019-C00909
         		B1 Intermediate 267
    135
    Figure US20230330127A1-20231019-C00910
         		B1 Intermediate 269
    136
    Figure US20230330127A1-20231019-C00911
         		B2 Intermediate 270
    137
    Figure US20230330127A1-20231019-C00912
         		B2 Intermediate 271
    138
    Figure US20230330127A1-20231019-C00913
         		B2 Intermediate 272
    139
    Figure US20230330127A1-20231019-C00914
         		B1 Intermediate 273
    140
    Figure US20230330127A1-20231019-C00915
         		B1 Intermediate 275
    141
    Figure US20230330127A1-20231019-C00916
         		B1 Intermediate 278
    142
    Figure US20230330127A1-20231019-C00917
         		B3 Intermediate 279
    143
    Figure US20230330127A1-20231019-C00918
         		B1 Intermediate 281
    144
    Figure US20230330127A1-20231019-C00919
         		B20 Intermediate 286
    145
    Figure US20230330127A1-20231019-C00920
         		B1 Intermediate 289
    146
    Figure US20230330127A1-20231019-C00921
         		B1 Intermediate 292
    147
    Figure US20230330127A1-20231019-C00922
         		B1 Intermediate 295
    148
    Figure US20230330127A1-20231019-C00923
         		B1 Intermediate 298
    149
    Figure US20230330127A1-20231019-C00924
         		B2 Intermediate 301
    150
    Figure US20230330127A1-20231019-C00925
         		B2 Intermediate 304
    151
    Figure US20230330127A1-20231019-C00926
         		B1 Intermediate 307
    152
    Figure US20230330127A1-20231019-C00927
         		B1 Intermediate 310
    153
    Figure US20230330127A1-20231019-C00928
         		B1 Intermediate 313
    154
    Figure US20230330127A1-20231019-C00929
         		B1 Intermediate 316
    155
    Figure US20230330127A1-20231019-C00930
         		B1 Intermediate 319
    156
    Figure US20230330127A1-20231019-C00931
         		B1 Intermediate 322
    157
    Figure US20230330127A1-20231019-C00932
         		B1 Intermediate 325
    158
    Figure US20230330127A1-20231019-C00933
         		B1 Intermediate 328
    159
    Figure US20230330127A1-20231019-C00934
         		B1 Intermediate 331
    160
    Figure US20230330127A1-20231019-C00935
         		B1 Intermediate 334
    161
    Figure US20230330127A1-20231019-C00936
         		B1 Intermediate 337
    222
    Figure US20230330127A1-20231019-C00937
         		B1 Intermediate 504
    223
    Figure US20230330127A1-20231019-C00938
         		B1 Intermediate 462
    224
    Figure US20230330127A1-20231019-C00939
         		B1 Intermediate 464
    236
    Figure US20230330127A1-20231019-C00940
         		B1 Intermediate 484
    240
    Figure US20230330127A1-20231019-C00941
         		B1 Intermediate 496
    241
    Figure US20230330127A1-20231019-C00942
         		B1 Intermediate 498
    242
    Figure US20230330127A1-20231019-C00943
         		B1 Intermediate 500
    243
    Figure US20230330127A1-20231019-C00944
         		B1 Intermediate 501
    244
    Figure US20230330127A1-20231019-C00945
         		B20 Intermediate 514
    245
    Figure US20230330127A1-20231019-C00946
         		B2 Intermediate 516
    246
    Figure US20230330127A1-20231019-C00947
         		B1 Intermediate 518
    247
    Figure US20230330127A1-20231019-C00948
         		B1 Intermediate 520
    248
    Figure US20230330127A1-20231019-C00949
         		B1 Intermediate 522
    249
    Figure US20230330127A1-20231019-C00950
         		B2 Intermediate 524
    251
    Figure US20230330127A1-20231019-C00951
         		B2 Intermediate 532
    • Example B6 Preparation of Compound 67 and Compound 68
  • Figure US20230330127A1-20231019-C00952
  • Intermediate 140 (210 mg, crude, ≈0.399 mmol) was dissolved in 5 ml of HCl/MeOH. The mixture was stirred at room temperature for 7 hours. The reaction was quenched by addition of NH3/MeOH to adjust the pH to around 8 at 0° C. The resulting solid was then removed by filtration and washed with CH2Cl2 (10 ml) and the combined organic filtrate was concentrated under reduced pressure to give the crude product. The residue was purified by preparative-HPLC (HPLC condition: Columns: Phenomenex Gemini 150*25 mm*10 um; mobile phase gradient elution with 21% Water in ACN;) to yield compound 67 (40 mg) and compound 68 (52 mg) as a white solid.
    • Example B7
  • Figure US20230330127A1-20231019-C00953
  • The reaction mixture of intermediate 85 (150 mg, ≈0.233 mmol) in 5 mL of mixed solvent AcOH, water and THF with ration as 13:7:3) was stirred overnight at 60° C. Then the mixture was stirred at 80° C. for 1 days.The solvent was concentrated in vacuum.The residue was dissolved in 4 ml of MeOH and the pH was adjusted to around 9 with Na2CO3 solid. The solvent was purified by preparative-HPLC (HPLC condition: Columns: Gemini 150*25 mm*5 µM; gradient elution with water (0.05% ammonia hydroxide v/v):ACN from 97:3 to 67:33) to give compound 69 as a white solid. (13 mg, 14% yield ).
    • Example B8
  • Figure US20230330127A1-20231019-C00954
  • Intermediate 152 (425 mg, 0.927 mmol)was dissolved in the mixed solution of AcOH (22 mL), THF (5 mL) and H2O (12 mL). The mixture was stirred at 50° C. for 12 hours. The solvent was concentrated in vacuum. The crude product was purified by preparative-HPLC (gradient elution: 0.05% NH3.H2O in MeOH / 0.05% NH3.H2O in H2O). The combined solvent was evaporated to give the desired compound 70 as a solid (69.3 mg, 18% yield).
    • Example B9
  • Figure US20230330127A1-20231019-C00955
  • To a solution of intermediate 59 (187 mg, ≈0.18 mmol) in 1,4-dioxane (5 mL) was added 4M HCl in dioxane (0.46 mL, 1.8 mmol). The reaction mixture was stirred at room temperature for 18 hours. The reaction was quenched by the addition of 1.5 mL 7 N solution of NH3 in MeOH. The solvents were evaporated. The residue was dissolved in dichloromethane with methanol (q.s.) and then purified over a SiO2 column, type Grace Reveleris SRC, 12 g, Si 40, on a Armen Spot II Ultimate purification system using dichloromethane and methanol as eluens in a gradient starting from 100% DCM for 5 column volumes and ending with 40% MeOH and 60% DCM over 25 column volumes. The fractions containing product were combined and the solvents were evaporated yielding 62 mg crude product mixture. The crude product mixture was purified by Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-10 µm, 30 × 150 mm, Mobile phase: 0.25% NH4HCO3 solution in water, CH3CN), yielding compound 71 (5.5 mg, 6% yield).
    • Example B10 Preparation of Compound 1a
  • Figure US20230330127A1-20231019-C00956
  • To a solution of intermediate 100 (9.26 g, ≈17.5 mmol) in 1,4-dioxane (300 mL) was added 4 M HCl in 1,4-dioxane (43.8 mL, 175 mmol). The recation mixture was stirred at room temperature for 4 hours. The reaction mixture was poured out into a beaker with DIPE (1 L). The suspension was stirred for 20 minutes and then the solvents were decantated off. The remaining precipitate was recrystallized in EtOH. The precipitate was filtered off, washed with DIPE and then dried in vacuo at 50° C. yielding compound 1a as salt with 2 equivalent of HCl (8.33 g, quantitive yield).
    • Example B11 Preparation of Compound 72 (via Intermediate 156) Step A:
  • Figure US20230330127A1-20231019-C00957
  • Isobutyric anhydride (2.36 mL, 14.2 mmol) was added to a stirred solution of compound 22 (688.3 mg, 1.418 mmol) in pyridine (25 mL, 310.361 mmol) at rt. After addition the reaction mixture was stirred at 50° C. for 18 hours. The solvents were evaporated. The residue was co-evaporated with toluene. The residue was dissolved in DCM and purified over a SiO2 column, type Grace Reveleris SRC, 40 g, Si 40, on a Armen Spot II Ultimate purification system using DCM and MeOH as eluens in a gradient starting from 100% DCM for 5 column volumes and ending with 40% MeOH and 60% DCM over 30 column volumes. The desired fractions were combined and the solvents were evaporated yielding 0.94 g of intermediate 156.
    • Step B:
  • Figure US20230330127A1-20231019-C00958
  • A solution of intermediate 156 (0.94 g, 1.372 mmol) and SOCl2 (99.493 µL, 1.372 mmol) in MeOH (20 mL, 0.791 g/mL, 493.725 mmol) was stirred and heated at 110° C. using microwave irradiation for 5 hours. The solvents were evaporated. The residue was dissolved in DCM and purified over a SiO2 column, type Grace Reveleris SRC, 12 g, Si 40, on a Armen Spot II Ultimate purification system using DCM and MeOH as eluens in a gradient starting from 100% DCM for 10 column volumes and ending with 20% MeOH and 80% DCM over 30 column volumes. The fractions containing product were combined and the solvents were evaporated yielding compound 72 (.HCl) (0.66 g, 74% yield).
  • Below compound was prepared by an analogous reaction protocol of example B11 using the appropriate starting materials (Table 22).
  • TABLE 22
    compound Structure Starting material
    73
    Figure US20230330127A1-20231019-C00959
         		Compound 2
    89
    Figure US20230330127A1-20231019-C00960
         		Compound 1
    • Example B12 Preparation of Compound 74
  • Figure US20230330127A1-20231019-C00961
  • To a solution of intermediate 160 (3.45 g, 6.9 mmol) in MeOH (10 mL) was added HCl/MeOH (4N, 10 mL), and the mixture was stirred at room temperature for 1 hour. The mixture was lyophilized to give crude Compound 74fraction 1 which was purified by prep-HPLC (Column: Phenomenex Synergi Max-RP 250*80 mm 10 µm, Condition: water (0.05% ammonia hydroxide v/v)-ACN, Start B: 30%, End B: 60, Gradient Time(min): 22, FlowRate(ml/min): 120). The desired fractions were collected and lyophilized to give crude Compound 74 fraction 2 which was further purified by prep-HPLC (Column Phenomenex Gemini 150*25 mm*10 µm, Condition: gradient water (0.05% ammonia hydroxide v/v)-ACN. The desired fractions were collected and lyophilized to give Compound 74 (1383 mg, yield: 43.1%) as solid.
  • Salt forms of Compound 74 were prepared according to state of the art procedures, known to the skilled person (Table 44).
  • TABLE 44
    Compound Structure Starting material
    116
    Figure US20230330127A1-20231019-C00962
         		Compound 74
    117
    Figure US20230330127A1-20231019-C00963
         		Compound 74
    118
    Figure US20230330127A1-20231019-C00964
         		Compound 74
    119
    Figure US20230330127A1-20231019-C00965
         		Compound 74
    • Example B13 Preparation of Compound 75
  • Figure US20230330127A1-20231019-C00966
  • A solution of intermediate 163 (680 mg, ≈1.04 mmol) in MeOH (q.s.) was dissolved in HCl/MeOH (4M, 15 mL), stirred at room temperature for 2 hours. The mixture was basified with NH3.H2O to pH > 7. The solution was washed with H2O (100 mL), extracted with ethyl acetate (150 mL × 3). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo to give the crude product as brown solid. The crude product was purified by prep-HPLC (Column:Waters Xbridge Prep OBD C18 150 × 30 mm, 5 µm; Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and lyophilized to give Compound 75 (129.8 mg, yield: 26.4%) as white solid.
    • Example B14 Preparation of Compound 76
  • Figure US20230330127A1-20231019-C00967
  • The mixture of intermediate 167 (250 mg) and K2CO3(185.3 mg, 1.34 mmol) in MeOH (3 ml) was stirred at 60° C. for 1 h. The mixture was filtered and evaporated under vacuo to obtain the crude product. This was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150×30 mm, 5 µm, Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and the solvent was evaporated to give Compound 76 as a white solid (82.2 mg, 45.3% yield).
    • Example B15 Preparation of Compound 77
  • Figure US20230330127A1-20231019-C00968
  • The mixture of intermediate 169 (120 mg, ≈0.185 mmol) and K2CO3 (76.40 mg, 0.554 mmol) in methanol (3 ml) was stirred at 60° C. for 1 h. The mixture was filtered and evaporated under vacuo to obtain a crude product. The crude product was purified by prep-HPLC (Column: Waters Xbridge Prep OBD C18 150×30 mm, 5 µm, Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and the solvent was evaporated to give Compound 77 as a white solid (21.4 mg, 29.4% yield).
  • Below Compounds were prepared by an analogous reaction protocol as was used for the preparation of compound 77 using the appropriate starting materials (Table 48).
  • TABLE 48
    compound Structure Starting materials
    250
    Figure US20230330127A1-20231019-C00969
         		intermediate 527
    232
    Figure US20230330127A1-20231019-C00970
         		intermediate 535
    • Example B16 Preparation of Compound 78
  • Figure US20230330127A1-20231019-C00971
  • The mixture of intermediate 171 (160 mg, ≈0.273 mmol) and K2CO3 (1 13.073 mg, 0.819 mmol) in methanol (3 ml) was stirred at 50° C. for 1 h. The mixture was filtered and evaporated under vacuo to obtain the crude product. This was purified by prep-HPLC (Column: Waters Xbridge Prep OBD C18 150×30 mm, 5 µm, Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and the solvent was evaporated to give Compound 78 (87.2 mg, 75.3% yield) as a white solid.
    • Example B17 Preparation of Compound 79
  • Figure US20230330127A1-20231019-C00972
  • The mixture of intermediate 173 (250 mg, ≈0.241 mmol) and K2CO3 (99.6 mg, 0.72 mmol) in methanol (3 ml) was stirred at 50° C. for 1 h. The mixture was filtered and evaporated under vacuo to obtain the crude product. This was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150 × 30 mm, 5 µm, Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and the solvent was evaporated to give Compound 79 (96.1 mg, 94.5% yield) as a white solid.
  • Below compound was prepared by an analogous reaction protocol of Compound 79 using the appropriate starting materials (Table 45).
  • TABLE 45
    Compound Structure Starting material
    228
    Figure US20230330127A1-20231019-C00973
         		Intermediate 472
    • Example B18 Preparation of Compound 80
  • Figure US20230330127A1-20231019-C00974
  • The mixture of intermediate 179 (350 mg) and K2CO3(102 mg, 0.74 mmol) in methanol (3 mL) was stirred at 60° C. for 1 h. The mixture was filtered and evaporated under vacuo to obtain a crude product. The crude product was purified by prep-HPLC (Column: Waters Xbridge Prep OBD C18 150 × 30 mm, 5 µm, Condition: gradient water (0.05% ammonia hydroxide v/v)-ACN). The desired fractions were collected and the solvent was evaporated to give Compound 80 (113.3 mg, 94.9% yield) as a white solid.
    • Alternative Preparation of Compound 80
  • Figure US20230330127A1-20231019-C00975
  • Intermediate 529 (21 g, 40.12 mmol) was dissolved in HCl/MeOH (250 mL). The mixture was stirred at room temperature for 2 hours. The solvent was concentrated in vacuum. Then H2O (100 mL) was added. The pH was adjusted to around 9 by progressively adding aq. Na2CO3 (800 mL). The precipitate was filtered off to give crude product. The crude product was recrystallized from EtOH (250 mL) to give 11.4 g of Compound 80 as a white solid. The filtrate of the recrystallization was concentrated in vacuum. This residue was added to EtOH (50 mL) and refluxed for 3 hours. The reaction was cooled and the precipitate was filtered off to give product 2.2 g of Compound 80. The filtrate of the second recrystallization was concentrated in vacuum to give another 2.2 g of Compound 80.
    • Example B19 Preparation of Compound 81
  • Figure US20230330127A1-20231019-C00976
  • The mixture of intermediate 184 (800 mg, 1.67 mmol ) and HCl in methanol (15 ml) was stirred at r.t. for 2 h. The mixture was neutralized with NH4OH. The mixture was extracted by EtOAc (20 mL × 3). The organic phase was evaporated and the crude product was purified by Prep-HPLC (gradient: water (10 mM NH4HCO3)-ACN). The combined solvent was evaporated to give Compound 81 (280 mg, 38% yield) as a white solid.
    • Example B20 Preparation of Compound 84
  • Figure US20230330127A1-20231019-C00977
  • Intermediate 193 (110 mg, 0.23 mmol) in EtOH (3.5 ml) was stirred at r.t.. HCl 1 N (2.3 ml, 2.3 mmol) was added dropwise. Stirring was continued for 72 h. Then the reaction mixture was treated with NH3 28% in water (0.235 ml, 3.5 mmol). The product started to precipitate. The precipitate was filtered off and was washed with EtOH / H2O ratio 9 to 1 and dried yielding compound 84 (90 mg, 89% yield)
    • Example B21 Preparation of Compound 162
  • Figure US20230330127A1-20231019-C00978
  • A solution of intermediate 338 (520 mg, 0.96 mmol) in HCl/MeOH (4N, 7 mL) and MeOH (2 mL) was stirred at room temperature for 1 h. The reaction was concentrated. The residue was dissolved in H2O (3 mL) and basified by aq.NH3.H2O. A precipitate was formed and collected. The solid was purified by prep-HPLC: conditions; A: (water (0.05% ammonia hydroxide v/v)-B: ACN, Begin B 30% End B 60%). The desired fractions were collected and lyophilized to give the product (250 mg). The product was further purified by prep-SFC (Column OD (250 mm × 30 mm, 10 µm); Conditions A: 0.1% ammonia hydroxide v/v), B: EtOH; Begin B 35%, End B 35%; flow rate (ml/min) 60). The desired fractions were collected and lyophilized to give compound 162 (206 mg, 43% yield) as a solid.
  • Below compounds were prepared by an analogous reaction protocol as was used for the preparation of compound 162 using the appropriate starting materials (Table 46).
  • TABLE 46
    Compound Structure Starting materials
    163
    Figure US20230330127A1-20231019-C00979
         		Intermediate 353
    164
    Figure US20230330127A1-20231019-C00980
         		Intermediate 354
    165
    Figure US20230330127A1-20231019-C00981
         		Intermediate 355
    166
    Figure US20230330127A1-20231019-C00982
         		Intermediate 356
    167
    Figure US20230330127A1-20231019-C00983
         		Intermediate 357
    168
    Figure US20230330127A1-20231019-C00984
         		Intermediate 358
    169
    Figure US20230330127A1-20231019-C00985
         		Intermediate 359
    170
    Figure US20230330127A1-20231019-C00986
         		Intermediate 360
    171
    Figure US20230330127A1-20231019-C00987
         		Intermediate 361
    172
    Figure US20230330127A1-20231019-C00988
         		Intermediate 362
    173
    Figure US20230330127A1-20231019-C00989
         		Intermediate 401
    174
    Figure US20230330127A1-20231019-C00990
         		Intermediate 402
    175
    Figure US20230330127A1-20231019-C00991
         		Intermediate 417
    176
    Figure US20230330127A1-20231019-C00992
         		Intermediate 377
    177
    Figure US20230330127A1-20231019-C00993
         		Intermediate 378
    178
    Figure US20230330127A1-20231019-C00994
         		Intermediate 339
    179
    Figure US20230330127A1-20231019-C00995
         		Intermediate 340
    180
    Figure US20230330127A1-20231019-C00996
         		Intermediate 367
    181
    Figure US20230330127A1-20231019-C00997
         		Intermediate 368
    182
    Figure US20230330127A1-20231019-C00998
         		Intermediate 369
    183
    Figure US20230330127A1-20231019-C00999
         		Intermediate 341
    184
    Figure US20230330127A1-20231019-C01000
         		Intermediate 342
    185
    Figure US20230330127A1-20231019-C01001
         		Intermediate 403
    186
    Figure US20230330127A1-20231019-C01002
         		Intermediate 343
    187
    Figure US20230330127A1-20231019-C01003
         		Intermediate 365
    188
    Figure US20230330127A1-20231019-C01004
         		Intermediate 366
    189
    Figure US20230330127A1-20231019-C01005
         		Intermediate 404
    190
    Figure US20230330127A1-20231019-C01006
         		Intermediate 379
    191
    Figure US20230330127A1-20231019-C01007
         		Intermediate 375
    192
    Figure US20230330127A1-20231019-C01008
         		Intermediate 380
    193
    Figure US20230330127A1-20231019-C01009
         		Intermediate 381
    194
    Figure US20230330127A1-20231019-C01010
         		Intermediate 344
    195
    Figure US20230330127A1-20231019-C01011
         		Intermediate 371
    196
    Figure US20230330127A1-20231019-C01012
         		Intermediate 345
    197
    Figure US20230330127A1-20231019-C01013
         		Intermediate 346
    198
    Figure US20230330127A1-20231019-C01014
         		Intermediate 347
    199
    Figure US20230330127A1-20231019-C01015
         		Intermediate 372
    200
    Figure US20230330127A1-20231019-C01016
         		Intermediate 373
    201
    Figure US20230330127A1-20231019-C01017
         		Intermediate 348
    202
    Figure US20230330127A1-20231019-C01018
         		Intermediate 349
    203
    Figure US20230330127A1-20231019-C01019
         		Intermediate 350
    204
    Figure US20230330127A1-20231019-C01020
         		Intermediate 374
    205
    Figure US20230330127A1-20231019-C01021
         		Intermediate 376
    206
    Figure US20230330127A1-20231019-C01022
         		Intermediate 351
    208
    Figure US20230330127A1-20231019-C01023
         		Intermediate 385
    209
    Figure US20230330127A1-20231019-C01024
         		Intermediate 405
    210
    Figure US20230330127A1-20231019-C01025
         		Intermediate 375
    225
    Figure US20230330127A1-20231019-C01026
         		Intermediate 465
    226
    Figure US20230330127A1-20231019-C01027
         		Intermediate 467
    227
    Figure US20230330127A1-20231019-C01028
         		Intermediate 470
    229
    Figure US20230330127A1-20231019-C01029
         		Intermediate 474
    230
    Figure US20230330127A1-20231019-C01030
         		Intermediate 475
    231
    Figure US20230330127A1-20231019-C01031
         		Intermediate 476
    232
    Figure US20230330127A1-20231019-C01032
         		Intermediate 479
    233
    Figure US20230330127A1-20231019-C01033
         		Intermediate 480
    234
    Figure US20230330127A1-20231019-C01034
         		Intermediate 481
    235
    Figure US20230330127A1-20231019-C01035
         		Intermediate 483
    237
    Figure US20230330127A1-20231019-C01036
         		Intermediate 486
    238
    Figure US20230330127A1-20231019-C01037
         		Intermediate 489
    239
    Figure US20230330127A1-20231019-C01038
         		Intermediate 492
    • Example B22 Preparation of Compound 163
  • Figure US20230330127A1-20231019-C01039
  • A mixture of intermediate 353 (260 mg, 0.49 mmol) in HCl/MeOH (4N, 1 mL) and MeOH (1 mL) was stirred at room temperature for 1 h. The reaction was concentrated. The residue was basified by NH3.H2O to pH>8. The residue was purified by HPLC: Column: Gemini 150 × 25 mm 5 µm; conditions: A: water (0.05% ammonia hydroxide v/v), B: MeCN; at the beginning: A (89%) and B (11%), at the end: A (59%) and B (41%); Gradient Time (min) 10; 100% B Hold Time (min) 2; Flow Rate(ml/min) 25. The desired fractions were collected and concentrated. The residue was lyophilized to give compound 163 (93.4 mg, 48.6% yield) as solid.
    • Example B23 Preparation of Compound 185
  • Figure US20230330127A1-20231019-C01040
  • A solution of intermediate 403 (600 mg, 1.28 mmol) in HCl/MeOH (4N, 2.7 mL) and MeOH (1 mL) was stirred at room temperature for 4 h. The reaction was concentrated. The residue was basified by NH3.H2O to pH>8. A precipitate was formed and collected by filtration. The precipitate was washed with water and MTBE. The precipitate was lyophilized to give compound 185 (345 mg, 61% yield) as solid.
    • Example B24 Preparation of Compound 187
  • Figure US20230330127A1-20231019-C01041
  • A solution of intermediate 365 (250 mg, 0.54 mmol) in HCl/MeOH (4N, 1.52 mL) and MeOH (1 mL) was stirred at room temperature for 1 h. The reaction was concentrated. The residue was basified by NH3.H2O to pH>8 and concentrated. The residue was purified by HPLC: column: Gemini 150 × 25 mm, 5 µm; conditions: A: water (0.05% ammonia hydroxide v/v), B: ACN); at the beginning: A (89%) and B (11%), at the end: A (59%) and B (41%); gradient time (min) 10; 100% B hold time (min) 2; flow rate(ml/min) 25. The desired fractions were collected and concentrated. The residue was lyophilized to give compound 187 (29.4 mg, 13% yield) as a solid.
    • Example B 25 Preparation of Compound 188
  • Figure US20230330127A1-20231019-C01042
  • A solution of intermediate 366 (410 mg, 0.76 mmol) in HCl/MeOH (4N, 7 mL) and MeOH (2 mL) was stirred at room temperature for 1 h. The reaction was concentrated. The residue was dissolved in H2O (3 mL) and basified by aq.NH3.H2O. A precipitate was formed and collected. The solid was purified by prep-HPLC (Phenomenex Gemini 150 × 25 mm,10 µm; conditions: A: water (0.05% ammonia hydroxide v/v), B:ACN); at the beginning: A (70%) and B (30%), at the end: A (40%) and B (60%); gradient time(min) 10; 100% B hold time(min) 3; flow rate(ml/min) 25. The desired fractions were collected and lyophilized to give compound 188 (131.3 mg, 34.5%) as solid.
    • Example B26 Preparation of Compound 211
  • Figure US20230330127A1-20231019-C01043
  • Potassium carbonate (155 mg, 1.1 mmol) was added to intermediate 383 (0.3 g, 0.376 mmol) in CH3CN (10 ml). The mixture was stirred at room temperature for 3 h. The mixture was evaporated under vacuo. The residue was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150 × 30 mm 5 µm; Condition: water (0.05% ammonia hydroxide v/v)-ACN, Begin: B 35%, End: B 65%, Gradient Time (min): 10, 100%B Hold Time (min): 3, FlowRate (ml/min): 25). The combined solvent was evaporated to give the product as a white solid. The product was purified by SFC separation (Column: OJ (250 mm × 30 mm, 10um), Condition: A: (0.1% ammonia hydroxide v/v) -B: EtOH, Begin: B 50%, End: B 50%, Flow Rate (ml/min): 80).The combined solvent was evaporated to give compound 211 (76 mg, yield:39%) as a white solid.
    • Example B27 Preparation of Compound 253
  • Compound 253 was prepared by an analogous reaction protocol as was used for the preparation of intermediate 382 described in A78 (Step 1) using the appropriate starting materials (Table 41).
  • TABLE 41
    Compound Structure Starting materials
    253
    Figure US20230330127A1-20231019-C01044
         		Compound 2
    • Example B28 Preparation of Compounds 207 and 208
  • Figure US20230330127A1-20231019-C01045
  • HCl/MeOH(1 mL, 4 mol/L) was added into the mixture of intermediate 384 and intermediate 385 (200 mg) in MeOH (1 mL) and stirred at room temperature for 30 min. The reaction mixture was added dropwise into aq. NH3.H2O (2 mL) and concentrated under vacuo to dryness to give the crude product. The crude product was purified by preparative high-performance liquid chromatography over Column: Phenomenex Gemin 150 × 25 mm 10 µm; Condition: A: water (0.05% ammonia hydroxide v/v), B: MeCN; at the beginning: A (85%) and B (15%), at the end: A: (55%) and B (45%). The pure fractions were collected and the solvent was evaporated under vacuum. The residues were lyophilized to give compound 207 (32 mg) and compound 208 (41 mg) as white solids.
    • Example B29 Preparation of Compound 215
  • Figure US20230330127A1-20231019-C01046
  • A mixture of intermediate 388 (1 g, 0.67 mmol) and K2CO3 (1 g, 7.25 mmol) in CH2Cl2 (10 mL) and dioxane (10 mL) was stirred at 50° C. for 2 hours. The mixture was filtered and the filtrate was concentrated to give the crude product. The crude product was purified by preparative-HPLC (gradient elution: 0.05% NH3.H2O in CH3OH / 0.05% NH3.H2O in H2O; Column: Kromasil 150 × 25 mm, 10 µm) to obtain compound 215 (102 mg, 34% yield) as a white solid.
    • Example B30 Preparation of Compound 216
  • Figure US20230330127A1-20231019-C01047
  • A mixture of intermediate 390 (300 mg, 0.60 mmol) and K2CO3 (0.25 g, 1.80 mmol) in methanol (10 mL) was stirred at 50° C. for 2 hours. The mixture was filtered and concentrated to give the crude product. The crude product was purified by preparative-HPLC (gradient elution: 0.05% NH3.H2O in CH3OH / 0.05% NH3.H2O in H2O; column: Kromasil 150 × 25 mm, 10 µm) to obtain compound 216 (37.9 mg, 15.5% yield) as a white solid.
    • Example B31 Preparation of Compound 198
  • Figure US20230330127A1-20231019-C01048
  • A mixture of intermediate 347 (1.2 g, 2.42 mmol) in HCl/MeOH (20 mL, 4 M) was stirred at room temperature for 2 hours. The solvent was concentrated in vacuum. Then H2O (50 ml) was added and the pH was adjusted to 9 by progressively adding solid NaHCO3. The solid was filtered and washed with H2O (100 mL × 6), methanol (100 mL × 2) and diisopropylether (100 mL × 2).The filtered cake was dried under vacuum to give compound 198 (273.7 mg, 24% yield) as white solid.
    • Example B32 Preparation of Compound 199
  • Figure US20230330127A1-20231019-C01049
  • A mixture of intermediate 372 (510 mg, 0.824 mmol) in HCl/MeOH (10 mL, 4 M) was stirred at room temperature for 2 hours. The solvent was concentrated in vacuum. Then H2O (50 ml) was added and the pH was adjusted to 9 by progressively adding solid NaHCO3. Then ethyl acetate (50 mL) was added. The organic layer was separated and the aqueous phase was extracted with ethyl acetate (50 mL × 2). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give crude product. The crude product was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150 × 30 mm, 5 µm, Conditions: A: water (0.05% ammonia hydroxide v/v)-B:ACN, Begin: B 13%, End: B 43%, Gradient Time(min): 10, 100% B Hold Time(min): 3, FlowRate (ml/min): 25)to obtain compound 199 (84.7 mg, 22% yield) as a white solid.
    • Example B33 Preparation of Compound 218
  • Figure US20230330127A1-20231019-C01050
  • To a solution of intermediate 232 (500 mg, 0.677 mmol, 1.0 eq) in DCM (15 mL) was added BBr3 (0.64 mL, 6.77 mmol, 10.0 eq) at -78° C. under N2. The resulted mixture was stirred overnight at 20° C. The solid was filtered, rinsed with CH2Cl2 and collected to give the crude product. The residue was triturated with water, and the pH was adjusted to around 8 by progressively added solid K2CO3. The resulting solid was filtered through a funnel rinsed with water (20 mL × 5) and collected. The residue was purified by preparative-HPLC. (HPLC condition; A: water (0.05% ammonia hydroxide v/v)-B: ACN; Columns: Gemini 150 × 25 mm, 5 µm; Begin B: 9%, End B: 39%) to afford the product compound 218 (79 mg, 0.193 mmol, 29% yield,) as a white solid.
    • Example B34 Preparation of Compound 201
  • Figure US20230330127A1-20231019-C01051
  • Intermediate 348 (450 mg, 0.855 mmol) was dissolved in MeOH (15 mL), HCl/MeOH (4N, 15 mL) was added. The reaction mixture was stirred at room temperature for 2 hours. The solvent was removed by evaporation. The residue was triturated with EtOAc (100 mL) and saturated Na2CO3 (30 mL). The organic layer was separated and washed by brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (Waters Xbridge Prep OBD C18 150 × 30 mm 5 µm, conditions: A: water (0.05% NH4OH v/v)-B: ACN, FlowRate: 25 ml/min, gradient from B 35% to B 65%) to afford compound 201 (148 mg, 35% yield) as a white solid.
    • Example B35 Preparation of Compound 200
  • Figure US20230330127A1-20231019-C01052
  • Intermediate 373 (340 mg, 0.595 mmol) was dissolved in MeOH (50 mL) and 4 N HCl/MeOH (10 mL) was added. The reaction mixture was stirred at room temperature for 2 hours. The solvent was removed by evaporation. The residue was triturated with EtOAc (100 mL) and saturated Na2CO3 (30 mL), the separated organic layer was washed by brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (Waters Xbridge Prep OBD C18 150 × 30 mm 5 µm, conditions; A: water (0.05% NH4OH v/v)- B: ACN, FlowRate: 25 ml/min, gradient from B 35% to B 65%) to afford the compound 200 (135 mg, 46% yield) as a white solid.
    • Example B36 Preparation of Compound 204
  • Figure US20230330127A1-20231019-C01053
  • A solution of intermediate 374 (350 mg, 0.73 mmol) in HCl/MeOH (4 M, 10 mL) was stirred at room temperature for 2 hours. The mixture was basified with NH3.H2O (20 mL) to pH > 7. The solution was washed with water (60 mL) and extracted with EtOAc (80 mL × 3). The combined organic layers were washed with brine (80 mL), dried (Na2SO4), filtered and concentrated by vacuum to give the crude product as brown solid. The crude product was purified by HPLC (Column: Waters Xbridge Prep OBD C18 150 × 30 mm 5 µm; Conditions; A: water (0.05% ammonia hydroxide v/v)-B: ACN; Begin B: 25%; End B: 55%; Gradient Time(min): 10; 100% B Hold Time(min): 3; FlowRate(ml/min): 25) to give compound 204 (102.9 mg, 32% yield) as white solid.
    • Example B37 Preparation of Compound 203
  • Figure US20230330127A1-20231019-C01054
  • A solution of intermediate 350 (300 mg, 0.61 mmol) in HCl/CH3OH(4 mol/L, 10 mL) was stirred at room temperature for 2 hours. The mixture was basified with NH3.H2O (8 mL) to pH > 7. The solution was treated with water(100 mL) and extracted with ethyl acetate (150 mL × 3). The combined organic layers were washed with brine (100 mL), dried (Na2SO4), filtered and concentrated by vacuum to give the crude product as a brown solid. The crude product was purified by HPLC (Column: Waters Xbridge Prep OBD C18 150 × 30 mm, 5 µm; Condition; A: water (0.05% ammonia hydroxide v/v)-B: ACN; Begin B: 25% ;End B: 55%; Gradient Time(min): 10; 100% B Hold Time(min): 3; FlowRate(ml/min): 25) to give compound 203 (129.8 mg, 47% yield) as a white solid.
    • Example B38 Preparation of Compound 202
  • Figure US20230330127A1-20231019-C01055
  • A solution of intermediate 349 (350 mg, 0.734 mmol) in HCl/CH3OH(4 M, 10 mL) was stirred at room temperature for 2 hours. The mixture was basified with NH3.H2O (10 mL) to pH > 7. The solution was washed with water (100 mL) and extracted with ethyl acetate (150 mL × 3). The combined organic layers were washed with brine (100 mL), dried (Na2SO4), filtered and concentrated by vacuum to give the crude product as a brown solid. The crude product was purified by HPLC to give compound 202 (149 mg, 46% yield) as white solid.
    • Example B39 Preparation of Compound 219
  • Figure US20230330127A1-20231019-C01056
  • To a solution of intermediate 422 (600 mg, 0.80 mmol) in DCM (11 mL) was added TFA (12 mL, 163 mmol) dropwise under N2 at 0° C. The reaction mixture was stirred at 0° C. for 30 minutes, then H2O (3 mL) was added. The reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum. The residue was dissolved in water (30 ml) and the pH was adjusted to 8 and was then filtered. The solid was collected, dried under vacuum to give compound 219 (326 mg, 86.5% yield) as a white solid.
    • Example B40 Preparation of Compound 220
  • Figure US20230330127A1-20231019-C01057
  • To a solution of intermediate 424 (1 g, 1.20 mmol) in DCM (10 mL) was added TFA (10 mL, 135 mmol) dropwise under N2 at 0° C. The reaction mixture was stirred at 0° C. for 30 minutes, then H2O (3 mL) was added. The reaction mixture was stirred at room temperature for 4 hours. The solvent was removed under vacuum. The residue was dissolved in MeOH (10 ml) and adjusted pH to 8, then filtered and the filtrate was concentrated to give the crude product. The crude product was purified by HPLC Column: DuraShell 150 × 25 mm, 5 µm; Conditions: A: water (0.05% NH4OH v/v), B: MeOH; at the beginning: A (60%) and B (40%), at the end: A (30%) and B (70%); Gradient Time (min) 10; 100% B Hold Time (min) 3; Flow Rate (ml/min) 25 to give compound 220 (106 mg, 19% yield) as a white solid.
    • Example B42 Preparation of Compound 221
  • Figure US20230330127A1-20231019-C01058
  • The mixture of intermediate 426 (150 mg, 0.123 mmol, ) and potassium carbonate (51 mg, 0.369 mmol) in methanol (3 ml) was stirred at 60° C. for 1 h. The mixture was filtered and the filtrate was evaporated under vacuo to obtain the crude product as a solid. This residue was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150 × 30 mm, 5 µm, Condition; A: water (0.05% ammonia hydroxide v/v) -B: ACN, Begin: B 13%, End: B 43%, Gradient Time (min): 10, 100% B Hold Time (min): 3, FlowRate (ml/min): 25). The combined solvents were evaporated to give compound 221 (39 mg) as a white solid.
    • C. Conversions of Compounds Example C1 Preparation of Compound 217
  • Figure US20230330127A1-20231019-C01059
  • To a solution of compound 2 (1.6 g, 2.88 mmol, 1.0 eq,), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (0.72 g, 5.76 mmol, 2.0 eq) and K2CO3 (0.796 g, 5.76 mmol, 2.0 eq) in dioxane/ H2O ratio 10/ 1 (30 mL) was added Pd(dppf)Cl2 (210 mg, 0.288 mmol, 0.1 eq). The resulting mixture was stirred at 90° C. under N2 for 16 hours. The resulting solid was filtered off. The filtrate was concentrated. The residue was triturated with water (30 ml), and DCM (30 ml) was added. A solid precipitated out of the reaction. The resulting solid was filtered to give the crude product. The residue was purified by column chromatography (gradient: petroleum ether/ethyl acetate/ MeOH ratio 20/1/0 to 0/20/1). The product fractions were collected and the solvent was evaporated to give the product as solid. The product was purified by preparative-HPLC (HPLC condition: A: water (0.05% ammonia hydroxide v/v)- B: ACN; Column: Gemini 150 × 25 mm, 5 µm; Begin B: 15%, End B: 45%) and to afford compound 217 (300 mg, 0.73 mmol, 25% yield,) as a white solid.
    • Example C2 Preparation of Compound 212
  • Figure US20230330127A1-20231019-C01060
  • To a solution of compound 2 (1 g, 1.8 mmol) in dioxane (40 ml) and H2O (10 ml) was added potassium isopropenyltrifluoroborate (319 mg, 2.16 mmol) and K3PO4 (764 mg, 3.6 mmol) at room temperature. 1,1′-bis(di-tert-butylphosphino)ferrocene palladium dichloride(58 mg, 0.09 mmol) was added to the above solution under nitrogen atmosphere. The reaction mixture was stirred at 80° C. under nitrogen atmosphere overnight. The mixture was extracted with ethylacetate, the organic layers were combined and concentrated under vacuo to give the crude product.
  • This crude product was purified by preparative-HPLC (gradient elution: 0.05% NH3.H2O in CH3CN / 0.05% NH3.H2O in H2O; Column: DuraShell 150 × 25 mm, 5 µm). The combined solvent was evaporated to give the desired product as a white solid of the product (300 mg, yield 35%). 100 mg of the product was purified by SFC separation (AD (250 mm × 30 mm, 10 µm)). The combined solvents were evaporated under vacuo to give the desired product as a white solid of compound 212 (71.9 mg).
    • Example C3 Preparation of Compound 213
  • Figure US20230330127A1-20231019-C01061
  • Pd/C (20 mg) was added into the mixture of compound 253 (200 mg, 0.429 mmol) in MeOH (20 ml). The mixture was hydrogenated at 25° C. for 24 h under H2 atmosphere. The mixture was filtered and evaporated under vacuo to obtain a crude product. It was purified by preparative-HPLC (gradient elution: 0.05% NH3.H2O in CH3CN / 0.05% NH3.H2O in H2O; Column: Waters Xbridge Prep OBD C18 150 × 30 mm, 5 mm). The combined solvent was evaporated to give compound 213 as a white solid (132 mg, yield 73%).
  • Below compounds were prepared by an analogous reaction protocol as was used for the preparation of compound 213 using the appropriate starting materials (Table 47).
  • TABLE 47
    compounds Structure Starting materials
    214
    Figure US20230330127A1-20231019-C01062
         		Compound 212
    • Analytical Part Nmr
  • For a number of compounds, 1H NMR spectra were recorded on a Bruker DPX-360 operating at 360 MHz, on a Bruker Avance 600 operating at 600 MHz, on a Bruker Avance 400 operating at 400 MHz, or on a Varian 400MR spectrometer operating at 400 MHz. As solvents CHLOROFORM-d (deuterated chloroform, CDCl3), Methanol-d4 or DMSO-d6 (deuterated DMSO, dimethyl-d6 sulfoxide) were used. Chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane (TMS), which was used as internal standard.
  • Co. 217: 1H NMR (400 MHz, DMSO-d6) δ ppm 2.44 (s, 3 H) 4.21 - 4.34 (m, 3 H) 4.34 - 4.43 (m, 1 H) 4.50 (q, J=5.7 Hz, 1 H) 5.37 (d, J=5.0 Hz, 1 H) 5.44 (d, J=6.3 Hz, 1 H) 6.17 (d, J=5.5 Hz, 1 H) 6.61 (d, J=3.8 Hz, 1 H) 7.01 (br s, 2 H) 7.27 (dd, J=8.8, 2.5 Hz, 1 H) 7.37 (d, J=3.8 Hz, 1 H) 7.41 (d, J=2.3 Hz, 1 H) 7.81 (d, J=9.0 Hz, 1 H) 8.05 (br s, 1 H) 8.07 (s, 1 H) 8.70 (d, J=2.0 Hz, 1 H).
  • Co. 218: 1H NMR (400 MHz, DMSO-d6) δ ppm 4.14 - 4.34 (m, 4 H) 4.48 (q, J=5.7 Hz, 1 H) 5.36 (d, J=5.0 Hz, 1 H) 5.44 (d, J=6.3 Hz, 1 H) 6.15 (d, J=5.5 Hz, 1 H) 6.33 (br s, 2 H) 6.58 (d, J=8.8 Hz, 1 H) 6.61 (d, J=3.8 Hz, 1 H) 6.83 (dd, J=8.7, 2.4 Hz, 1 H) 6.91 (d, J=2.3 Hz, 1 H) 7.02 (br s, 2 H) 7.35 (d, J=3.8 Hz, 1 H) 7.53 (d, J=8.8 Hz, 1 H) 7.79 (d, J=8.8 Hz, 1 H) 8.07 (s, 1 H).
  • Co. 74: 1H NMR (600 MHz, DMSO-d6) δ ppm 0.24 - 0.27 (m, 2 H) 0.45 - 0.48 (m, 2 H) 1.08 - 1.14 (m, 1 H) 1.52 (dt, J=12.4, 10.3 Hz, 1 H) 1.67 - 1.74 (m, 1 H) 1.84-1.92 (m, 1 H) 1.96 (ddt, J=13.0, 9.3, 6.4, 6.4 Hz, 1 H) 2.25 (dt, J=12.7, 7.9 Hz, 1 H) 2.65 -2.72 (m, 1 H) 2.72 - 2.79 (m, 1 H) 3.26 (dd, J=6.5, 5.6 Hz, 2 H) 3.75 (q, J=4.9 Hz, 1 H) 4.21 (dt, J=7.6, 6.2 Hz, 1 H) 4.63 (d, J=4.8 Hz, 1 H) 4.77 (d, J=6.3 Hz, 1 H) 4.81 (dt, J=10.5, 8.0 Hz, 1 H) 6.55 (d, J=3.5 Hz, 1 H) 6.72 (d, J=8.9 Hz, 1 H) 6.91 (br s, 2 H) 6.99 - 7.03 (m, 2 H) 7.26 (d, J=3.5 Hz, 1 H) 7.33 (s, 1 H) 7.50 (d, J=8.1 Hz, 1 H) 7.76 (d, J=8.8 Hz, 1 H) 8.04 (s, 1 H).
  • Co. 129: 1H NMR (360 MHz, DMSO-d6) δ ppm 1.53 (dt, J=12.3, 10.2 Hz, 1 H) 1.69 -1.81 (m, 1 H) 1.82 - 1.93 (m, 1 H) 1.95 - 2.05 (m, 1 H) 2.25 (dt, J=12.4, 7.9 Hz, 1 H) 2.78 - 2.93 (m, 2 H) 3.76 (q, J=5.0 Hz, 1 H) 4.21 (q, J=5.9 Hz, 1 H) 4.66 (d, J=4.8 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.55 (d, J=3.3 Hz, 1 H) 6.95 (br s, 2 H) 7.27 (d, J=3.7 Hz, 1 H) 7.59 (dd, J=8.4, 1.8 Hz, 1 H) 7.87 (s, 1 H) 7.91 (d, J=8.4 Hz, 1 H) 8.03 (s, 1 H) 8.68 (d, J=2.2 Hz, 1 H) 8.91 (d, J=2.6 Hz, 1 H).
  • Co. 130: 1H NMR (400 MHz, DMSO-d6) δ ppm 4.22 - 4.39 (m, 3 H) 4.59 (q, J=5.0 Hz, 1 H) 5.49 (br d, J=4.5 Hz, 1 H) 5.60 (d, J=6.0 Hz, 1 H) 6.29 (d, J=5.5 Hz, 1 H) 6.64 (m, J=9.0 Hz, 2 H) 6.78 (d, J=3.8 Hz, 1 H) 6.90 (dd, J=8.7, 1.9 Hz, 1 H) 6.97 (d, J=1.5 Hz, 1 H) 7.58 (d, J=8.5 Hz, 1 H) 7.87 (d, J=9.0 Hz, 1 H) 7.97 (d, J=4.0 Hz, 1 H) 8.69 (s, 1 H).
  • Co. 176: 1H NMR (400 MHz, Methanol-d4) δ ppm 2.32 - 2.45 (m, 1 H) 2.48 - 2.62 (m, 1 H) 2.65 - 2.83 (m, 2 H) 3.01 - 3.12 (m, 1 H) 3.45 (s, 3 H) 3.49 - 3.63 (m, 2 H) 3.69 (d, J=4.8 Hz, 3 H) 4.53 - 4.61 (m, 1 H) 5.05 - 5.11 (m, 1 H) 5.51 (d, J=4.8 Hz, 1 H) 5.60 (d, J=6.3 Hz, 1 H) 5.70 - 5.81 (m, 1 H) 7.47 (d, J=8.8 Hz, 1 H) 7.50 (d, J=3.8 Hz, 1 H) 7.73 (br q, J=5.0 Hz, 1 H) 7.84 (dd, J=8.0, 1.5 Hz, 1 H) 8.17 (br s, 1 H) 8.32 (d, J=8.0 Hz, 1 H) 8.53 (d, J=3.5 Hz, 1 H) 8.58 (d, J=8.8 Hz, 1 H) 9.43 (s, 1 H).
  • Co. 80: 1H NMR (600 MHz, DMSO-d6) δ ppm 1.50 - 1.56 (m, 1 H) 1.68 - 1.75 (m, 1 H) 1.85 - 1.92 (m, 1 H) 1.96 (ddt, J=13.0, 9.0, 6.5, 6.5 Hz, 1 H) 2.25 (dt, J=12.7, 7.9 Hz, 1 H) 2.69 - 2.80 (m, 2 H) 3.76 (br t, J=4.7 Hz, 1 H) 4.21 (dd, J=7.6, 6.0 Hz, 1 H) 4.57 (br s, 1 H) 4.72 (br s, 1 H) 4.80 (dt, J=10.5, 7.9 Hz, 1 H) 6.50 (br s, 2 H) 6.59 (d, J=3.5 Hz, 1 H) 7.07 (br s, 2 H) 7.12 (dd, J=8.2, 1.6 Hz, 1 H) 7.29 (d, J=3.6 Hz, 1 H) 7.34 (s, 1 H) 7.58 (d, J=8.1 Hz, 1 H) 8.07 (s, 1 H) 8.31 (s, 1 H).
  • Co. 185: 1H NMR (400 MHz, DMSO-d6) δ ppm 2.96 (br d, J=3.5 Hz, 3 H) 4.16 - 4.36 (m, 4 H) 4.44 - 4.55 (m, 1 H) 5.38 (br d, J=5.3 Hz, 1 H) 5.47 (br d, J=6.2 Hz, 1 H) 6.16 (d, J=5.7 Hz, 1 H) 6.63 (d, J=4.0 Hz, 1 H) 6.70 (br d, J=9.3 Hz, 1 H) 6.89 - 6.97 (m, 1 H) 7.05 - 7.23 (m, 3 H) 7.37 (d, J=3.5 Hz, 1 H) 7.63 (br d, J=9.3 Hz, 1 H) 7.84 - 7.95 (m, 1 H) 8.09 (s, 1 H).
  • Co. 75: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.45 - 1.59 (m, 1 H) 1.65 - 1.77 (m, 1 H) 1.83 - 2.02 (m, 2 H) 2.25 (dt, J=12.5, 7.9 Hz, 1 H) 2.63 - 2.83 (m, 2 H) 3.72 - 3.89 (m, 3 H) 4.16 - 4.24 (m, 1 H) 4.64 (d, J=4.8 Hz, 1 H) 4.77 (d, J=6.3 Hz, 1 H) 4.79 -4.84 (m, 1 H) 6.22 (tt, J=56.7, 4.1 Hz, 1 H) 6.54 (d, J=3.5 Hz, 1 H) 6.78 (d, J=8.8 Hz, 1 H) 6.91 (br s, 2 H) 7.09 (dd, J=8.2, 1.6 Hz, 1 H) 7.26 (d, J=3.5 Hz, 1 H) 7.36 (t, J=6.0 Hz, 1 H) 7.40 (br s, 1 H) 7.57 (d, J=8.0 Hz, 1 H) 7.87 (d, J=8.8 Hz, 1 H) 8.03 (s, 1 H). Co. 81: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.42 - 1.60 (m, 1 H) 1.62 - 1.77 (m, 1 H) 1.81 - 2.00 (m, 2 H) 2.24 (dt, J=12.7, 7.8 Hz, 1 H) 2.64 - 2.83 (m, 2 H) 3.70 - 3.79 (m, 1 H) 4.16 - 4.25 (m, 1 H) 4.62 (br d, J=4.9 Hz, 1 H) 4.71 - 4.87 (m, 2 H) 6.54 (d, J=3.5 Hz, 1 H) 6.65 (br s, 2 H) 6.90 (br s, 2 H) 7.12 (br d, J=7.5 Hz, 1 H) 7.25 (d, J=3.5 Hz, 1 H) 7.34 (s, 1 H) 7.58 (d, J=8.4 Hz, 1 H) 8.03 (s, 1 H) 8.14 (s, 1 H).
  • Co. 151: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.45 - 1.57 (m, 1 H) 1.62 - 1.77 (m, 1 H) 1.82 - 2.01 (m, 2 H) 2.25 (dt, J=12.4, 7.9 Hz, 1 H) 2.65 - 2.82 (m, 2 H) 3.75 (q, J=4.8 Hz, 1 H) 4.20 (dt, J=7.6, 6.2 Hz, 1 H) 4.26 - 4.39 (m, 2 H) 4.64 (d, J=4.8 Hz, 1 H) 4.73 - 4.87 (m, 2 H) 6.54 (d, J=3.5 Hz, 1 H) 6.82 (d, J=8.8 Hz, 1 H) 6.91 (br s, 2 H) 7.12 (dd, J=8.0, 1.5 Hz, 1 H) 7.26 (d, J=3.5 Hz, 1 H) 7.42 (s, 1 H) 7.54 (br t, J=6.4 Hz, 1 H) 7.59 (d, J=8.0 Hz, 1 H) 7.91 (d, J=8.9 Hz, 1 H) 8.03 (s, 1 H).
  • Co. 152: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.39 - 0.62 (m, 2 H) 0.67 - 0.84 (m, 2 H) 1.46 - 1.62 (m, 1 H) 1.64 - 1.78 (m, 1 H) 1.82 - 2.02 (m, 2 H) 2.25 (dt, J=12.6, 8.0 Hz, 1 H) 2.63 - 2.83 (m, 3 H) 3.70 - 3.79 (m, 1 H) 4.15 - 4.25 (m, 1 H) 4.63 (d, J=4.9 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.54 (d, J=3.5 Hz, 1 H) 6.75 (br d, J=8.8 Hz, 1 H) 6.90 (br s, 2 H) 7.05 (dd, J=8.2, 1.5 Hz, 1 H) 7.13 (br d, J=2.6 Hz, 1 H) 7.26 (d, J=3.5 Hz, 1 H) 7.37 (br s, 1 H) 7.54 (d, J=7.9 Hz, 1 H) 7.84 (d, J=8.8 Hz, 1 H) 8.03 (s, 1 H).
  • Co. 146: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.38 - 1.63 (m, 5 H) 1.65 - 1.75 (m, 3 H) 1.82 - 2.04 (m, 4 H) 2.25 (dt, J=12.5, 7.9 Hz, 1 H) 2.63 - 2.80 (m, 2 H) 3.71 - 3.78 (m, 1 H) 4.14 - 4.25 (m, 1 H) 4.33 (dq, J=13.6, 6.7 Hz, 1 H) 4.63 (d, J=4.9 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.54 (d, J=3.1 Hz, 1 H) 6.66 (d, J=8.8 Hz, 1 H) 6.76 - 6.97 (m, 3 H) 7.01 (dd, J=7.9, 1.3 Hz, 1 H) 7.26 (d, J=3.5 Hz, 1 H) 7.32 (s, 1 H) 7.49 (d, J=8.4 Hz, 1 H) 7.74 (d, J=8.8 Hz, 1 H) 8.03 (s, 1 H).
  • Co. 76: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.43 - 1.57 (m, 1 H) 1.62 - 1.76 (m, 1 H) 1.79 - 2.01 (m, 2 H) 2.18 - 2.29 (m, 1 H) 2.65 - 2.79 (m, 2 H) 3.70 - 3.78 (m, 1 H) 4.14 - 4.25 (m, 1 H) 4.63 (br d, J=4.9 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.42 (br s, 2 H) 6.54 (br d, J=3.5 Hz, 1 H) 6.69 (br d, J=8.8 Hz, 1 H) 6.92 (br s, 2 H) 7.05 (br d, J=8.4 Hz, 1 H) 7.26 (br d, J=3.5 Hz, 1 H) 7.28 (br s, 1 H) 7.54 (br d, J=7.9 Hz, 1 H) 7.84 (br d, J=8.8 Hz, 1 H) 8.02 (s, 1 H).
  • Co. 121: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.56 - 1.68 (m, 1 H) 1.69 - 1.82 (m, 1 H) 1.84 - 2.05 (m, 2 H) 2.24 - 2.37 (m, 1 H) 2.63 - 2.81 (m, 2 H) 2.88 (d, J=4.4 Hz, 3 H) 3.73 - 3.81 (m, 1 H) 4.25 - 4.35 (m, 1 H) 4.73 (d, J=4.4 Hz, 1 H) 4.86 (d, J=6.6 Hz, 1 H) 4.93 - 5.04 (m, 1 H) 6.66 (d, J=8.8 Hz, 1 H) 6.69 (d, J=3.5 Hz, 1 H) 6.87 - 6.94 (m, 1 H) 7.03 (br dd, J=7.9, 1.3 Hz, 1 H) 7.37 (s, 1 H) 7.51 (d, J=8.4 Hz, 1 H) 7.77 (br d, J=8.8 Hz, 1 H) 7.95 (d, J=4.0 Hz, 1 H) 8.63 (s, 1 H).
  • Co. 113: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.48 - 1.58 (m, 1 H) 1.70 - 1.80 (m, 1 H) 1.82 - 1.94 (m, 1 H) 1.95 - 2.04 (m, 1 H) 2.25 (dt, J=12.5, 8.1 Hz, 1 H) 2.46 (s, 3 H) 2.75 - 2.90 (m, 2 H) 3.71 - 3.80 (m, 1 H) 4.20 (br dd, J=14.1, 6.2 Hz, 1 H) 4.65 (d, J=5.3 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.54 (d, J=3.5 Hz, 1 H) 6.92 (br s, 2 H) 7.26 (d, J=3.5 Hz, 1 H) 7.47 (dd, J=8.4, 1.8 Hz, 1 H) 7.76 - 7.85 (m, 2 H) 8.02 (s, 1 H) 8.07 (br s, 1 H) 8.72 (d, J=2.2 Hz, 1 H).
    • OR (optical Rotation)
  • Optical rotations were measured on a Perkin-Elmer 341 polarimeter with a sodium lamp (wavelength of light used is 589 nm (the sodium D line)). (‘T’ means temperature).
  • Table
    Optical rotation values for enantiomerically pure compounds
    Co. Nr. αD (°) Wavelength (nm) Concentration (w/v%) Solvent T (° C)
    129 -8.6 589 0.3835 DMF 20
    130 -84.95 589 0.3555 DMF 20
    151 -11.15 589 0.5380 DMF 20
    113 -8 589 0.5125 DMF 20
    176 -20.63 589 0.2715 DMF 20
    74 -9.7 589 0.3610 DMF 20
    75 -11.97 589 0.5345 DMF 20
    146 -10.19 589 0.5005 DMF 20
    217 -92.69 589 0.5265 DMF 20
    185 -88.93 589 0.5195 DMF 20
    80 -1.88 589 0.5315 DMF 20
    121 -18.82 589 0.3560 DMF 20
    76 -3.37 589 0.2670 DMF 20
    218 -79.03 589 0.3505 DMF 20
    152 -8.19 589 0.5370 DMF 20
    81 -2.48 589 0.3625 DMF 20
    • LCMS (Liquid chromatography/Mass Spectrometry)
  • The High Performance Liquid Chromatography (HPLC) measurement was performed using a LC pump, a diode-array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).
  • Flow from the column was brought to the Mass Spectrometer (MS) which was configured with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound’s nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.
  • Compounds are described by their experimental retention times (Rt) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the [M+H]+ (protonated molecule) and/or [M-H]- (deprotonated molecule). In case the compound was not directly ionizable the type of adduct is specified (i.e. [M+NH4]+, [M+HCOO]-, etc...). For molecules with multiple isotopic patterns (Br, Cl), the reported value is the one obtained for the lowest isotope mass. All results were obtained with experimental uncertainties that are commonly associated with the method used.
  • Hereinafter, “SQD” means Single Quadrupole Detector, “MSD” Mass Selective Detector, “RT” room temperature, “BEH” bridged ethylsiloxane/silica hybrid, “DAD” Diode Array Detector, “HSS” High Strength silica., “Q-Tof” Quadrupole Time-of-flight mass spectrometers, “CLND”, ChemiLuminescent Nitrogen Detector, “ELSD” Evaporative Light Scanning Detector,
  • Table
    LCMS Method codes (Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes)
    Method code Instrument Column Mobile phase Gradient Flow -------Col T Run time
    1 Waters: Acquity® UPLC®- DAD and SQD Waters: BEH C18 (1.7 µm, 2.1*50 mm) A: 10 mM CH3COONH4 in 90% H2O + 10% CH3CN B: MeOH From 95% A to 5% A in 1.3 min, held for 0.2 min, to 95% A in 0.2 min held for 0.1 min. 0.7 -------70 1.8
    2 Waters: Acquity® UPLC®- DAD and SQD Waters: BEH C18 (1.7 µm, 2.1*50 mm) A: 10 mM CH3COONH4 in 95% H2O + 5% CH3CN B: CH3CN From 95% A to 5% A in 1.3 min, held for 0.7 min. 0.8 -------55 2
    3 Waters: Acquity® UPLC® -DAD and SQD Waters: HSS T3 (1.8 µm, 2.1*100 mm) A: 10 mM CH3COONH4 in 95% H2O + 5% CH3CN B: CH3CN From 100% A to 5% A in 2.10 min, to 0% A in 0.90 min, to 5% A in 0.5 min 0.7 -------55 3.5
    4 Waters: Acquity® UPLC® -DAD and SQD Waters: HSS T3 (1.8 µm, 2.1*100 mm) A: 10 mM CH3COONH4 in 95% H2O + 5% CH3CN B: CH3CN From 100% A to 5% A in 2.10 min, to 0% A in 0.90 min, to 5% A in 0.5 min 0.7 -------55 3.5
    5 Waters: Acquity UPLC®- DAD and Quattro Micro™ Waters: BEH C18 (1.7 µm, 2.1×100 mm) A: 95% CH3COONH4 7 mM / 5% CH3CN, B: CH3CN 84.2% A for 0.49 min, to 10.5% A in, 2.18 min, held for 1.94 min, back to 84.2% AB in 0.73 min, held for 0.73 min. 0.343 -------40 6.2
    6 Agilent: 1100/1200 -DAD and MSD Waters: XBridgeTM Shield RP18 (5 µm, 2.1×50 mm) A: NH4OH 0.05% in water, B: CH3CN 100% A for 1 min, to 40% A in 4 min, held for 2.5 min, back to 100% A in 2 min. 0.8 -------40 10.5
    7 Agilent: 1200-DAD and MSD6110 Phenomenex: Luna-C18 (5 µm, 2 ×50 mm) ACF3COOH 0.1% in water, B: CF3COOH 0.05%in CH3CN 100% A for 1 min, to 40% A in 4 min, to 15% A in 2.5 min, back to 100% A in 2 min. 0.8 -------50 10
    8 Waters: Acquity® UPLC®- DAD and SQD Waters: HSS T3 (1.8 µm, 2.1*100 mm) A: 10 mM CH3COONH4 in 95% H2O + 5% CH3CN B: CH3CN From 100% A to 5% A in 2.10 min, to 0% A in 0.90 min, to 5% A in 0.5 min 0.7 -------55 3.5
    9 Agilent: 1100/1200 -DAD and MSD Agilent: TC-C18 (5 µm, 2.1 ×50 mm) A: CF3COOH 0.1% in water, B: CF3COOH 0.05% in CH3CN 100% A for 1 min, to 40% A in 4 min, to15% A in 2.5 min, back to 100% A in 2 min. 0.8 -------50 10.5
    10 Agilent: 1100/1200 -DAD and MSD Agilent: TC-C18 (5 µm, 2.1 ×50 mm) A: CF3COOH 0.1% in water, B: CF3COOH 0.05% in CH3CN 90% A for 0.8 min, to 20% A in 3.7 min, held for 3 min, back to 90% A in 2 min. 0.8 -------50 10.5
    11 Agilent: 1200-DAD and MSD6110 Phenomenex: Luna-C 18 (5 µm, 2 ×50 mm) A: CF3COOH 0.1% in water, B: CF3COOH 0.05% in CH3CN 90% A for 0.8 min, to 20% A in 3.7 min, held for 3 min, back to 90% A in 2 min. 0.8 -------50 10
    12 Waters: Acquity® UPLC®- DAD and SQD Waters: BEH C18 (1.7 µm, 2.1*50 mm) A: 10 mM CH3COONH4 in 95% H2O + 5% CH3CN B: CH3CN From 95% A to 5% A in 1.3 min, held for 0.2 min, to 95% A in 0.2 min held for 0.1 min 0.7 -------70 1.8
  • Table: Co. No. means compound number; Retention time (Rt) in min; n.d. means not determined
    Co. No. Rt [M+H]+ LCMS Method
    1 0.71 394 1
    1a 0.60 394 2
    2 1.41 472 4
    3 2.00 520 5
    4 0.98 462 1
    5 0.66 394 1
    6 0.70 394 1
    7 0.76 394 1
    8 0.77 394 1
    9 2.31 393 5
    10 0.74 394 1
    11 0.65 394 1
    12 0.62 394 1
    13 0.66 394 1
    14 0.96 395 4
    15 1.02 395 4
    16 0.44 395 2
    17 0.58 395 1
    18 0.55 410 1
    19 0.91 424 1
    20 0.89 428 1
    21 0.833 408 1
    22 1.51 462 4
    23 0.88 437 1
    24 0.80 412 1
    25 1.39 428 4
    26 0.79 424 1
    27 0.97 462 1
    28 0.66 453 2
    29 0.47 434 2
    30 0.69 483 2
    31 0.50 464 2
    32 1.91 408 5
    33 1.36 428 3
    34 0.91 4047 2
    35 1.11 462 1
    36 0.69 458 2
    37 0.96 462 1
    38 0.86 462 1
    39 2.00 408 5
    40 1.90 520 5
    41 0.70 428 1
    42 1.01 506 1
    43 0.98 486 1
    44 1.24 412 4
    45 0.97 472 1
    46 0.84 392 1
    47 1.49 470 4
    48 0.79 410 1
    49 1.61 393 5
    50 1.36 427 4
    51 1.39 471 3
    52 1.43 485 4
    53 0.99 485 1
    54 1.04 469 1
    55 1.29 388 4
    56 0.91 390 1
    57 1.12 422 1
    57a 1.44 424 4
    58 1.77 424 6
    59 1.45 426 4
    60 0.69 394 1
    61 0.76 390 1
    62 0.81 392 1
    63 1.97 388 5
    64 0.82 392 1
    65 0.76 392 1
    66 1.24 376 3
    67 0.79 408 1
    68 0.82 408 1
    69 0.50 395 1
    70 0.74 419 1
    71 0.95 487 2
    72 1.22 602 2
    73 1.17 612 2
    74 0.80 459 2
    75 4.23 469 6
    76 3.65 405 6
    77 0.90 390 1
    78 2.77 419 7
    79 3.59 420 7
    80 2.99 483 7
    81 3.08 439 7
    245 3.06 437 9
    246 3.41 451 6
    85 3.50 392 6
    175 3.52 438 6
    82 1.24 408 4
    83 1.26 408 4
    54a 1.43 469 4
    91 2.80 428 9
    86 1.84 504 4
    87 0.89 486 2
    88 0.94 500 2
    84 1.38 434 4
    89 1.02 534 2
    90 1.57 375 4
    92 1.52 506 8
    94 1.43 506 8
    217 0.87 408 1
    222 3.64 426 9
    95 1.21 376 3
    96 3.98 540 9
    97 3.51 451 6
    98 1.16 419 4
    99 3.68 462 9
    100 1.49 462 8
    219 1.43 507 8
    213 2.82 422 9
    101 1.40 462 8
    220 1.34 473 8
    102 1.35 428 8
    212 4.04 434 6
    214 2.99 436 9
    103 1.21 392 4
    104 2.89 424 6
    105 3.65 436 6
    218 3.39 409 6
    106 1.45 490 8
    107 3.25 499 7
    108 1.49 486 4
    109 3.24 462 7
    110 3.72 424 7
    185 3.60 423 6
    111 1.49 470 4
    112 3.19 450 7
    113 2.92 404 7
    114 2.17 548 8
    115 2.90 478 11
    116 0.79 459 2
    117 1.60 459 8
    118 1.60 459 8
    119 1.60 459 8
    120 2.75 438 7
    121 1.71 438 8
    122 2.97 420 7
    123 3.82 406 6
    124 2.53 529 11
    189 3.16 451 6
    166 3.01 444 7
    125 3.10 418 7
    126 2.98 419 7
    127 3.14 550 11
    128 3.55 440 7
    171 2.55 514 11
    164 2.93 404 7
    129 1.58 468 4
    130 3.13 428 7
    131 2.01 552 8
    132 3.44 533 7
    176 3.01 418 7
    190 3.02 458 7
    172 3.42 480 7
    193 2.35 528 11
    133 3.29 426 7
    134 2.58 407 7
    167 2.87 392 7
    135 1.74 531 8
    136 3.20 442 7
    187 1.36 424 8
    137 2.89 421 7
    169 3.83 406 6
    138 3.82 480 7
    191 3.79 476 7
    139 3.13 461 7
    165 2.55 516 11
    140 1.81 482 8
    192 3.77 406 6
    168 3.20 446 7
    186 2.78 423 7
    163 3.48 394 6
    177 2.54 530 11
    141 3.24 460 7
    142 3.06 463 7
    205 2.48 532 11
    208 1.03 41 8
    143 3.74 425 7
    174 3.71 408 6
    170 3.09 448 7
    173 4.76 518 6
    144 1.34 520 4
    215 3.96 425 6
    216 4.67 406 6
    145 3.85 446 6
    146 3.38 473 7
    147 2.26 493 11
    148 1.96 537 8
    149 3.22 447 7
    150 3.36 461 7
    221 3.14 406 7
    151 3.07 487 7
    152 3.17 445 7
    153 4.75 523 6
    154 1.54 473 8
    155 1.75 477 8
    178 3.06 433 7
    179 3.20 459 7
    194 3.09 453 7
    156 3.28 459 7
    211 4.80 470 6
    180 3.72 434 7
    181 3.89 460 7
    188 5.10 502 6
    182 4.91 484 6
    195 4.61 454 6
    196 2.30 481 11
    157 3.03 437 7
    183 2.32 473 11
    209 2.30 473 11
    184 3.16 483 7
    197 4.45 479 6
    210 2.91 474 11
    158 3.90 441 6
    198 4.03 455 6
    200 4.67 488 6
    161 1.85 515 8
    202 4.01 437 6
    203 4.24 451 6
    162 4.66 501 6
    206 4.55 461 6
    201 4.34 487 6
    159 3.80 423 6
    204 4.31 438 6
    199 3.66 456 7
    160 4.27 461 6
    223 3.03 441 7
    224 3.18 461 7
    225 3.30 475 7
    226 3.00 435 7
    227 1.47 455 8
    228 1.69 456 8
    229 1.35 439 8
    230 1.56 440 8
    231 1.24 425 8
    232 3.99 501 6
    233 2.88 487 7
    234 0.87 488 1
    235 2.98 485 7
    236 3.06 485 7
    237 3.11 499 7
    238 1.57 497 8
    239 1.48 499 8
    249 3.59 423 7
    240 3.59 473 7
    250 3.49 424 7
    241 3.79 458 7
    242 3.07 424 7
    248 3.10 423 7
    243 3.14 439 7
    244 1.47 475 8
    247 3.13 423 7
    251 3.09 467 7
    252 1.48 482 4
    253 3.80 420 6
    • Experimental Procedures in Vitro Assay (Assay 1a and 1b)
  • Reagents. PRMT5-MEP50 enzyme was purchased from Charles River (Argenta). The enzyme complex was produced in insect cells (Sf9) infected simultaneously with two baculoviruses. One virus expresses full length human PRMT5 with Flag-tag at N-terminus, the second virus expresses full length MEP50 with His6-TEV cleavage at N-terminus. The protein was affinity purified using anti-Flag (M2) beads eluted with 3×FLAG peptide, followed by His-Select eluted with 0.5 M imidazole. Eluted protein was then dialysed against tris-buffered saline (TBS) (pH 8.0) containing 20% glycerol and 3 mM dithiothreitol (DTT).
  • Full-length untagged human recombinant histone H2A (residues 1-130, Genbank Accession# NM_021052, MW = 14.1 kDa) expressed in E. coli was purchased from Reaction Biology Corporation, Cat# HMT-11-146. Reagents used for making reaction buffer or stopping reaction were purchased including Tris base (Sigma Cat# T-1503), NaCl (Sigma Cat# RGF-3270), MgCl2 (Sigma Cat # M0250), DTT (Invitrogen Cat# 15508-013) and Formic Acid (Riedel deHaen, Cat# 33015)
  • High Throughput Mass Spectrometer Assay PRMT5 catalyzes the sequential methylations of the terminal nitrogen atoms on the guanidine groups of arginine residues within proteins using co-substrate S-adenosyl-L-methionine (AdoMet, SAM), forming mono-methyl (MMA), symmetric-dimethyl arginine (sDMA) and S-adenosyl-L-homocysteine (AdoHcy, SAH). The enzyme activity was determined by following the product SAH formation using high throughput mass spectrometry (Agilent Rapidfire 300 System coupled to a Sciex 4000 series QTrap® triple-quad MS/MS). The reaction buffer was 20 mM Tris-HCl, pH 8.5, 50 mM NaCl, 5 mM MgCl2 and 1 mM DTT. The reaction activity was stopped using 1% formic acid (final concentration). Inhibition Studies. The IC50 Studies were performed using eleven point dosing series made for each compound by serially diluted 1:2 in dimethyl sulfoxide (DMSO), with point 12 being a DMSO control. Compounds were first spotted to plates, and followed by addition of 2 µM SAM and 0.6 µM H2A (histone H2A) solution mixture. The same volume of enzyme solution was added to initiate the enzymatic reactions. The final concentrations of the reaction are at 1 µM SAM, 0.3 µM H2A and 10 nM enzyme (assay 1a) or or 1.25 nM enzyme (assay 1b). The reaction was incubated at 30° C. for 60 minutes (min) when 10 nM enzyme was used and for 120 min when 1.25 nM enzyme was used. Subsequently, the reaction was quenched by addition of formic acid to a final concentration of 1%. The inhibitions of SAH formation in the presence of compounds were calculated as a percentage of the control relative to the uninhibited reaction as a function of inhibitor concentration. The data were fit as follows: Y = Bottom + (Top- Bottom)/(1+10^((log IC50 -X)*h)) where IC50 is the inhibitor concentration (same unit as X) at 50% inhibition and h is the Hill slope. Y is percent of inhibition, X is log of compound concentration. Bottom and Top are the plateaus in same units as Y.
    • Experimental Procedure PD Assay (assay 2) Reagents
  • A549 cells (ATCC, Cat # CCL-185) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma, Cat #D5796), supplemented with 10% Fetal Calf Serum (FCS) (HyClone™, Cat #SV30160.03), 100 mM Sodium Pyruvate (Sigma, Cat #S8636), 200 mM L-Glutamine (Sigma, Cat #G7513) and 50 mg/mL Gentamycing (Gibco, Cat #15750-037).
  • Reagents used for buffers were purchased: Dulbecco’s phosphate buffered saline (DPBS) without Ca/Mg (Sigma, Cat #D8537), phosphate buffered saline (PBS) 10X (Roche, Cat #11 666 789 001), Formalin solution 10% (Sigma, HT50-1-128-4L), Methanol 100% (Sigma, Cat #32213-2.5L), Triton X-100 (Acros, Cat #215680010), Bovine Serum Albumin (BSA) (Sigma, Cat #A2153), Alexa fluor 488 goat anti-rabbit antibody (Life Technologies, Cat # A1 1034), HCS CellMask Deep Red Stain (Life Technologies, Cat #H32721), Hoechst Stain (Life Technologies, Cat #33258), Anti-dimethyl-Arginine, sym (SYM10) antibody (Millipore, 07-412).
    • Immunohistochemistry Procedure
  • Cells were plated at 400 cells/40 µL/well in 384 well black µplates clear bottom (Perkin Elmer) and overnight incubated at 37° C., 5% CO2. The IC50 Studies were performed using nine point dosing series ranging from 10 µM to 1 pM for each compound. 80 nL of the respective dilution of the compounds was added using the Labcyte POD 810 (Labcyte ) reaching a final DMSO concentration of 0.2% in cell culture. After an incubation period of 48 h at 37° C. and 5% CO2, cells were fixed in 10% formalin solution for 15 min at room temperature and 20 min in ice-cold methanol, after which they were washed 3x in DPBS. Subsequently, the cells were blocked for 1 h in blocking buffer (PBS + 1% BSA and 0.5% Triton X-100) and incubated overnight at 4° C. with the SYM10 antibody diluted 1/2000 in blocking buffer. The cells were washed 3x with washing buffer (PBS + 0.1% Triton X-100) and incubated with the Alexa fluor 488 goat anti-rabbit antibody diluted 1/200 in blocking buffer for 1 h at room temperature. Subsequently, they were washed 3x with washing buffer and incubated for 30 min at room temperature with PBS containing a 1/5000 dilution of Hoechst Stain and a 1/5000 dilution of the HCS CellMask Deep Red Stain. After a final wash with PBS, the plates were imaged using the 10×W lens of the Opera® system (Perkin Elmer Life Sciences) using following settings (values in nm):
  • laser Filter camera Primary dichrome Detect dichrome
    488 540/75 405/488/561/635 510
    405 450/50 405/488/561/635 510
    635 690/50 405/488/561/635 510
    • Analyses:
  • The inhibition of nuclear symmetric Arginine dimethylation in the presence of compounds (% effect) was calculated as the “median nuclear SYM10 intensity” / “median cytoplasmic SYM10 intensity”, normalized by below equation:
  • n o r m a l i z e d = 100 − r a w − l o w M e d i a n h i g h M e d i a n − l o w M e d i a n ∗ 100
  • In the above equations, the following variable names are used:
  • normalized The normalized feature value
    raw The raw feature value
    lowMedian The median of the raw values of the low control wells
    highMedian The median of the raw values of the high control wells
  • In the above equations, the following controls were used for normalization:
  • Low control: minimum level of symmetrically dimethylated Arginines (cells treated with reference compound at 10 µM).
  • High control: maximum level of symmetrically dimethylated Arginines (DMSO treated cells).
  • IC50 and pIC50 (-logIC50) values were calculated using the appropriate software.
  • The pIC50 values in the Table below are averaged values (Co. No. means compound number; n.d. means not determined).
  • Co. No. pIC50 Assay 1a pIC50 Assay 1b pIC50 Assay 2
    5 5.7 5.3 <5
    1 7.8 7.9 7.1
    1a n.d. n.d. n.d.
    10 5.5 5.4 ∼5.15
    6 5.5 5.3 <5
    11 5.5 5.1 <5
    12 5.8 5.4 <5
    8 5.2 4.9 <5
    7 5.9 5.6 ∼4.76
    13 6.1 5.7 4.8
    14 5.9 5.6 <4.7
    33 6.8 6.1 6.3
    22 5.2 4.6 ∼4.75
    2 8.1 7.6 7.4
    15 6.0 n.d. <5.4
    66 5.7 5.3 <4.7
    45 6.6 n.d. 6.2
    44 7.2 6.9 6.6
    25 7.9 7.4 6.9
    9 5.5 n.d. <4.7
    60 6.6 6.4 5.9
    46 7.7 7.2 6.9
    48 7.0 n.d. 6.4
    68 5.6 <4 ∼5.14
    67 7.0 n.d. 6.5
    17 6.0 5.8 5.1
    245 5.7 5.5 <4.7
    49 8.4 8.0 8.0
    16 6.6 5.9 5.3
    61 6.4 6.0 ∼5.88
    55 8.1 7.5 ~7.29
    246 5.5 n.d <4.7
    71 5.5 5.7 5.0
    3 7.4 6.8 6.2
    32 7.4 6.9 6.3
    21 5.9 5.8 5.3
    20 5.7 5.6 5.2
    64 6.9 6.1 ~5.97
    39 5.6 5.6 5.7
    40 5.6 5.8 ~4.92
    27 6.4 6.1 ~5.94
    19 5.8 5.5 <4.7
    65 5.5 6.0 4.8
    85 <5 5.1 4.9
    63 7.6 6.9 6.7
    56 8.2 7.8 8.1
    28 <5 5.1 <4.7
    31 5.5 5.4 <4.7
    30 <5 4.4 <5
    36 5.1 5.6 <4.7
    34 5.1 <4 <4.7
    29 6.3 5.9 4.8
    62 6.2 6.1 5.8
    69 6.2 5.5 <4.7
    35 6.4 6.1 6.4
    23 6.3 6.5 6.4
    24 7.4 6.9 6.1
    18 7.1 6.5 ~5
    175 <5 5.5 <5
    51 8.0 7.8 ~7.81
    26 7.2 6.7 ∼6.6
    70 6.2 5.8 5.2
    4 7.2 6.7 ∼6.21
    42 7.3 6.9 6.5
    41 5.2 5.0 <5
    43 7.1 6.7 6.5
    37 6.0 6.2 5.3
    82 6.7 6.3 5.9
    83 7.4 6.9 6.7
    54 7.8 7.8 7.5
    54a 8.1 7.8 7.4
    91 6.9 6.3 6.4
    57a 7.5 7.3 7.2
    47 7.6 7.2 7.3
    86 5.6 6.0 5.3
    72 <5 <4 <5
    50 8.0 8.1 7.6
    38 6.7 6.4 6.1
    52 7.2 6.8 6.4
    87 6.3 6.0 5.8
    88 <5 5.1 <5
    53 7.4 7.3 7.3
    73 <5 <4 7.0
    84 7.8 7.1 6.7
    89 <5 4.5 7.2
    90 7.0 6.2 <5
    57 7.5 n.d. ∼6.82
    92 7.2 n.d. 6.1
    94 6.0 n.d. ∼6
    217 8.3 7.7 7.4
    222 7.5 7.2 ∼6.76
    95 6.5 6.3 <5
    59 7.6 7.1 6.9
    96 6.7 6.3 6.7
    97 <5 4.8 <5
    58 7.9 7.7 7.4
    98 6.2 5.8 5.0
    99 <5 <4 <5
    100 6.9 6.7 6.1
    219 5.4 <4 5.1
    213 8.1 7.8 7.2
    101 6.0 6.1 5.7
    220 6.5 6.3 5.6
    102 7.0 6.3 <5
    212 7.7 7.3 5.6
    214 7.5 7.0 8.3
    103 6.4 5.9 6.4
    104 5.3 4.8 8.4
    105 6.8 6.0 5.6
    218 8.6 8.3 6.7
    106 7.2 6.8 6.4
    107 8.9 8.4 5.1
    108 7.4 7.0 <5
    109 6.9 6.7 5.6
    110 8.7 8.8 8.3
    111 7.9 8.1 7.2
    112 8.3 6.7 6.4
    113 8.3 8.0 8.3
    114 7.8 7.6 7.9
    115 8.0 8.3 ~8.26
    74 9.1 9.9 9.4
    116 n.d n.d n.d
    117 n.d n.d n.d
    118 n.d n.d n.d
    119 n.d n.d n.d
    120 7.1 6.5 6.5
    121 8.4 8.4 7.7
    122 7.9 7.3 7.1
    123 8.3 7.4 7.5
    124 8.7 8.3 9.2
    189 6.5 6.0 6.6
    166 9.0 8.3 9.0
    125 8.4 7.6 7.7
    126 9.3 8.6 9.5
    127 7.9 7.0 6.9
    128 8.1 7.2 6.7
    171 9.1 8.2 8.5
    164 9.4 8.0 >8.93
    129 8.6 7.8 7.9
    130 9.2 8.1 7.9
    131 8.1 7.2 ~7.18
    132 9.1 8.6 8.6
    76 9.6 n.d. 9.8
    176 9.3 8.4 8.5
    190 9.3 8.3 ∼8.73
    172 9.3 8.4 >8.93
    193 9.0 8.1 8.5
    133 9.2 8.2 8.2
    134 9.4 8.5 8.8
    167 9.1 8.3 8.5
    135 9.0 8.2 ∼8.55
    136 8.1 7.3 6.3
    187 8.0 7.1 7.6
    137 8.8 7.7 8.2
    169 8.0 7.2 7.3
    138 8.1 7.1 6.9
    191 6.7 6.2 5.9
    139 8.9 8.0 8.2
    165 8.4 7.5 7.7
    140 8.2 7.3 6.1
    192 9.2 8.0 8.5
    168 8.4 7.3 6.9
    186 8.7 7.8 7.1
    163 9.3 8.3 8.2
    177 8.0 7.5 7.2
    141 8.1 7.3 7.2
    142 8.9 8.1 7.8
    205 8.5 7.6 7.3
    208 5.6 5.9 <5
    143 8.0 7.3 5.6
    174 8.0 7.3 6.9
    170 8.2 7.2 7.1
    173 8.7 7.8 7.4
    77 9.3 n.d. >8.93
    78 8.9 n.d. 9.5
    144 n.d. n.d. n.d.
    79 9.4 n.d. >8.93
    215 8.1 7.4 5.9
    216 9.0 8.1 8.0
    145 7.8 7.1 7.1
    146 9.6 8.6 >8.93
    147 6.6 6.6 7.5
    80 9.9 9.7 9.6
    148 6.4 6.1 6.7
    75 9.6 9.3 8.8
    149 9.5 8.3 9.0
    150 9.0 7.8 7.5
    221 7.6 6.8 7.3
    81 9.6 n.d. 9.7
    151 9.1 7.8 8.3
    152 9.3 8.4 >8.93
    153 n.d. 6.7 7.5
    154 n.d. 9.5 8.6
    155 n.d. 6.8 6.6
    178 n.d. 9.1 8.0
    179 n.d. 9.2 8.3
    194 n.d. 9.2 8.8
    156 n.d. 9.5 >8.93
    211 n.d. 8.5 ~5.59
    180 n.d. 8.9 7.4
    181 n.d. 8.9 7.4
    188 n.d. 7.4 6.2
    182 n.d. 8.2 6.5
    195 n.d. 9.3 7.6
    196 n.d. 8.7 7.0
    157 n.d. 6.2 6.3
    183 n.d. 9.3 8.2
    209 n.d. 9.5 7.8
    184 n.d. 8.7 7.2
    197 n.d. 9.2 7.5
    210 n.d. 8.6 6.9
    158 n.d. 9.9 8.5
    198 n.d. 8.4 7.2
    200 n.d. 8.2 6.0
    161 n.d. 8.8 7.4
    202 n.d. 8.8 7.8
    203 n.d. <5.6 5.2
    162 n.d. 8.1 6.8
    206 n.d. 8.8 7.6
    201 n.d. 8.8 7.4
    159 n.d. 9.9 >8.93
    204 n.d. 8.4 7.2
    199 n.d. 7.4 6.6
    160 n.d. 9.1 7.8
    223 n.d. 9.7 8.9
    224 n.d. >9.7 n.d.
    225 n.d. 8.2 n.d.
    226 n.d. 8.2 7.0
    227 n.d. 8.9 n.d.
    228 n.d. 8.3 n.d.
    229 n.d. 7.4 n.d.
    230 n.d. 6.2 n.d.
    231 n.d. 9.2 n.d.
    232 n.d. 8.4 n.d.
    233 n.d. >9.7 n.d.
    234 n.d. 6.1 n.d.
    235 n.d. 9.7 n.d.
    236 n.d. >9.7 n.d.
    237 n.d. 8.8 8.2
    238 n.d. 9.1 8.9
    239 n.d. 8.0 7.6
    249 n.d. 7.7 6.3
    240 n.d. >9.7 >8.93
    250 n.d. 7.5 6.7
    241 n.d. 8.6 >8.93
    242 n.d. 9.0 >8.93
    248 n.d. 7.3 6.8
    243 n.d. 9.1 >8.93
    244 n.d. 8.5 n.d.
    247 n.d. 9.1 n.d.
    251 n.d. 10.4 n.d.
    252 n.d. 9.2 n.d.
    253 7.7 n.d. n.d.
    • COMPOSITION EXAMPLES
  • “Active ingredient” (a.i.) as used throughout these examples relates to compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof; in particular to any one of the exemplified compounds.
  • Typical examples of recipes for the formulation of the invention are as follows:
    • 1. Tablets
  • Active ingredient 5 to 50 mg
    Di-calcium phosphate 20 mg
    Lactose 30 mg
    Talcum 10 mg
    Magnesium stearate 5 mg
    Potato starch ad 200 mg
    • 2. Suspension
  • An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient, 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.
    • 3. Injectable
  • A parenteral composition is prepared by stirring 1.5% (weight/volume) of active ingredient in 0.9% NaCl solution or in 10% by volume propylene glycol in water.
    • 4. Ointment
  • Active ingredient 5 to 1000 mg
    Stearyl alcohol 3 g
    Lanoline 5 g
    White petroleum 15 g
    Water ad 100 g
  • In this Example, active ingredient can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.

Claims (8)

1-15. (canceled)
16. A compound selected from:
Figure US20230330127A1-20231019-C01063
Figure US20230330127A1-20231019-C01064
Figure US20230330127A1-20231019-C01065
or a pharmaceutically acceptable addition salt or a solvate thereof.
17. The compound as claimed in claim 16, wherein the compound is
Figure US20230330127A1-20231019-C01066
or a pharmaceutically acceptable addition salt or a solvate thereof.
18. The compound as claimed in claim 17, wherein the compound is
Figure US20230330127A1-20231019-C01067
.
19. The compound as claimed in claim 16, wherein the compound is
Figure US20230330127A1-20231019-C01068
or a pharmaceutically acceptable addition salt or a solvate thereof.
20. The compound as claimed in claim 19, wherein the compound is
Figure US20230330127A1-20231019-C01069
.
21. The compound as claimed in claim 1, wherein the compound is
Figure US20230330127A1-20231019-C01070
or a pharmaceutically acceptable addition salt or a solvate thereof.
22. The compound as claimed in claim 21, wherein the compound is
Figure US20230330127A1-20231019-C01071
.
US18/187,463 2015-08-26 2023-03-21 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors Pending US20230330127A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/187,463 US20230330127A1 (en) 2015-08-26 2023-03-21 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562209941P 2015-08-26 2015-08-26
EP15184011 2015-09-07
EP15184011.3 2015-09-07
US201662306233P 2016-03-10 2016-03-10
PCT/EP2016/070097 WO2017032840A1 (en) 2015-08-26 2016-08-25 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
US201815755475A 2018-02-26 2018-02-26
US16/825,024 US11318157B2 (en) 2015-08-26 2020-03-20 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US17/690,587 US11883367B2 (en) 2015-08-26 2022-03-09 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US18/187,463 US20230330127A1 (en) 2015-08-26 2023-03-21 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/690,587 Continuation US11883367B2 (en) 2015-08-26 2022-03-09 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors

Publications (1)

Publication Number Publication Date
US20230330127A1 true US20230330127A1 (en) 2023-10-19

Family

ID=54065259

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/755,475 Active 2036-09-04 US10653711B2 (en) 2015-08-26 2016-08-25 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US16/825,024 Active US11318157B2 (en) 2015-08-26 2020-03-20 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US17/690,587 Active US11883367B2 (en) 2015-08-26 2022-03-09 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US18/187,463 Pending US20230330127A1 (en) 2015-08-26 2023-03-21 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US15/755,475 Active 2036-09-04 US10653711B2 (en) 2015-08-26 2016-08-25 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US16/825,024 Active US11318157B2 (en) 2015-08-26 2020-03-20 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US17/690,587 Active US11883367B2 (en) 2015-08-26 2022-03-09 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors

Country Status (33)

Country Link
US (4) US10653711B2 (en)
EP (3) EP3341368B1 (en)
JP (3) JP6917978B2 (en)
KR (1) KR20180041222A (en)
CN (2) CN107922413B (en)
AR (1) AR105820A1 (en)
AU (4) AU2016311295B2 (en)
BR (2) BR122023020317A2 (en)
CA (1) CA2992688A1 (en)
CL (1) CL2018000510A1 (en)
CO (1) CO2018002063A2 (en)
DK (1) DK3341368T3 (en)
EA (1) EA201890573A1 (en)
ES (1) ES2901972T3 (en)
HK (2) HK1253898A1 (en)
HR (1) HRP20211997T1 (en)
HU (1) HUE057312T2 (en)
IL (2) IL257664B (en)
LT (1) LT3341368T (en)
MA (1) MA42678B1 (en)
MD (1) MD3341368T2 (en)
MX (2) MX2018002326A (en)
MY (1) MY198472A (en)
PE (2) PE20221629A1 (en)
PH (1) PH12018500425A1 (en)
PL (1) PL3341368T3 (en)
PT (1) PT3341368T (en)
RS (1) RS62698B1 (en)
SG (1) SG10202003775VA (en)
SI (1) SI3341368T1 (en)
TN (1) TN2018000043A1 (en)
TW (3) TW202321249A (en)
WO (1) WO2017032840A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321249A (en) * 2015-08-26 2023-06-01 比利時商健生藥品公司 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
EA201892031A1 (en) * 2016-03-10 2019-02-28 Янссен Фармацевтика Нв SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
BR112019004764A2 (en) 2016-09-14 2019-05-28 Janssen Pharmaceutica Nv fused bicyclic inhibitors of girl-mll interaction
MX2019002962A (en) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction.
MX2019003843A (en) * 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors.
EP3555103B1 (en) 2016-12-15 2021-09-22 Janssen Pharmaceutica NV Azepane inhibitors of menin-mll interaction
GB201700526D0 (en) * 2017-01-12 2017-03-01 Univ Of Hull Therapeutic use
EA201990851A1 (en) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS
JP7225106B2 (en) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Use of biomarkers in identifying cancer patients who respond to treatment with PRMT5 inhibitors
US10570140B2 (en) 2017-08-09 2020-02-25 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
CN111542525B (en) * 2017-10-26 2023-06-27 普莱鲁德疗法有限公司 Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5)
CN111741964A (en) * 2017-12-05 2020-10-02 安杰斯制药公司 Heterocyclic compounds as PRMT5 inhibitors
CA3084449A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
PT3724190T (en) 2017-12-13 2022-10-03 Lupin Ltd Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
CA3092357A1 (en) * 2018-03-14 2019-09-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US20210309687A1 (en) * 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) * 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
MA53287A (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme PRMT5 INHIBITORS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020132603A2 (en) * 2018-12-21 2020-06-25 Memorial Sloan-Kettering Cancer Center Salicyl-adenosinemonosulfamate analogs and uses thereof
CN109400545B (en) * 2018-12-24 2022-03-25 济南大学 Arginine methyltransferase 5 inhibitor and application thereof
CN109369507A (en) * 2018-12-26 2019-02-22 重庆市碚圣医药科技股份有限公司 A kind of method of purification of N- (2,2- diethoxy ethyl) phthalimide
BR112021015796A2 (en) * 2019-02-13 2021-10-13 Prelude Therapeutics, Incorporated SELECTIVE INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
EP3939988A4 (en) * 2019-03-20 2022-08-24 Korea Research Institute of Chemical Technology Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient
MX2021011524A (en) * 2019-03-25 2021-12-15 California Inst Of Techn Prmt5 inhibitors and uses thereof.
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
WO2020206299A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
EP3952874A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
JP2022534998A (en) * 2019-05-30 2022-08-04 エンジェクス ファーマシューティカル インコーポレイテッド Heterocyclic compounds as PRMT5 inhibitors
TW202112375A (en) 2019-06-06 2021-04-01 比利時商健生藥品公司 Methods of treating cancer using prmt5 inhibitors
AU2020293021A1 (en) * 2019-06-10 2021-12-23 Lupin Limited PRMT5 inhibitors
WO2020249663A1 (en) * 2019-06-12 2020-12-17 Janssen Pharmaceutica Nv Novel spirobicyclic intermediates
MX2022003340A (en) * 2019-09-18 2022-06-14 Prelude Therapeutics Inc Selective inhibitors of protein arginine methyltransferase 5 (prmt5).
CR20220175A (en) * 2019-10-22 2022-06-21 Lupin Ltd Pharmaceutical combination of prmt5 inhibitors
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs
CN115135651A (en) * 2019-12-03 2022-09-30 鲁皮恩有限公司 Substituted nucleoside analogs as PRMT5 inhibitors
TW202322824A (en) 2020-02-18 2023-06-16 美商基利科學股份有限公司 Antiviral compounds
CN111233869B (en) * 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 Novel compound for preparing Rudexilvir key intermediate and preparation method thereof
WO2021202480A1 (en) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Compounds targeting prmt5
WO2022074391A1 (en) * 2020-10-08 2022-04-14 Storm Therapeutics Limited Compounds inhibitors of mettl3
CN112645875A (en) * 2020-12-09 2021-04-13 深圳海王医药科技研究院有限公司 Preparation method of procaterol hydrochloride impurity
CN117120444A (en) 2021-04-16 2023-11-24 吉利德科学公司 Method for preparing carbanucleoside using amide
CN113234079B (en) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 Nucleoside analogs as PRMT5 inhibitors
CN117157297A (en) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 PRMT5 inhibitors
CN115703796A (en) * 2021-08-09 2023-02-17 苏州恩泰新材料科技有限公司 Preparation method of important intermediate of Reidesciclovir
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN116655638B (en) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 Deuterated PRMT5 inhibitors
CN116003339A (en) * 2022-12-01 2023-04-25 南京师范大学 Macrophage migration inhibition factor MIF two-photon fluorescent probe and preparation method and application thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
WO2003039523A2 (en) 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
IL163613A0 (en) * 2002-02-19 2005-12-18 Cv Therapeutics Inc Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US7144674B2 (en) * 2002-03-20 2006-12-05 Sumitomo Chemical Company, Limited Positive resist composition
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
WO2005005450A1 (en) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. Method of synthesizing cyclic bisdinucleoside
JP2007537999A (en) 2003-12-19 2007-12-27 コローニス ファーマシューティカルズ インコーポレイテッド Mutagenic heterocycle
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
JP2009542608A (en) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド Pharmaceutical combination
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
EP2513298A4 (en) 2009-12-18 2013-03-27 Harvard College Beta-cell replication promoting compounds and methods of their use
EP2646455A4 (en) 2010-12-03 2014-04-02 Epizyme Inc Modulators of histone methyltransferase, and methods of use thereof
WO2012075500A2 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
CA2819894A1 (en) 2010-12-16 2012-06-21 Abbvie Inc. Anti-viral compounds
EP2694524B1 (en) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
EP2771012A4 (en) 2011-10-24 2015-06-24 Glaxosmithkline Ip No 2 Ltd New compounds
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (en) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
UA118548C2 (en) * 2012-12-21 2019-02-11 Епізайм, Інк. Teatrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2975938A4 (en) 2013-03-15 2017-02-15 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN106999479B (en) 2014-07-01 2021-07-16 米伦纽姆医药公司 Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
JP6584521B2 (en) 2015-02-24 2019-10-02 ファイザー・インク Substituted nucleoside derivatives useful as anticancer agents
TW202321249A (en) 2015-08-26 2023-06-01 比利時商健生藥品公司 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
CN108884108B (en) 2016-03-10 2021-08-31 詹森药业有限公司 Substituted nucleoside analogs for use as PRMT5 inhibitors
MX2019003843A (en) * 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors.
EA201990851A1 (en) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS
JP7225106B2 (en) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Use of biomarkers in identifying cancer patients who respond to treatment with PRMT5 inhibitors
CA3084449A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues

Also Published As

Publication number Publication date
TW201718575A (en) 2017-06-01
AU2021200345B2 (en) 2022-08-04
WO2017032840A1 (en) 2017-03-02
EP3974428A1 (en) 2022-03-30
SG10202003775VA (en) 2020-06-29
JP2018528946A (en) 2018-10-04
MX2018002326A (en) 2018-04-11
MA42678A (en) 2021-05-19
PE20180929A1 (en) 2018-06-08
CA2992688A1 (en) 2017-03-02
AR105820A1 (en) 2017-11-15
HK1253898A1 (en) 2019-07-05
US11318157B2 (en) 2022-05-03
CO2018002063A2 (en) 2018-07-19
BR122023020317A2 (en) 2023-12-12
AU2024202052A1 (en) 2024-04-18
HRP20211997T1 (en) 2022-04-01
CN107922413B (en) 2021-10-01
AU2021200345A1 (en) 2021-03-18
PH12018500425A1 (en) 2018-09-10
EP3341368A1 (en) 2018-07-04
TW202146414A (en) 2021-12-16
JP2021169520A (en) 2021-10-28
SI3341368T1 (en) 2022-01-31
JP2024012405A (en) 2024-01-30
IL282537A (en) 2021-06-30
US11883367B2 (en) 2024-01-30
KR20180041222A (en) 2018-04-23
MA42678B1 (en) 2021-11-30
US20200360416A1 (en) 2020-11-19
IL257664A (en) 2018-04-30
AU2016311295B2 (en) 2020-10-22
EP3341368B1 (en) 2021-10-06
US20230071711A1 (en) 2023-03-09
TW202321249A (en) 2023-06-01
IL257664B (en) 2021-05-31
ES2901972T3 (en) 2022-03-24
TWI730980B (en) 2021-06-21
CN114057815A (en) 2022-02-18
US20180243328A1 (en) 2018-08-30
TWI791251B (en) 2023-02-01
MD3341368T2 (en) 2022-02-28
AU2022215260A1 (en) 2022-09-01
MY198472A (en) 2023-08-31
LT3341368T (en) 2021-12-10
AU2016311295A1 (en) 2018-02-08
BR112018003595A2 (en) 2018-09-25
BR112018003595B1 (en) 2024-03-12
HUE057312T2 (en) 2022-05-28
PE20221629A1 (en) 2022-10-19
RS62698B1 (en) 2022-01-31
HK1257099A1 (en) 2019-10-11
US10653711B2 (en) 2020-05-19
TN2018000043A1 (en) 2019-07-08
PL3341368T3 (en) 2022-02-14
PT3341368T (en) 2021-12-09
EP4219496A1 (en) 2023-08-02
MX2022005182A (en) 2022-05-16
EA201890573A1 (en) 2018-07-31
JP6917978B2 (en) 2021-08-11
CL2018000510A1 (en) 2018-07-06
AU2022215260B2 (en) 2024-04-18
CN107922413A (en) 2018-04-17
DK3341368T3 (en) 2021-12-20

Similar Documents

Publication Publication Date Title
US11883367B2 (en) 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
EP3426664B1 (en) Substituted nucleoside analogues for use as prmt5 inhibitors
US11098062B2 (en) Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
US11702441B2 (en) Spirobicyclic analogues
US10898504B2 (en) Substituted nucleoside analogues for use as PRMT5 inhibitors
EA045894B1 (en) NEW NUCLEOSIDE ANALOGUES SUBSTITUTED WITH A 6-6-BICYCLIC AROMATIC RING FOR APPLICATION AS PRMT5 INHIBITORS

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED